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Guideline development process linked to service delivery priorities. Furthermore, implementing National 
Clinical Guidelines sets a standard nationally, to enable healthcare professionals to deliver safe and 
effective care and treatment while monitoring their individual, team and organisation’s performance.
The aim of these National Clinical Guidelines is to reduce unnecessary variations in practice and provide 
a robust basis for the most appropriate healthcare in particular circumstances. As a consequence of 
Ministerial mandate, it is expected that NCEC National Clinical Guidelines are implemented across all 
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The NCEC is a partnership between key stakeholders in patient safety. NCEC’s mission is to provide a 
framework for national endorsement of clinical guidelines and audit to optimise patient and service 
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1 Background
Cancer is a major healthcare challenge. Each year in Ireland, approximately 20,804 people are diagnosed 
with invasive cancer. Cancer is the second leading cause of death in Ireland after diseases of the 
circulatory system. 
Deaths from cancer averaged about 8,655 deaths per year during 2011-2013, representing about 30% of 
all deaths in that period (NCRI, 2016). 
Lung cancer was the single most common cause of cancer death in Ireland from 2011-2012 (See Section 
3.1 Epidemiology). Averaging 1,827 deaths annually, lung cancer is the leading cause of cancer deaths 
in both sexes (NCRI, 2016). The incidence of lung cancer in Ireland is projected to rise more rapidly 
in females than in males. By 2040 the rate of lung cancer is projected to increase by 136% in females 
(Nordpred model) and 52% in males (NCRI, 2014).
Cancer incidence data from the National Cancer Registry Ireland (NCRI) and population projections from 
the Central Statistics Office (CSO) have been combined by the NCRI to estimate the number of new cancer 
cases expected in five year bands from 2015 to 2040. The total number of new invasive cancer cases 
(including non-melanoma skin cancer) is projected to increase by 84% for females and 107% for males 
between 2010 and 2040, based only on changes in population size and age distribution (demography). If 
trends in incidence since 1994 are also taken into account, the number of cases is expected to increase 
by between 86% and 125% for females (depending on the method of projection used) and by between 
126% and 133% for males (NCRI, 2014).
In Ireland, there are eight hospitals designated as cancer centres and one satellite breast unit (Letterkenny 
General Hospital). A cancer centre is characterised by the geographic concentration of all oncology 
disciplines with sub-specialised expertise on a tumour specific/discipline basis to provide the critical mass 
and support to achieve best practice in cancer care. 
As well as these designated cancer centres, other hospitals provide cancer services such as chemotherapy 
(Figure 1).
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Figure 1 Cancer Services in Ireland
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The National Cancer Control Programme (NCCP) engages regularly with the individual cancer centres and 
with Hospital Group structures. Discussion of performance data, improvement plans, resources including 
manpower, service planning and development takes place at regular review meetings between the NCCP 
and senior management at cancer centre and Hospital Group level. This provides an opportunity to share 
good practice from other cancer centres, if relevant. Where resource issues are identified, these are 
included in the service planning process. As specific issues arise in hospitals, these are managed by senior 
hospital management. 
A Lead Clinician has been nominated for each of the common tumour sites (e.g. breast, lung, prostate, 
colorectal) in each of the designated cancer centres, and for rarer tumour sites (e.g. oesophageal 
cancer) in those centres which offer a service for that cancer. The Lead Clinician chairs the governance 
arrangements for their service within the cancer centre and participates in a National Leads forum for 
that tumour site. In order to operate as a cohesive national clinical network for the purpose of clinical 
audit, sharing of good practice and problem solving, the lead clinicians from the cancer centres meet 
collectively as a National Lead Clinicians Network. This supports consistency of care across the eight 
cancer centres. 
The National Cancer Strategy (DoHC, 2006) recommended that national site-specific multidisciplinary 
groups be convened to develop national evidence-based clinical guidelines for cancer care. The principal 
objective of developing these guidelines is to improve the quality of care received by patients.
A Guideline Development Group was established to develop evidence based guidelines for the diagnosis, 
staging and treatment of patients with lung cancer.
The National Cancer Strategy 2017-2026 (DoH, 2017) recommends: The NCCP will develop further 
guidelines for cancer care in line with National Clinical Effectiveness Committee (NCEC) standards.
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2 National Clinical Guideline recommendations
2.1 Summary of recommendations.
Section Recommendation Grade
Ra
di
ol
og
y
2.2.1.1
Contrast enhanced CT scanning of the chest and upper abdomen to include the entire 
liver is recommended in all patients with suspected lung cancer, regardless of chest X-ray 
results.
(B)
2.2.1.2
A tissue diagnosis of lung cancer should not be inferred from CT appearances alone. (D)
2.2.1.3
PET-CT is recommended for mediastinal and hilar lymph node staging in patients with 
potentially radically treatable non-small cell lung cancer (NSCLC) prior to invasive staging.
(C)
2.2.1.4
In patients with PET activity in a mediastinal lymph node and normal appearing nodes by 
CT (and no distant metastases), sampling of the mediastinum is recommended over staging 
by imaging alone.
(C)
2.2.2.1
Percutaneous FNA, TTNB, guided bronchoscopy and VATS are all appropriate first-line 
modalities for tissue diagnosis of peripheral lung nodules.
(C)
2.2.2.2
While percutaneous TTNA/biopsy has a higher diagnostic yield, bronchoscopy (including 
guided approaches where available) may provide a diagnosis for peripheral lesions.
(B)
2.2.3.1
In patients with clinical stage Ia tumours who are high risk surgical candidates, ablative 
techniques may be considered to achieve local control.
(D)
2.2.4.1
Consider close follow-up for patients who have undergone treatment with curative intent 
(including surgery and radiotherapy), to include periodic radiological evaluation with CT.
(C)
2.2.5.1
A negative PET-CT reliably excludes adrenal metastases in patients with NSCLC.
(B)
2.2.5.2
In NSCLC patients with PET-CT positive for adrenal metastasis, histological confirmation 
should be considered unless there is overwhelming clinical and imaging evidence of 
widespread metastatic disease.
(B)
2.2.5.3
In NSCLC patients with indeterminate adrenal lesions on PET-CT further assessment with 
adrenal specific CT or MRI criteria may be considered. If non-invasive imaging findings are 
indeterminate, adrenal sampling such as EUS-FNA, percutaneous biopsy or adrenalectomy 
may be considered.
(D)
2.2.6.1
Offer patients with signs/symptoms suggestive of brain metastases a contrast-enhanced CT 
of the head followed by contrast-enhanced MRI if normal or MRI as an initial test.
(B)
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Section Recommendation Grade
Ra
di
ol
og
y
2.2.6.2
Offer MRI or CT of the head in patients with stage III NSCLC selected for treatment with 
curative intent.
(C)
2.2.6.3 
Do not routinely offer imaging of the brain in patients with stage I and II NSCLC. (C)
2.2.7.1 
For patients with NSCLC with suspected bone metastasis, evaluation with PET-CT is 
recommended over bone scintigraphy or CT.
(B)
2.2.7.2 
Bone scintigraphy is not necessary when PET-CT has not shown bone metastases.
(B)
2.2.8.1 
In patients with clinically limited-stage small-cell lung cancer (SCLC), PET-CT is suggested to 
exclude occult metastases.
(C)
2.2.9
Staging algorithm for patients with suspected lung cancer (Figure 2).
Section Recommendation Grade
Re
sp
ira
to
ry
 M
ed
ic
in
e
2.3.1.1 
Patients with central lesions (within proximal one-third of the hemithorax) alone 
(considered reachable by standard bronchoscopy) who are otherwise fit should undergo 
flexible bronchoscopy in order to establish a histological or cytological diagnosis.
(B)
2.3.1.2 
Visible tumours should be sampled using more than one technique to optimise sensitivity.
(B)
2.3.1.3 
Consider bronchoscopy to provide a diagnosis for peripheral lesions, although 
percutaneous FNA biopsy has a higher diagnostic yield.
(B)
2.3.2.1
Endoscopic assessment of the mediastinal lymph nodes with EBUS-TBNA with or without 
EUS-FNA should be offered to patients with suspected lung cancer prior to mediastinoscopy.
(A)
2.3.3.1 
In patients being considered for active therapy, pleural effusion should be investigated with 
pleural aspiration.
(C)
2.3.3.2 
If pleural fluid cytology is negative, and treatment will change depending on the nature 
of the pleural fluid, pleural biopsy using image guided or thoracoscopic biopsy is 
recommended.
(D)
2.3.4.1
In lung cancer patients with symptomatic (including breathlessness, haemoptysis and 
cough) malignant airway obstruction, any of the following therapeutic interventions may be 
considered: bronchoscopic debulking, tumour ablation modalities, airway stent placement 
and radiotherapy (external beam or brachytherapy).
(D)
2.3.5
Staging algorithm for patients with suspected lung cancer (Figure 3).
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Section Recommendation Grade
Pa
th
ol
og
y
2.4.1.1 
Distinguishing between small-cell carcinoma and non-small cell carcinoma of the lung is 
recommended. For challenging cases, a diagnostic panel of immunohistochemical assays is 
recommended to increase the diagnostic accuracy.
(B)
2.4.1.2 
In individuals with pathologically diagnosed non-small cell lung cancer (NSLC), additional 
discrimination between adenocarcinoma and squamous cell carcinoma, even on cytologic 
material or small tissue samples is recommended.
(B)
2.4.2.1 
Endobronchial ultrasound rapid on-site evaluation (EBUS ROSE) should be made available 
whenever resources permit.
(B)
2.4.2.2 
Consider intra-operative frozen section analysis in primary diagnosis when preoperative 
diagnosis is not available.
(C)
2.4.2.3 
In selected cases intra-operative frozen section analysis for staging may be considered.
(C)
2.4.3.1 
Cytology samples can be used to provide material suitable for both NSCLC sub-typing and 
some molecular analysis, provided the samples are appropriately handled and processed.
(B)
2.4.4.1 
Fixation times of 6 to 12 hours for small biopsy samples and 8 to 18 hours for larger surgical 
specimens generally give best results, although expert consensus opinion is that fixation 
times of 6 to 48 hours should give acceptable results.
(D)
Section Recommendation Grade
Su
rg
er
y
2.5.1.1 
For patients with clinical stage I and II non-small cell lung cancer (NSCLC) who are medically 
fit for surgical resection, a lobectomy rather than sublobar resection is recommended.
(B)
2.5.2.1 
For patients with clinical stage I NSCLC, video-assisted thoracic surgery (thoracoscopy) 
should be considered as an alternative to thoracotomy for anatomic pulmonary resection.
(B)
2.5.3.1 
Pulmonary function testing (spirometry, diffusion capacity, lung volume) should be 
performed in all patients being considered for surgical resection.
(C)
2.5.3.2 
Postoperative predictive values should be calculated using broncho-pulmonary segment 
counting. If a mismatch is suspected ventilation perfusion scan should be performed.
(C)
2.5.3.3 
Offer patients surgery if they have an FEV1 & DLCO within normal limits (postoperative 
predicted values >60%).
(C)
2.5.3.4 
Patients with ppo-FEV1 and/or DLCO <30% should have formal cardiopulmonary exercise 
testing with measurement of VO2 max.
(C)
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Section Recommendation Grade
Su
rg
er
y
2.5.3.5 
Patients with ppo-FEV1 and/or DLCO >30% and <60% – supplementary functional exercise 
assessments should be considered.
(D)
2.5.3.6 
In patients with lung cancer being considered for surgery and a VO2 max <15mL/kg/min 
predicted, it is recommended that they are counselled about minimally invasive surgery, 
sublobar resections or non-operative treatment options for their lung cancer.
(C)
2.5.4.1 
Lung cancer surgery remains the best opportunity for potential cure in patients with 
significant co-morbidity. Efforts to contain and manage that risk should start with 
preoperative scoring (thoracoscore) and should ideally include attendance at a preoperative 
assessment clinic, where practical.
(D)
2.5.4.2 
Seek a cardiology review in patients with an active cardiac condition or ≥3 risk factors or 
poor cardiac functional capacity. 
(C)
2.5.4.3 
Offer surgery without further investigations to patients with ≤2 risk factors and good cardiac 
functional capacity. 
(B)
2.5.5.1 
Age >80 years should not automatically preclude surgery. Decisions should be based on 
oncological stage, co-morbidity and physiological testing. 
(D)
2.5.6.1 Multifocal
In patients with suspected or proven multifocal lung cancer (without mediastinal or 
extrapulmonary disease), curative-intent treatment may be considered, following 
discussion at a multidisciplinary team meeting. 
(D)
2.5.6.2 Synchronous
In patients with suspected or proven synchronous primary lung cancer (without mediastinal 
or extrapulmonary disease), curative-intent treatment may be considered, following 
discussion at a multidisciplinary team meeting. 
(C)
2.5.7.1 
Systematic mediastinal lymph node dissection should be performed in all patients having a 
lung cancer resection. 
(B)
2.5.8.1 
In patients with malignant pleural effusion whose symptoms improved following drainage, 
a number of options are available depending on performance status and documentation of 
lung re-expansion:
- In patients with good performance status with lung re-expansion, thoracoscopy with 
talc pleurodesis is recommended. 
(C)
- In patients with non-expandable lung, tunnelled catheters may be considered. (C)
- In patients with poor performance status with lung re-expansion, options include: 
tunnelled plerual catheter, serial thoracentesis, or bedside talc pleurodesis. 
(D)
2.5.9.1 
In patients with an isolated brain metastasis and a synchronous resectable primary NSCLC, 
sequential resection of the primary tumour and definitive treatment of the brain metastasis 
may be considered, following discussion at a multidisciplinary team meeting. 
(C)
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2.5.9.2 
In patients with an isolated adrenal metastasis and a synchronous resectable primary 
NSCLC, sequential resection of the primary tumour and definitive treatment of the adrenal 
metastasis may be considered, following discussion at a multidisciplinary team meeting.
(D)
2.5.10.1 
Consider surgery as part of multimodality management in patients with T1–3 N2 (non-
fixed, non-bulky, single zone) M0 disease. 
(C)
2.5.11.1 
Patients with clinical stage I small-cell lung cancer (SCLC) and excellent performance status 
may be considered for resection following extensive staging investigation as part of a 
multimodality treatment regimen. 
(C)
Section Recommendation Grade
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2.6.1.1 Preoperative chemoradiotherapy
For patients with non-small cell lung cancer (NSCLC) who are suitable for surgery, do not 
offer neoadjuvant chemoradiotherapy outside a clinical trial. 
(B)
2.6.1.2 Preoperative chemotherapy
Following discussion at a multidisciplinary team meeting, appropriate patients with NSCLC 
who are suitable for surgery can be considered for neoadjuvant chemotherapy. 
(A)
2.6.2.1 
Concurrent chemoradiotherapy should be administered to patients with locally advanced 
NSCLC (suitable for radical radiotherapy) who have a good performance status (0-1). 
(A)
2.6.3.1 
Induction or consolidation chemotherapy are not routinely recommended for patients 
receiving concurrent radical chemoradiotherapy. 
(B)
2.6.4.1 Effectiveness of first-line cytotoxic chemotherapy
In patients with a good performance status (PS) (i.e. Eastern Cooperative Oncology Group 
[ECOG] level 0 or 1) and stage IV NSCLC, a platinum-based chemotherapy regimen is 
recommended based on the survival advantage and improvement in quality of life (QOL) 
over best supportive care (BSC).
(A)
2.6.4.2 Effectiveness of first-line cytotoxic chemotherapy
In patients with stage IV NSCLC and a good performance status, two-drug combination 
chemotherapy is recommended. The addition of a third cytotoxic chemotherapeutic agent 
is not recommended because it provides no survival benefit and may be harmful. 
(A)
2.6.4.3 Effectiveness of first-line cytotoxic chemotherapy
In patients receiving palliative chemotherapy for stage IV NSCLC, it is recommended that 
the choice of chemotherapy is guided by histological type of NSCLC. 
(B)
2.6.4.4 Effectiveness of first-line cytotoxic chemotherapy 
Bevacizumab plus platinum-based chemotherapy may be considered an option in carefully 
selected patients with advanced NSCLC. Risks and benefits should be discussed with 
patients before decision making. 
(B)
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2.6.4.5 Effectiveness of first-line targeted therapy
First-line single agent EGFR tyrosine kinase inhibitors (TKI) should be offered to patients 
with sensitising EGFR mutation positive NSCLC. Adding combination chemotherapy to TKI 
confers no benefit and should not be used. 
(A)
2.6.4.6 Effectiveness of first-line targeted therapy 
Crizotinib should be considered as first-line therapy in patients with ALK positive NSCLC 
tumours. 
(B)
2.6.5.1
In patients with stage IV non-squamous NSCLC who do not experience disease progression 
and have a preserved performance status after 4-6 cycles of platinum-based therapy, 
treatment with maintenance pemetrexed is suggested. 
(B)
2.6.5.2 
In patients with stage IV NSCLC, switch maintenance therapy with chemotherapy agents 
other than pemetrexed has not demonstrated an improvement in overall survival and is not 
recommended. 
(B)
2.6.5.3 
In patients with stage IV NSCLC who do not experience disease progression after 4-6 
cycles of platinum-based double agent chemotherapy, there is insufficient evidence to 
recommend maintenance therapy with erlotinib. 
(B)
2.6.6.1 
In elderly patients (age 70-79 years) with stage IV NSCLC who have good performance 
status and limited co-morbidities, treatment with a platinum doublet chemotherapy is 
recommended. 
(B)
2.6.6.2 
In patients with stage IV NSCLC with a performance status of 2, single agent chemotherapy 
may be considered. Platinum doublet chemotherapy is suggested over single agent 
chemotherapy if the performance status of 2 is cancer related rather than co-morbidity 
associated. 
(B)
2.6.6.3 
Unfit patients of any age (performance status (3-4)) do not benefit from cytotoxic 
chemotherapy. However if patients harbor an EGFR or ALK mutation positive tumour, they 
may be considered for treatment with targeted therapies.
(C)
2.6.7.1 
Second-line systemic anticancer therapy (SACT) with single agent drugs should be 
considered. The choice of agent to be used should be made on a case by case basis taking 
into account previous treatment, mutation status and co-morbidities. 
(B)
2.6.8.1 
In patients with either limited-stage or extensive-stage small-cell lung cancer (SCLC), 
platinum-based chemotherapy with either cisplatin or carboplatin plus etoposide is 
recommended. 
(A)
2.6.8.2 
Non-platinum combinations can be considered in patients with limited-stage and extensive-
stage SCLC. 
(A)
2.6.9.1 
There is no data to support maintenance therapy in limited-stage or extensive-stage SCLC. 
(C)
2.6.10.1
In patients with relapsed refractory SCLC, second-line therapy should be considered. 
(B)
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Re-initiation of the previously administered first-line chemotherapy regimen is 
recommended in patients with SCLC who relapse greater than six months from completion 
of initial chemotherapy. 
(B)
2.6.10.3 
Single agent chemotherapy should be considered in patients with primary refractory SCLC 
to maintain or improve quality of life. 
(B)
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2.7.1.1 
Every patient with early stage disease (T1-T2 N0 M0) should be evaluated for fitness for 
surgery. If unfit for surgery, or surgery is declined, patients should be considered for radical 
treatment, preferably SBRT/SABR or radical radiotherapy.
(A)
2.7.1.2 
Radiofrequency ablation (RFA) can be considered for patients with clinical stage Ia tumours 
who are not suitable for surgery following discussion at a multidisciplinary team meeting. 
(Refer to Clinical question 2.2.3). 
(D)
2.7.2.1 
In patients receiving combined chemoradiotherapy standard fractionation should be used 
to deliver a radical dose equivalent to 60 – 66 Gy.
(A)
2.7.2.2 
When a radical dose is considered 3D-CRT is the minimum technique to be used. 
(B)
2.7.2.3 
When available, CHART can be considered in patients with non-operable stage I-III non-
small cell lung cancer (NSCLC) not receiving chemotherapy. 
(A)
2.7.3.1 
Perform three-dimensional treatment planning in patients undergoing radical thoracic 
radiotherapy. 4DCT should be performed where available. 
(B)
2.7.3.2 
The dose volume parameters for the organs at risk (e.g. oesophagus, lung) need to be taken 
into account. It is prudent to limit V20 to ≤30–35% and mean lung dose to ≤20–23 Gy (with 
conventional fractionation) if one wants to limit the risk of radiation pneumonitis to ≤20% 
in definitively treated patients with NSCLC.
(B)
2.7.4.1 
In patients with R1 resection, regardless of N status, postoperative radiotherapy (PORT) 
should be proposed sequentially delivering a radical dose of 60 Gy in 30 fractions. 
(B)
2.7.4.2 
In patients with a pN2 stage and a complete resection there is no consensus to the benefit 
of PORT. If considered, PORT should be delivered at a dose of 50 Gy standard fractionation. 
(B)
2.7.4.3 
PORT is not indicated in patients with a complete resection R0 and N0 disease. (B)
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2.7.5.1 
Consolidation prophylactic cranial irradiation (PCI) is recommended in patients with limited-
stage small-cell lung cancer (SCLC) having a response to chemoradiotherapy.
(A)
2.7.5.2 
In combined modality care, thoracic radiotherapy is recommended in patients with limited-
stage SCLC and should be initiated as early as possible. 
(A)
2.7.5.3 
Consolidation PCI is recommended in patients with extensive-stage SCLC having a response 
to chemotherapy. 
(A)
2.7.5.4 
Consolidation thoracic radiotherapy may be considered in patients with extensive-stage 
SCLC having a response to chemotherapy. 
(A)
Section Recommendation Grade
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2.8.1.1 
Patients with stage IV non-small cell lung cancer (NSCLC) should be offered concurrent 
specialist palliative care and standard oncological care at initial diagnosis. (B)
Good practice point
Recommended best practice based on the clinical experience of the Guideline Development Group.
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2.2 Radiology
The following are responsible for implementation of the radiology recommendation:
While the CEO, General Manager and the Clinical Director of the hospital have corporate responsibility 
for the implementation of the recommendations in this National Clinical Guideline, each member of the 
multidisciplinary team is responsible for the implementation of the individual guideline recommendations 
relevant to their discipline.
The literature used in the development of this guideline was based on the 7th edition of the Lung 
Cancer TNM staging system. The 8th edition of the TNM staging system was published in December 
2016 (Brierley et al., 2016), this may lead to changes in recommendations over time, which should be 
taken into consideration at multidisciplinary team meetings. 
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Clinical question 2.2.1
In non-small cell lung cancer (NSCLC) patients with mediastinal and hilar adenopathy, what is the 
efficacy of CT (contrast and non-contrast) and PET-CT in the diagnosis of lung cancer?
Evidence summary
Two clinical guidelines (SIGN, 2014, NICE, 2011), and a Cochrane meta-analysis (Schmidt-Hansen et al., 
2014) addressed this clinical question. 
Two International guidelines (SIGN, 2014, NICE, 2011) recommend that patients with suspected lung 
cancer should undergo a contrast enhanced computed tomography (CT) (See Figure 2 ‘Staging algorithm 
in patients with suspected lung cancer’.)
 “Contrast enhanced CT scanning of the chest and abdomen is recommended in all patients with 
suspected lung cancer, regardless of chest X-ray results.” [SIGN, 2014]
 “Patients with known or suspected lung cancer should be offered a contrast enhanced chest CT scan 
to further the diagnosis and stage the disease. The scan should also include the liver and adrenals.” 
[NICE, 2011]
Hilar nodes (N1) 
The reliability of CT, magnetic resonance imaging (MRI) and thoracoscopy in staging N1 nodes is poor 
(Roberts et al., 1999, Detterbeck and Jones, 2001, Glazer et al., 1985, Wain, 1993). This may be a concern 
if radical radiotherapy is being considered and the primary tumour is distant from the hilum. (SIGN, 2014) 
CT scanning of mediastinal nodes (N2/3) 
For all categories of patients with lung cancer, the reliability of CT in the assessment of mediastinal nodes 
is poor with average false positive and negative rates of 45% and 13% respectively (Detterbeck et al., 
2001a). The false negative rate is higher with central tumours and adenocarcinomas (22% and 19%). 
(SIGN, 2014) 
PET scanning of mediastinal nodes (N2/3) 
18F-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography (FDG PET-CT) is 
more accurate than CT in detecting mediastinal nodal metastases in patients with NSCLC (Birim et al., 
2005). The false negative rate of FDG PET in mediastinal nodes of 10 mm in short axis diameter on CT was 
very low (5%) (de Langen et al., 2006). (SIGN, 2014) 
The false negative rate of FDG PET in mediastinal nodes >15 mm in short axis diameter on CT was 
relatively high (21%) (de Langen et al., 2006). These patients should have mediastinal nodal sampling 
before radical surgery, unless FDG PET-CT reveals distant metastases. 
FDG PET-CT staging may be limited by the pathology type, metabolic activity and location of the primary 
tumour, and status of the hilar nodes. Mediastinal nodal sampling may be considered in patients with 
central tumours, low FDG uptake in the primary tumour, PET positive N1 node, or enlarged nodes on CT 
(ACCP, 2007, De Leyn et al., 2007). (SIGN, 2014) 
The specificity of FDG PET in mediastinal nodal staging is approximately 80% (Silvestri et al., 2007). Given 
a relatively high false positive rate, FDG PET positive mediastinal nodes should be confirmed with nodal 
sampling, if this will alter management (Silvestri et al., 2007). (SIGN, 2014)
A Cochrane report (Schmidt-Hansen et al., 2014) included 45 prospective and retrospective studies 
that assessed the diagnostic accuracy of integrated PET-CT for diagnosing N2 disease in patients with 
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suspected resectable NSCLC. Two primary analyses were conducted as the criteria for test positivity – 
activity > background and SUVmax ≥ 2.5. The summary sensitivity and specificity estimates for activity > 
background test positivity were 77.4% (95% CI 65.3 to 86.1) and 90.1% (95% CI 85.3 to 93.5), respectively. 
The summary sensitivity and specificity estimates for SUVmax ≥ 2.5 were 81.3% (95% CI 70.2 to 88.9) 
and 79.4% (95% CI 70 to 86.5), respectively. Substantial heterogeneity was observed in both analyses. 
The study concluded that the sensitivity and specificity although reasonable, is insufficient to allow 
management based on PET-CT alone. PET-CT should form part of a clinical pathway supported by other 
investigations and cannot be used as a stand-alone test.
Recommendation 2.2.1.1 Grade
Contrast enhanced CT scanning of the chest and upper abdomen to include the entire 
liver is recommended in all patients with suspected lung cancer, regardless of chest X-ray 
results.
B
Recommendation 2.2.1.2 Grade
A tissue diagnosis of lung cancer should not be inferred from CT appearances alone. D
Recommendation 2.2.1.3 Grade
PET-CT is recommended for mediastinal and hilar lymph node staging in patients with 
potentially radically treatable non-small cell lung cancer (NSCLC) prior to invasive staging.
C
Recommendation 2.2.1.4 Grade
In patients with PET activity in a mediastinal lymph node and normal appearing nodes 
by CT (and no distant metastases), sampling of the mediastinum is recommended over 
staging by imaging alone. 
C
Good practice point
In the presence of hilar and mediastinal PET positive adenopathy the highest stage node should be 
biopsied to confirm metastic spread.
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Clinical question 2.2.2
In patients with peripheral lung nodules, what is the efficacy of the following tests in the diagnosis of 
lung cancer?
 -  Percutaneous fine needle aspiration (FNA) and transthoracic needle biopsy (TTNB)
 - Guided bronchoscopy 
 - Video-assisted thoracoscopic surgery (VATS)
Evidence summary 
Two clinical guidelines (SIGN, 2014, NICE, 2011), a meta-analysis (Wang Memoli et al., 2012) and a 
systematic review (Yao et al., 2012) addressed this clinical question. 
Percutaneous fine needle aspiration and Transthoracic needle biopsy
Transthoracic needle biopsy is used to obtain diagnostic samples from lesions that are not accessible via 
the bronchial tree and where there is no obvious lymph node involvement. This is usually where there 
are one or more peripheral lesions. CT is used to guide biopsy where lesions are in difficult to reach 
locations or where they are completely surrounded by aerated lung. Ultrasound is used where the lesion 
abuts the chest wall and is visible on ultrasound. (NICE, 2011)
Percutaneous FNA/biopsy is a highly sensitive technique for diagnosing lung cancer (sensitivity of 88–
92%) (Schreiber and McCrory, 2003, Detterbeck and Rivera, 2001b). Fine needle aspirations can be guided 
by fluoroscopy, ultrasound, CT or MRI. Larger cutting needles can also be used to obtain biopsy cores of 
intact tissue for histology. Sensitivity is greater for peripheral lung lesions than fibre optic bronchoscopy 
(Detterbeck and Rivera, 2001b). There is a high false negative rate (25%) resulting in limited ability 
to confirm a benign diagnosis. This may be improved by using core biopsies for histology rather than 
aspirates for cytology (Detterbeck and Rivera, 2001b). (SIGN, 2014) 
Yao et al. (2012) performed a systematic review which compared fine needle aspiration biopsy (FNA) with 
core-needle biopsy (CB) for diagnostic characteristics and yields for diagnosing lung cancer in patients 
with lung lesions. For overall diagnostic characteristics (benign vs. malignant) of FNA and CB, the ranges 
of sensitivity, specificity and of accuracy are displayed in Table 1. For specific diagnostic characteristics 
of FNA and CB (identifying the histologic subtype of malignancies or the specific benign diagnoses), the 
ranges of sensitivity, specificity and of accuracy are displayed in Table 2. Compared with FNA, CB did not 
result in a higher complication rate (pneumothorax or haemoptysis). 
Table 1. Overall diagnostic characteristics (benign vs. malignant) of FNA and CB
Fine needle aspiration biopsy Core-needle biopsy
Sensitivity 81.3%-90.8% 85.7%-97.4%
Specificity 75.4%-100.0% 88.6%-100.0%
Accuracy 79.7%-91.8% 89.0%-96.9%
Table 2. For specific diagnostic characteristics of FNA and CB
Fine needle aspiration biopsy Core-needle biopsy
Sensitivity 56.3%-86.5% 56.5%-88.7%
Specificity 6.7%-57.1% 52.4%-100.0%
Accuracy 40.4%-81.2% 66.7%-93.2%
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Guided bronchoscopy
A recent meta-analysis (Wang Memoli et al., 2012) was undertaken to determine the overall diagnostic 
yield of guided bronchoscopy using one or a combination of electromagnetic navigation bronchoscopy 
(ENB), virtual bronchoscopy (VB), radial endobronchial ultrasound (R-EBUS), ultrathin bronchoscope, 
and guide sheath. A total of 3,052 lesions from 39 studies were included. The pooled diagnostic yield 
was 70%, which is higher than the yield for traditional transbronchial biopsy. The yield increased as 
the lesion size increased. The pneumothorax rate was 1.5%, which is significantly smaller than that 
reported for transthoracic needle aspiration (TTNA). The results showed that the diagnostic yield of 
guided bronchoscopic techniques is better than that of traditional transbronchial biopsy. Although the 
yield remains lower than that of TTNA, the procedural risk is lower. However guided bronchoscopy 
allows both sampling of mediastinal lymph nodes and peripheral lung nodules in appropriately selected 
patients during the same procedure. Guided bronchoscopy may be an alternative or be complementary 
to TTNA for tissue sampling of pulmonary nodules, but further study is needed to determine its role in 
the evaluation of peripheral pulmonary lesions. 
Flexible bronchoscopy has a lower diagnostic sensitivity for peripheral lesions compared with central 
lesions. Fluoroscopy may improve the diagnostic yield of bronchoscopy in sampling peripheral lesions but 
diagnostic yield remains lower than TTNA/biopsy (Detterbeck and Rivera, 2001a, Schreiber and McCrory, 
2003). (SIGN, 2014)
Video-assisted thoracoscopic surgery
VATS provides a highly sensitive (97–100%) method of obtaining histological and cytological material 
for confirmation of the diagnosis of lung cancer in patients with pleural effusions or peripheral lesions 
where this has not been possible to achieve by other less invasive means. It is also a sensitive method of 
obtaining material intraoperatively prior to definitive resection (Mack et al., 1993, Mitruka et al., 1995). It 
has a low complication rate (0.8% open conversion rate). (SIGN, 2014)
VATS should be performed by a well trained thoracic surgeon with extensive open experience in a 
recognised VATS unit (Ferguson and Walker, 2006). (SIGN, 2014)
While the above options are acceptable (see Figure 2 – 2.2.9 Staging algorithm for patients with 
suspected lung cancer), they will depend on multiple factors including; patient comorbidities, patient 
preference, local availability and expertise and size and location of the nodule. 
Recommendation 2.2.2.1 Grade
Percutaneous FNA, TTNB, guided bronchoscopy and VATS are all appropriate first-line 
modalities for tissue diagnosis of peripheral lung nodules.
C
Recommendation 2.2.2.2 Grade
While percutaneous TTNA/biopsy has a higher diagnostic yield, bronchoscopy (including 
guided approaches where available) may provide a diagnosis for peripheral lesions. 
B
Good practice point
In the presence of hilar and mediastinal PET positive adenopathy the highest stage node should be 
biopsied to confirm metastatic spread.
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Clinical question 2.2.3
In NSCLC patients with early stage disease who are high risk surgery candidates, what is the 
effectiveness of ablative techniques? 
Evidence summary 
A clinical guideline (Lim et al., 2010) and two retrospective studies (Lanuti et al., 2012, Hiraki et al., 2011) 
addressed this clinical question.
Radiofrequency ablation (RFA) for primary lung tumours has developed as a minimally invasive treatment 
for both radical treatment and palliation. It is well tolerated and complication rates are low. The treatment 
can be delivered in a single session, usually requiring only a short admission. RFA is suitable for small 
tumours, usually of 3 cm diameter or less, although larger lesions may be considered suitable in certain 
circumstances. (Lim et al., 2010) 
No data have been published so far on the combination of RFA with chemotherapy for early stage non-
small cell lung cancer. (Lim et al., 2010) 
Lanuti et al. (2012) performed 55 ablations in 45 patients (age, 51 to 89 years) with stage I NSCLC. At a 
median follow-up of 32 months, locoregional recurrence (LRR) occurred in 21 (38%) within a mean of 
12±10 (range, 1-44) months from RFA. Recurrence was observed locally in the tumour bed in 18 (33%), 
in regional nodes in 4 (7%), and distant in 2 (4%). The mean maximal tumour diameter was 2.3±1.3 
(range, 0.7 to 4.5) cm. In tumours exceeding 3 cm, 10 (80%) were associated with LRR. Recurrent lesions 
were treated with repeat RFA (5), radiotherapy (8), chemoradiotherapy (5), and chemotherapy (2). 
Local control was achieved by repeat RFA in 2 of 5 (40%) or by radiotherapy in 8 lesions (100%), with 2 
regional nodal failures (median follow-up, 40±13 months). Overall survival among patients who did or 
did not experience LRR was similar (32% to 35%). Repeat RFA was not associated with any significant 
complications or procedure-related 30-day mortality. The authors concluded lung RFA is associated with 
increased rates of local failure in tumours exceeding 3 cm and in contact with larger segmental vessels. 
However, patients with local failure can be promptly salvaged with stereotactic ablative radiation therapy 
(SBRT/SABR) or repeat RFA, without detriment to overall survival. 
A retrospective cohort study (Hiraki et al., 2011) comprising of 50 non-surgical candidates (29 men and 21 
women; mean age, 74.7 years) with clinical stage I (Ia, n = 38; Ib, n = 12) histologically proven non–small 
cell lung cancer treated a total of 52 tumours with 52 ablation sessions. The median follow-up period was 
37 months. Local progression was observed in 16 (31%) of the 52 tumours. The median survival time was 
67 months. The overall, cancer-specific, and disease-free survivals were 94%, 100%, and 82% at 1 year, 
86%, 93%, and 64% at 2 years, and 74%, 80%, and 53% at 3 years, respectively. The authors concluded 
RFA of clinical stage I non–small cell lung cancer was minimally invasive and provided promising patient 
survival, although the local efficacy needs to be improved.
Recommendation 2.2.3.1 Grade
In patients with clinical stage Ia tumours who are high risk surgical candidates, ablative 
techniques may be considered to achieve local control. 
D
Good practice point
Radiofrequency ablation should only be considered for patients following discussion at a 
multidisciplinary team meeting.
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Clinical question 2.2.4
For patients with NSCLC who have undergone surgical resection or radiotherapy with curative intent, 
is there a role for imaging surveillance?
Evidence summary 
A meta-analysis (Calman et al., 2011) addressed this clinical question.
A meta-analysis examined the role of follow-up in patients with lung cancer (Calman et al., 2011). The 
study included eight observational studies and one randomised trial, the primary outcomes were overall 
survival and survival comparing symptomatic and asymptomatic recurrence. Six studies examined survival 
in patients with lung cancer comparing more intensive versus less-intensive follow-up programmes 
(Benamore et al., 2007, Moore et al., 2002, Sugiyama et al., 2008, Younes et al., 1999, Virgo et al., 1995, 
Zieren et al., 1994). The studies of follow-up care after potentially curative resection included patients 
with stages I to III disease, reflecting the stage of disease deemed appropriate for curative intent 
treatment. They showed a general trend for improvement in survival favoured more intensive follow-
up: Hazard Ratio (HR) 0.83 (0.66 –1.05), but this was not statistically significant (p=0.13). Between-study 
heterogeneity was low. High rates of relapse (between 21% and 71%) were reported even when curative 
treatment was intended. In the curative intent subgroup, all the studies found that asymptomatic 
recurrence was associated with a significantly longer survival time: HR 0.61 (0.50–0.74) (p<0.01), with 
a low level of heterogeneity. The study concluded that there is scope for further research in lung cancer 
follow-up of patients after different treatment regimes. 
Recommendation 2.2.4.1 Grade
Consider close follow-up for patients who have undergone treatment with curative intent 
(including surgery and radiotherapy), to include periodic radiological evaluation with CT.
C
Good practice point
The evidence for this practice is limited and the optimal scanning interval remains to be determined.
Good practice point
Schedule choice of radiological investigation should be discussed at multidisciplinary team meeting, 
and follow-up should include clinical evaluation with consideration of symptoms, quality of life, co-
morbidities and smoking cessation (see Tools on smoking cessation in Appendix 3: Summary of the tools 
to assist in the implementation of this National Clinical Guideline).
Good practice point
Patients should be advised of the benefits of smoking cessation.
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Clinical question 2.2.5
For patients with NSCLC which of the following tests is most accurate for detecting metastatic spread 
to indeterminate adrenal nodules/masses: chemical shift MRI, non-contrast CT, PET-CT? 
Evidence summary 
A current guideline (SIGN, 2014) addressed this clinical question. 
An adrenal adenoma can be reliably diagnosed by chemical shift magnetic resonance imaging (MRI), 
unenhanced computed tomography (CT) and delayed contrast-enhanced CT, making these suitable 
techniques for excluding metastases (Detterbeck et al., 2001b, Detterbeck et al., 2001c). Percutaneous 
needle biopsy has an overall complication rate of 8-9% with 3-4% having major complications (e.g. 
pneumothorax or significant haemorrhage) (Welch et al., 1994). At less than 5%, positron emission 
tomography (PET) scanning appears to have the lowest false positive (FP) and false negative (FN) rates for 
adrenal metastases (Detterbeck et al., 2001c). (SIGN, 2014) 
In a meta-analysis, FDG positron emission tomography-computed tomography (PET-CT) was found to 
be highly sensitive (97%) and specific (91%) in differentiating malignant from benign adrenal disease 
although studies were highly heterogeneous (Boland et al., 2011). Although FDG PET-CT interpretation 
criteria varied, there was no significant difference in their accuracy. Several primary studies also showed 
high sensitivity and specificity of FDG PET-CT in adrenal staging in lung cancers (Cho et al., 2011, Lu et al., 
2010). No trials of head- to-head comparison of PET-CT, MRI and ultrasound were identified. (SIGN, 2014) 
High FDG activity in an adrenal mass has high specificity for metastasis although there are variations in 
FDG PET-CT interpretation criteria (visual analysis, standardised uptake value (SUV), SUV ratio etc) (Boland 
et al., 2011, Lu et al., 2010, Brady et al., 2009, Kumar et al., 2004). EUS-FNA has also been shown to be 
effective in adrenal staging especially of the left adrenal gland (Bodtger et al., 2009, DeWitt et al., 2007). 
(SIGN, 2014)
Recommendation 2.2.5.1 Grade
A negative PET-CT reliably excludes adrenal metastases in patients with NSCLC. B
Recommendation 2.2.5.2 Grade
In NSCLC patients with PET-CT positive for adrenal metastasis, histological confirmation 
should be considered unless there is overwhelming clinical and imaging evidence of 
widespread metastatic disease. 
B
Recommendation 2.2.5.3 Grade
In NSCLC patients with indeterminate adrenal lesions on PET-CT further assessment with 
adrenal specific CT or MRI criteria may be considered. If non-invasive imaging findings are 
indeterminate, adrenal sampling such as EUS-FNA, percutaneous biopsy or adrenalectomy 
may be considered. 
D
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Clinical question 2.2.6
For patients with NSCLC which of the following tests is most accurate for detecting brain metastases: 
MRI, CT, PET-CT?
Evidence summary 
Two clinical guidelines (SIGN, 2014, Lim et al., 2010) addressed this clinical question. 
CT
Contrast-enhanced CT is the most commonly used imaging method to detect brain metastases and is 
as reliable as non-contrast-enhanced MRI (Hatter et al., 1994, Kormas et al., 1992, Ichinose et al., 1989, 
Ferrigno and Buccheri, 1994, Akeson et al., 1995, Taphoorn et al., 1989, Sze et al., 1988, Davis et al., 
1991). Contrast-enhanced MRI will detect more metastases than contrast-enhanced CT but does not 
detect metastases in a greater number of patients. CT of the head is not warranted in asymptomatic 
patients initially staged as clinical stage I-II (Kormas et al., 1992, Ichinose et al., 1989). In patients with N2 
disease who are still being considered for curative treatment, a CT scan of the head is warranted (Kormas 
et al., 1992). (SIGN, 2014) 
MRI
MRI of the brain detects more and smaller lesions than CT (Yokoi et al., 1999, Davis et al., 1991). The 
prevalence of cerebral metastases may be influenced by both stage and cell type. In patients with clinical 
features suggestive of intracranial pathology, CT may be the preferred first test because it is generally 
more easily accessed than MRI. However, a normal CT scan of the head should always be followed by 
an MRI owing to the better sensitivity of MRI. The use of routine MRI in staging patients with negative 
clinical evaluation findings has not been adequately studied. In the post-PET era it may be prudent to 
consider cerebral imaging, using contrast-enhanced MRI or CT if contraindicated, in patients with stage III 
non-small cell lung cancer. (Lim et al., 2010)
PET-CT
The main limitations of PET–CT scanning is that high glucose metabolism in the brain and kidney makes 
evaluation of metastases at these sites difficult and unreliable. (SIGN, 2014) 
Recommendation 2.2.6.1 Grade
Offer patients with signs/symptoms suggestive of brain metastases, a contrast-enhanced 
CT of the head followed by contrast-enhanced MRI if normal or MRI as an initial test. 
B
Recommendation 2.2.6.2 Grade
Offer MRI or CT of the head in patients with stage III NSCLC selected for treatment with 
curative intent. 
C
Recommendation 2.2.6.3 Grade
Do not routinely offer imaging of the brain in patients with stage I and II NSCLC. C
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Clinical question 2.2.7
For patients with NSCLC which of the following tests is most accurate for detecting bone metastases: 
isotope bone scan, CT, MRI, PET-CT? 
Evidence summary 
Clinical guidelines (SIGN, 2014, NICE, 2011, Lim et al., 2010) addressed this clinical question. 
Bone Scanning 
Four studies of low to moderate quality examined the accuracy of bone scintigraphy ± single-photon 
emission computed tomography (SPECT) in detecting bone metastases due to lung cancer (Cheran et 
al., 2004, Hetzel et al., 2003, Song et al., 2009, Takenaka et al., 2009). The sensitivity, specificities and 
accuracies of bone scintigraphy reported by these studies ranged between 52-96%, 83-99% and 81-95%, 
respectively. (NICE, 2011) 
Technetium-99m (99mTc) bone scanning has a high false positive rate (30 to 60%). Compared to 
conventional isotope bone scanning, PET-CT is more specific and sensitive (NICE, 2011). Tc-99m nuclear 
bone scans may be helpful if a PET scan is not indicated and symptoms of bone metastases are present. A 
positive bone scan should be confirmed by additional studies (e.g. X-ray, MRI, biopsy). (SIGN, 2014) 
PET is more sensitive in detecting bone metastases than conventional bone scintigraphy (Hsia et al., 
2002), and PET-CT is likely to be superior. The role of bone scintigraphy is limited to those with a high 
clinical suspicion of metastatic disease as a positive result will effectively exclude a patient from further 
radical treatment. (Lim et al., 2010) 
PET-CT 
Two studies of low-moderate quality examined the accuracy of PET-CT in M-staging (Song et al., 2009, 
Takenaka et al., 2009), and found that the sensitivities, specificities and overall accuracy of PET-CT to be 
between 94-96%, 86-99% and 89-98% for bone metastases detection, respectively (NICE, 2011). 
MRI 
One study (Takenaka et al., 2009) examined the ability of MRI to detect bone metastases and reported 
sensitivities, specificities and accuracies of 64-96%, 79-90% and 83-91%, respectively, for bone metastasis 
detection. (NICE, 2011) 
MRI has an established role in problem solving isolated boney abnormalities identified by other imaging.
Recommendation 2.2.7.1 Grade
For patients with NSCLC with suspected bone metastasis, evaluation with PET-CT is 
recommended over bone scintigraphy or CT. 
B
Recommendation 2.2.7.2 Grade
Bone scintigraphy is not necessary when PET-CT has not shown bone metastases. B
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Clinical question 2.2.8
In patients with limited-stage small-cell lung cancer (SCLC) on diagnostic CT, does PET-CT change 
management?
Evidence summary
A meta-analysis (Gould et al., 2001), two prospective studies (Brink et al., 2004, Bradley et al., 2004) and 
a focused review (Kalemkerian and Gadgeel, 2013) addressed this clinical question. 
A meta-analysis to estimate the diagnostic accuracy of FDG-PET for malignant focal pulmonary lesions 
(Gould et al., 2001) found FDG-PET is an accurate non-invasive imaging test for diagnosis of pulmonary 
nodules and larger mass lesions, although few data exist for nodules smaller than 1 cm in diameter. In 
current practice, FDG-PET has high sensitivity and intermediate specificity for malignancy.
Brink et al. (2004) performed FDG-PET in 120 consecutive patients with SCLC during primary staging. 
Complete agreement between FDG-PET results and other staging procedures was observed in 75 
patients. Differences occurred in 45 patients at 65 sites. In 47 sites the FDG-PET results were proven to 
be correct, and in ten, incorrect. In the remaining eight sites, the discrepancies could not be clarified. In 
14/120 patients, FDG-PET caused a stage migration, correctly upstaging ten patients to extensive disease 
and downstaging three patients by not confirming metastases of the adrenal glands previously suspected 
on CT. Only 1/120 patients was incorrectly staged by FDG-PET, owing to failure to detect brain metastases. 
In all cases the stage migration led to a significant change in the treatment protocol. Sensitivity of FDG-
PET was significantly superior to that of CT in the detection of extrathoracic lymph node involvement 
(100% vs 70%, specificity 98% vs 94%) and distant metastases except to the brain (98% vs 83%, specificity 
92% vs 79%). However, FDG-PET was significantly less sensitive than cranial MRI/CT in the detection of 
brain metastases (46% vs 100%, specificity 97% vs 100%). 
Bradley et al. (2004) prospectively performed pretreatment FDG-PET on 24 patients determined by 
conventional staging methods to have limited-stage SCLC. FDG-PET correctly upstaged two (8.3%) of 24 
patients to extensive-stage disease (95% CI, 1.03% to 27.0%). PET correctly identified tumour in each SCLC 
mass (primary or nodal) that was suspected on CT imaging, thus giving a lesion-based sensitivity relative 
to CT of 100%. PET identified unsuspected regional nodal metastasis in six (25%) of 24 patients, and the 
radiation therapy plan was significantly altered to include the PET-positive/CT-negative nodes within the 
high-dose region in each of these patients. The authors concluded FDG-PET has high sensitivity for SCLC and 
appears to be of value for initial staging and treatment planning of patients with presumed limited-stage 
disease.
A focused review published in the Journal of the National Comprehensive Cancer Network (Kalemkerian 
and Gadgeel, 2013) included 14 studies comparing pretreatment FDG-PET with conventional staging 
procedures for the initial staging of patients with SCLC. Seven studies evaluated changes in ini tial 
management based on PET-CT in patients with SCLC (Kamel et al., 2003, Bradley et al., 2004, Blum et 
al., 2004, Kut et al., 2007, van Loon et al., 2008, van Loon et al., 2010). Overall, PET find ings led to a 
change in initial management in 28% (range, 0%–47%) of 211 patients. Of the 59 patients with a change 
in management, 32% underwent an alteration in the general treatment plan as a result of stage shift, 
whereas 68% had changes in the extent of the radiation field for the treatment of limited-stage SCLC. The 
study concluded that PET-CT can improve both staging ac curacy and treatment planning in patients with 
SCLC, although further prospective studies are needed to fully define its role.
Recommendation 2.2.8.1 Grade
In patients with clinically limited-stage small-cell lung cancer (SCLC), PET-CT is suggested to 
exclude occult metastases.
C
Good practice point
MRI or CT of brain is also recommended.
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2.2.9 Staging algorithm for patients with suspected lung cancer
Negative Positive
Patient with suspected non-small cell lung cancer
Contrast enhanced CT of the chest (to include the entire liver) and PET
or
Whole body integrated PET-CT
Stage I*
T1N0M0
Peripheral  
lesion$
Central 
lesion$
Low suspicion of 
N2/3
MDT discussion 
on best approach 
to peripheral 
nodule work up
Surgical resection 
with mediastinal 
lymph node 
sampling/
dissection
Chemotherapy 
+/- radiotherapy 
(stage III); 
chemotherapy or 
targeted therapy 
(stage IV)
Bronchoscopy ±
EBUS-TBNA ±
EUS-FNA of
mediastinum
EBUS-TBNA±
EUS-FNA of
suspicious
lymph node
EBUS-TBNA±
EUS-FNA of
suspicious
mass
Intermediate 
suspicion of N2/3
Assessment of risk and biopsy size
High suspicion of 
N2/3
Negative
Additional
biopsy∆
Positive
Discrete nodal 
disease$
Bulky
nodal disease$
High suspicion of 
metastases
Stage Ib/II*
T2aN0M0, 
T2b/3 N0M0, 
T1-2a N1 M0
Stage III*
T3N1M0,
Any N2/3 M0,
Any T4
Stage IV*
Any T, Any  
N/M1a/b
Biopsy of 
suspicious 
metastasis
(safest site if 
multiple)
Figure 2. Staging algorithm in patients with suspected lung cancer. Modified from (Thomas and Gould, 2016).
For explanatory notes, see over page.
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* Please note that this refers to the 7th edition of the IASLC TNM staging system.
$ Definitions: 
Peripheral lesions Normal mediastinal and N1 nodes (<1cm) and a peripheral tumour (within outer 
two-thirds of hemithorax) (Silvestri et al., 2013).
Central lesions Normal mediastinal nodes (<1cm) but enlarged N1 nodes (≥ 1cm) or a central 
tumour (with proximal one-third of the hemithorax) (Silvestri et al., 2013).
Bulky nodal disease Correlates with the radiographic group A, as described in the American College of 
Chest Physicians (ACCP) evidence-based Clinical Practice Guidelines (Silvestri et al., 
2013). This group is defined as mediastinal infiltration, where the discrete lymph 
nodes cannot be distinguished or measured.
Discrete nodal disease Correlates to radiographic group B, as described in the American College of Chest 
Physicians (ACCP) evidence-based Clinical Practice Guideline (Silvestri et al., 2013). 
This group is defined as patients with mediastinal node enlargement, in whom the 
size of the discrete nodes can be measured.
∆ Mediastinoscopy/video assisted mediastinoscopy/extended cervical mediastinoscopy/oesophageal ultrasound
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2.3 Respiratory Medicine
Responsibility for the implementation of respiratory medicine recommendations
While the CEO, General Manager and the Clinical Director of the hospital have corporate responsibility 
for the implementation of the recommendations in this National Clinical Guideline, each member of the 
multidisciplinary team is responsible for the implementation of the individual guideline recommendations 
relevant to their discipline.
The literature used in the development of this guideline was based on the 7th edition of the Lung 
Cancer TNM staging system. The 8th edition of the TNM staging system was published in December 
2016 (Brierley et al., 2016), this may lead to changes in recommendations over time, which should be 
taken into consideration at multidisciplinary team meetings. 
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Clinical question 2.3.1
What is the efficacy of bronchoscopy in identifying lung cancer?
Evidence summary 
A clinical guideline (SIGN, 2014) addressed this clinical question. 
The value of bronchoscopy depends on the location of the primary tumour. Peripheral tumours in 
subsegmental bronchi may not be visible. (SIGN, 2014) 
The evidence base for the role of bronchoscopy in both central and peripheral tumours comes from two 
large systematic reviews (Detterbeck and Rivera, 2001a, Schreiber and McCrory, 2003). (SIGN, 2014) 
Central tumours 
Central lesions are defined as normal mediastinal nodes (<1cm) but enlarged N1 nodes (≥ 1cm) or a 
central tumour (within proximal one-third of the hemithorax) (Silvestri et al., 2013).
Flexible bronchoscopy has good diagnostic sensitivity (83% to 88%) for central lesions (Detterbeck and 
Rivera, 2001a, Schreiber and McCrory, 2003). Sampling using multiple techniques gives the highest 
diagnostic yield. As a single procedure, bronchial biopsy is the most reliable. Table 3 shows the variation 
in sensitivity for each method. (SIGN, 2014)
Table 3. Percentage diagnostic sensitivity in central tumours
Technique % Sensitivity
Detterbeck and Rivera, 2001a Schreiber et al., 2003
Biopsy 83 74
Brushing 64 59
Washing 48 48
All three modalities 83 88
Peripheral tumours 
Peripheral lesions are defined as normal mediastinal and N1 nodes (<1cm) and a peripheral tumour 
(within outer two-thirds of hemithorax) (Silvestri et al., 2013). 
Flexible bronchoscopy has a lower diagnostic sensitivity for peripheral lesions compared with central 
lesions (see Table 3 and Table 4). Fluoroscopy may improve the diagnostic yield of bronchoscopy in 
sampling peripheral lesions but diagnostic yield remains lower than percutaneous fine needle aspiration 
(FNA) biopsy (Detterbeck and Rivera, 2001a, Schreiber and McCrory, 2003). (SIGN, 2014)
Table 4. Percentage diagnostic sensitivity in peripheral tumours
Technique % Sensitivity
Detterbeck and Rivera, 2001a Schreiber et al., 2003
Biopsy 60 46
Brushing 48 52
Washing 37 43
All three modalities 66 69
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There is international consensus (Detterbeck et al., 2013, Sanchez de Cos et al., 2011, De Leyn et al., 
2014) that patients with a central lesion and radiographically normal mediastinum by PET-CT should 
undergo EBUS evaluation (See Figure 3 ‘Staging algorithm for patients with suspected lung cancer’).
Recommendation 2.3.1.1 Grade
Patients with central lesions (within proximal one-third of the hemithorax) alone 
(considered reachable by standard bronchoscopy) who are otherwise fit should undergo 
flexible bronchoscopy in order to establish a histological or cytological diagnosis.
B
Recommendation 2.3.1.2 Grade
Visible tumours should be sampled using more than one technique to optimise sensitivity. B
Recommendation 2.3.1.3 Grade
Consider bronchoscopy to provide a diagnosis for peripheral lesions, although percutaneous 
FNA biopsy has a higher diagnostic yield. 
B
Good practice point
In patients with central lesions and negative mediastinum on PET-CT, consideration should be given to 
EBUS evaluation of mediastinum before definitive therapy.
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Clinical question 2.3.2
In patients with mediastinal adenopathy: What is the efficacy of EBUS, EBUS/EUS and mediastinoscopy 
in the diagnosis of lung cancer? 
Evidence summary 
Two clinical guidelines (SIGN, 2014, Lim et al., 2010) addressed this clinical question. 
Endoscopic sampling of the mediastinal lymph nodes 
Assessing the mediastinum with endobronchial ultrasound fine needle aspiration (EBUS-FNA) and 
endoscopic ultrasound fine needle aspiration (EUS-FNA) offers a less invasive technique with higher 
sensitivity (94% vs 79%) and negative predicted probability (93% vs 86%) than surgical staging alone 
(Sharples et al., 2012). The technique is associated with low risk and less need for general anaesthesia 
and thoracotomy. The use of these techniques readily allows for repeat sampling of the mediastinum 
which is simpler than repeat mediastinoscopy (Yasufuku et al., 2011). (SIGN, 2014) 
Mediastinoscopy 
The indications for cervical mediastinoscopy have evolved with the increasing availability of PET, EBUS, 
EUS and broader selection criteria for surgery. With a sensitivity of 85% for PET imaging, many consider 
that confirmatory mediastinoscopy and lymph node biopsies are not required following a ‘negative’ 
PET. Microscopic N2 disease may have a better prognosis, but this will only be confirmed if appropriate 
lymph node sampling is performed. Although the specificity of PET is high, minimally invasive sampling 
followed by mediastinoscopy is indicated to screen for false positive results in order not to deny the 
small proportion of patients the potential of radical treatment. As broader selection criteria are in place, 
the clinical utility of pretreatment lymph node staging has evolved to assess the location and number 
of lymph stations that are involved rather than the presence or absence of mediastinal lymph node 
metastases. (Lim et al., 2010) 
Anterior mediastinotomy/mediastinoscopy 
Anterior mediastinotomy/mediastinoscopy may be used to establish a tissue diagnosis in selected 
patients presenting with mediastinal or hilar masses where this has not been achieved by other less 
invasive means (Best et al., 1987). (SIGN, 2014)
Recommendation 2.3.2.1 Grade
Endoscopic assessment of the mediastinal lymph nodes with EBUS-TBNA with or without 
EUS-FNA should be offered to patients with suspected lung cancer prior to mediastinoscopy. 
A
Good practice point
Negative EBUS does not entirely exclude nodal disease. Surgical staging is still indicated where EBUS-
TBNA (EBUS-FNA) is negative if clinical suspicion of mediastinal nodal disease remains high.
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Clinical question 2.3.3
In patients with pleural effusion and suspected lung cancer, what is the efficacy of pleural sampling in 
the diagnosis of lung cancer? 
Evidence summary 
A clinical guideline (SIGN, 2014) and a retrospective diagnostic study (Bielsa et al., 2008) addressed this 
clinical question.
Pleural aspiration is essential for accurate staging in patients with a pleural effusion. A pleural biopsy 
should be undertaken in patients with negative fluid cytology (Dales et al., 1990). Some patients may 
require thoracoscopic biopsy to confirm pleural malignancy as aspiration and closed biopsy alone may be 
insufficient. (SIGN, 2014)
In instances where the first cytological analysis is not conclusive, a retrospective analysis of 1,427 
patients with pleural effusion, including 466 patients with malignant pleural effusion (Bielsa et al., 2008) 
concluded that at least one more specimen should be submitted immediately for cytologic analysis and 
that delaying this secondary analysis will lead to a low diagnostic yield. 
Since cytological examination of aspirated effusion fluid may provide a cytological diagnosis, it should be 
performed, rather than fluid being discarded. When cytological examination fails to confirm malignancy, 
both radiologically guided biopsy procedures and thoracoscopic biopsy are equally effective with similar 
diagnostic yields (87.5–94.1%) (Metintas et al., 2010). (SIGN, 2014)
Recommendation 2.3.3.1 Grade
In patients being considered for active therapy, pleural effusion should be investigated 
with pleural aspiration. 
C
Recommendation 2.3.3.2 Grade
If pleural fluid cytology is negative, and treatment will change depending on the nature of the 
pleural fluid, pleural biopsy using image guided or thoracoscopic biopsy is recommended. 
D
Good practice point
Aim for 50 ml of pleural fluid and cell block preparation.
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Clinical question 2.3.4
What is the role of palliative interventions in the management of malignant airway obstruction? 
Evidence summary 
A clinical guideline (NICE, 2011) and an UpToDate® review (Herth et al., 2016) addressed this clinical 
question.
There are a range of treatments to prevent or treat airway obstruction including conventional 
external beam radiotherapy, endobronchial surgical debulking of the cancer, stenting and endoscopic 
endobronchial treatments. 
Choosing among the interventions is dependent upon factors including the nature of the lesion, predicted 
response to therapy, operator experience, available expertise, patient prognosis or health status, patient 
preference, and the ability of the patient to tolerate a selected procedure (Ernst et al., 2004, Bolliger et 
al., 2002, Ernst et al., 2003, Stephens and Wood, 2000, Seijo and Sterman, 2001). (Herth et al., 2016 - 
UpToDate®).
Endobronchial surgical debulking of the cancer can be undertaken using either rigid or flexible 
bronchoscopy. Advantages of rigid bronchoscopic procedures under general anaesthesia include the 
ability to remove large pieces of cancer, maintain adequate ventilation, and allow control of large volume 
haemorrhage. Nonetheless, flexible bronchoscopy is increasingly used for debulking procedures. These 
treatments are usually given to palliate symptoms and improve quality of life, but in some patients, relief 
of endobronchial obstruction will allow assessment for subsequent treatment with curative intent. (NICE, 
2011) 
Endobronchial techniques available are either a) used to debulk the cancer (brachytherapy, 
electrocautery, cryotherapy, thermal laser ablation and photodynamic therapy) or b) used to maintain/
re-establish airway patency (endobronchial stenting). Thermal ablation, surgical debulking and stent 
insertion were all favoured options where immediate relief of endobronchial obstruction is required, 
especially if there is a relatively large cancer. Endobronchial debulking procedures are generally not 
suitable in cases where the predominant cause of airway obstruction is extrinsic compression. In such 
cases airway stenting to maintain/re-establish airway patency and/or external beam radiotherapy aimed 
at treating the surrounding cancer may be considered. External beam radiotherapy is effective in around 
two-thirds of patients and is less invasive than the other endobronchial treatments (NICE, 2011).
Recommendation 2.3.4.1 Grade
In lung cancer patients with symptomatic (including breathlessness, haemoptysis and 
cough) malignant airway obstruction, any of the following therapeutic interventions may be 
considered: bronchoscopic debulking, tumour ablation modalities, airway stent placement 
and radiotherapy (external beam or brachytherapy). 
D
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2.3.5 Staging algorithm for patients with suspected lung cancer
Negative Positive
Patient with suspected non-small cell lung cancer
Contrast enhanced CT of the chest (to include the entire liver) and PET
or
Whole body integrated PET-CT
Stage I*
T1N0M0
Peripheral  
lesion$
Central 
lesion$
Low suspicion of 
N2/3
MDT discussion 
on best approach 
to peripheral 
nodule work up
Surgical resection 
with mediastinal 
lymph node 
sampling/
dissection
Chemotherapy 
+/- radiotherapy 
(stage III); 
chemotherapy or 
targeted therapy 
(stage IV)
Bronchoscopy ±
EBUS-TBNA ±
EUS-FNA of
mediastinum
EBUS-TBNA±
EUS-FNA of
suspicious
lymph node
EBUS-TBNA±
EUS-FNA of
suspicious
mass
Intermediate 
suspicion of N2/3
Assessment of risk and biopsy size
High suspicion of 
N2/3
Negative
Additional
biopsy∆
Positive
Discrete nodal 
disease$
Bulky
nodal disease$
High suspicion of 
metastases
Stage Ib/II*
T2aN0M0, 
T2b/3 N0M0, 
T1-2a N1 M0
Stage III*
T3N1M0,
Any N2/3 M0,
Any T4
Stage IV*
Any T, Any  
N/M1a/b
Biopsy of 
suspicious 
metastasis
(safest site if 
multiple)
Figure 3. Staging algorithm in patients with suspected lung cancer. Modified from (Thomas and Gould, 2016).
For explanatory notes, see over page.
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* Please note that this refers to the 7th edition of the IASLC TNM staging system.
$ Definitions:
Peripheral lesions Normal mediastinal and N1 nodes (<1cm) and a peripheral tumour (within outer 
two-thirds of hemithorax) (Silvestri et al., 2013).
Central lesions Normal mediastinal nodes (<1cm) but enlarged N1 nodes (≥ 1cm) or a central 
tumour (with proximal one-third of the hemithorax) (Silvestri et al., 2013).
Bulky nodal disease Correlates with the radiographic group A, as described in the American College of 
Chest Physicians (ACCP) evidence-based Clinical Practice Guidelines (Silvestri et al., 
2013). This group is defined as mediastinal infiltration, where the discrete lymph 
nodes cannot be distinguished or measured.
Discrete nodal disease Correlates to radiographic group B, as described in the American College of Chest 
Physicians (ACCP) evidence-based Clinical Practice Guideline (Silvestri et al., 2013). 
This group is defined as patients with mediastinal node enlargement, in whom the 
size of the discrete nodes can be measured.
∆ Mediastinoscopy/video assisted mediastinoscopy/extended cervical mediastinoscopy/oesophageal ultrasound
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2.4 Pathology
Responsibility for the implementation of pathology recommendations
While the CEO, General Manager and the Clinical Director of the hospital have corporate responsibility 
for the implementation of the recommendations in this National Clinical Guideline, each member of the 
multidisciplinary team is responsible for the implementation of the individual guideline recommendations 
relevant to their discipline.
The literature used in the development of this guideline was based on the 7th edition of the Lung 
Cancer TNM staging system. The 8th edition of the TNM staging system was published in December 
2016 (Brierley et al., 2016), this may lead to changes in recommendations over time, which should be 
taken into consideration at multidisciplinary team meetings. 
Pathology Terminology & Reporting
Guidance on the appropriate terminology for use in Biopsy/Cytological/Resections specimen reports is 
covered by the RCPath reporting proforma template (RCPath, 2016) and further detailed in the WHO 
Classification of Tumours of the Heart, Lung, Pleura Thymus and Heart (4th Edition, 2015). 
Lung resection specimens
When reporting lung resection specimens use the information/terminology of the current RCPath 
template (Appendix - Histopathology reporting proforma for lung cancer resection specimens). 
Lung biopsy/cytology specimens
When reporting lung biopsy/cytology specimens use the information/terminology of the current RCPath 
template (Appendix - Reporting proforma for lung cancer biopsy/cytology specimens.)
Good practice point
A comment should be included if there is insufficient tissue for molecular analysis in non-squamous 
non-small cell lung cancer (NSCLC).
Good practice point
The term bronchioloalveolar carcinoma (BAC) should be discontinued.
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Clinical question 2.4.1
a) What is the benefit of histopathological analysis for small-cell lung cancer (SCLC) vs non-small cell 
lung cancer (NSCLC)? 
b)  When should immunohistochemical analysis be performed? 
c)  What is the best panel(s) of immunohistochemical stains for NSCLC subtypes? 
Evidence summary
Clinical guidelines (Travis et al., 2011, SIGN, 2014) a diagnostic study (Bishop et al., 2010) and a review 
(Travis, 2002) addressed this clinical question.
a) Benefit of histopathological analysis for SCLC and NSCLC
Lung cancer can be divided into many subtypes, the most important distinction is between SCLC and 
NSCLC, this is important because of the major clinical differences in presentation, metastatic spread 
and response to therapy. Another important feature of the pathology of lung cancer is histologic 
heterogeneity, which consists of a mixture of histologic types that represents the derivation of lung 
cancer from a pluripotent stem cell. (Travis, 2002)
b) Purpose of immunohistochemical analysis 
Immunohistochemistry should be used in all NSCLC cases which cannot be sub-typed on morphological 
grounds. (SIGN, 2014) 
In cases where a specimen shows NSCLC lacking either definite squamous or adenocarcinoma 
morphology, immunohistochemistry may refine diagnosis (Travis et al., 2011). 
Immunohistochemistry has been routinely used for separating metastatic tumours from primary lung 
cancers especially in patients with no known primary tumours, it is also becoming more important in 
the classification of primary lung tumours. Indeed, recent advances in targeted therapies (e.g. tyrosine 
kinase inhibitors and angiogenesis inhibitors) have made the distinction between adenocarcinomas 
and squamous cell carcinomas of the lung even more important (Besse et al., 2007, Cohen et al., 2007, 
Herbst, 2006, Herbst and Sandler, 2008, Johnson et al., 2004, Lam and Watkins, 2007) because not only 
are tyrosine kinase inhibitors more efficacious in adenocarcinomas than in squamous cell carcinomas, but 
also the use of antiangiogenic modalities can be associated with life-threatening pulmonary haemorrhage 
in squamous cell carcinomas (Besse et al., 2007, Herbst, 2006). (Bishop et al., 2010)
c) Immunohistochemical panel(s) 
At the present time, thyroid transcription factor-1 (TTF-1) seems to be the single best marker for 
adenocarcinoma. TTF-1 provides the added value of serving as a pneumocyte marker that can help 
confirm a primary lung origin in 75 to 85% of lung adenocarcinomas (Motoi et al., 2008, Yatabe et al., 
2002, Lau et al., 2002). This can be very helpful in addressing the question of metastatic adenocarcinoma 
from other sites such as the colon or breast. Diastase-periodic acid Schiff or mucicarmine mucin stains 
may also be of value. p63 is consistently reported as a reliable marker for squamous histology and CK5/6 
also can be useful (Loo et al., 2010, Nicholson et al., 2010, Camilo et al., 2006, Wu et al., 2003, Chu and 
Weiss, 2002, Ordonez, 2000, Kaufmann and Dietel, 2000, Kargi et al., 2007, Khayyata et al., 2009). (Travis 
et al., 2011)
Napsin A appears to be a useful marker when used in combination with TTF-1 as it provides increased 
sensitivity and specificity for both classifying primary lung tumours as adenocarcinoma and for identifying 
lung origin in the setting of a metastatic adenocarcinoma (Bishop et al., 2010). 
It is possible that cocktails of nuclear and cytoplasmic markers (TTF-1/CK5/6 or p63/napsin-A) may allow 
for use of fewer immunohistochemical studies of multiple antibodies (Rossi et al., 2009a). (Travis et al., 
2011)
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Strategic use of small biopsy and cytology samples is important, i.e., use the minimum specimen necessary 
for an accurate diagnosis, to preserve as much tissue as possible for potential molecular studies (Suh et 
al., 2011). Methods that use substantial amounts of tissue to make a diagnosis of adenocarcinoma versus 
squamous cell carcinoma, such as large panels of immunohistochemical stains or molecular studies, may 
not provide an advantage over routine light microscopy with a limited immunohistochemical workup 
(Rossi et al., 2009b). (Travis et al., 2011)
Immunohistochemical stains to distinguish between primary lung adenocarcinoma and squamous cell 
carcinoma are p63, p40, CK 5/6 (present in squamous cell carcinoma) and TTF-1, Napsin A (present in 
adenocarcinoma).
Every effort should be made, during the diagnostic phase, to preserve tumour material for molecular 
biomarker analysis. (SIGN, 2014)
Recommendation 2.4.1.1 Grade
Distinguishing between small-cell carcinoma and non-small cell carcinoma of the lung is 
recommended. For challenging cases, a diagnostic panel of immunohistochemical assays 
is recommended to increase the diagnostic accuracy. 
B
Recommendation 2.4.1.2 Grade
In individuals with pathologically diagnosed non-small cell cancer (NSCLC), additional 
discrimination between adenocarcinoma and squamous cell carcinoma, even on cytologic 
material or small tissue samples is recommended. 
B
Good practice point 
Recommended immunohistochemical stains to distinguish between NSCLC/SCLC/Lymphoma include: 
Keratin, CD56, TTF – 1, CD45, Ki – 67 and synaptophysin. 
Good practice point
Use of neuron specific enolase (NSE) is not recommended. 
Good practice point
Recommended immunohistochemical stains to distinguish between primary lung adenocarcinoma and 
squamous cell carcinoma are p63, p40, CK 5/6 (present in squamous cell carcinoma) and TTF-1, Napsin 
A (present in adenocarcinoma). 
Good practice point
Judicious use of tissue is extremely important and non- discriminatory immunostains and levels should 
be avoided. 
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Clinical question 2.4.2
What is the efficacy of the following diagnostic tools in identifying and staging lung cancer? 
- ROSE at EBUS 
- Frozen section 
Evidence summary 
A clinical guideline (Travis et al., 2011), two randomised controlled trials (Oki et al., 2013, Trisolini et al., 
2011) and a diagnostic study (Marchevsky et al., 2004) addressed this clinical question. 
ROSE at EBUS
A randomised controlled trial (RCT) was conducted in 2013 (Oki et al., 2013) to evaluate the efficacy of 
rapid on-site evaluation (ROSE) during endobronchial ultrasound guided-transbronchial needle aspiration 
(EBUS-TBNA) in the diagnosis of lung cancer. One hundred and twenty patients suspected of having 
lung cancer with hilar/mediastinal lymphadenopathy were randomised to undergo EBUS-TBNA with or 
without ROSE. The sensitivity and accuracy for diagnosing lung cancer were 88% and 89% in the ROSE 
group, and 86% and 89% in the non-ROSE group, respectively. No complications were associated with 
the procedures. Additional procedures including EBUS-TBNA for lesions other than the main target lesion 
and/or transbronchial biopsy in the same setting were performed in 11% of patients in the ROSE group 
and 57% in the non-ROSE group (p<0.001). Mean puncture number was significantly lower in the ROSE 
group (2.2 vs. 3.1 punctures, p<0.001), and mean bronchoscopy time was similar between both groups 
(22.3 vs. 22.1 min, p=0.95). The authors concluded that ROSE during EBUS-TBNA is associated with a 
significantly lower need for additional bronchoscopic procedures and puncture number. 
In addition an RCT of 168 patients with enlarged lymph nodes were randomised to undergo TBNA with 
or without ROSE (Trisolini et al., 2011). There was no significant difference between the TBNA group 
and the ROSE group in terms of diagnostic yield (75% vs 78%, respectively; p=0.64), and percentage of 
adequate specimens (87% vs 78%, respectively; p=0.11). However, similar to the findings reported by Oki 
et al. (2013), the complication rate of bronchoscopy was significantly lower in patients undergoing on-site 
review (6% vs 20%; p=0.01), whereas the complication rate of TBNA was similar among the study groups. 
Frozen section 
For a limited resection to be adequate oncologically, a precise pre- and intra-operative diagnosis is 
critical. The accuracy of intra-operative frozen section analysis in determining whether small lung 
adenocarcinomas have an invasive component still needs to be defined. The predictive value of frozen 
section ranges from 93% to 100% but not all articles clearly report the accuracy of frozen section analysis 
(Yamato et al., 2001, Yamada and Kohno, 2004, Yoshida et al., 2005, Watanabe et al., 2005). In addition, 
evaluation of margins by frozen section may be problematic, especially when stapler cartridges have been 
used on both sides. Scraping or washing of staple lines with subsequent cytological analysis has been 
attempted (Higashiyama et al., 2003, Utsumi et al., 2010). When a sublobar resection is performed, frozen 
section analysis of an interlobar, hilar, or any suspicious lymph node is a useful staging evaluation, and 
when positive nodes are found, a lobectomy is indicated when there is no functional cardiopulmonary 
limitation. (Travis et al., 2011) 
Marchevsky et al., (2004) reviewed the frozen section diagnoses of 183 consecutive pulmonary nodules 
smaller than 1.5 cm in diameter and calculated the sensitivity, specificity, and predictive values of this 
diagnostic procedure. One hundred and seventy four nodules were correctly classified by frozen section 
as neoplastic or non-neoplastic, six lesions were diagnosed equivocally, and two neoplasms were missed 
owing to sampling errors. The sensitivities for a diagnosis of neoplasia were 86.9% and 94.1% for nodules 
smaller than 1.1 cm in diameter and measuring 1.1 to 1.5 cm, respectively. The diagnostic accuracy of 
frozen sections was significantly better in nodules larger than 1.0 cm in diameter (p=0.05). There were no 
false-positive diagnoses of malignancy, resulting in 100% specificity. 
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Intraoperative consultation with frozen section is a sensitive and specific procedure for the diagnosis of 
malignancy from small pulmonary nodules. The distinction between lepidic pattern adenocarcinoma and 
atypical adenomatous hyperplasia, and of small peripheral carcinoid tumours from other lesions, can be 
difficult by frozen section (Marchevsky et al., 2004).
Recommendation 2.4.2.1 Grade
Endobronchial ultrasound rapid on-site evaluation (EBUS ROSE) should be made available 
whenever resources permit. B
Recommendation 2.4.2.2 Grade
Consider intra–operative frozen section analysis in primary diagnosis when preoperative 
diagnosis is not available. C
Recommendation 2.4.2.3 Grade
In selected cases intra-operative frozen section analysis for staging may be considered. C
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Clinical question 2.4.3
In patients with NSCLC, how do cytological samples compare with tissue biopsy samples for tumour 
sub-typing, immunohistochemistry and predictive markers assessed by FISH or mutational analysis?
Evidence summary 
Two clinical guidelines (Travis et al., 2011, Lindeman et al., 2013) addressed this clinical question. 
Cytology is a powerful tool in the diagnosis of lung cancer, in particular in the distinction of 
adenocarcinoma from squamous cell carcinoma (Rivera et al., 2007). In a recent study of 192 preoperative 
cytology diagnoses, definitive versus favoured versus unclassified diagnoses were observed in 88% versus 
8% versus 4% of cases, respectively (Rekhtman et al., 2011). When compared with subsequent resection 
specimens, the accuracy of cytologic diagnosis was 93% and for definitive diagnoses, it was 96%. For the 
adenocarcinoma and squamous cell carcinoma cases, only 3% of cases were unclassified, and the overall 
accuracy was 96%. When immunohistochemistry was used in 9% of these cases, the accuracy was 100% 
(Rekhtman et al., 2011). (Travis et al., 2011)
Whenever possible, cytology should be used in conjunction with histology in small biopsies (Nicholson 
et al., 2010, Sigel et al., 2011). In another study where small biopsies were evaluated in conjunction with 
cytology for the diagnosis of adenocarcinoma versus squamous cell carcinoma versus unclassified non-
small cell lung cancer-not otherwise specified (NSCLC-NOS), the result for cytology was 70% versus 19% 
versus 11% and for biopsies, it was 72%, 22%, and 6%, respectively (Sigel et al., 2011). Still when cytology 
was correlated with biopsy, the percentage of cases diagnosed as NSCLC-NOS was greatly reduced to 
only 4% of cases (Sigel et al., 2011). In a small percentage of cases (<5%), cytology was more informative 
than histology in classifying tumours as adenocarcinoma or squamous cell carcinoma (Sigel et al., 2011). 
The factors that contributed the greatest to difficulty in a specific diagnosis in both studies were poor 
differentiation, low specimen cellularity, and squamous histology (Rekhtman et al., 2011, Sigel et al., 
2011). (Travis et al., 2011)
Small biopsies and/or cytologic samples including pleural fluids can be used for many molecular analyses 
(Rekhtman et al., 2011, Zhang et al., 2008, Wu et al., 2008, Li et al., 2008, Lim et al., 2009, Savic et al., 
2008, Miller et al., 2008, Kimura et al., 2006, Borczuk et al., 2004, Zudaire et al., 2008, Gordon et al., 
2003, Solomon et al., 2010, Asano et al., 2006, Otani et al., 2008). Epidermal growth factor receptor 
(EGFR) mutation testing and Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation testing are 
readily performed on these specimens (Rekhtman et al., 2011, Sigel et al., 2011, Zhang et al., 2008, Li et 
al., 2008, Lim et al., 2009, Savic et al., 2008, Miller et al., 2008, Kimura et al., 2006, Solomon et al., 2010, 
Asano et al., 2006, Otani et al., 2008). Formalin fixed paraffin-embedded samples can be used effectively 
for polymerase chain reaction-based mutation testing and for fluorescence in situ hybridisation (FISH) or 
chromogenic in situ hybridisation (CISH) testing for gene amplification and for immunohistochemistry. 
Cytology smears can be analysed for immunohistochemical and certain molecular studies, but it is far 
preferable if cell blocks are available. (Travis et al., 2011)
Specimen requirements for anaplastic lymphoma kinase fluorescence in situ hybridisation (ALK FISH) are 
generally similar to those for EGFR mutation testing: formalin fixation is acceptable, specimens should 
have enough cancer cells to analyse clearly, and DNA-damaging fixatives or acidic decalcifying agents 
should be avoided, as should specimens with abundant necrosis. Unlike EGFR mutation testing, however, 
FISH testing can be problematic when performed on alcohol fixed samples. (Lindeman et al., 2013)
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Recommendation 2.4.3.1 Grade
Cytology samples can be used to provide material suitable for both NSCLC sub-typing and 
some molecular analysis, provided the samples are appropriately handled and processed. B
Good practice point
When paired cytology and biopsy specimens exist, a review of both modalities is advised if there is 
discordance.
Good practice point 
In general, immunohistochemistry work-up should not be duplicated on both samples. 
Good practice point 
ALK FISH can be problematic when performed on alcohol-fixed samples.
48 | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
| A National Clinical Guideline
Clinical question 2.4.4
What are optimal formalin fixation times for future molecular diagnostics? 
Evidence summary 
A clinical guideline (Lindeman et al., 2013) addressed this clinical question. 
Processing specimens for epidermal growth factor receptor (EGFR) mutation testing 
The relatively broad time range of specimen fixation found in pathology practice usually has no effect 
on morphologic details, but longer durations of fixation adversely affect the quality of nucleic acid 
(Srinivasan et al., 2002). Fixation times of 6 to 12 hours for small biopsy samples and 8 to 18 hours for 
larger surgical specimens generally give best results, although expert consensus opinion is that fixation 
times of 6 to 48 hours should give acceptable results (Wolff et al., 2007, College of American Pathologists, 
2012). This is a generalisation, however, and the effect of extreme fixation times should be assessed by 
each laboratory during validation. This knowledge should be incorporated into the interpretation and 
reporting of molecular pathology results when fixation times are extreme. (Lindeman et al., 2013) 
Methods for anaplastic lymphoma kinase (ALK) testing 
Specimen requirements for anaplastic lymphoma kinase fluorescence in situ hybridisation (ALK FISH) are 
generally similar to those for EGFR mutation testing: formalin fixation is acceptable, specimens should 
have enough cancer cells to analyse clearly, and DNA-damaging fixatives or acidic decalcifying agents 
should be avoided, as should specimens with abundant necrosis. (Lindeman et al., 2013)
Recommendation 2.4.4.1 Grade
Fixation times of 6 to 12 hours for small biopsy samples and 8 to 18 hours for larger surgical 
specimens generally give best results, although expert consensus opinion is that fixation 
times of 6 to 48 hours should give acceptable results. 
D
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2.5 Surgery
Responsibility for the implementation of surgery recommendations
While the CEO, General Manager and the Clinical Director of the hospital have corporate responsibility 
for the implementation of the recommendations in this National Clinical Guideline, each member of the 
multidisciplinary team is responsible for the implementation of the individual guideline recommendations 
relevant to their discipline.
The literature used in the development of this guideline was based on the 7th edition of the Lung 
Cancer TNM staging system. The 8th edition of the TNM staging system was published in December 
2016 (Brierley et al., 2016), this may lead to changes in recommendations over time, which should be 
taken into consideration at multidisciplinary team meetings. 
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Clinical question 2.5.1
In patients with stage I & II non-small cell lung cancer (NSCLC) how does the extent of lung resection 
effect outcomes?
Evidence summary
A clinical guideline (SIGN, 2014) and a prospective, multicentre, randomised trial (Ginsberg and 
Rubinstein, 1995) addressed this clinical question. 
Lobectomy is an anatomical resection of the lung which includes resection of the lymphatic drainage, N1 
and N2 nodes.
Sublobar resections include segmentectomy and wedge resections and may not deliver complete 
lymphatic drainage with N1 clearance. Segmentectomy and wedge resection procedures are not 
consistently defined in the literature making comparative review of outcomes difficult to interpret. 
In 1995, the Lung Cancer Study Group reported on the only randomised trial of elective sublobar 
resection vs. lobectomy (Ginsberg and Rubinstein, 1995). This prospective, multicentre randomised 
trial compared limited resection with lobectomy for patients with peripheral T1 N0 non-small cell 
lung cancer documented at operation, 247 of 276 randomised patients were considered eligible for 
analysis. No significant differences were observed for all stratification variables, selected prognostic 
factors, perioperative morbidity, mortality, or late pulmonary function. In patients undergoing limited 
resection, there was an observed 75% increase in recurrence rates (p=0.02, one-sided) attributable to an 
observed tripling of the local recurrence rate (p=0.008 two-sided), an observed 30% increase in overall 
death rate (p=0.08, one-sided), and an observed 50% increase in death with cancer rate (p=0.09, one-
sided) compared to patients undergoing lobectomy (p=0.10, one-sided was the predefined threshold 
for statistical significance for this equivalency study). The authors concluded that when compared with 
lobectomy, limited pulmonary resection does not confer improved perioperative morbidity, mortality, or 
late postoperative pulmonary function. Because of the higher death rate and locoregional recurrence rate 
associated with limited resection, lobectomy still must be considered the surgical procedure of choice for 
patients with peripheral T1 N0 non-small cell lung cancer. 
Lobectomy is preferred to sub-lobar resection and segmentectomy is superior to non-anatomical wedge 
resection on the basis of a reduced recurrence rate (Ginsberg and Rubinstein, 1995), except in patients 
who are of marginal fitness (SIGN, 2014). 
Lobectomy remains the procedure of choice for fit patients. (SIGN, 2014)
Recommendation 2.5.1.1 Grade
For patients with clinical stage I and II non-small cell lung cancer (NSCLC) who are medically 
fit for surgical resection, a lobectomy rather than sublobar resection is recommended. 
B
Good practice point 
Offer more extensive surgery (bronchoangioplastic surgery, bilobectomy, pneumonectomy) if 
anatomically required to achieve clear margins.
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Clinical question 2.5.2
In patients with clinical stage I NSCLC undergoing lobectomy, how does video-assisted thoracic surgery 
(VATS) compare to thoracotomy? 
Evidence summary 
A clinical guideline (SIGN, 2014) addressed this clinical question.
Video-assisted thoracoscopic surgery in patients with stage I NSCLC is associated with a lower incidence 
of complications, less disturbance to the immune response, and a shorter hospital stay compared to open 
thoracotomy (Ng et al., 2007, Paul et al., 2010, Whitson et al., 2008, Flores et al., 2009). Survival rates at 
two and five years are comparable (Whitson et al., 2008, Flores et al., 2009, Yang et al., 2009). Patients 
over the age of 70 also had fewer complications following VATS (28% v 45%, p=0.04), shorter hospital 
stay (five days, range 2–20 v six days, range 2–27, p<0.001) and comparable survival rates (Cattaneo et 
al., 2008). All evidence identified related to stage I disease rather than later stages. VATS is comparable to 
open surgery for systematic node dissection in terms of numbers of nodes dissected, operative mortality, 
morbidity and recurrence (Watanabe et al., 2005). (SIGN, 2014)
Recommendation 2.5.2.1 Grade
For patients with clinical stage I NSCLC, video-assisted thoracic surgery (thoracoscopy) 
should be considered as an alternative to thoracotomy for anatomic pulmonary resection. 
B
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Clinical question 2.5.3
Which pulmonary function tests should be used to determine fitness for resection? 
Evidence summary 
Two clinical guidelines (SIGN, 2014, Lim et al., 2010) addressed this clinical question. 
Evaluation of lung function is an important aspect of preoperative assessment to estimate the risk of 
operative mortality and impact of lung resection on quality of life, especially in relation to unacceptable 
post-resection dyspnoea. (Lim et al., 2010) 
FEV
1
/D
LCO
 
Past studies have stated a cut-off of 40% for the post operative predictive (ppo) forced expiratory volume 
(FEV1) and carbon monoxide transfer factor (TLCO) for surgery. Many of these studies had small sample 
sizes (Lim et al., 2010). To increase resection rates it may be necessary to look at patients with ppo FEV1 
and TLCO of less than 30%. It may also be important to consider patients with poor FEV1s preoperatively, 
such as patients considered for lung reduction surgery (Lim et al., 2006). These patients would represent 
a select group and would need careful preoperative assessment which may involve perfusion scanning 
and pulmonary artery pressure measurement (Lim et al., 2010). (SIGN, 2014)
Patients who perform well at the six minute walk or shuttle test, but have ppo FEV1 or TLCO less than 30% 
have also been associated with good surgical outcomes. Surgery may be possible as a sub-lobar resection 
and VATS surgery may make surgery feasible in some patients (Ginsberg and Rubinstein, 1994). (SIGN, 
2014)
Patients with lung cancer present as a very heterogeneous group and all management decisions, including 
suitability for surgery, should be tailored on the basis of a multidisciplinary team meeting. The thoracic 
surgeon is a key member of the multidisciplinary team. (SIGN, 2014)
VO
2
 max 
A meta-analysis has confirmed the finding that lower levels of VO2 max are associated with increasing 
‘complications’ after lung resection (Benzo et al., 2007). However, numerous values have been used to 
define ‘prohibitive risk’ for lung surgery, and the studies are difficult to interpret owing to the widespread 
use of composite endpoints. When scrutinised, individual endpoints included lobar collapse, high levels 
of carbon dioxide tension (PCO2), arrhythmia and readmission to ICU. It is doubtful that many patients 
would consider the risk of developing these complications as ‘prohibitive’ for surgical resection. (Lim et 
al., 2010)
With sample sizes ranging from 8 to 160 patients (Benzo et al., 2007) and an average death rate of 2.6% 
for lobectomy, the discriminating cut-off points for VO2 max to predict death is likely to be poor and, 
without valid risk adjustment, it is not possible to estimate an independent contribution of VO2 max. 
The arbitrary use of cut-off values for defining patient groups with no adverse outcome carries a large 
degree of imprecision; for example, the 95% binomial CI of no adverse outcomes in a typical sample of 30 
patients would be 0-13.6%. (Lim et al., 2010)
Perhaps the best conducted study was the Cancer and Leukemia Group B (CALBG) Protocol 9238 in which 
403 patients were classified into low, high and very high risk groups. Of the 68 patients in the very high 
risk group (VO2 max <15 ml/ kg/min), surgery was only undertaken at the ‘physician’s discretion’ with an 
operative mortality rate of 4% and no difference in postoperative complication rate. A central message 
from this study was that, in patients in the very high risk subgroup who underwent lung resection, the 
median survival was 36 months compared with 15.8 months for those in the same risk group who did not 
undergo surgical resection (p<0.001) (Loewen et al., 2007). The evidence for cardiopulmonary exercise 
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testing providing a useful definition of ‘high risk’ is therefore limited and there are no data available to 
show how it can help predict unacceptable levels of postoperative dyspnoea. (Lim et al., 2010)
Stair Test 
A number of authors have reported on the association between stair climbing and surgical outcomes 
(Holden et al., 1992, Olsen et al., 1991, Von Nostrand et al., 1968, Girish et al., 2001, Brunelli et al., 
2002). However, the data are difficult to interpret as there is a lack of standardisation of the height of the 
stairs, the ceiling heights, different parameters used in the assessment (e.g. oxygen saturations, extent of 
lung resection) and different outcomes. (Lim et al., 2010)
Shuttle Walk 
The shuttle walk test is the distance measured by walking a 10 m distance usually between two cones at 
a pace that is progressively increased. This test has good reproducibility and correlates well with formal 
cardiopulmonary exercising testing (VO2 max) (Singh et al., 1994, Morgan, 1989). Previous British Thoracic 
Society (BTS) recommendations that the inability to walk 25 shuttles classifies patients as high risk has 
not been reproduced by a prospective study (Win et al., 2004). Some authors report that shuttle walk 
distance may be useful to stratify low-risk groups (ability to walk >400 m) who would not need further 
formal cardiopulmonary exercise testing (Win et al., 2006). (Lim et al., 2010)
Recommendation 2.5.3.1 Grade
Pulmonary function testing (spirometry, diffusion capacity, lung volume) should be 
performed in all patients being considered for surgical resection. 
C
Recommendation 2.5.3.2 Grade
Postoperative predictive values should be calculated using broncho-pulmonary segment 
counting. If a mismatch is suspected ventilation perfusion scan should be performed. 
C
Recommendation 2.5.3.3 Grade
Offer patients surgery if they have an FEV1 & DLCO within normal limits (postoperative 
predicted values >60%).
C
Recommendation 2.5.3.4 Grade
Patients with ppo-FEV1 and/or DLCO <30% should have formal cardiopulmonary exercise 
testing with measurement of VO2 max. 
C
Recommendation 2.5.3.5 Grade
Patients with ppo-FEV1 and/or DLCO >30% and <60% – supplementary functional exercise 
assessments should be considered. D
Recommendation 2.5.3.6 Grade
In patients with lung cancer being considered for surgery and a VO2 max <15mL/kg/min 
predicted, it is recommended that they are counselled about minimally invasive surgery, 
sublobar resections or non-operative treatment options for their lung cancer.
C
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Clinical question 2.5.4
In patients with lung cancer, how should non-pulmonary co-morbidity influence surgical selection?
Evidence summary 
A clinical guideline (Lim et al., 2010) and a validation study (Falcoz et al., 2007) addressed this clinical 
question. 
Patient demographics and risk-factors for lung cancer contribute to significant co-morbidities in our 
surgical candidate population. This has implications for surgical case selection and outcomes. 
For patients who had undergone prior coronary bypass surgery, the risk of death and myocardial 
infarction was observed to be reduced from 5.8% and 1.9% to 2.4% and 1.2%, respectively (Eagle et al., 
1997). (Lim et al., 2010) 
The current evidence base that guides clinical management of the specific thoracic surgical patient with 
coronary artery disease is limited. (Lim et al., 2010) 
Thoracoscore is a multifactorial risk assessment model to predict in-hospital mortality in various thoracic 
procedures. The model was first published by the French Society of Thoracic and Cardiovascular Surgery 
(Falcoz et al., 2007). Thoracoscore is recommended for use in the UK by the ‘British Thoracic Society’ and 
the ‘National Institute for Health and Care Excellence’ (NICE). However, a recent multicentre prospective 
study (Sharkey et al., 2015) aimed to evaluate Thoracoscore as a valid tool for use in patients undergoing 
lung resection at six UK centres. They found the mean thoracoscore was 2.66%, almost double the 
observed mortality of 1.38%. However, mean thoracoscore for the patients who died was statistically 
significantly higher than those who survived, 4.01% versus 2.64% (p<0.001). 
A history (including assessment of functional status), physical examination and resting ECG are 
prerequisites for cardiac risk assessment. All patients with an audible murmur or unexplained dyspnoea 
should also have an echocardiogram. The first step in cardiac risk assessment is to identify patients with 
an active cardiac condition, as they all require evaluation by a cardiologist and correction before surgery. 
(Lim et al., 2010) 
In patients who do not have an active cardiac condition, risk assessment is performed using the revised 
cardiac index.
Table 5, shows a validated model with receiver operator characteristic (ROC) area under the curve (AUC) 
of 0.81 (Lee et al. 1999). (Lim et al., 2010)
Table 5. Revised cardiac risk index
Number of Factors Risk of Major Cardiac Complication*
0 0.4% 
1 1% 
2 7% 
≥3 11% 
Risk factors: high-risk type of surgery (includes all thoracic surgery), ischaemic heart disease, history of 
congestive cardiac failure, history of cerebrovascular disease, insulin therapy for diabetes, preoperative serum 
creatinine >177 mmol/l. 
*Cardiac complications defined as myocardial infarction, pulmonary oedema, ventricular fibrillation or primary 
cardiac arrest, complete heart block. The risks have been quoted from the validation cohort. 
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Patients with ≤2 risk factors and good cardiac functional capacity (able to climb a flight of stairs without 
cardiac symptoms) can proceed to surgery without further investigations. Patients with poor cardiac 
functional capacity or with ≥3 risk factors should have further investigations to screen for reversible 
cardiac ischaemia (e.g. exercise stress testing, exercise thallium scan) and, if necessary, cardiology review 
prior to surgery. (Lim et al., 2010)
Recommendation 2.5.4.1 Grade
Lung cancer surgery remains the best opportunity for potential cure in patients with 
significant co-morbidity. Efforts to contain and manage that risk should start with 
preoperative scoring (thoracoscore) and should ideally include attendance at a preoperative 
assessment clinic, where practical. 
D
Recommendation 2.5.4.2 Grade
Seek a cardiology review in patients with an active cardiac condition or ≥3 risk factors or 
poor cardiac functional capacity. 
C
Recommendation 2.5.4.3 Grade
Offer surgery without further investigations to patients with ≤2 risk factors and good 
cardiac functional capacity. 
B
Good practice point 
All anatomically resectable patients should be seen by a surgeon before they are deemed surgically 
unfit.
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Clinical question 2.5.5
Should lung cancer surgery be offered to octogenarians?
Evidence summary 
A clinical guideline (British Thoracic Society, 2001) and a non-systematic review (Weinmann et al., 2003) 
addressed this clinical question. 
Most studies in octogenarians (80 years and over) are small and involve patients presenting with stage 
I disease treated by lobectomy or more limited resection. Earlier studies suggested a high perioperative 
mortality rate (Shirakusa et al., 1989) but more recent reports suggest this has fallen, reflecting a similar 
fall in operative mortality seen previously in less elderly patients (Tanita et al., 1995; Pagni et al., 1997). 
(British Thoracic Society, 2001)
A non-systematic review of 37 studies of surgery in the elderly with NSCLC (Weinmann et al., 2003) 
concluded that careful preoperative assessment of a patient including vigorous techniques of 
improvement of their physical and mental status are a must for a successful treatment outcome in elderly 
patients with lung cancer.
Recommendation 2.5.5.1 Grade
Age >80 years should not automatically preclude surgery. Decisions should be based on 
oncological stage, co-morbidity and physiological testing.
D
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Clinical question 2.5.6
In patients with NSCLC what is the optimum surgical approach for?
a) Multifocal tumours 
b) Synchronous tumours 
Evidence summary 
A clinical guideline (Kozower et al., 2013) addressed this clinical question. 
Multifocal 
The literature is limited in this area and pathological definitions have evolved recently. 
The approach used here is to define such patients according to clinical features as opposed to pathologic 
features, which generally are not available until after treatment (i.e., resection) has been carried out. 
Multifocal lung cancers (MFLCs) are defined as multiple lesions arising from ground glass opacities 
(GGOs), which may have or develop a solid component. There may be a limited number or multiple 
lesions. The following patients are also included: those with a GGO lesion suspected or proven to be 
malignant and other small GGO lesions that are more likely adenomatous alveolar hyperplasia (AAH) than 
an invasive carcinoma because data suggest that AAH is a precursor to such tumours (Kakinuma et al., 
2004, Nakata et al., 2004, Travis et al., 2005). Including such patients also satisfies the need for a clinically 
applicable definition. At the other end of the spectrum are patients with an infiltrative pattern of disease 
either confined to a particular area (segment or lobe) or appearing diffusely in the lung parenchyma (also 
called pneumonic type of adenocarcinoma). These conditions should also be included among multifocal 
cancers. (Kozower et al., 2013) 
There is a growing body of data that demonstrates excellent survival after resection of small solitary GGO 
lesions (Howington et al., 2013). Furthermore, data support that sublobar resection of single lesions 
presenting as a GGO is adequate. Much fewer data have been published on the outcome of patients with 
multiple cancers presenting as GGO lesions (i.e., multifocal cancers). Good survival and a low recurrence 
rate after resection of MFLC have been reported (Kim et al., 2009, Park et al., 2009). (Kozower et al., 
2013) 
It is reasonable to suggest that limited resection of MFLCs should be performed. This is supported by 
the good outcomes of limited resection for single GGO lesions (Howington et al., 2013), the perception 
of a decreased propensity for nodal and systemic metastases, an increased propensity to develop 
new pulmonary foci of cancer, and the need to preserve lung parenchyma when patients present with 
multiple lesions. The good survival that is reported after resection argues for an aggressive, curative-
intent approach rather than palliative treatment. (Kozower et al., 2013) 
Often, patients with MFLC also have lesions not believed to be malignant (i.e. < 10 mm pure GGO lesions, 
which are AAH in the majority). We suggest that these patients be approached according to the data 
available for isolated lesions with the same characteristics (Pastorino et al., 2003). Lesions that are 
sufficiently suspicious of being malignant should prompt treatment, whereas those that are not should 
continue to be observed. (Kozower et al., 2013) 
Synchronous 
The term synchronous tumour refers to two separate primary lung cancers occurring at the same time. 
The distinction from metastatic disease may be clear when there are two separate histological subtypes. 
Where the same subtype is in both lesions, the criteria proposed by Martini and Melamed (1975) can be 
useful (Kozower et al., 2013).
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The survival of patients with synchronous primary lung cancer is fairly variable, suggesting that a 
thoughtful approach is necessary in classifying two synchronous foci of cancer as two separate primary 
lung cancers. (Kozower et al., 2013)
Approximately 60% of synchronous primary lung cancer reported in the past 25 years are squamous cell 
cancers, and in about 60% of the cases, the tumours are of the same histologic type (Van Bodegom et al., 
1989, Deschamps et al., 1990, Rosengart et al., 1991, Antakli et al., 1995, Ribet and Dambron, 1995, Lee 
et al., 2008, Ferguson et al., 1985). (Kozower et al., 2013)
The average 5-year survival of patients who undergo resection is only about 25%, and that of patients 
with pathological stage I disease is about 40%. Nevertheless, this appears to be better than the natural 
history of untreated lung cancer (Detterbeck and Gibson, 2008). In the absence of distant metastases, 
lymph node involvement, or evidence that the second focus of cancer is a metastasis, resection is 
preferable to observation according to the available data. (Kozower et al., 2013)
Recommendation 2.5.6.1 Grade
Multifocal 
In patients with suspected or proven multifocal lung cancer (without mediastinal or 
extrapulmonary disease), curative-intent treatment may be considered, following 
discussion at a multidisciplinary team meeting. 
D
Recommendation 2.5.6.2 Grade
Synchronous 
In patients with suspected or proven synchronous primary lung cancers (without 
mediastinal or extrapulmonary disease), curative-intent treatment may be considered, 
following discussion at a multidisciplinary team meeting. 
C
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Clinical question 2.5.7
In patients with NSCLC, what is the optimal lymph node strategy at surgical resection? 
Evidence summary 
A clinical guideline (Lim et al., 2010) and a randomised controlled trial (Darling et al., 2011) addressed 
this clinical question. 
The British Thoracic Society states that systematic mediastinal lymph node dissection is the removal of 
all present and accessible N1 and N2 lymph nodes. The Union for International Cancer Control (UICC) 
recommends that at least six lymph node stations should be removed or sampled before the confirmation 
of pN0 status (Goldstraw, 2009). Three of these nodes/stations should be mediastinal (including the 
subcarinal station) and three should be from N1 stations (Lim et al., 2010). 
There is considerable variation in practice, from no lymph node sampling through lobe-specific sampling 
to systematic nodal dissection. Postoperative morbidity is usually cited against the use of routine 
systematic nodal dissection and, in response to this, the results of the American ACOSOG Z30 trial 
confirm that patients randomised to complete mediastinal lymphadenectomy had little added morbidity 
compared with those who underwent lymph node sampling (Allen et al., 2006). Two trials comparing 
systematic nodal dissection with lymph node sampling reported better survival in patients randomised to 
systematic nodal dissection (Izbicki et al., 1995, Wu et al., 2002). (Lim et al., 2010)
Mediastinal lymph node dissection (MLND) does not improve long-term survival in patients with early-
stage (T1 or T2, N0 or nonhilar N1) NSCLC who have pathologically negative mediastinal and hilar nodes 
after rigorous systematic preresection lymph node sampling. In such patients, mediastinal lymph node 
dissection also does not affect the rate of local or regional recurrence. Darling et al. states that the results 
do not apply to patients with T3 or T4 tumours or those with known hilar or N2 disease because they 
were not included in the study. Staging by PET-CT or CT alone is not equivalent to the invasive staging 
performed in this study, and surgeons cannot use this study to justify excluding invasive mediastinal 
staging from their evaluation of patients with early-stage NSCLC. (Darling et al., 2011)
Mediastinal lymph node dissection provides patients with the most accurate staging and the opportunity 
for adjuvant therapy if occult metastatic disease is present. Because current preoperative staging cannot 
definitively identify patients with mediastinal lymph node involvement, and because patients with known 
hilar or mediastinal disease (N2) or with T3 or T4 tumours may benefit from mediastinal lymph node 
dissection because the pre-test probability of N2 disease is higher, we still recommend that all patients 
with resectable NSCLC undergo mediastinal lymph node dissection because the procedure does not 
increase mortality or morbidity. (Darling et al., 2011).
Recommendation 2.5.7.1 Grade
Systematic mediastinal lymph node dissection should be performed in all patients having 
a lung cancer resection. 
B
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Clinical question 2.5.8
In patients with malignant pleural effusion associated with lung cancer, what is the best treatment 
strategy?
Evidence summary 
A clinical guideline (SIGN, 2014) and an UpToDate® review (Light and Doelken, 2015) addressed this 
clinical question. 
In patients with malignant pleural effusion whose symptoms improve following fluid drainage, a number 
of options are available depending on performance status and documentation of lung re-expansion. 
(Light and Doelken, 2015)
The optimal technique for pleurodesis in malignant pleural effusion has been investigated in a Cochrane 
review (Shaw and Agarwal, 2004). The main agent used in the UK for pleurodesis is talc. Talc appears to be 
the most effective sclerosant, with a relative risk for successful pleurodesis of 1.26 (95% CI 1.07 to 1.48) 
compared with bleomycin or tetracycline. Adult respiratory distress syndrome following talc pleurodesis 
has been reported as a complication in case reports but not in RCTs. Meta-analysis indicates there is 
no evidence of excess mortality with talc pleurodesis compared with other sclerosants. Thoracoscopic 
pleurodesis was found to be more effective than medical thoracostomy pleurodesis, with a relative risk of 
non-recurrence of an effusion of 1.19 (95% CI 1.04 to 1.36) in favour of thoracoscopic pleurodesis. There 
was no evidence for increased mortality following thoracoscopic pleurodesis. (SIGN, 2014) 
There is evidence to support the use of tunnelled pleural catheters in the management of malignant 
pleural effusions when talc pleurodesis is not possible (Sabur et al., 2013, Suzuki et al., 2011, Thornton et 
al., 2010, Tremblay and Michaud, 2006). They provide a safe means of palliation of symptoms secondary 
to the effusion and enable the patient to be managed at home rather than hospital (Sudharshan et 
al., 2011). The main complications appear to be blockage or dislodgement of the catheter or seeding 
down the drain tract. In a retrospective audit seeding affected 6.7% of 45 patients (Janes et al., 2007). 
Spontaneous pleurodesis occurred in up to 25% of cases. Very few cases of pleural infection secondary 
to the drain have been reported (Janes et al., 2007). Achieving complete lung re-expansion prior to 
pleurodesis remains the most important prerequisite for success. (SIGN, 2014) 
Serial thoracentesis is commonly practiced. 
Recommendation 2.5.8.1 Grade
In patients with malignant pleural effusion whose symptoms improved following drainage, 
a number of options are available depending on performance status and documentation 
of lung re-expansion: 
- In patients with good performance status with lung re-expansion, thoracoscopy with 
talc pleurodesis is recommended. C
- In patients with non-expandable lung, tunnelled catheters may be considered. C
- In patients with poor performance status with lung re-expansion, options include: 
tunnelled pleural catheter, serial thoracentesis, or bedside talc pleurodesis. D
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Clinical question 2.5.9
Should surgical resection be considered in patients with NSCLC, who have treatable isolated brain or 
adrenal metastases at the time of presentation?
Evidence summary 
A best evidence topic (Modi et al., 2009) including eleven retrospective studies (1,035 patients) addressed 
the treatment of brain metastases, and a retrospective study (Raz et al., 2011) addressed the issue of 
treatment of adrenal metastases in this clinical question.
Brain metastasis
A best evidence topic (Modi et al., 2009) including eleven retrospective studies (Bonnette et al., 2001, 
Getman et al., 2004, Penel et al., 2001, Mussi et al., 1996, Iwasaki et al., 2004, Girard et al., 2006, 
Wronski et al., 1995, Mozami et al., 2002, Furak et al., 2005, Billing et al., 2001, Abrahams et al., 2001) 
addressed the issue of surgical resection of the primary tumour in patients with NSLC and cerebral 
metastases. In these studies, the median survival for the curative intent groups (bifocal therapy ± 
adjuvant treatment) ranged from 19 to 27 months (mean=23.12±3.3 months) and at 1, 2 and 5 years 
from 56% to 69% (mean= 63.9±5.6%), 28% to 54% (mean= 38.7±11%) and 11% to 24% (mean=18±5.7%), 
respectively. In comparison, the median and 1-year survival of the palliative groups were 7.1–12.9 months 
(mean=10.3±2.9 months) and 33–39.7% (mean= 35.3±3.8%), respectively. The study concluded that in 
the absence of mediastinal lymph node involvement, surgical resection of NSCLC with complete resection 
of the brain metastasis improves prognosis.
Adrenal 
Raz et al. (2011) identified 37 patients with isolated adrenal metastasis from NSCLC. Twenty patients 
underwent adrenalectomy. Patients did not undergo adrenalectomy owing to suspicion of N2 disease, 
medical comorbidities, or patient preference. Seven patients (35%) treated surgically had tumours that 
were ipsilateral to their primary tumour, and eight (40%) had metachronous metastases. Five-year overall 
survival was 34% for patients treated operatively and 0% for patients treated nonoperatively p=0.002). 
Among patients treated with adrenalectomy, patients with ipsilateral metastases had a 5-year survival of 
83% compared with 0% for patients with contralateral metastases (p=0.003). Patients without mediastinal 
nodal disease had a 5-year survival of 52% compared with 0% for patients with mediastinal nodal disease 
(p=0.008). Survival of patients who underwent adrenalectomy for synchronous and metachronous adrenal 
metastases was not significantly different (p=0.81). Surgical resection of isolated adrenal metastasis from 
lung cancer provides a survival benefit in well-selected patients compared with nonoperative management. 
No patient with contralateral adrenal metastases or mediastinal nodal disease survived long term after 
adrenalectomy. The time interval between treatment of the primary lung cancer and adrenal metastasis 
was not significantly associated with survival, but the cohort size was small.
Recommendation 2.5.9.1 Grade
In patients with an isolated brain metastasis and a synchronous resectable primary NSCLC, 
sequential resection of the primary tumour and definitive treatment of the brain metastasis 
may be considered, following discussion at a multidisciplinary team meeting. 
C
Recommendation 2.5.9.2 Grade
In patients with an isolated adrenal metastasis and a synchronous resectable primary 
NSCLC, sequential resection of the primary tumour and definitive treatment of the adrenal 
metastasis may be considered, following discussion at a multidisciplinary team meeting. 
D
Good practice point 
The management of these patients should be discussed at a multidisciplinary team meeting including 
the role of systemic therapy.
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Clinical question 2.5.10
Should surgical resection be considered as part of the multimodality treatment of patients with stage 
IIIa (N2) NSCLC? 
Evidence summary 
Two clinical guidelines (Lim et al., 2010, SIGN, 2014) addressed this clinical question. 
N2 disease describes any metastatic involvement of ipsilateral or subcarinal mediastinal nodes. This term 
encompasses a spectrum of disease from micrometastatic disease in one node to extranodal extension 
from malignant disease in several lymph node stations and therefore the management of N2 disease 
should take this into consideration. (Lim et al., 2010) 
The IASLC Lung Cancer Staging Project identified that overall disease burden (in the lymph nodes) had 
more influence on prognosis than anatomical site of lymph node involvement (Rusch et al., 2007); hence 
nodal stations are now consolidated into lymph node zones (Rusch et al., 2009). The prognosis of single 
zone N2 disease (N2a) was better than multi-zone N2 (N2b) disease with post-resection 5-year survivals 
of 34% and 20%, respectively (p<0.001) (Rusch et al., 2007). (Lim et al., 2010) 
Single zone N2 disease 
Resection may be considered in patients with single zone N2 disease as survival is similar to patients with 
multi-zone N1b disease (Rusch et al., 2007). (Lim et al., 2010) 
Multi-zone disease 
Patients with bulky or fixed N2 disease are not considered for surgery and are treated by combinations of 
chemotherapy, radical radiotherapy or concurrent chemoradiotherapy. (Lim et al., 2010) 
A number of retrospective case series with relatively small numbers (30–100 cases) have been published 
detailing the clinical outcomes achieved following surgery in selected patients with stage IIIa disease 
(Detterbeck, 2001). Patients were managed using a multimodality approach that included preoperative 
chemotherapy and occasionally radiotherapy. Most studies suggested a survival benefit with a 
chemotherapy plus surgical resection protocol, compared with contemporary non-surgical management. 
(SIGN, 2014) 
Patients who are suitable for surgery should have non-fixed, non-bulky disease and should be expected to 
tolerate multimodality treatment (Lim et al., 2010).
Recommendation 2.5.10.1 Grade
Consider surgery as part of multimodality management in patients with T1–3 N2 (non-
fixed, non-bulky, single zone) M0 disease. 
C
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Clinical question 2.5.11
In patients with small-cell lung cancer (SCLC) what is the role of surgery?
Evidence summary 
A clinical guideline (SIGN, 2014) addressed this clinical question.
In general, routine surgery for limited-stage SCLC is not recommended. An RCT examining the role of 
surgery in patients who had responded to five cycles of cyclophosphamide, doxorubicin and vincristine 
(CAV) systemic therapy failed to show any benefit for the surgical arm (Lad et al., 1994). (SIGN, 2014) 
No RCTs were identified comparing adjuvant surgery to systemic anticancer therapy and radiotherapy 
alone. Retrospective trials indicate a combination of primary surgery and adjuvant systemic anticancer 
therapy and thoracic and cranial irradiation improves survival (Lim et al., 2008, Vallières et al., 2009, 
Weksler et al., 2012), but further research is required before strong conclusions can be drawn. (SIGN, 
2014) 
There are two specific situations in which surgery may be beneficial: 
1. Patients with clinical stage T1-2 N0 SCLC should be evaluated for potential surgical resection. On 
confirmation of localised disease, surgery should be considered. Case series examining systemic 
anticancer therapy following resection of early stage SCLC suggest that adjuvant systemic anticancer 
therapy may confer a survival advantage (Fujimori et al., 1997, Shepherd et al., 1989, Davis et al., 
1993, Schreiber et al., 2010). 
2. Occasionally a peripheral mass with no preoperative histology is found to be SCLC following resection. 
This tends to occur in patients at an early stage of the disease, who have operable cancer according 
to the standard criteria for NSCLC. Adjuvant systemic anticancer therapy may confer a survival 
advantage (Fujimori et al., 1997, Shepherd et al., 1989, Davis et al., 1993). (SIGN, 2014) 
Recommendation 2.5.11.1 Grade
Patients with clinical stage I small-cell lung cancer (SCLC) and excellent performance status 
may be considered for resection following extensive staging investigation as part of a 
multimodality treatment regimen.
C
64 | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
| A National Clinical Guideline
2.6 Medical Oncology 
Responsibility for the implementation of medical oncology recommendations
While the CEO, General Manager and the Clinical Director of the hospital have corporate responsibility 
for the implementation of the recommendations in this National Clinical Guideline, each member of the 
multidisciplinary team is responsible for the implementation of the individual guideline recommendations 
relevant to their discipline.
The literature used in the development of this guideline was based on the 7th edition of the Lung 
Cancer TNM staging system. The 8th edition of the TNM staging system was published in December 
2016 (Brierley et al., 2016), this may lead to changes in recommendations over time, which should be 
taken into consideration at multidisciplinary team meetings. 
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Clinical question 2.6.1
In patients with non-small cell lung cancer (NSCLC) (excluding pancoast tumours) having curative 
surgery, how effective is preoperative (neoadjuvant) chemotherapy or chemoradiotherapy?
Evidence summary 
A clinical guideline (Bezjak et al., 2015) and a meta-analysis (NSCLC Meta-analysis Collaborative Group, 
2014) addressed this clinical question.
Preoperative chemotherapy
A recent meta-analysis (NSCLC Meta-analysis Collaborative Group, 2014) of individual participant 
data from 15 randomised control trials (2,385 patients) aimed to establish the effect of preoperative 
chemotherapy for patients with resectable NSCLC. The study showed a significant benefit of preoperative 
chemotherapy on survival (hazard ratio (HR) 0.87, 95% CI 0.78–0.96, p=0.007), a 13% reduction in the 
relative risk of death (no evidence of a difference between trials; p=0.18, I²=25%). This finding represents 
an absolute survival improvement of 5% at 5 years, from 40% to 45%. Recurrence-free survival (HR 0.85, 
95% CI 0.76–0.94, p=0.002) and time to distant recurrence (0.69, 0.58–0.82, p<0.0001) results were 
both significantly in favour of preoperative chemotherapy although most patients included were stage 
Ib–IIIa. Findings, which are based on 92% of all patients who were randomised, and mainly stage Ib–IIIa, 
show preoperative chemotherapy significantly improves overall survival, time to distant recurrence, and 
recurrence free survival in resectable NSCLC. The findings suggest this is a valid treatment option.
Preoperative chemoradiotherapy
The American Society for Radiation Oncology guideline states that there is no level I evidence 
recommending the use of induction radiotherapy (or chemoradiotherapy) followed by surgery for 
patients with resectable stage III NSCLC. (Bezjak et al., 2015)
Recommendation 2.6.1.1 Grade
Preoperative chemoradiotherapy
For patients with non-small cell lung cancer (NSCLC) who are suitable for surgery, do not 
offer neoadjuvant chemoradiotherapy outside a clinical trial. 
B
Recommendation 2.6.1.2 Grade
Preoperative chemotherapy
Following discussion at a multidisciplinary team meeting, appropriate patients with NSCLC 
who are suitable for surgery can be considered for neoadjuvant chemotherapy.
A
Good practice point 
This evidence does not apply to pancoast tumours.
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Clinical question 2.6.2
In patients with locally advanced NSCLC having radical radiotherapy, is concurrent chemoradiotherapy 
more effective than sequential chemoradiotherapy? 
Evidence summary 
A clinical guideline (SIGN, 2014) addressed this clinical question.
In patients with locally advanced NSCLC, concurrent systemic anti cancer therapy confers a significant 
survival benefit over sequential treatment (HR 0.84, 95% CI, 0.74 to 0.95; p=0.004; absolute survival 
benefit 4.5% at five years) or radiotherapy alone (Aupérin et al., 2010, O’Rourke et al., 2010). This benefit 
is seen at a cost of increased radiotherapy toxicity to the oesophagus. The optimal chemotherapy and 
radiotherapy schedule remain unclear (O’Rourke et al., 2010). (SIGN, 2014)
Recommendation 2.6.2.1 Grade
Concurrent chemoradiotherapy should be administered to patients with locally advanced 
NSCLC (suitable for radical radiotherapy) who have a good performance status (0-1).
A
Good practice point 
A sequential approach may be chosen for patients considered at higher risk for toxicity or in patients 
with good performance status for other clinical reasons such as: the reduction in the radiotherapy field 
obtained if radiation is preceded by chemotherapy.
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Clinical question 2.6.3
In patients with locally advanced NSCLC having concurrent radical chemoradiotherapy, what is the 
effectiveness of:
a) Induction (first-line) chemotherapy
b) Consolidation chemotherapy
Evidence summary
A clinical guideline (NICE, 2011) and a randomised controlled trial (Ahn et al., 2015) addressed this clinical 
question. 
The NICE (2011) guideline discusses three studies examining the effectiveness of the following 
interventions: 
Study Intervention 
Vokes et al., 2007 Concurrent chemoradiation ± induction chemotherapy
Hanna et al., 2008 Concurrent chemoradiation ± consolidation chemotherapy
Kelly et al., 2008 Concurrent chemoradiation + consolidation chemotherapy ± maintenance 
chemotherapy
In an RCT of moderate quality Vokes et al. (2007) found no effect of induction chemotherapy on survival, 
disease-free survival or toxicity other than higher rates of grade 4 maximum toxicity and grade 3-4 absolute 
neutrophil count (ANC) in the patients who received induction treatment. Apart from higher rates of 
grade 3-5 infections and pneumonitis in the patients who received consolidation chemotherapy, Hanna et 
al. (2008) did not find any effect of consolidation chemotherapy on survival, progression-free survival or 
treatment-related deaths in an RCT of low-moderate quality. Kelly et al. (2008) in a low-moderate quality RCT 
found that although progression-free survival did not differ between the treatment groups, maintenance 
gefitinib was associated with significantly shorter survival than placebo. (NICE, 2011)
A recent randomised phase III trial aimed to determine the efficacy of consolidation chemotherapy with 
docetaxel and cisplatin (DP) after concurrent chemoradiotherapy with the same agents in locally advanced 
non-small cell lung cancer (Ahn et al., 2015). Patients were randomised to an observation arm (n=211) or 
a consolidation arm (n=209). In the observation arm patients received concurrent chemoradiotherapy 
with docetaxel (20 mg/m2) and cisplatin (20 mg/m2) every week for 6 weeks with a total dose of 66 Gy 
of thoracic radiotherapy in 33 fractions. In the consolidation arm patients received the same concurrent 
chemoradiotherapy followed by three cycles of DP (35 mg/m2 each on days 1 and 8, every 3 weeks). 
In the consolidation arm, 143 patients (68%) received consolidation chemotherapy, of whom 88 (62%) 
completed three planned cycles. The median PFS was 8.1 months in the observation arm and 9.1 months 
in the consolidation arm (HR 0.91; 95% CI, 0.73 to 1.12; p=0.36). Median overall survival times were 20.6 
and 21.8 months in the observation and consolidation arms, respectively (HR 0.91, 95% CI, 0.72 to 1.25; 
p=0.44). The study concluded that consolidation chemotherapy after concurrent chemoradiotherapy with 
weekly DP in locally advanced non-small cell lung cancer failed to further prolong PFS and concurrent 
chemoradiotherapy alone should remain the standard of care.
Recommendation 2.6.3.1 Grade
Induction or consolidation chemotherapy are not routinely recommended for patients 
receiving concurrent radical chemoradiotherapy. B
Good practice point 
Ensure patients are offered participation in a clinical trial when available and appropriate.
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Clinical question 2.6.4
In patients with advanced/stage IV NSCLC what is the effectiveness of first-line chemotherapy and is 
there any evidence that particular regimens or drugs are more effective or less toxic than others?
Evidence summary
A Cochrane review (NSCLC Collaborative Group, 2010) and two randomised studies (Delbaldo et al., 2007, 
Scagliotti et al., 2008,) addressed the effectiveness of chemotherapy in patients with advanced NSCLC. 
Effectiveness of first-line cytotoxic chemotherapy 
A Cochrane review (NSCLC Collaborative Group, 2010) assessed the effect on survival of supportive care 
and chemotherapy versus supportive care alone in advanced NSCLC. Survival analyses, based on 2,533 
deaths and 2,714 patients from 16 trials show a highly statistically significant benefit of chemotherapy 
on survival (HR 0.77; 95% CI 0.71 to 0.83, p<0.0001) translating to an absolute improvement of 9% at 12 
months, increasing survival from 20% to 29% or an absolute increase in median survival of 1.5 months 
(from 4.5 months to 6 months). There was some evidence of heterogeneity between the trials (p=0.02, I2 
= 47%).
A meta-analysis of randomised controlled trials evaluated the clinical benefit of adding a drug to single 
agent or 2-agent chemotherapy regimen in patients with advanced NSCLC (Delbaldo et al., 2007). In total, 
57 trials (11,160 patients) were analysed. In the trials comparing a doublet regimen with a single-agent 
regimen, a significant increase was observed in tumour response (OR, 0.42; 95% confidence interval [CI], 
0.37-0.47; p<0.001) and 1-year survival (OR, 0.80; 95% CI, 0.70-0.91; p<0.001) in favour of the doublet 
regimen. The median survival ratio was 0.83 (95% CI, 0.79-0.89; p<0.001). An increase was also observed 
in the tumour response rate (OR, 0.66; 95% CI, 0.58- 0.75; p<0.001) in favour of the triplet regimen, but 
not for 1-year survival (OR, 1.01; 95% CI, 0.85-1.21; p=0.88). The median survival ratio was 1.00 (95% CI, 
0.94-1.06; p=0.97). The study concluded that in patients with advanced NSCLC a second drug improved 
tumour response and survival rate and that adding a third drug had a weaker effect on tumour response 
and no effect on survival.
A non inferiority, phase III, randomised study (Scagliotti et al., 2008) compared the overall survival of 
cisplatin/pemetrexed with cisplatin/gemcitabine in chemotherapy-naive patients with advanced NSCLC. 
Overall survival for patients randomly assigned to cisplatin/pemetrexed was noninferior to the overall 
survival of patients assigned to cisplatin/gemcitabine (median overall survival, 10.3 vs. 10.3 months; HR 
0.94, 95% CI, 0.84 to 1.05). However, in patients with adenocarcinoma randomly assigned to cisplatin/
pemetrexed, survival was significantly better than for those assigned to cisplatin/gemcitabine (12.6 v 10.9 
months, respectively; p=0.03). This is supported by a recent meta-analysis (Pilkington et al., 2015) that 
combined the results from Scalgliotti et al. (2009) and Gronberg et al. (2009) and found that in patients 
with non-squamous disease, there is evidence that pemetrexed+platinum increases OS compared with 
gemcitabine+platinum (MA: HR 0.85, 95% CI 0.73 to 1.00; MTC-1: HR 0.85, 95% CI 0.74 to 0.98). 
A number of phase II/III trials (Johnson et al., 2004, Sandler et al., 2006, Reck et al., 2009, Herbst et 
al., 2007, Niho et al., 2012) looked at the addition of bevacizumab in combination with chemotherapy. 
Additionally, four meta-analyses (Soria et al., 2013, Botrel et al., 2011, Cao et al., 2012, Lima et al., 2011) 
have addressed this issue, they broadly agree that the addition of bevacizumab to chemotherapy in 
patients with advanced NSCLC improves OS, PFS and RR. However, the absolute benefits are small and 
the adverse effects of treatment are considerable. 
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Effectiveness of first-line targeted therapy 
A Cochrane review (Greenhalgh et al., 2016) and a phase III trial (Solomon et al., 2014) addressed the 
effectiveness of first-line targeted therapy in patients with advanced NSCLC.
 
The Guideline Development Group highlighted this as a rapidly evolving area of research.
EGFR
A recent Cochrane review (Greenhalgh et al., 2016) assessed the clinical effectiveness of EGFR TKI 
therapies in the first-line treatment of patients with EGFR mutation positive (M+) NSCLC compared 
with cytotoxic chemotherapy (used alone or in combination) and best supportive care. The study found 
that erlotinib, gefitinib, and afatinib are all active agents in EGFR M+ NSCLC patients, and demonstrate 
an increased tumour response rate and prolonged progression-free survival compared to cytotoxic 
chemotherapy. 
Intervention Control Relative effect (95% CI)
Overall Survival PFS
Erlotinib vs. Cytotoxic chemotherapy HR 0.95 (0.75 to 1.22) HR 0.30 (0.24 to 0.38)
Gefitinib vs. Paclitaxel + carboplatin HR 0.95 (0.77 to 1.18) HR 0.39 (0.32 to 0.48)
Afatinib vs. Cytotoxic chemotherapy HR 0.93 (0.74 to 1.17) HR 0.42 (0.34 to 0.53)
Adapted from (Greenhalgh et al., 2016)
Greenhalgh et al. (2016) concluded that erlotinib, gefitinib, and afatinib are effective in prolongation 
of PFS but not OS in EGFR M+ NSCLC patients with acceptable toxicity. Quality of life and response are 
closely linked, and the available data would favour selection of TKIs over chemotherapy as first-line 
treatment based on both these criteria. The review included six trials that measured quality of life for 
participants with EGFR M+ tumours by a number of different methods (two comparing afatinib with 
cytotoxic chemotherapy, two comparing erlotinib with cytotoxic chemotherapy, and two comparing 
gefitinib with cytotoxic chemotherapy); all six trials reported a beneficial effect of the TKI compared 
to cytotoxic chemotherapy. All three TKIs showed symptom palliation of cough, pain, and dyspnoea, 
although the methodology used was not standardised. 
The majority of trials included people with a performance status (PS) of 1 and 2, but the data on AEs 
suggest that some PS 3 as well as elderly patients might tolerate the agents better than cytotoxic 
chemotherapy (Chen et al., 2012, Reck et al., 2010).
ALK
Solomon et al. (2014) conducted an open-label, phase III trial comparing crizotinib treatment with 
pemetrexed-plus-platinum chemotherapy in patients with previously untreated advanced ALK-positive 
NSCLC. Progression-free survival was significantly longer with crizotinib than with chemotherapy (median, 
10.9 months vs. 7.0 months; hazard ratio for progression or death with crizotinib, 0.45; 95% confidence 
interval [CI], 0.35 to 0.60; p<0.001). Objective response rates were 74% and 45%, respectively (p<0.001). 
Median overall survival was not reached in either group (hazard ratio for death with crizotinib, 0.82; 
95% CI, 0.54 to 1.26; p=0.36); the probability of 1-year survival was 84% with crizotinib and 79% with 
chemotherapy. The most common adverse events of any cause for which the incidence was at least 5 
percentage points higher in the crizotinib group than in the chemotherapy group were vision disorder 
(occurring in 71% of the patients), diarrhoea, (in 61%), and odema (in 49%); and the events for which 
the incidence was at least 5 percentage points higher in the chemotherapy group than in the crizotinib 
group were fatigue (occurring in 38% of the patients), anaemia (in 32%), and neutropenia (in 30%). There 
was a significantly greater overall improvement from baseline in global quality of life among patients who 
received crizotinib than among those who received chemotherapy (p<0.001). The study concluded that 
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crizotinib was superior to standard first-line pemetrexed-plus-platinum chemotherapy in patients with 
previously untreated advanced ALK-positive NSCLC.
Recommendation 2.6.4.1 Grade
Effectiveness of first-line cytotoxic chemotherapy
In patients with a good performance status (PS) (i.e. Eastern Cooperative Oncology Group 
[ECOG] level 0 or 1) and stage IV NSCLC, a platinum-based chemotherapy regimen is 
recommended based on the survival advantage and improvement in quality of life (QOL) 
over best supportive care (BSC).
A
Recommendation 2.6.4.2 Grade
Effectiveness of first-line cytotoxic chemotherapy
In patients with stage IV NSCLC and a good performance status, two-drug combination 
chemotherapy is recommended. The addition of a third cytotoxic chemotherapeutic agent 
is not recommended because it provides no survival benefit and may be harmful.
A
Recommendation 2.6.4.3 Grade
Effectiveness of first-line cytotoxic chemotherapy
In patients receiving palliative chemotherapy for stage IV NSCLC, it is recommended that 
the choice of chemotherapy is guided by histological type of NSCLC. 
B
Recommendation 2.6.4.4 Grade
Effectiveness of first-line cytotoxic chemotherapy 
Bevacizumab plus platinum-based chemotherapy may be considered an option in carefully 
selected patients with advanced NSCLC. Risks and benefits should be discussed with 
patients before decision making. 
B
Recommendation 2.6.4.5 Grade
Effectiveness of first-line targeted therapy
First-line single agent EGFR tyrosine kinase inhibitors (TKI) should be offered to patients 
with sensitising EGFR mutation positive NSCLC. Adding combination chemotherapy to TKI 
confers no benefit and should not be used.
A
Recommendation 2.6.4.6 Grade Resource implication: 
Effectiveness of first-line targeted therapy
Crizotinib should be considered as first-line 
therapy in patients with ALK positive NSCLC 
tumours. 
B
Crizotinib is licensed for this indication in 
the Republic of Ireland but is not currently 
reimbursed. The HSE reimbursement 
application is expected to be submitted in 
2017.
Good practice point 
Ensure patients are offered participation in a clinical trial when available and appropriate. 
Good practice point 
Patients should be referred for assessment by the palliative care service.
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Clinical question 2.6.5
In patients with advanced/stage IV NSCLC is there any evidence for maintenance systemic therapy?
Evidence summary 
Two clinical guidelines (SIGN, 2014, and Kulkarni et al., 2015- Cancer Care Ontario) addressed this clinical 
question. 
The Cancer Care Ontario Guideline Development Group (Kulkarni et al., 2015) conducted a meta-analysis 
of three RCTs (Ciuleanu et al., 2009, Paz-Ares et al., 2012, Rittmeyer et al., 2013). They found that patients 
randomised to pemetrexed as maintenance therapy had longer overall survival compared with those who 
did not receive maintenance pemetrexed therapy (HR 0.78; 95% confidence interval [CI], 0.69 to 0.89; 
p=0.0003, I2=0%). At a baseline risk of 51% at 12 months, there would be 8% (83 per 1000) fewer deaths 
at 12 months (95% CI from 40 fewer to 121 fewer) for patients who received pemetrexed maintenance 
therapy. 
The three RCTs reported on quality of life and found either no difference in the majority of scores or 
significant delays in symptom deterioration in favour of patients who received pemetrexed maintenance 
treatment (Ciuleanu et al., 2009, Paz-Ares et al., 2012, Rittmeyer et al., 2013). (Kulkarni et al., 2015)
A significant interaction was observed between histology (squamous versus non-squamous carcinoma) 
and treatment for progression-free survival and overall survival in Ciuleanu 2009. The two other RCTs 
included only patients with non-squamous histology (Barlesi et al., 2013, Paz-Ares et al., 2013). Meta-
analysis with these two RCTs, plus the data from patients with non-squamous carcinoma from Ciuleanu 
2009, found that patients with non-squamous cell histology who received pemetrexed as maintenance 
therapy had longer OS (HR 0.74; 95% CI, 0.64 to 0.86; p<0.0001) and PFS (HR 0.51; 95% CI, 0.41 to 0.63; 
p<0.00001) compared with those who did not receive pemetrexed as maintenance therapy. (Kulkarni et 
al., 2015) 
Erlotinib maintenance treatment provided a statistically significant increase in progression-free survival 
and overall survival in patients treated with standard first-line platinum-based chemotherapy, both 
in the whole study population and in a post hoc analysis in patients with stable disease. In the whole 
study population the changes in these outcomes were considered to be of modest size. Median PFS was 
statistically significantly longer in the erlotinib group compared with placebo group, 12.3 weeks versus 
11.1 weeks, (HR 0.71, 95% CI 0.62 to 0.82), with a similar HR in patients with EGFR IHC-positive tumours, 
representing around 70% of the patient population, (0.69, 95% CI 0.58 to 0.82) (Cappuzzo et al., 2010). 
(SIGN, 2014) 
Recommendation 2.6.5.1 Grade
In patients with stage IV non-squamous NSCLC who do not experience disease progression 
and have a preserved performance status after 4-6 cycles of platinum-based therapy, 
treatment with maintenance pemetrexed is suggested. 
B
Recommendation 2.6.5.2 Grade
In patients with stage IV NSCLC, switch maintenance therapy with chemotherapy agents 
other than pemetrexed has not demonstrated an improvement in overall survival and is 
not recommended. 
B
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Recommendation 2.6.5.3 Grade
In patients with stage IV NSCLC who do not experience disease progression after 4-6 
cycles of platinum-based double agent chemotherapy, there is insufficient evidence to 
recommend maintenance therapy with erlotinib. 
B
Good practice point
Ensure patients are offered participation in a clinical trial when available and appropriate.
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Clinical question 2.6.6
In patients with advanced/stage IV NSCLC aged over 70, and/or with poor performance status, what is 
the effectiveness of first-line therapy?
Evidence summary 
A clinical guideline (NCCN, V8 2017), a Cochrane review (Santos et al., 2015) and a randomised phase III 
trial (Zukin et al., 2013) addressed this clinical question.
Poor performance status
A multicentre phase III randomised trial (Zukin et al., 2013) compared single-agent pemetrexed versus 
combination carboplatin/pemetrexed as first-line management in patients with advanced NSCLC and 
a ECOG performance status of 2. The analysis included 205 patients, 102 patients assigned to receive 
pemetrexed and 103 assigned to receive carboplatin/pemetrexed. However, the guideline development 
group noted that the prevalence of comorbidities amongst patients in the trial was low in both arms. 
Although the median number of cycles was four in both arms, only 53.9% of patients in the pemetrexed 
arm completed the prescribed four cycles compared with 70.9% in the carboplatin/pemetrexed arm 
(p=0.012). Best response could not be determined in 34.4% and 23.3% of patients in the pemetrexed 
and carboplatin/pemetrexed arms, respectively, due to the lack of confirmation by response evaluation 
criteria in solid tumours (RECIST). Among evaluable patients, objective response rates were 10.5% in the 
pemetrexed arm (seven of 67) and 24% in the carboplatin/pemetrexed arm (19 of 79; p=0.032). The 6- 
and 12-month PFS rates were 18.4% and 2% versus 48.9% and 17%, respectively. The OS distributions 
were statistically significant in favour of the combination arm (HR 0.62; 95% CI, 0.46 to 0.83; p=0.001). 
However, there were four documented treatment-related deaths in the combination arm (3.9%) and the 
frequency of grades 3 and 4 anaemia (3.9% v 11.7%), neutropenia (1.0% v 6.8%), and thrombocytopenia 
(0% v 1.0%) were higher in the combination arm. The study concluded that combination chemotherapy 
with carboplatin/pemetrexed is superior to single-agent therapy in patients with advanced NSCLC and an 
ECOG performance status of 2, combination therapy should be offered to these patients. 
The National Comprehensive Cancer Network (NCCN, V8 2017) guideline states that unfit patients of 
any age (performance status (3-4) do not benefit from cytotoxic treatments, except erlotinib, afatinib, or 
gefitinib for EGFR mutation-positive and crizotinib for ALK-positive tumours of non-squamous NSCLC or 
NSCLC NOS. (NCCN, V8 2017)
Elderly patients
A recent Cochrane review (Santos et al., 2015) aimed to assess the effectiveness and safety of different 
cytotoxic chemotherapy regimens for previously untreated elderly patients with advanced (stage IIIb 
and IV) NSCLC. The study included 51 trials: non-platinum single-agent therapy versus non-platinum 
combination therapy (seven trials) and non-platinum combination therapy versus platinum combination 
therapy (44 trials). The reviews results were as follows:
Non-platinum single-agent versus non-platinum combination therapy
 Low-quality evidence suggests that these treatments have similar effects on overall survival (HR 
0.92, 95% confidence interval (CI) 0.72 to 1.17; participants = 1062; five RCTs), one year OS (risk 
ratio (RR) 0.88, 95% CI 0.73 to 1.07; participants = 992; four RCTs), and PFS (HR 0.94, 95% CI 0.83 
to 1.07; participants = 942; four RCTs). Non-platinum combination therapy may better improve ORR 
compared with non-platinum single-agent therapy (RR 1.79, 95% CI 1.41 to 2.26; participants = 1014; 
five RCTs; low-quality evidence). (Santos et al., 2015)
 Differences in effects on major adverse events between treatment groups were as follows: 
anaemia: RR 1.10, 95% CI 0.53 to 2.31; participants = 983; four RCTs; very low-quality evidence; 
neutropenia: RR 1.26, 95% CI 0.96 to 1.65; participants = 983; four RCTs; low-quality evidence; and 
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thrombocytopenia: RR 1.45, 95% CI 0.73 to 2.89; participants = 914; three RCTs; very low-quality 
evidence. (Santos et al., 2015)
Non-platinum therapy versus platinum combination therapy
 Platinum combination therapy probably improves OS (HR 0.76, 95% CI 0.69 to 0.85; participants = 
1705; 13 RCTs; moderate quality evidence), 1 year OS (RR 0.89, 95% CI 0.82 to 0.96; participants = 
813; 13 RCTs; moderate-quality evidence), and ORR (RR 1.57, 95% CI 1.32 to 1.85; participants = 1432; 
11 RCTs; moderate-quality evidence) compared with non-platinum therapies. Platinum combination 
therapy may also improve PFS, although our confidence in this finding is limited because the quality 
of evidence was low (HR 0.76, 95% CI 0.61 to 0.93; participants = 1273; nine RCTs). (Santos et al., 
2015)
 Effects on major adverse events between treatment groups were as follows: 
 anaemia: RR 2.53, 95% CI 1.70 to 3.76; participants = 1437; 11 RCTs; low-quality evidence; 
thrombocytopenia: RR 3.59, 95% CI 2.22 to 5.82; participants = 1260; nine RCTs; low-quality evidence; 
fatigue: RR 1.56, 95% CI 1.02 to 2.38; participants = 1150; seven RCTs; emesis: RR 3.64, 95% CI 1.82 
to 7.29; participants = 1193; eight RCTs; and peripheral neuropathy: RR 7.02, 95% CI 2.42 to 20.41; 
participants = 776; five RCTs; low-quality evidence. (Santos et al., 2015)
Recommendation 2.6.6.1 Grade
In elderly patients (age 70-79 years) with stage IV NSCLC who have good performance 
status and limited co-morbidities, treatment with a platinum doublet chemotherapy is 
recommended.
B
Recommendation 2.6.6.2 Grade
In patients with stage IV NSCLC with a performance status of 2, single agent chemotherapy 
may be considered. Platinum doublet chemotherapy is suggested over single agent 
chemotherapy if the performance status of 2 is cancer related rather than co-morbidity 
associated.
B
Recommendation 2.6.6.3 Grade
Unfit patients of any age (performance status (3-4)) do not benefit from cytotoxic 
chemotherapy. However if patients harbor an EGFR or ALK mutation positive tumour, they 
may be considered for treatment with targeted therapies.
C
Good practice point 
A comprehensive geriatric assessment should be considered in patients over 70 years. 
Good practice point 
In patients with stage IV NSCLC, who are 80 years or over, the benefit of chemotherapy is unclear and 
should be decided based on individual circumstances.
Good practice point 
Ensure patients are offered participation in a clinical trial when available and appropriate.
Good practice point 
Patients should be referred for assessment by the palliative care service.
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Clinical question 2.6.7
In patients with advanced/stage IV NSCLC how effective is second and third-line therapy in patients 
with NSCLC who progress and relapse? 
Evidence summary 
This is a rapidly evolving area of research. Not all treatments discussed in the evidence summary are 
currently reimbursed in Ireland.1
In patients with advanced NSCLC who have received platinum as part of their first-line treatment 
randomised evidence does not support the use of combination chemotherapy as second-line treatment 
(Di Maio et al., 2009). 
The following single agent treatments have shown benefit in clinical trials as second and/or third-line 
treatment:
Docetaxel
Patient population: Study/Author: Results:
Patients with performance 
status (PS) of 0 to 2 and stage 
IIIb/IV NSCLC previously 
treated with a platinum-
based chemotherapy 
regimen.
(Shepherd et al., 2000) Time to progression was longer for docetaxel patients 
than for best supportive care patients (10.6 v 6.7 
weeks, respectively; p<.001), as was median survival 
(7.0 v 4.6 months; log-rank test, p=.047).
Intervention:
Docetaxel
Comparison:
Best Supportive Care
Pemetrexed (non squamous histology only)
Patient population: Study/Author: Results:
Patients with advanced
NSCLC, PS 0-2, previously 
treated with chemotherapy.
(Hanna et al., 2004) Median progression-free survival was 2.9 months for 
each arm, and median survival time was 8.3 versus 
7.9 months (p=not significant) for pemetrexed and 
docetaxel, respectively.
Intervention:
Pemetrexed
Comparison:
Docetaxel
Erlotinib
Patient population: Study/Author: Results:
Patients with advanced 
NSCLC previously treated 
with a platinum-based 
chemotherapy, and wild-type 
EGFR.
(Garassino et al., 2013) Median overall survival was 8.2 months (95% CI 5.8–
10.9) with docetaxel versus 5.4 months (4.5–6.8) with 
erlotinib (adjusted HR 0.73, 95% CI 0.53–1.00; p=0.05). 
Progression-free survival was significantly better with 
docetaxel than with erlotinib: median progression-
free survival was 2.9 months (95% CI 2.4–3.8) with 
docetaxel versus 2.4 months (2.1–2.6) with erlotinib 
(adjusted HR 0.71, 95% CI 0.53–0.95; p=0.02).
Intervention:
Erlotinib
Comparison:
Docetaxel
___________________________
1 The process for reimbursement is outlined on page 130.
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Erlotinib (cont.)
Patient population: Study/Author: Results:
Patients with stage IIIb or IV 
NSCLC, previous treatment 
with chemotherapy, and 
performance status of 0 to 2 
were eligible.
(Kawaguchi et al., 2014) Median progression-free survival for erlotinib versus 
docetaxel was 2.0 v 3.2 months (HR 1.22; 95% CI, 
0.97 to 1.55; p=.09), and median OS was 14.8 v 
12.2 months (HR 0.91; 95% CI, 0.68 to 1.22; p=.53), 
respectively. 
Intervention:
Erlotinib
Comparison:
Docetaxel
Patient population: Study/Author: Results:
Patients with NSCLC 
that progressed on first-
line, platinum-doublet 
chemotherapy.
(Ciuleanu et al., 2012) Median overall survival was 5.3 months (95% CI 
4.0–6.0) with erlotinib and 5.5 months (4.4–7.1) 
with chemotherapy (HR 0.96, 95% CI 0.78–1.19; 
log-rank p=0.73). Median PFS in the erlotinib group 
was 6.3 weeks (95% CI 6.1–6.9) versus 8.6 weeks 
(7.1–12.1) in the chemotherapy group. There was no 
statistically significant difference in PFS between the 
two treatment groups (HR 1.19, 95% CI 0.97–1.46; 
p=0.089).
Intervention:
Erlotinib
Comparison:
Chemotherapy (standard 
docetaxel or pemetrexed 
regimens, at the treating 
investigators’ discretion)
Patient population: Study/Author: Results:
Patients with stage 
IIIb or IV NSCLC, with 
performance status from 0 
to 3, were eligible if they had 
received one or two prior 
chemotherapy regimens.
(Shepherd et al., 2005) Progression-free survival was 2.2 months and 
1.8 months, respectively (HR 0.61, adjusted for 
stratification categories; p<0.001). Overall survival was 
6.7 months and 4.7 months, respectively (HR 0.70; 
p<0.001), in favour of erlotinib.
Intervention:
Erlotinib
Comparison:
Placebo
Afatinib (Squamous histology only)
Patient population: Study/Author: Results:
Stage IIIb or IV squamous 
cell carcinoma of the lung 
who had progressed after at 
least four cycles of platinum-
based-chemotherapy.
(Soria et al., 2015) Median progression-free survival was 2.6 months (95% 
CI 2.0–2.9) with afatinib and 1.9 months (1.9–2.1) 
with erlotinib (HR 0.81 [95% CI 0.69–0.96]; p=0.0103). 
Median overall survival was 7.9 months (95% CI 
7.2–8.7) in the afatinib group and 6.8 months (5.9–7.8) 
in the erlotinib group (HR 0.81 [95% CI 0.69–0.95]; 
p=0.0077).
Intervention:
Afatinib
Comparison:
Erlotinib
Patient population: Study/Author: Results:
Patients with stage IIIb or 
IV adenocarcinoma and an 
ECOG PS of 0–2 who had 
received one or two previous 
chemotherapy regimens 
and had disease progression 
after at least 12 weeks of 
treatment with erlotinib or 
gefitinib.
(Miller et al., 2012) Median overall survival was 10.8 months (95% CI 10.0–
12.0) in the afatinib group and 12.0 months (10.2–
14.3) in the placebo group (HR 1.08, 95% CI 0.86–1.35; 
p=0.74). Median progression-free survival was longer 
in the afatinib group (3.3 months, 95% CI 2.79–4.40) 
than it was in the placebo group (1.1 months, 0.95–
1.68; HR 0.38, 95% CI 0.31–0.48; p<0.0001).
Intervention:
Afatinib
Comparison:
Placebo
77| A National Clinical Guideline | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
Nivolumab
Patient population: Study/Author: Results:
Patients with non-squamous 
NSCLC that had progressed 
during or after platinum-
based doublet chemotherapy.
(Borghaei et al., 2015) Median overall survival was 12.2 months (95% CI, 9.7 
to 15.1) with nivolumab and 9.4 months (95% CI, 8.1 
to 10.7) with docetaxel, representing a 28% lower risk 
of death with nivolumab (HR 0.72; 95% CI, 0.60 to 
0.88; p<0.001). The median progression-free survival 
was 2.3 months (95% CI, 2.2 to 3.3) in the nivolumab 
group and 4.2 months (95% CI, 3.5 to 4.9) in the 
docetaxel group.
Intervention:
Nivolumab
Comparison:
Docetaxel
Patient population: Study/Author: Results:
Patients with advanced 
squamous-cell NSCLC who 
have disease progression 
during or after first-line 
chemotherapy.
(Brahmer et al., 2015) The median overall survival was 9.2 months (95% 
confidence interval [CI], 7.3 to 13.3) with nivolumab 
versus 6.0 months (95% CI, 5.1 to 7.3) with docetaxel. 
The median progression-free survival was 3.5 months 
with nivolumab versus 2.8 months with docetaxel (HR 
for death or disease progression, 0.62; 95% CI, 0.47 to 
0.81; p<0.001).
Intervention:
Nivolumab
Comparison:
Docetaxel
Pembrolizumab (PDL1 positive)
Patient population: Study/Author: Results:
Patients with previously 
treated, PD-L1-positive, 
advanced NSCLC.
(Herbst et al., 2016) Overall survival was significantly longer for 
pembrolizumab 2 mg/kg versus docetaxel (HR 0.71, 
95% CI 0.58–0.88; p=0.0008) and for pembrolizumab 
10 mg/kg versus docetaxel (0.61, 0.49–0.75; 
p<0.0001). Median progression-free survival was 3.9 
months with pembrolizumab 2 mg/kg, 4.0 months 
with pembrolizumab 10 mg/kg, and 4.0 months 
with docetaxel, with no significant difference for 
pembrolizumab 2 mg/kg versus docetaxel (0.88, 0.74–
1.05; p=0.07) or for pembrolizumab 10 mg/kg versus 
docetaxel (HR 0.79, 95% CI 0.66–0.94; p=0.004).
Intervention:
Pembrolizumab (2 mg/kg) 
Pembrolizumab (10 mg/kg)
Comparison:
Docetaxel
The following single agents have also shown benefit as second/third-line treatment in patients with ALK 
positive tumours:
Crizotinib
Patient population: Study/Author: Results:
Patients with locally advanced 
or metastatic ALK-positive 
lung cancer who had received 
one prior platinum-based 
regimen.
PROFILE 1007
(Shaw et al., 2013)
The median progression-free survival was 7.7 
months in the crizotinib group and 3.0 months in the 
chemotherapy group (HR for progression or death 
with crizotinib, 0.49; 95% CI, 0.37 to 0.64; p<0.001). 
The median overall survival was 20.3 months (95% CI, 
18.1 to not reached) with crizotinib and 22.8 months 
(95% CI, 18.6 to not reached) with chemotherapy (HR 
for death in the crizotinib group, 1.02; 95% CI, 0.68 to 
1.54; p=0.54)
Intervention:
Crizotinib
Comparison:
Pemetrexed or 
Docetaxel
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Ceritinib (previously treated with crizotininb)
Patient population: Study/Author: Results:
Patients with ALK-rearranged 
locally advanced or metastatic 
cancer that progressed 
despite standard therapy.
ASCEND-1, 
- Phase I study, 
- (Kim et al., 2016, Shaw 
et al., 2014)
An overall response was reported in 60 (72% [95% CI 
61–82]) of 83 ALK inhibitor-naive patients and 92 (56% 
[49–64]) of 163 ALK inhibitor-pretreated patients. 
Median duration of response was 17.0 months (95% 
CI 11.3–non-estimable [NE]) in ALK inhibitor-naive 
patients and 8.3 months (6.8–9.7) in ALK inhibitor-
pretreated patients. Median progression-free survival 
was 18.4 months (95% CI 11.1–NE) in ALK inhibitor-
naive patients and 6.9 months (5.6–8.7) in ALK 
inhibitor pretreated patients.
Intervention:
Ceritinib
Comparison:
–
Alectinib (previously treated with crizotinib)
Patient population: Study/Author: Results:
Patients with locally advanced 
or metastatic ALK-rearranged 
NSCLC who had experienced
progression while receiving 
crizotinib.
(Ou et al., 2016) 
- Phase II study
ORR by independent review committee (IRC) was 50% 
(95% CI, 41% to 59%), and the median duration of 
response (DOR) was 11.2 months (95% CI, 9.6 months 
to not reached). Median IRC-assessed progression-free 
survival for all 138 patients was 8.9 months (95% CI, 
5.6 to 11.3 months).
Intervention:
Alectinib 
Comparison:
–
Patient population: Study/Author: Results:
Patients with stage IIIb–IV, 
ALK-positive NSCLC who 
progressed on
previous crizotinib.
(Shaw et al., 2016)
- Phase II study
At the time of the primary analysis (median follow-
up 4.8 months [IQR 3.3–7.1]), 33 of 69 patients with 
measurable disease at baseline had a confirmed partial 
response; thus, the proportion of patients achieving 
an objective response by the independent review 
committee was 48% (95% CI 36–60).
Intervention:
Alectinib
Comparison:
–
The following single agent has also shown benefit as second/third-line treatment in patients with EGFR 
positive tumours:
Osimertinib (T790M mutation positive)
Patient population: Study/Author: Results:
Patients with advanced lung 
cancer who had radiologically 
documented disease 
progression after previous 
treatment with EGFR tyrosine 
kinase inhibitors.
(Janne et al., 2015)
- Phase I study
Among 127 patients with centrally confirmed EGFR 
T790M who could be evaluated for response, the 
response rate was 61% (95% CI, 52 to 70). In contrast, 
among 61 patients without centrally detectable EGFR 
T790M who could be evaluated for response, the 
response rate was 21% (95% CI, 12 to 34). The median 
progression-free survival was 9.6 months (95% CI, 
8.3 to not reached) in EGFR T790M–positive patients 
and 2.8 months (95% CI, 2.1 to 4.3) in EGFR T790M–
negative patients.
Intervention:
Osimertinib
Comparison:
–
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Osimertinib (T790M mutation positive) cont.
Patient population: Study/Author: Results:
Patients with T790M-positive 
advanced non–small cell 
lung cancer, who had disease 
progression after first-line 
EGFR-TKI therapy.
Mok et al., 2017 
- Phase III study
The median duration of progression-free survival 
was significantly longer with osimertinib than with 
platinum therapy plus pemetrexed (10.1 months vs. 
4.4 months; HR 0.30; 95% CI, 0.23 to 0.41; p<0.001). 
The objective response rate was significantly better 
with osimertinib (71%; 95% CI, 65 to 76) than with 
platinum therapy plus pemetrexed (31%; 95% CI, 24 
to 40) (odds ratio for objective response, 5.39; 95% CI, 
3.47 to 8.48; p<0.001).
Intervention:
Osimertinib
Comparison:
Pemetrexed 
plus either carboplatin 
or cisplatin
Recommendation 2.6.7.1 Grade
Second-line systemic anticancer therapy (SACT) with single agent drugs should be 
considered. The choice of agent to be used should be made on a case by case basis taking 
into account previous treatment, mutation status and co-morbidities. 
B
Good practice point
This is a rapidly evolving area; please refer to the NCCP protocols for the latest information.
Good practice point
In all cases if patients are eligible for entry into clinical trials, it is recommended.
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Clinical question 2.6.8
Is there any evidence that particular regimens or drugs are more effective or less toxic than others for 
the first-line treatment of limited-stage and extensive-stage small-cell lung cancer (SCLC)?
Evidence summary 
A Cochrane review (Amarasena et al., 2015) addressed this clinical question.
Amarasena et al. (2015) aimed to determine the effectiveness of platinum chemotherapy regimens 
compared with non-platinum chemotherapy regimens in the treatment of SCLC with respect to survival, 
tumour response, toxicity and quality of life.
Survival at 24 months
There was no statistically significant difference between interventions (RR 1.06, 95% CI 0.85 to 1.31). 
There was no substantial heterogeneity present in the data (I2 = 31%). 
 Subgroup LD-SCLC: 
 Nine studies reported data from 12-month survival comparisons for participants with limited 
disease, involving 1,209 participants. Of these, 597 received a platinum-based and 612 received a 
non-platinum based regimen. At 24 months, 255 participants were alive: 133 from the platinum-
based arm and 122 from the non-platinum based arm. There was no statistically significant difference 
between interventions (RR 1.07, 95% CI 0.7 to 1.65). There was substantial heterogeneity present in 
the data (I2 = 57%). 
 Subgroup ED-SCLC: 
 Fifteen studies reported data from 24-month survival comparisons for participants with extensive 
disease, involving 2,381 participants. Of these, 1,200 received a platinum-based and 1,181 received a 
non-platinum-based regimen. There was no statistically significant difference between interventions 
(RR 1.11, 95% CI 0.71 to 1.75). There was substantial heterogeneity present in the data (I2 = 35%).
Complete response
There was a statistically significant effect favouring platinum-based chemotherapy regimens (RR 1.32, 
95% CI 1.14 to 1.54). There was no substantial heterogeneity present in the data (I2 = 46%) 
 Subgroup LD-SCLC: 
 There was a statistically significant effect favouring platinum-based regimens (RR 1.19, 95% CI 1.02 
to 1.40). There was no heterogeneity (I2 = 0%). 
 Subgroup ED-SCLC: 
 There was a statistically significant effect, favouring platinum-based chemotherapy regimens (RR 
1.45, 95% CI 1.17 to 1.80). There was no substantial heterogeneity present in the data (I2 = 24%).
The effect on quality of life could not be adequately assessed.
Many other combinations have been evaluated in patients with extensive-stage disease, with little 
consistent evidence of benefit when compared with EP. While phase III data exists regarding irinotecan 
and platinum combinations (Lara et al., 2009, Hanna et al., 2006, Noda et al., 2002, Hermes et al., 2008) 
they do not appear superior with potentially significant toxicity.
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Recommendation 2.6.8.1 Grade
In patients with either limited-stage or extensive-stage small-cell lung cancer (SCLC), 
platinum-based chemotherapy with either cisplatin or carboplatin plus etoposide is 
recommended. 
A
Recommendation 2.6.8.2 Grade
Non-platinum combinations can be considered in patients with limited-stage and extensive-
stage SCLC. 
A
Good practice point 
Ensure patients are offered participation in a clinical trial when available and appropriate.
Good practice point 
Patients should be referred for assessment by the palliative care service.
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Clinical question 2.6.9
In patients with limited-stage and extensive-stage SCLC is there any role for maintenance 
chemotherapy?
Evidence summary
A meta-analysis (Zhou et al., 2013) addressed this clinical question.
A meta-analysis (Zhou et al., 2013) reported that maintenance chemotherapy did not prolong overall 
survival (HR 0.87; 95% CI: 0.71–1.06; p=0.172). Overall, maintenance chemotherapy was associated with 
a 13% improvement in OS, but the difference was not statistically significant and there was significant 
heterogeneity in the included studies. The authors noted that the results were not affected by exclusion 
of any specific trial.
Recommendation 2.6.9.1 Grade
There is no data to support maintenance therapy in limited-stage or extensive-stage SCLC. C
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Clinical question 2.6.10
How effective is second-line systemic therapy in patients with SCLC who progress and relapse?
Evidence summary 
Two randomised phase III trials (O’Brien et al., 2006, von Pawel et al., 2014) addressed this clinical 
question. 
For patients with small-cell lung cancer, further chemotherapy is routinely considered at relapse after 
first-line therapy. However, proof of clinical benefit has not been documented. (O’Brien et al., 2006)
 
O’Brien et al. (2006) randomly assigned patients with relapsed SCLC not considered as candidates for 
standard intravenous therapy to best supportive care (BSC) alone (n = 70) or oral topotecan (2.3 mg/m2/d, 
days 1 through 5, every 21 days) plus BSC (topotecan; n = 71). In the intent-to-treat population, survival was 
prolonged in the topotecan group (log-rank p=0.0104). Median survival with BSC was 13.9 weeks (95% CI, 
11.1 to 18.6) and with topotecan, 25.9 weeks (95% CI, 18.3 to 31.6). Statistical significance for survival was 
maintained in a subgroup of patients with a short treatment-free interval (≤ 60 days). Response to topotecan 
was 7% partial and 44% stable disease. Patients on topotecan had slower quality of life deterioration and 
greater symptom control. Principal toxicities with topotecan were haematological: grade 4 neutropenia, 
33%; grade 4 thrombocytopenia, 7%; and grade 3/4 anaemia, 25%. Comparing topotecan with BSC, 
infection grade 2 was 14% versus 12% and sepsis 4% versus 1%; other grade 3/4 events included vomiting 
3% versus 0, diarrhoea 6% versus 0, dyspnoea 3% versus 9%, and pain 3% versus 6%. Toxic deaths occurred 
in four patients (6%) in the topotecan arm. All cause mortality within 30 days of random assignment was 
13% on BSC and 7% on topotecan. Chemotherapy with oral topotecan is associated with prolongation of 
survival and quality of life benefit in patients with relapsed SCLC. 
von Pawel et al. (2014) randomly assigned 637 patients with refractory or sensitive SCLC at a ratio of 2:1 
to 21-day cycles of amrubicin 40 mg/m2 intravenously (IV) on days 1 to 3 or topotecan 1.5 mg/m2 IV on 
days 1 to 5. Median OS was 7.5 months with amrubicin versus 7.8 months with topotecan (HR 0.880; 
p=0.170); in refractory patients, median OS was 6.2 and 5.7 months, respectively (HR 0.77; p=0.047). 
Median PFS was 4.1 months with amrubicin and 3.5 months with topotecan (HR 0.802; p=0.018). ORR 
was 31.1% with amrubicin and 16.9% with topotecan (odds ratio, 2.223; p<0.001). Grade ≥ 3 treatment-
emergent adverse events in the amrubicin and topotecan arms were: neutropenia (41% v 54%; p=0.004), 
thrombocytopenia (21% v 54%; p<0.001), anaemia (16% v 31%; p<0.001), infections (16% v 10%; 
p=0.043), febrile neutropenia (10% v 3%; p=0.003), and cardiac disorders (5% v 5%; p=0.759); transfusion 
rates were 32% and 53% (p<0.001), respectively. NQO1 polymorphisms did not influence safety 
outcomes. Amrubicin had demonstrable activity and a safety profile comparable to that of topotecan in 
patients with SCLC. Amrubicin also demonstrated higher response rates and a minimal survival advantage 
of 2 weeks in patients with refractory disease.
Recommendation 2.6.10.1 Grade
In patients with relapsed refractory SCLC, second-line therapy should be considered. B
Recommendation 2.6.10.2 Grade
Re-initiation of the previously administered first-line chemotherapy regimen is 
recommended in patients with SCLC who relapse greater than six months from completion 
of initial chemotherapy. 
B
Recommendation 2.6.10.3 Grade
Single agent chemotherapy should be considered in patients with primary refractory SCLC 
to maintain or improve quality of life. 
B
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2.7 Radiation Oncology
Responsibility for the implementation of radiation oncology recommendations
While the CEO, General Manager and the Clinical Director of the hospital have corporate responsibility 
for the implementation of the recommendations in this National Clinical Guideline, each member of the 
multidisciplinary team is responsible for the implementation of the individual guideline recommendations 
relevant to their discipline.
The literature used in the development of this guideline was based on the 7th edition of the Lung 
Cancer TNM staging system. The 8th edition of the TNM staging system was published in December 
2016 (Brierley et al., 2016), this may lead to changes in recommendations over time, which should be 
taken into consideration at multidisciplinary team meetings. 
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Clinical question 2.7.1 
In patients with non-small cell lung cancer (NSCLC) early stage disease (T1-T2 N0 M0) who are unfit 
for surgery, what is the effectiveness of stereotactic radiotherapy, standard radical radiotherapy and 
radiofrequency ablation? 
Evidence summary 
Two clinical guidelines (NICE, 2011, Vansteenkiste et al., 2013) and a retrospective study (Ambrogi et al., 
2015) addressed this clinical question. 
Crabtree et al. (2010) found that among their group of patients with clinical stage I NSCLC significantly 
more patients who had received surgical treatment were alive at 3 years than patients who had received 
SBRT/SABR. The treatment groups did not differ in terms of 3-year cancer-specific survival or local control. 
When the analyses were limited to patients with clinical stage Ia 3-year disease-free survival did not differ 
significantly between the SBRT/SABR (n = 57) and surgery (n = 288) patients, but the surgery patients 
achieved significantly higher rates of local control at 3 years compared to the SBRT/SABR patients. 
Analysis of the patients with clinical stage Ib found no differences in 3-year disease-free survival or local 
control between the SBRT/SABR (n = 19) and surgery (n = 174) patients. In a separate series of analyses 
the authors attempted to address the baseline differences between the treatment groups in terms of age, 
clinical T stage, comorbidities and % predicted FEV1 and DLCO by matching surgery patients to the SBRT/
SABR patients. Subsequent matched-patient analyses revealed no differences between the groups in 
terms of overall survival, disease-specific survival, or local control. No treatment-related deaths occurred 
as a consequence of SBRT although some other complications were associated with the treatment. In 
the surgery group, the operative mortality rate was 15/462 patients and 179/462 patients experienced 
complications associated with the surgical treatment. (NICE, 2011) 
Grills et al. (2010) reported that rates of freedom from any failure, causes-specific survival, distant 
metastasis and local, regional, and loco-regional recurrence did not differ significantly between patients 
with stage I NSCLC who had received treatment with either SBRT/SABR or wedge resection, but the 
overall survival rate was significantly higher in the surgery patients than in those patients who had 
received SBRT/SABR. A second set of analyses excluding patients with pT4, synchronous primary or no 
biopsy revealed similar results with the exception of the loco-regional occurrence rate which was now 
significantly higher in the patients who had received surgery. Multivariate analyses showed that in the 
patients who had received SBRT/SABR squamous histology and the presence of synchronous primary 
tumour were significant predictors of distant metastasis and in the patients who had received wedge 
resection, visceral pleural invasion and stage Ib were significant predictors of distant metastasis. In 
addition, in all patients, age > 71 years was a significant predictor of overall survival. No treatment-
related deaths were observed as a consequence of either treatment, but a number of adverse events 
were associated with both treatments. (NICE, 2011)
In patients unfit for surgery, SBRT/SABR is the treatment of choice for peripherally located stage I NSCLC (if 
SBRT/SABR is not available, a hypofractionated radiotherapy schedule with a high biologically equivalent 
dose is advised). (Vansteenkiste et al., 2013) 
SBRT/SABR has led to improved population-based survival in elderly patients (Haasbeek et al., 2012), and 
the convenience of this outpatient therapy over three to eight visits has also led to a reduction in the 
proportion of untreated patients. The SBRT/SABR dose should be to a biologically equivalent tumour dose 
of ≥100 Gy, prescribed to the encompassing isodose. (Vansteenkiste et al., 2013) 
A systematic review comparing outcomes of SBRT/SABR and surgery in patients with severe COPD 
revealed a higher 30-day mortality following surgery but similar OS at 1 and 3 years (Palma et al., 2012). 
Analysis of SBRT/SABR outcomes in 676 patients found a median OS of 40.7 months, and actuarial 5-year 
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rates of initial local, regional and distant recurrence of 10.5%, 12.7% and 19.9%, respectively (Senthi et 
al., 2012). A systematic review of SABR in centrally located tumours found local control rates of >85% 
with biologically equivalent doses ≥100 Gy (Senthi et al., 2013). The risk of high grade toxic effect was 
<9% when the biologically equivalent normal tissue dose was ≤210 Gy. Prospective trials of SBRT/SABR 
versus primary resection are now underway. (Vansteenkiste et al., 2013) 
Radiofrequency ablation 
Ambrogi et al. (2015) compared RFA and wedge resection in terms of disease recurrence and survival, as 
intent-to-treat therapy for stage I NSCLC in 121 marginal or non-surgical candidates. 
Over a 7 year period, 59 patients were treated for stage I NSCLC with wedge resection and 62 with RFA. 
At a median follow-up of 36 and 42 months for wedge resection and for RFA (p=0.232), local recurrence 
rate was 2 and 23%, respectively (p=0.002). The 1-, 2- and 5-year overall survival (disease-free interval) 
rates were 100% (96%), 96% (90%) and 52% (76%) for wedge resection, and 93% (87%), 72% (63%), and 
35% (55%) for RFA (p=0.044 and p=0.01, respectively). None of the analysed parameters was found to 
be risk factor for disease recurrence and survival, except stage T2, which significantly affected disease-
recurrence, overall and cancer-related survival and disease-free interval in the RFA group. 
Nevertheless, the debate seems open for patients with stage Ia disease. In these cases, RFA seems to have 
equivalent outcomes compared with wedge resection, thus the selection of patients is more challenging 
due to the acceptable risk level, which depends also on the different success rate of the non-surgical 
alternative therapies. Further prospective randomised studies are necessary, in order to clearly compare 
the outcomes of different modality therapies, but also to better define patients considered at high risk. 
(Ambrogi et al., 2015)
There is some evidence to show radiofrequency ablation can achieve local tumour control in patients 
with clinical stage Ia tumours; however there are no published studies that determine its utility compared 
to other management strategies and further clinical trials comparing RFA to other local therapies are 
therefore needed. 
Recommendation 2.7.1.1 Grade
Every patient with early stage disease (T1-T2 N0 M0) should be evaluated for fitness for 
surgery. If unfit for surgery or surgery is declined, patients should be considered for radical 
treatment, preferably SBRT/SABR or radical radiotherapy. 
A
Recommendation 2.7.1.2 Grade
Radiofrequency ablation (RFA) can be considered for patients with clinical stage Ia tumours 
who are not suitable for surgery following discussion at a multidisciplinary team meeting. 
(Refer to Clinical question 2.2.3).
D
Good practice point 
If SBRT/SABR is not available or not feasible radical radiotherapy may be considered.
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Clinical question 2.7.2 
In patients with stage I-III NSCLC undergoing radical external beam radiation therapy what is the role 
and effectiveness of the following: 
a)  New technology (IMRT/4DCT - breathing adapted radiotherapy) 
b)  Altered radiation fractionation schedules (Hyper and/or accelerated fractionation) 
c)  Dose 
Evidence summary 
Three clinical guidelines (NICE, 2011, SIGN, 2014, Vansteenkiste et al., 2013), two retrospective studies 
(Cole et al., 2014, Liao et al., 2010) and an individual patient data meta-analysis (Mauguen et al., 2012) 
addressed this clinical question. 
a) New technology 
Newer technologies can reduce target volumes and hence normal tissue toxicity and can allow dose 
escalation to take place with the goal of increasing the biologically effective dose (BED) to a level to 
achieve maximal tumour treatment with acceptable toxicity outcomes (De Ruysscher et al., 2012, 
Machtay et al., 2012). Using isotoxic dose escalation, 4D planning in this study would allow, on average, an 
additional increase in total dose by a factor of 1.19 compared with 3D planned dose escalation. For 55 Gy 
in 20 fractions with a BED of 70.13 Gy10 this would mean an average increase to a BED of 83.3 Gy10. Some 
studies suggest that an increase in absolute dose of 1 Gy is associated with a 3% reduction in death (Kong 
et al., 2005). By optimising dose prescription, potential gains for the patient in tumour control probability 
(TCP) can be realised while balancing the risk of acceptable normal tissue complication probability (NTCP) 
(Machtay et al., 2012). Mean Lung Dose (MLD) was lower for 19/20 of 4D planned cases, with an average 
reduction from 13.1 Gy to 11.1 Gy. This reduction in MLD can allow for dose escalation and where this is 
not possible, such as for conventional treatments that are not adapted or escalated, could theoretically 
lead to lower lung toxicity rates. (Cole et al., 2014) 
Four-dimensional computed tomography (4DCT) based plans had lower planning target volume (PTV), 
a lower dose to organs at risk and lower predicted NTCP rates on LKB modelling (p<0.006). The clinical 
algorithm showed no difference for predicted 2-year survival and dyspnoea rates between the groups, 
but did predict for lower oesophageal toxicity with 4DCT plans (p=0.001). There was no correlation 
between LKB modelling and the clinical algorithm for lung toxicity or survival. Dose escalation was 
possible in 15/20 cases, with a mean increase in dose by a factor of 1.19 (10.45 Gy) using 4DCT compared 
with 3DCT plans. (Cole et al., 2014) 
4DCT can theoretically improve therapeutic ratio and dose escalation based on dosimetric parameters 
and mathematical modelling. However, when individual characteristics are incorporated, this gain may be 
less evident in terms of survival and dyspnoea rates. 
4DCT allows potential for isotoxic dose escalation, which may lead to improved local control and better 
overall survival. (Cole et al., 2014) 
Mean follow-up times in the 4DCT/IMRT and CT/3DCRT groups were 1.3 (range, 0.1–3.2) and 2.1 (range, 
0.1–7.9) years, respectively. The hazard ratios for 4DCT/IMRT were <1 for all disease end points; the 
difference was significant only for OS. The toxicity rate was significantly lower in the IMRT/4DCT group 
than in the CT/ 3DCRT group. V20 was significantly higher in the 3DCRT group and was a significant factor 
in determining toxicity. Freedom from DM was nearly identical in both groups. (Liao et al., 2010) 
Treatment with 4DCT/IMRT was at least as good as that with 3DCRT in terms of the rates of freedom from 
locoregional progression (LRP) and distant metastasis (DM). There was a significant reduction in toxicity 
and a significant improvement in OS. (Liao et al., 2010) 
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b) Altered radiation fractionation schedules
One study of low quality was identified that examined the effectiveness of induction chemotherapy 
+ hyperfractionated accelerated radiotherapy (HART) relative to the effectiveness of induction 
chemotherapy + standard once-daily RT in patients with stage IIIa and IIIb NSCLC (Belani et al., 2005). 
Overall survival, progression-free survival, response and incidence of grade 3 and above toxicities did not 
differ between the treatment groups. (NICE, 2011) 
The European Society for Medical Oncology (ESMO) (Vansteenkiste et al., 2013) recommends the use of 
accelerated radiotherapy (e.g. 66Gy in 24 fractions) based on the results of a meta-analysis conducted 
by Maugen et al. (2012). The meta-analysis included individual patient data from phase III trials, it found 
that modified fractionation improved OS as compared with conventional schedules (hazard ratio (HR) = 
0.88, 95% CI, 0.80 to 0.97; p=.009), resulting in an absolute benefit of 2.5% (8.3% to 10.8%) at 5 years. In 
both NSCLC and SCLC, the use of modified radiotherapy increased the risk of acute oesophageal toxicity 
(odds ratio [OR] = 2.44 in NSCLC and OR = 2.41 in SCLC; p<.001) but did not have an impact on the risk of 
other acute toxicities. The study concluded that patients with nonmetastatic NSCLC derived a significant 
OS benefit from accelerated or hyperfractionated radiotherapy; a similar but non-significant trend was 
observed for SCLC.
The Scottish Intercollegiate Guideline Network (SIGN) looked at hyperfractionated and/or accelerated 
radiotherapy in stage III NSCLC. They identified a meta-analysis and two RCTs (Lung Cancer Disease 
Group, 2000, Sause et al., 2000, Saunders et al., 1999) that suggest a survival benefit for accelerated 
and hyperfractionated radical radiation therapy compared with conventional radiotherapy. No benefit 
was observed for hyperfractionated radical radiation therapy of standard time length over conventional 
radiotherapy (SIGN, 2014).
Saunders et al. (1997) showed that continuous hyperfractionated accelerated radiation therapy 
(CHART) is more effective than 60 Gy over six weeks in patients with disease stage I to III not receiving 
chemotherapy.
c) Dose
A Cochrane review and a systematic review identified 44 retrospective case series including a total of 
3,683 patients treated with regimens of radiotherapy with doses of more than 50 Gy in 25 fractions 
or its radiobiological equivalent (Rowell and Williams, 2004, Qiao et al., 2003). The studies are difficult 
to compare because of unknown variation in entry criteria or pre-treatment prognostic criteria. Study 
results are inconsistent, with three and five year survival rates ranging from 0–55%. It is not clear whether 
the inconsistencies are due to variations in patient selection, treatment techniques or completeness of 
follow-up. (SIGN 2014)
Recommendation 2.7.2.1 Grade
In patients receiving combined chemoradiotherapy standard fractionation should be used 
to deliver a radical dose equivalent to 60 – 66 Gy. 
A
Recommendation 2.7.2.2 Grade
When a radical dose is considered, 3D-CRT is the minimum technique to be used. B
Recommendation 2.7.2.3 Grade
When available, CHART can be considered in patients with non-operable stage I-III non-
small cell lung cancer (NSCLC) not receiving chemotherapy. 
A
Good practice point 
4DCT should be used when available.
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Clinical question 2.7.3 
In patients with stage III NSCLC undergoing radical three-dimensional conformal radiotherapy 
(3DCRT): 
a)  What are the most useful predictors of lung and oesophageal toxicity? 
b)  What are the most useful measures to reduce toxicity: clinical/technical?
Evidence summary 
Two clinical guidelines (SIGN, 2014, Lim et al., 2010), two retrospective studies (Cole et al., 2014, Liao et 
al., 2010) and a review (Marks et al., 2010) addressed this clinical question. 
A clinical oncologist specialising in lung oncology should determine suitability for radical radiotherapy, 
taking into account performance status and comorbidities. (SIGN, 2014) 
When planning radical radiotherapy to the thorax it is crucial to take into account the dose delivered 
to the normal lung tissue, oesophagus, spinal cord and heart. In order to ensure the maximum sparing 
of normal tissues, three-dimensional treatment planning is mandatory (Senan et al., 2004). However, 
defining limits of dose tolerated by these tissues is complex as these limits vary according to the total dose 
delivered, fractionation regimen and use of concurrent chemotherapy (Milano et al., 2007, Schultheiss et 
al., 1995, van Baardwijk et al., 2008a, van Baardwijk et al., 2008b). The risk of developing radiotherapy-
induced lung toxicity can be estimated by calculating the dose-volume histogram of the lungs, including 
V20 and mean lung dose (MLD) (Graham et al., 1999, Kwa et al., 1998). (Lim et al., 2010) 
The greatest limitation of thoracic radiotherapy is radiotherapy induced lung toxicity (Graham et al., 
1999, Kwa et al., 1998, Roach et al., 1995, Gandara et al., 2003). Radiotherapy planning parameters such 
as V20 and MLD are effective tools for predicting radiation pneumonitis (Graham et al., 1999, Kwa et al., 
1998). (Lim et al., 2010) 
There is a paucity of RCT data on reducing radiation-related morbidity, either by altering the radiation 
technique or by adding in other agents to treatment regimes. In many chemoradiotherapy trials 
pulmonary function limits are set for exclusion criteria. Safe lower limits of respiratory function (FEV1 or 
TLCO) for radical radiotherapy have not been established (Lim et al., 2010). (SIGN, 2014) 
According to the Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) lung-specific 
paper (Marks et al., 2010) it is prudent to limit V20 to ≤30–35% and mean lung dose to ≤20–23 Gy (with 
conventional fractionation) if one wants to limit the risk of radiation pneumonitis to ≤20% in definitively 
treated patients with non–small cell lung cancer. 
Cole et al. (2014) investigated the potential dosimetric and clinical benefits predicted by using four-
dimensional computed tomography (4DCT) compared with 3DCT in the planning of radical radiotherapy 
for non-small cell lung cancer. 
Twenty patients were planned using free breathing 4DCT then retrospectively delineated on three-
dimensional helical scan sets (3DCT). Beam arrangement and total dose (55 Gy in 20 fractions) were 
matched for 3D and 4D plans. Plans were compared for differences in planning target volume (PTV) 
geometrics and NTCP for organs at risk using dose volume histograms. Tumour control probability and 
NTCP were modelled using the Lyman–Kutcher–Burman (LKB) model. This was compared with a predictive 
clinical algorithm (Maastro), which is based on patient characteristics, including: age, performance status, 
smoking history, lung function, tumour staging and concomitant chemotherapy, to predict survival and 
toxicity outcomes. Potential therapeutic gains were investigated by applying isotoxic dose escalation to 
both plans using constraints for MLD (18 Gy), oesophageal maximum (70 Gy) and spinal cord maximum 
(48 Gy). (Cole et al., 2014)
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In addition to oesophageal dosimetry, the use of concurrent delivery of chemotherapy has been shown 
to increase toxicity rates (Belderbos et al., 2005, Auperin et al., 2010). (Cole et al., 2014) 
Radiation pneumonitis is an important consideration for patients with lung cancer, particularly for those 
with already compromised respiratory function (Wang et al., 2002). This potentially life-threatening 
complication is generally experienced in the first months after treatment. Established theoretical models 
to predict the risk of pneumonitis include MLD or the volume of lung receiving more than a threshold 
dose (e.g. V20) (Kwa et al., 1998, Fay et al., 2005). Predicted rates for lung toxicity in this group were 22% 
less for the 4D group. When specific tumour and patient characteristics were combined with dosimetric 
parameters, this apparent improvement was not seen. This suggests that despite close attention to dose 
constraints and dose volume histogram (DVH) characteristics, clinical factors may have a larger impact on 
pneumonitis risks and outweigh any improvements that 4DCT may convey on an individual basis. (Cole et 
al., 2014) 
Treatment with 4DCT/IMRT was at least as good as that with 3DCRT in terms of the rates of freedom from 
locoregional progression (LRP) and distant metastasis (DM). There was a significant reduction in toxicity 
and a significant improvement in OS (Liao et al., 2010). 
Recommendation 2.7.3.1 Grade
Perform three-dimensional treatment planning in patients undergoing radical thoracic 
radiotherapy. 4DCT should be performed where available. 
B
Recommendation 2.7.3.2 Grade
The dose volume parameters for the organs at risk (e.g. oesophagus, lung) need to be 
taken into account. It is prudent to limit V20 to ≤30–35% and mean lung dose to ≤20–23 Gy 
(with conventional fractionation) if one wants to limit the risk of radiation pneumonitis to 
≤20% in definitively treated patients with NSCLC. 
B
Good practice point 
Pre-radical radiotherapy pulmonary function tests are recommended.
Good practice point 
A clinical oncologist specialising in lung oncology should determine suitability for radical radiotherapy, 
taking into account performance status, comorbidities and tumour volume.
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Clinical question 2.7.4
In patients with NSCLC post surgery, which groups should receive postoperative radiotherapy (PORT) 
or adjuvant RT? 
a) pN2 R0 
b) any pN, R1, R2 resection 
Evidence summary 
A clinical guideline (Lim et al., 2010) and a meta-analysis (PORT meta-analysis Trialist Group, 1998) 
addressed this clinical question. 
a) pN2 R0
The role of postoperative radiotherapy in treatment of patients with completely resected NSCLC remains 
unclear. The PORT Meta-analysis Trialists Group undertook a systematic review and meta-analysis of the 
available evidence from randomised trials. 
Updated data were obtained on individual patients from all available randomised trials of postoperative 
radiotherapy versus surgery alone. Data on 2128 patients from nine randomised trials (published and 
unpublished) were analysed by intention to treat. Median follow-up was 3.9 years (2.3–9.8 for individual 
trials) for surviving patients. The results show a significant adverse effect of postoperative radiotherapy 
on survival (HR 1.21 [95% CI 1.08–1.34]). Subgroup analyses suggest that this adverse effect was greatest 
for patients with stage I/II, N0–N1 disease, whereas for those with stage III, N2 disease there was no clear 
evidence of an adverse effect. The authors concluded that postoperative radiotherapy is detrimental to 
patients with early-stage completely resected NSCLC and should not be used routinely for such patients. 
The role of postoperative radiotherapy in the treatment of N2 tumours is not clear and may warrant 
further research. (PORT Meta-analysis Trialists Group, 1998) 
b) Any pN, R1, R2 resection
The role of PORT in patients with a positive resection margin (R1 resection) is unknown as there are no 
randomised trials examining the role of radiotherapy in this group of patients (Wind et al., 2007, Jassem, 
2007). PORT is often given in routine practice if pathological examination shows tumour at the resection 
margin on the basis of retrospective series showing a reduction in the local recurrence rates following 
PORT (Massard et al., 2000, Kimura and Yamaguchi, 1994, Ghiribelli et al., 1999, Gebitekin et al., 1994, 
Heikkila et al., 1986) or an excess of local recurrence rates without PORT (Snijder et al., 1998). However, 
some retrospective series have shown high local recurrence rates despite the use of PORT (Gebitekin 
et al., 1994, Snijder et al., 1998). It should also be noted that a retrospective study showed an adverse 
impact of radiotherapy on survival in patients irradiated for positive margins (Massard et al., 2000). (Lim 
et al., 2010)
A literature review on this topic suggested that patients with stage I and II disease and positive margins 
are more likely to benefit from PORT than patients with stage III disease (Wind et al., 2007). Indeed, 
survival of patients with stage I and II non-small cell lung cancer and an R1 resection of the bronchial 
resection margin is significantly worse compared with the stage corrected survival after radical surgery 
(Liewald et al., 1992). The potential benefit of this treatment in terms of reduction of the risk of local 
recurrence rate has to be weighed carefully against the risk of morbidity and mortality related to PORT. 
(Lim et al., 2010) 
The optimal dose/fractionation for PORT is not known, but modern studies suggest that a dose in the 
range of 50-55 Gy using conventional fractionation should be used (Trodella et al., 2002, Bogart and 
Aronowitz, 2005). There are few randomised data investigating the benefit of PORT and its optimal 
sequencing in the context of adjuvant chemotherapy. In adjuvant chemotherapy trials allowing the use 
of PORT, the radiotherapy was delivered after completion of adjuvant chemotherapy and did not seem 
92 | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
| A National Clinical Guideline
to offset the beneficial effect of adjuvant chemotherapy (Douillard et al., 2006, Arriagada et al., 2004, 
Scagliotti et al., 2003). (Lim et al., 2010)
Recommendation 2.7.4.1 Grade
In patients with R1 resection, regardless of N status, postoperative radiotherapy (PORT) 
should be proposed sequentially delivering a radical dose of 60 Gy in 30 fractions. 
B
Recommendation 2.7.4.2 Grade
In patients with a pN2 stage and a complete resection there is no consensus to the benefit 
of PORT. If considered, PORT should be delivered at a dose of 50 Gy standard fractionation. 
B
Recommendation 2.7.4.3 Grade
PORT is not indicated in patients with a complete resection R0 and N0 disease. B
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Clinical question 2.7.5
In patients with small-cell lung cancer (SCLC), what is the evidence supporting the role of radiotherapy 
(including technical parameters) 
a) Limited-stage prophylactic cranial irradiation (PCI) 
b) Limited-stage thoracic radiotherapy 
c) Extensive-stage PCI 
d) Extensive-stage thoracic radiotherapy 
Evidence summary 
A meta-analysis (Pignon et al., 1992), three randomised controlled trials (Le Pechoux et al., 2009, Slotman 
et al., 2007, Slotman et al., 2015) and a retrospective study (Patel et al., 2009) addressed this clinical 
question. 
a) Limited-stage prophylactic cranial irradiation (PCI)
A large retrospective analysis evaluating the effects of PCI on overall survival and cause-specific survival 
(Patel et al., 2009) found overall survival at 2 years, 5 years, and 10 years was 23%, 11%, and 6%, 
respectively, in patients who did not receive PCI. In patients who received PCI, the 2-year, 5-year, and 
10-year overall survival rates were 42%, 19%, and 9%, respectively (p<0.001). The cause-specific survival 
rate at 2 years, 5 years, and 10 years was 28%, 15%, 11%, respectively, in patients who did not receive PCI 
and 45%, 24%, 17%, respectively, in patients who did receive PCI (p<0.001). On multivariate analysis of 
cause-specific and overall survival, age at diagnosis, sex, grade, extent of primary disease, size of disease, 
extent of lymph node involvement, and PCI were found to be significant (p<0.001). Significantly improved 
overall and cause-specific survival was observed in patients treated with prophylactic cranial irradiation 
on unadjusted and adjusted analyses. This study concurs with the previously published European 
experience. PCI should be considered for patients with limited-stage small cell lung cancer. 
The optimum dose of prophylactic cranial irradiation (PCI) for limited-stage small-cell lung cancer (SCLC) 
is unknown. A randomised clinical trial (Le Pechoux et al., 2009) compared the effect of standard versus 
higher PCI doses on the incidence of brain metastases. Seven hundred and twenty patients with limited-
stage SCLC in complete remission after chemotherapy and thoracic radiotherapy from 157 centres 
in 22 countries were randomly assigned to a standard (n=360, 25 Gy in 10 daily fractions of 2.5 Gy) or 
higher PCI total dose (n=360, 36 Gy) delivered using either conventional (18 daily fractions of 2 Gy) or 
accelerated hyperfractionated (24 fractions in 16 days with two daily sessions of 1.5 Gy separated by a 
minimum interval of 6 h) radiotherapy. After a median follow-up of 39 months (range 0–89 months), 145 
patients had brain metastases; 82 in the standard-dose group and 63 in the higher-dose group.
There was no significant difference in the 2-year incidence of brain metastases between the standard PCI 
dose group and the higher-dose group, at 29% (95% CI 24–35) and 23% (18–29), respectively (HR 0.80 
[95% CI 0.57–1.11], p=0.18). Two hundred and twenty six patients in the standard-dose group and 252 in 
the higher-dose group died; 2-year overall survival was 42% (95% CI 37–48) in the standard-dose group 
and 37% (32–42) in the higher-dose group (HR 1.20 [1.00–1.44]; p=0.05). The authors concluded that no 
significant reduction in the total incidence of brain metastases was observed after higher-dose PCI, but 
there was a significant increase in mortality. PCI at 25 Gy should remain the standard of care in limited-
stage SCLC. (Le Pechoux et al., 2009)
b) Limited-stage thoracic radiotherapy
Pignon et al. (1992) performed a meta-analysis of thoracic RT for SCLC. It included 13 trials comparing 
chemotherapy alone to chemotherapy and thoracic RT totalling 2,140 patients, of which 433 were 
excluded as they had extensive disease. 1,862 of the 2,103 patients who could be evaluated died; the 
median follow-up of the surviving patients was 43 months. The relative risk of death in the combined 
therapy group compared to the chemotherapy group was 0.86 (95% CI 0.78-0.94; p=0.001). There was 
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a 5.4% benefit in terms of overall survival at three years for the combined therapy group. The authors 
concluded that thoracic RT moderately improves survival in patients with limited SCLC who are treated 
with combination chemotherapy. 
There is controversy regarding the optimal timing of thoracic radiotherapy, with some meta-analysis 
suggesting a small OS benefit of early delivery concomitantly to chemotherapy. However, this is associated 
with an increase in treatment related toxicity (Lu et al., 2014, Spiro et al., 2006, Pijls-Johannesma et al., 
2005, Huncharek and McGarry, 2004, Fried et al., 2004). 
c) Extensive-stage PCI
Slotman et al., (2007) conducted a randomised trial (European Organisation for Research and Treatment 
of Cancer 08993-22993) of PCI in patients with extensive-stage small-cell lung cancer who had had any 
degree of response to chemotherapy. Patients were randomly assigned to undergo PCI or to receive no 
further therapy. The primary end point was the time to symptomatic brain metastases. CT scanning or 
MRI of the brain was performed when any predefined key symptom suggestive of brain metastases was 
present, but was not done routinely prior to PCI. The two groups (each with 143 patients) were well 
balanced regarding baseline characteristics. The cumulative risk of brain metastases within 1 year was 
14.6% in the PCI group and 40.4% in the control group (HR 0.27; p<0.001). PCI was associated with an 
increase in median overall survival from 5.4 to 6.7 months after randomisation. The 1-year survival rate 
was 27.1% in the PCI group and 13.3% in the control group (p=0.003). PCI had side effects but did not 
have a clinically significant effect on global health status. The largest mean difference between the two 
arms was observed in fatigue and hair loss, which were greater in those who received PCI (Slotman et 
al., 2009). PCI reduced the incidence of symptomatic brain metastases and prolonged overall survival in 
patients with extensive-stage small-cell lung cancer (Slotman et al., 2007).
d) Extensive-stage thoracic radiotherapy
Most patients with extensive-stage small-cell lung cancer who undergo chemotherapy, and prophylactic 
cranial irradiation, have persistent intrathoracic disease. Slotman et al. (2015) assessed thoracic 
radiotherapy for treatment of this patient group. 
A phase III randomised controlled trial at 42 hospitals: 16 in Netherlands, 22 in the UK, three in Norway, 
and one in Belgium, enrolled patients with WHO performance score 0–2 and confirmed extensive-stage 
small-cell lung cancer who responded to chemotherapy. Four hundred and ninety-eight patients were 
randomly assigned (1:1) to receive either thoracic radiotherapy (30 Gy in ten fractions) or no thoracic 
radiotherapy. All underwent prophylactic cranial irradiation. Three withdrew informed consent, leaving 
247 patients in the thoracic radiotherapy group and 248 in the control group. 
Mean interval between diagnosis and randomisation was 17 weeks. Median follow-up was 24 months. 
Overall survival at 1 year was not significantly different between groups: 33% (95% CI 27–39) for the 
thoracic radiotherapy group versus 28% (95% CI 22–34) for the control group (HR 0.84, 95% CI 0.69–1.01; 
p=0.066). However, in a secondary analysis, 2-year overall survival was 13% (95% CI 9–19) versus 3% 
(95% CI 2–8; p=0.004). Progression was less likely in the thoracic radiotherapy group than in the control 
group (HR 0.73, 95% CI 0.61–0.87; p=0.001). At 6 months, progression-free survival was 24% (95% CI 19–
30) versus 7% (95% CI 4–11; p=0.001). No severe toxic effects were recorded. The most common grade 3 
or higher toxic effects were fatigue (11 vs 9) and dyspnoea (three vs four). (Slotman et al., 2015) 
The authors concluded that thoracic radiotherapy in addition to prophylactic cranial irradiation should 
be considered for all patients with extensive-stage small-cell lung cancer who respond to chemotherapy. 
(Slotman et al., 2015)
95| A National Clinical Guideline | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
This is supported by a recent meta-analysis (Palma et al., 2016) that combined the RCT detailed above 
(Slotman et al., 2015) with an older RCT (Jeremic et al., 1999). Palma et al. (2016) examined the role 
of thoracic radiotherapy (TRT) in patients receiving platinum-based chemotherapy for extensive-stage 
small-cell lung cancer. Overall, the delivery of TRT was associated with improved overall survival (HR 
0.81; 95% confidence interval, 0.69-0.96; p=.014) and progression-free survival (HR 0.74; 95% confidence 
interval, 0.64-0.87, p<.001). Bronchopulmonary toxicity (grade 3 or higher) was similar in both groups 
(≤2%). Oesophageal toxicity (grade 3 or higher) was 6.6% in the TRT arm and 0% in the non-TRT arm 
(p<.001). The study concluded that TRT improves overall survival and progression-free survival in patients 
with extensive-stage small-cell lung cancer, with a small incremental risk of oesophageal toxicity. Future 
randomised trials to identify possible survival benefits of TRT dose escalation in patients with extensive-
stage small-cell lung cancer would assist clinicians in selecting the optimal dose while minimising 
oesophageal toxicity.
Recommendation 2.7.5.1 Grade
Consolidation prophylactic cranial irradiation (PCI) is recommended in patients with 
limited-stage small-cell lung cancer (SCLC) having a response to chemoradiotherapy. 
A
Recommendation 2.7.5.2 Grade
In combined modality care, thoracic radiotherapy is recommended in patients with limited-
stage SCLC and should be initiated as early as possible. 
A
Recommendation 2.7.5.3 Grade
Consolidation PCI is recommended in patients with extensive-stage SCLC having a response 
to chemotherapy. A
Recommendation 2.7.5.4 Grade
Consolidation thoracic radiotherapy may be considered in patients with extensive-stage 
SCLC having a response to chemotherapy. 
A
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2.8 Palliative Care
Responsibility for the implementation of palliative care recommendations
While the CEO, General Manager and the Clinical Director of the hospital have corporate responsibility 
for the implementation of the recommendations in this National Clinical Guideline, each member of the 
multidisciplinary team is responsible for the implementation of the individual guideline recommendations 
relevant to their discipline.
The literature used in the development of this guideline was based on the 7th edition of the Lung 
Cancer TNM staging system. The 8th edition of the TNM staging system was published in December 
2016 (Brierley et al., 2016), this may lead to changes in recommendations over time, which should be 
taken into consideration at multidisciplinary team meetings. 
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Clinical question 2.8.1
Does the involvement of specialist palliative care result in better quality of life for patient or family, 
symptom control, or improved cost effectiveness compared with standard care alone (no involvement 
from specialist palliative care)? 
Evidence summary 
An ASCO provisional clinical opinion (Smith et al., 2012) addressed this clinical question. 
Based on strong evidence from a phase III RCT (Temel et al., 2010), patients with metastatic NSCLC should 
be offered concurrent palliative care and standard oncologic care at initial diagnosis. Patients assigned to 
early palliative care had a better quality of life than patients assigned to standard care (mean score on the 
FACT-L scale [in which scores range from 0 to 136, with higher scores indicating better quality of life], 98.0 
vs. 91.5; p=0.03). In addition, fewer patients in the palliative care group than in the standard care group 
had depressive symptoms (16% vs. 38%, p=0.01). Despite the fact that fewer patients in the early palliative 
care group than in the standard care group received aggressive end-of-life care (33% vs. 54%, p=0.05), 
median survival was longer among patients receiving early palliative care (11.6 months vs. 8.9 months, 
p=0.02). While a survival benefit from early involvement of palliative care has not yet been demonstrated 
in other oncology settings, substantial evidence demonstrates that palliative care when combined with 
standard cancer care or as the main focus of care leads to better patient and caregiver outcomes. These 
include improvement in symptoms, QOL, and patient satisfaction, with reduced caregiver burden. Earlier 
involvement of palliative care also leads to more appropriate referral to and use of hospice, and reduced 
use of futile intensive care. While evidence clarifying optimal delivery of palliative care to improve patient 
outcomes is evolving, no trials to date have demonstrated harm to patients and caregivers, or excessive 
costs, from early involvement of palliative care. (Smith et al., 2012)
Recommendation 2.8.1.1 Grade
Patients with stage IV non-small cell lung cancer (NSCLC) should be offered concurrent 
specialist palliative care and standard oncological care at initial diagnosis. 
B
Good practice point 
All patients with advanced stage lung cancer should have their palliative care needs assessed.
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Clinical question 2.8.2 
Who should comprise the palliative care multidisciplinary team?
Evidence summary 
A report from the National Advisory Committee on Palliative Care (DoH, 2001) addressed the clinical 
question. 
Better outcomes tend to be observed where teams are categorised as ‘specialist’ and consist of 
multidisciplinary trained staff. There is no strong evidence to support a particular team composition in 
each setting, and no research evidence on the level of specialisation required for team members. There 
is no evidence on the number of team members from each profession required to enable provision of an 
effective and efficient service. 
According to the Report of the National Advisory Committee on Palliative Care (DoH, 2001) all specialist 
palliative care services should have at least one consultant in palliative medicine, with a support team of 
non-consultant hospital doctors (NCHDs). 
Specialist palliative care services should have nursing staff with a skill mix to meet the requirements of 
the service. 
Specialist services should also have the following staff available full-time, part-time or with regular 
sessions: 
• Physiotherapist(s) 
• Occupational therapist(s) 
• Social worker(s) 
• Staff specifically trained to meet the psychosocial needs of the patient, family and carers 
• Suitably trained and experienced members of staff who will be responsible for bereavement services 
• Co-ordinator of spiritual care 
• Speech and language therapist 
• Dietitian/clinical nutritionist 
• Pharmacist 
• Complementary therapist(s). (DoH, 2001)
Good practice point 
A specialist palliative care multidisciplinary team meeting should be available to provide, physical, 
psychological, social and spiritual care to patients with lung cancer and their carers.
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3 Development of this National Clinical Guideline
3.1 Epidemiology
Smoking 
The biggest risk factor in the development of lung cancer is smoking. In Ireland, it is estimated that 5,200 
people die annually from smoking related diseases. The overall prevalence of cigarette smoking in Ireland 
in 2014 was 19.5%, compared to 21.5% for 2013. This equates to over 70,000 fewer smokers in 2014 
compared to 2013 (Hickey and Evans, 2014). 
Incidence
The National Cancer Registry Ireland (NCRI), reported that on average approximately 37,500 neoplasms 
were registered annually in Ireland between 2012-2014 (NCRI, 2016). The annual average incidence of 
lung cancer in Ireland was 2,381 (C33-34 bronchus, lung and trachea) per annum (2012-2014) (NCRI, 
2016) (Table 6). Lung cancer overtook colorectal cancer as the second most common cancer diagnosed in 
females (average counts 2011-2013) for the first time in 2015 (NCRI, 2015). Lung cancer was the leading 
cause of cancer death in both sexes, comprising 18% of cancer deaths in women and 24% of cancer 
deaths in men during the period 2011-2013 (NCRI, 2016).
Table 6. Annual average incidence of lung cancer in Ireland. (NCRI, 2016)
Lung Cancer Cases (2012-2014)
Females Males Total
Lung cancer (C33-34) 1,078 1,303 2,381
According to the NCRI (2016) there was little change observed in the relative frequency or ranks of the 
common cancer types from the last annual report NCRI (2015). Figure 4 shows the relative frequencies 
of the most common invasive cancers diagnosed in females in Ireland from 2009-2013, including non-
melanoma skin cancer. Lung cancer made up 7.5% of all female cancers (NCRI, 2015).
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Figure 4. Shows the relative frequencies of the most common invasive cancers diagnosed in females in Ireland, 
2011-2013.(NCRI, 2015)
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Figure 5 shows the relative frequencies reported in 2015, of the most common invasive cancers 
diagnosed in males in Ireland from 2009-2013, including non-melanoma skin cancer. Lung cancer made 
up 8% of all male cancers. 
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Figure 5. Shows the relative frequencies of the most common invasive cancers diagnosed in males in Ireland, 
2011-2013 (NCRI, 2015)
Table 7 shows the ranking of the most commonly diagnosed invasive cancers in Ireland from 2012-2014, 
excluding non-melanoma skin cancer. Colorectal and lung cancer were the 2nd and 3rd most common 
cancers in males, lung cancer is the second most common ahead of colorectal cancer in females (NCRI, 
2016).
Table 7. Ranking of most commonly diagnosed invasive cancers in Ireland, 2012-2014 (NCRI, 2016)
Invasive cancer 
Female Male
% Rank % Rank
Breast 30.1 1 - -
Prostate - - 30.3 1
Lung 11.1 2 11.7 3
Colorectal 10.4 3 13.3 2
Mortality
Table 8 shows the mortality rate from lung cancer in Ireland, 2011-2013. The number of deaths from lung 
cancer was 749 females and 1,079 males (NCRI, 2016).
Table 8. Number of deaths and mortality rate from lung cancer, 2011-2013 (NCRI, 2016)
Death Rate/100,000
Female Male Female Male
Lung 749 1,079 28.2 47.7
Figure 6 and Figure 7 shows the relative frequencies of the most common cancer deaths as reported in 
2015 (NCRI, 2015). In 2015, lung cancer was ranked as the most common cancer death in Ireland in both 
sexes (Table 9), comprising 18.4% of cancer deaths in women and 23.5% of cancer deaths in men during 
the period 2012-2014 (NCRI, 2016).
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Figure 6. Relative frequency of the most common cancer deaths in females in Ireland, 2011-2012 (NCRI, 2015) 
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Figure 7. Relative frequency of the most common cancer deaths in males in Ireland, 2011-2012 (NCRI, 2015) 
Table 9. Ranking of most common cancer deaths in Ireland, 2012-2014 (NCRI, 2016)
Invasive cancer Female Male
% Rank % Rank
Breast 17.1 2 - -
Prostate - - 11.5 3
Lung 18.4 1 23.5 1
Colorectal 10.4 3 12.9 2
Survival
Out of 2,338 patients diagnosed with lung cancer during 2013, a total of 1,389 were still alive at the 
end of that year (one-year prevalence). Lung cancer has very high mortality and, of the >37,000 cases 
diagnosed during 1994-2013, only 12% were alive at the close of 2013 (NCRI, 2015).
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Cancer projections 2015-2040
Lung cancer case numbers increased significantly for females from 1994 to 2010, by 3.9% annually. For 
males the numbers increased by 0.7% annually from 1994 to 2005 and by 3.3% thereafter. Incidence 
rates of lung cancer increased by 2.3% annually in females and decreased by 0.7% annually in males 
(NCRI, 2014). Cancer of the lung is projected to increase by 95%-196% in females and by 72%-121% in 
males. Table 10 displays the projected number of incident cases of lung cancer 2015-2040 based on 
demographic projections (NCRI, 2014). 
Table 10. Projected numbers of incident cases 2015-2040 (with % increase/decrease compared to 2010): cancer 
of the lung (NCRI, 2014)
Lung cancer
Female Male
Year Projected no. of inci-
dent cases 2015-2040 
(demographic projec-
tions)
% increase compared 
to 2010
Projected no. of inci-
dent cases 2015-2040 
(demographic projec-
tions)
% increase compared 
to 2010
2015 1,013 6 1,477 13
2020 1,161 21 1,728 32
2025 1,334 39 2,012 54
2030 1,515 58 2,314 77
2035 1,694 77 2,610 100
2040 1,862 95 2,889 121
3.2 Rationale for this National Clinical Guideline
The National Cancer Strategy (DoHC, 2006) recommended that national site-specific multidisciplinary 
groups be convened to develop national evidence-based clinical guidelines for cancer care. The principal 
objective of developing these guidelines is to improve the quality of care received by patients. Other 
objectives include:
• Improvement in patient outcomes,
• Potential for reduction in morbidity and mortality,
• Improvement in quality of life,
• Promotion of interventions of proven benefit and discouragement of ineffective ones,
• Improvements in the consistency and standard of care.
The National Cancer Strategy 2017-2026 (DoH, 2017) recommends: The NCCP will develop further 
guidelines for cancer care in line with National Clinical Effectiveness Committee (NCEC) standards.
3.3 Clinical and financial impact of lung cancer
The diagnosis, staging, and treatment of patients with lung cancer requires multidisciplinary care in an 
acute hospital setting. The majority of patients will require diagnostic tests (radiology, pathology) and 
depending on the treatment plan may require surgery, radiotherapy and chemotherapy. 
A population-based cost analysis (Luengo-Fernandez et al., 2013) illustrated the economic burden of 
cancer on the European Union (EU). In 2009, cancer is estimated to have cost the EU €126 billion, with 
healthcare costs accounting for €51 billion (40%). They found that lung cancer had the highest economic 
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cost (€18.8 billion, 15% of overall cancer costs), followed by breast cancer (€15.0 billion, 12%), colorectal 
cancer (€13.1 billion, 10%), and prostate cancer (€8.43 billion, 7%). 
Inpatient care was the major component of health-care costs in lung cancer (€2.87 billion, 68%). The 
highest productivity losses attributable to mortality were identified for lung cancer (€9.92 billion; 23% 
of the €42.6 billion in productivity losses because of all cancers). The costs of informal care were also 
highest for patients with lung cancer (€3.82 billion; 16% of the €23.2 billion total informal care provided). 
With lung cancer incidence expected to increase by 136% in females (Nordpred model) and 52% in males 
(NCRI, 2014), there could be a significant increase seen in healthcare costs per person in Ireland. 
Most of the recommendations in this guideline represent current standard practice and are therefore 
cost neutral. However, the GDG have identified areas that require change in practice to ensure full 
implementation of the guideline. The potential resource implications of applying these recommendations 
have been considered (Appendix 6: Budget Impact Assessment). However, it is important to note that the 
cost effectiveness analysis and the budget impact analysis are carried out separately from the generation 
of clinical recommendations. The methodology applied is documented in Section 3.8 Methodology and 
literature review. For areas where additional resources are required to implement the guideline the 
resources required will be sought through the HSE service planning process.
3.4 Aim and objectives 
The overall objectives of the NCCP’s National Clinical Guideline ‘Diagnosis, staging and treatment of 
patients with lung cancer’ are: 
• To improve the quality of clinical care,
• To reduce variation in practice, 
• To address areas of clinical care with new and emerging evidence.
The guideline is based on the best research evidence in conjunction with clinical expertise, and developed 
using a clear evidence-based internationally used methodology.
3.5 Scope of the National Clinical Guideline, target population & target audience
3.5.1 Guideline scope 
This National Clinical Guideline was developed to improve the standard and consistency of clinical 
practice in line with the best and most recent scientific evidence available.
This guideline focuses on the diagnosis, staging, and treatment of patients with lung cancer. This guideline 
does not include recommendations covering every detail of diagnosis, staging, and treatment. Instead 
this guideline focuses on areas of clinical practice: 
(i) known to be controversial or uncertain, 
(ii) where there is identifiable practice variation, 
(iii) where there is new or emerging evidence, 
(iv) where guidelines have potential to have the most impact.
This guideline focuses solely on the clinical management of patients with lung cancer. The NCCP 
has developed general practitioner (GP) referral guidelines, standardised GP referral forms, and GP 
electronic referral for patients with lung cancer. The NCCP in partnership with the Irish Cancer Society has 
commenced a cancer survivorship programme. The main goal for the NCCP Survivorship Programme is to 
empower patients to achieve their best possible health while living with and beyond a diagnosis of cancer. 
This involves providing information, guidance and support to survivors and their families and healthcare 
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professionals in relation to healthy lifestyle, disease prevention and control. It aims to promote a good 
quality of life and prolonged survival for people who experience cancer.
The NCCP has also a Lung National Clinical Leads Network with defined terms of reference. The output of 
this network includes the following: 
• Development and agreement of Key Performance Indicators (KPIs),
• Organising annual multidisciplinary Cancer Quality and Audit Fora,
• Focus on cancer specific issues such as the development of information resources for patients and 
health professionals.
Patient information booklets/leaflets covering various aspects of the cancer journey are available on the 
NCCP website.
3.5.2 Target population 
Patients that are covered by this guideline are:
 Adults (18 years or older) with newly diagnosed lung cancer, or, those that have a suspected diagnosis 
of lung cancer in a hospital setting. 
For guidance regarding patients with suspected lung cancer in the GP setting please refer to Appendix 3: 
Summary of the tools to assist in the implementation of the National Clinical Guideline. 
3.5.3 Target audience
This guideline is intended for all health professionals involved in the diagnosis, staging and treatment of 
patients with lung cancer. While the CEO, General Manager and the Clinical Director of the hospital have 
corporate responsibility for the implementation of the recommendations in this Clinical Guideline, each 
member of the multidisciplinary team is responsible for the implementation of the individual guideline 
recommendations relevant to their discipline.
This guideline is also relevant to those involved in clinical governance, in both primary and secondary 
care, to help ensure that arrangements are in place to deliver appropriate care for the population covered 
by this guideline.
Whilst the guideline is focused on clinical care, it is expected to be of interest to patients with lung cancer 
and their significant others. A list of medical abbreviations used throughout the guideline can be found in 
Appendix 9: Glossary and abbreviations.
3.6 Governance and Conflicts of Interest
Governance of the guideline development process was provided by a multidisciplinary Guideline Steering 
Group which was chaired by the Director of the NCCP. Details of GDG members and Guideline Steering 
Group members are provided at the beginning of the document. Figure 8 outlines the stages of guideline 
development. 
 
A GDG was responsible for the development and delivery of this National Clinical Guideline and included 
representatives from relevant professional groups (radiology, respiratory medicine, pathology, surgery, 
medical oncology, radiation oncology, palliative care) with expertise in the diagnosis, staging and 
treatment of patients with lung cancer, a project manager, a methodologist, a research officer, and a 
clinical librarian. 
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3.6.1 Conflict of interest statement 
A conflict of interest form (see ‘NCCP Methodology Manual’) was signed by all GDG members and 
reviewers. The GDG was managed by the Chair to promote the highest professional standard in the 
development of this guideline. Where a conflict arises a GDG member absents themselves from 
discussion pertaining to their area of conflict.
3.7 Sources of funding 
The guideline was commissioned and funded by the NCCP; however, the guideline content was not 
influenced by the NCCP or any other funding body. This process is fully independent of lobbying powers. 
All recommendations were based on the best research evidence integrated with clinical expertise.
3.8 Methodology and literature review
The methodology for the development of the guideline was designed by a research methodologist and 
is based on the principles of Evidence-Based Practice (EBP) (Sackett et al., 2000). The methodology is 
described in detail in the NCCP Methodology Manual for guideline development. 
3.8.1 Step 1: Develop clinical questions 
The first step in guideline development was to identify areas of new and emerging evidence, areas with 
identifiable variation in practice, or areas with potential to impact on patients care. These questions then 
formed the basis for the types of evidence being gathered, the search strategy, and the inclusion and 
exclusion criteria.
To formulate the clinical questions they were broken down into their component parts using the PICO(T) 
framework:
• Participant/Population 
• Intervention/Exposure 
• Control/Comparison
• Outcome 
• Time 
This process was carried out by discipline specific sub-groups. The GDG signed off the entire list of clinical 
questions to ensure a comprehensive guideline. The resulting 44 clinical questions are listed in Appendix 
2: Clinical Questions in PICO format. 
3.8.2 Step 2: Search for the evidence
The clinical questions formulated in step one were used to conduct literature searches of the primary 
literature. The systematic literature review protocol was developed for the guideline development 
process by the HSE librarians in conjunction with the NCCP (Appendix 4: Literature review protocol). The 
following bibliographic databases were searched in the order specified below using keywords implicit in 
the PICO(T) question and any identified subject headings:
• Cochrane Library
• Point-of-Care Reference Tools
• Medline
• Embase (where available)
• Other bibliographic databases such as PsycINFO, CINAHL, as appropriate.
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The literature was searched based on the hierarchy of evidence. The literature was updated prior to 
publication. This necessitated a complete review and rewrite of the medical oncology section in July 
2016. This is a live document, updates and reviews are carried out at three year intervals.
A literature search for the budget impact assessment was performed using the SIGN economic filter (Table 
11. Economic literature review protocol). Full details of this search strategy are available in Appendix 6: 
Budget Impact Assessment.
3.8.3 Step 3: Appraise the literature for validity and applicability
International guidelines were appraised using the international, validated tool the AGREE II instrument 
(Brouwers et al., 2010). Primary papers were appraised using validated checklists developed by the 
Scottish Intercollegiate Guideline Network (SIGN). 
Economic papers included in the Budget Impact Assessment (Appendix 6: Budget Impact Assessment) 
were appraised by a health economist using validated economic checklists developed by SIGN.
 
There were three main points considered when appraising all the research evidence:
• Are the results valid? (internal validity)
• What are the results? (statistical and clinical significance)
• Are the results applicable/generalisable to the patient/population of this guideline? (external validity) 
3.9 Formulation and grading of recommendations 
The evidence which addressed each clinical question, both from international guidelines and primary 
literature, was extracted into evidence tables. Recommendations were formulated through a formal 
structured process. A ‘considered judgment form’ (adapted from SIGN) was completed for each clinical 
question. 
The following items were considered and documented: 
• What evidence is available to answer the clinical question? 
• What is the quality of the evidence? 
» Is the evidence consistent? 
» Is the evidence generalisable to the Irish population? 
» Is the evidence applicable in the Irish context? 
• What is the potential impact on the health system? 
• What is the potential benefit versus harm to the patient? 
• Are there resource implications? 
The evidence summaries and recommendations were then written. Each recommendation was assigned 
a grade by the GDG. The grade reflected the level of evidence upon which the recommendations 
were based, the directness of the evidence, and whether further research is likely to change the 
recommendation. The levels of evidence tables and grading systems used are documented in Appendix 
10: Levels of Evidence & Grading Systems. 
Good practice points were based on the clinical expertise of the GDG. For the economic literature, key 
messages are presented in boxes entitled ‘relevance to the guideline recommendations’.
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Figure 8. The Stages of Guideline Development
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3.10 Consultation process
3.10.1 Patient Advocacy
A collaborative approach is used in the development of the NCCP patient information, clinical guidelines 
and other national projects. All NCCP booklets are submitted to the National Adult Literacy Agency (NALA) 
(www.nala.ie) for the Plain English Award. This is to ensure comprehension and readability are in line 
with health literacy best practice standards. Service user testing is a key part of the process, and includes 
liaising with the HSE Patient Forum, online surveys, and engaging with other relevant patient groups e.g. 
Irish Cancer Society, Marie Keating Foundation.
The views and preferences of the target population were sought by inviting patient advocacy groups 
(HSE Patient Forum, Irish Cancer Society, Cancer Care West, Marie Keating Foundation, Gary Kelly Cancer 
Support Centre and Bray Cancer Support Centre) to engage in the National Stakeholder Review process 
(Appendix 5: Details of consultation process).
3.10.2 National Stakeholder review
The draft guideline was signed off by the entire GDG, and the NCCP Guideline Steering Group before going 
to National Stakeholder Review. It was circulated to relevant organisations and individuals for comment 
between June 12th – July 24th 2014. A full list of those invited to review this guideline is available in 
Appendix 5: Details of consultation process.
Stakeholders were asked to comment on the comprehensiveness of evidence used to form the 
recommendations. Stakeholders were required to submit feedback with supporting evidence on a form 
provided (see ‘NCCP Methodology Manual’) along with a completed conflict of interest form. A time-
period of six weeks was allocated to submit comments. 
All feedback and supporting evidence received was reviewed by the GDG. All modifications were 
documented. 
3.11 External review
The amended draft guideline was then submitted for international expert review. The GDG nominated 
three international reviewers to provide feedback on the draft guideline. These reviewers were chosen 
based on their in-depth knowledge of the subject area and guideline development processes. The review 
followed the same procedure as the National Stakeholder Review. The guideline was circulated for 
comment between the 19th May 2016 and the 4th of July 2016.
A log was recorded of all submissions and amendments from the national stakeholder review and 
international expert review process and is available on request from the GDG.
3.12 Procedure to update this National Clinical Guideline
This guideline, published in 2017, will be considered for review by the NCCP in three years. Surveillance 
of the literature base will be carried out periodically by the NCCP. Any updates to the guideline in the 
interim period or as a result of three year review will be subject to the NCEC approval process and noted 
in the guidelines section of the NCCP and NCEC websites.
3.13 Implementation 
This National Clinical Guideline should be reviewed by the multidisciplinary team and senior management 
in the hospital to plan the implementation of the recommendations.
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The CEO, General Manager and the Clinical Director of the hospital have corporate responsibility for the 
implementation of the National Clinical Guideline and to ensure that all relevant staff are appropriately 
supported to implement the guideline. A Cancer Network Manager from the NCCP meets with each 
cancer centre on a quarterly basis for performance monitoring and service planning.
All medical staff with responsibility for the care of patients with lung cancer are required to:
• Comply with this National Clinical Guideline and any related procedures or protocols.
• Adhere to their code of conduct and professional scope of practice guidelines as appropriate to their 
role and responsibilities.
• Maintain their competency for the management and treatment of patients with lung cancer.
The implementation plan is based on the COM-B theory of behaviour change (Michie et al., 2011), as 
outlined in the NCCP Methodology Manual. The implementation plan outlines facilitators and barriers to 
implementation (Appendix 7: Implementation Plan).
This National Clinical Guideline will be circulated and disseminated through the professional networks 
who participated in developing and reviewing this document. The guideline will also be available on the 
NCEC and NCCP websites.
A multidisciplinary team (MDT) is responsible for the implementation of the guideline recommendations. 
A summary of tools to assist in the implementation of this National Clinical Guideline are available in 
Appendix 3: Summary of the tools to assist in the implementation of the National Clinical Guideline. 
3.14 Monitoring and evaluation 
The National Cancer Control Programme engages regularly with the individual cancer centres and with 
Hospital Group structures. Discussion of performance data, improvement plans, resources including 
manpower, service planning and development takes place at regular review meetings between the NCCP 
and senior management at cancer centre and Hospital Group level. 
3.15 Audit
It is important that both the implementation of the guideline and patient outcomes are audited to ensure 
that this guideline positively impacts on patient care. For audit criteria see Appendix 8: Audit criteria and 
monitoring. 
3.16 Recommendations for research
Clinical trials are needed to compare the effectiveness of radiofrequency ablation and other local 
therapies in patients with early stage NSCLC who are high risk surgery candidates. (CQ 2.2.3)
The role of imaging surveillance in patients with NSCLC treated with curative intent needs to be 
elucidated. (CQ 2.2.4)
The role of MRI in staging patients with negative clinical evaluation findings has not been adequately 
studied. (CQ 2.2.6)
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4 Appendices
Appendix 1: Guideline Development Group terms of reference
Membership of the Guideline Development Group is outlined at the beginning of this document. 
Terms of Reference 
To develop a national evidence-based clinical guideline for the diagnosis, staging, and treatment of 
patients with lung cancer. Full terms of reference are available in the NCCP Methodology Manual for 
guideline development.
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Appendix 2: Clinical Questions in PICO format 
Radiology 
Clinical question 2.2.1
In non-small cell lung cancer (NSCLC) patients with mediastinal and hilar adenopathy what is the efficacy of 
CT (contrast and non-contrast) and PET-CT in the diagnosis of lung cancer? 
Population: NSCLC patients with mediastinal and hilar adenopathy
Intervention: CT contrast, non-contrast CT, PET-CT
Comparison: Mediastinoscopy and/or surgery
Outcome: Mediastinal and hilar staging specificity and sensitivity
Clinical question 2.2.2
In patients with peripheral lung nodules, what is the efficacy of the following tests in the diagnosis of lung 
cancer?
-  Percutaneous fine needle aspiration and transthoracic needle biopsy
- Guided bronchoscopy
- Video assisted thoracoscopic surgery (VATS)
Population: Patients with peripheral lung nodules
Intervention: -  Percutaneous fine needle aspiration
- Transthoracic needle biopsy 
- Guided bronchoscopy
- Video assisted thoracoscopic surgery
Comparison: Histology
Outcome: Complication rate, diagnosis of lung cancer, sensitivity and specificity
Clinical question 2.2.3
In NSCLC patients with early stage disease who are high risk surgery candidates, what is the effectiveness of 
ablative techniques?
Population: Patients with NSCLC early stage disease who are high risk candidates for surgery
Intervention: Radiofrequency ablation
Comparison: -
Outcome: Local tumour control and survival
Clinical question 2.2.4
For patients with NSCLC who have undergone surgical resection or radiotherapy with curative intent, is there 
a role for imaging surveillance?
Population: Patients with NSCLC who have been treated with surgery or radiotherapy with 
curative intent
Intervention: Imaging surveillance
Comparison: -
Outcome: Disease-free survival, progression-free survival, overall survival, recurrence
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Clinical question 2.2.5
For patients with NSCLC which of the following tests is most accurate for detecting metastatic spread to 
indeterminate adrenal nodules/ masses: chemical shift MRI, non-contrast CT, PET-CT? 
Population: Patients with lung cancer with metastatic spread of indeterminate adrenal nodules/
masses
Intervention: Chemical shift MRI, non-contrast CT, PET-CT
Comparison: -
Outcome: Detection of metastatic spread to indeterminate adrenal nodules
Clinical question 2.2.6
For patients with NSCLC which of the following tests is most accurate for detecting brain metastases: MRI, CT, 
PET-CT?
Population: Patients with NSCLC with brain metastases
Intervention: MRI, CT, PET-CT
Comparison: -
Outcome: Detection of brain metastases
Clinical question 2.2.7
For patients with NSCLC which of the following tests is most accurate for detecting bone metastases: isotope 
bone scan, CT, MRI, PET-CT? 
Population: For patients with NSCLC with suspected bone metastases
Intervention: Isotope bone scan, CT, MRI, PET-CT
Comparison: –
Outcome: Detection of bone metastases
Clinical question 2.2.8
In patients with limited-stage SCLC on diagnostic CT, does PET-CT change management?
Population: Patients with limited-stage SCLC on diagnostic CT
Intervention: PET-CT
Comparison: –
Outcome: Outcome management decisions
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Respiratory Medicine 
Clinical question 2.3.1 
What is the efficacy of bronchoscopy in identifying lung cancer?
Population: Patients with suspected lung cancer
Intervention: Bronchoscopy
Comparison: Clinical follow-up
Outcome: Diagnosis of lung cancer, sensitivity and specificity
Clinical question 2.3.2 
In patients with mediastinal adenopathy: What is the efficacy of EBUS, EBUS/EUS and mediastinoscopy in the 
diagnosis of lung cancer? 
Population: Patients with mediastinal adenopathy
Intervention: Diagnostic tests
 a. EBUS 
 b. EBUS/EUS 
 c. Mediastinoscopy
Comparison: Surgery
Outcome: Treatment plan sensitivity and specificity
Clinical question 2.3.3
In patients with pleural effusion and suspected lung cancer, what is the efficacy of pleural sampling in the 
diagnosis of lung cancer?
Population: Patients with pleural effusion and suspected lung cancer
Intervention: Pleural sampling 
Comparison: -
Outcome: Diagnosis of lung cancer, sensitivity and specificity
Clinical question 2.3.4
What is the role of palliative interventions in the management of malignant airway obstruction?  
Population: Patients with malignant airway obstruction
Intervention: Palliative interventions (delivered by bronchoscopy or external beam radiotherapy)
Comparison: -
Outcome: Quality of life and morbidity
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Pathology
Clinical question 2.4.1:
A) What is the benefit of histopathological analysis for small-cell lung cancer  (SCLC) vs. non-small cell lung 
cancer (NSCLC)? 
B) When should immunohistochemical analysis be performed? 
C) What is the best panel(s) of immunohistochemical stains for NSCLC subtypes?
Population: Patients with NSCLC and SCLC 
Intervention: Histopathological subtype analysis, immunohistochemical analysis and staining
Comparison: -
Outcome: Sensitivity, specificity, negative predictive value (NPV) and positive predictive value 
(PPV)
Clinical question 2.4.2: 
What is the efficacy of the following diagnostic tools in identifying and staging lung cancer:
- Rose at EBUS
- Frozen section
Population: Patients with lung cancer
Intervention: ROSE at EBUS and frozen section
Comparison: -
Outcome: Sensitivity, specificity, negative predictive value (NPV) and positive predictive value 
(PPV)
Clinical question 2.4.3:
In patients with NSCLC, how do cytological samples compare with tissue biopsy samples for tumour 
sub-typing, immunohistochemistry and predictive markers assessed by FISH or mutational analysis?
Population: Patients with lung cancer
Intervention: Cytological samples
Comparison: Tissue biopsy samples
Outcome: Sensitivity, specificity, negative predictive value (NPV) and positive predictive value 
(PPV)
Clinical question 2.4.4
What are optimal formalin fixation times for future molecular diagnostics?
Population: Patients with non-small cell lung cancer
Intervention: Use of formalin for future molecular diagnostics
Comparison: -
Outcome: Fixation times to allow for adequate DNA extraction
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Surgery 
Clinical queation 2.5.1
In patients with stage I & II non-small cell lung cancer (NSCLC) how does the extent of lung resection effect 
outcomes? 
Population: Patients with stage I & stage II NSCLC
Intervention: Lung resection (wedge resection, anatomical segmentectomy and lobectomy)
Comparison: -
Outcome: Two year survival, five year survival, progression-free survival, overall survival, 
recovery from procedure, accuracy of technique, pain/symptoms
Clinical question 2.5.2
In patients with clinical stage I NSCLC undergoing lobectomy, how does video-assisted thoracic surgery (VATS) 
compare to thoracotomy? 
Population: Patients with clinical stage I NSCLC
Intervention: VATS
Comparison: Thoracotomy
Outcome: Two year survival, five year survival, progression-free survival, overall survival, 
recovery from procedure, accuracy of technique, pain/symptoms
Clinical question 2.5.3
Which pulmonary function tests should be used to determine fitness for resection?
Population: Patients with lung cancer who are potential surgical candidates
Intervention: ppo-FEV1, ppo-DLCO, VO2 max or stair test
Comparison: -
Outcome: Postoperative morbidity, 30 day mortality, extent of resection
Clinical question 2.5.4 
In patients with lung cancer, how should non-pulmonary co-morbidity influence surgical selection?
Population: Patients with potentially operable lung cancer
Intervention: Selection for surgery
Comparison: -
Outcome: Peri-operative morbidity & mortality
Clinical question 2.5.5
Should lung cancer surgery be offered to octogenarians?
Population: Patients (>80 yrs) with lung cancer who are potential candidates for surgery
Intervention: Surgery
Comparison: -
Outcome: Two year survival, five year survival, peri-operative mortality
Clinical question 2.5.6: 
In patients with NSCLC what is the optimum surgical approach for?
a) Multifocal tumours 
b) Synchronous tumours
Population: NSCLC patients with multifocal or synchronous tumours
Intervention: Surgery
Comparison: -
Outcome: Two year survival, five year survival, progression-free survival, overall survival
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Clinical question 2.5.7 
In patients with NSCLC, what is the optimal lymph node strategy at surgical resection? 
Population: Patients with NSCLC undergoing surgical resection
Intervention: Optimal lymph node strategy
Comparison: -
Outcome: Two year survival, five year survival, progression-free survival, overall survival, 
accuracy of technique
Clinical question 2.5.8 
In patients with malignant pleural effusion associated with lung cancer, what is the best treatment strategy?
Population: Patients with malignant pleural effusion associated with lung cancer
Intervention: Interventions to reduce recurrent effusion
Comparison: -
Outcome: Time to recurrence of effusion
Clinical question 2.5.9
Should surgical resection be considered in patients with NSCLC, who have treatable isolated brain or adrenal 
metastases at the time of presentation? 
Population: Patients with NSCLC with isolated metastases
Intervention: Surgical resection
Comparison: -
Outcome: Survival (one year, three year, five year)
Clinical question 2.5.10
Should surgical resection be considered as part of the multimodality treatment of patients with stage IIIa 
(N2) NSCLC?
Population: Patients with stage IIIa (N2) NSCLC
Intervention: Surgical resection 
Comparison: -
Outcome: Survival
Clinical question 2.5.11
In patients with small-cell lung cancer (SCLC) what is the role of surgery? 
Population: Patients with SCLC
Intervention: Surgery
Comparison: -
Outcome: Survival
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Medical Oncology
Clinical question 2.6.1
In patients with NSCLC (excluding pancoast tumours) having curative surgery, how effective is pre-operative 
(neoadjuvant) chemotherapy or chemoradiotherapy ? 
Population: Patients with NSCLC having curative surgery (excluding pancoast tumours)
Intervention: Pre-op chemotherapy or pre-op chemotherapy plus RT
Comparison: -
Outcome: Survival, progression-free survival, time to progression, symptom control, quality of 
life, toxicity
Clinical question 2.6.2
In patients with locally advanced NSCLC having radical radiotherapy, is concurrent chemoradiotherapy more 
effective than sequential chemoradiotherapy? 
Population: Patients with locally advanced NSCLC having radical radiotherapy
Intervention: Concurrent chemoradiotherapy
Comparison: Sequential chemoradiotherapy
Outcome: Survival, progression-free survival, time to progression, symptom control, quality of 
life, toxicity
Clinical question 2.6.3
In patients with locally advanced NSCLC having concurrent radical chemoradiotherapy, what is the 
effectiveness of:
a) Induction (first-line) chemotherapy
b) Consolidation chemotherapy
Population: Patients with locally advanced NSCLC having concurrent radical chemoradiotherapy
Intervention: Induction (first-line) chemotherapy; consolidation chemotherapy
Comparison: -
Outcome: Survival, progression-free survival, time to progression, symptom control, quality of 
life, toxicity
Clinical question 2.6.4
In patients with advanced/stage IV NSCLC what is the effectiveness of first-line therapy and is there any 
evidence that particular regimens or drugs are more effective or less toxic than others?
Population: Patients with advanced/stage IV NSCLC 
Intervention: First-line chemotherapy
Comparison: -
Outcome: Survival, progression-free survival, time to progression, symptom control, quality of 
life, toxicity
Clinical Question 2.6.5
In patients with advanced/stage IV NSCLC is there any evidence for maintenance systemic therapy?
Population: Patients with advanced/stage IV NSCLC
Intervention: Maintenance systemic therapy
Comparison: -
Outcome: Survival, progression-free survival, time to progression, symptom control, quality of 
life
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Clinical question 2.6.6
For patients with advanced/stage IV NSCLC aged over 70, and/or with poor performance status, what is the 
effectiveness of first-line therapy? 
Population: Patients with advanced/stage IV NSCLC over 70 and/or with poor performance 
status
Intervention: First-line therapy
Comparison: -
Outcome: Survival, symptom control, quality of life, toxicity, tumour response
Clinical question 2.6.7
In patients with advanced/stage IV NSCLC how effective is second and third-line therapy in patients with 
NSCLC who progress and relapse? 
Population: Patients with advanced / stage IV NSCLC
Intervention: Second and third-line systemic therapy (docetaxel, pemetrexed, erlotinib, crizotinib 
and afatinib)
Comparison: -
Outcome: Survival, time to progression, tumour response, toxicity (especially neutropenic 
sepsis/death)
Clinical question 2.6.8
Is there any evidence that particular regimens or drugs are more effective or less toxic than others for the 
first-line treatment of limited-stage and extensive-stage small-cell lung cancer (SCLC)? 
Population: Patients with limited-stage and extensive-stage SCLC
Intervention: First-line treatment
Comparison: -
Outcome: Survival, progression-free survival, time to progression, symptom control, quality of 
life, toxicity.
Clinical question 2.6.9
In patients with limited-stage and extensive-stage SCLC is there any role for maintenance chemotherapy?
Population: Patients with limited-stage and extensive-stage SCLC
Intervention: Maintenance chemotherapy
Comparison: -
Outcome: Survival, progression-free survival, time to progression, symptom control, quality of 
life, toxicity
Clinical question 2.6.10
How effective is second-line systemic therapy in patients with SCLC who progress and relapse?
Population: Patients with SCLC who progress and relapse
Intervention: Second-line systemic therapy
Comparison: -
Outcome: Survival, progression-free survival, time to progression, symptom control, quality of 
life, toxicity
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Radiation Oncology
Clinical question 2.7.1
In patients with non-small cell lung cancer (NSCLC) early stage disease (T1-T2 N0 M0) who are unfit 
for surgery, what is the effectiveness of stereotactic radiotherapy, standard radical radiotherapy and 
radiofrequency ablation?
Population: In patients with Stage I, II who are unfit for surgery
Intervention: Stereotactic RT, standard radical radiotherapy, and radiofrequency ablation
Comparison: -
Outcome: Median survival, two year survival, five year survival, progression-free survival, 
overall survival, response rate, declining lung function, pneumonitis, pulmonary 
fibrosis, quality of life
Clinical question 2.7.2
In patients with stage I-III NSCLC undergoing radical external beam radiation therapy what is the role and 
effectiveness of the following:
a) New technology (IMRT/4DCT- breathing adapted radiotherapy)
b) Altered radiation fractionation schedules (Hyper and/or accelerated fractionation)
c) Dose 
Population: Patients with stage I-III NSCLC undergoing radical EBRT (excluding those suitable for 
SABR)
Intervention: a) New technology (IMRT/4DCT- breathing adapted radiotherapy)
b) Altered radiation fractionation schedules (Hyper and/or accelerated 
fractionation)
c) Dose 
Comparison: 3DCRT; Chemotherapy and 3DCRT
Outcome: Survival and disease free progression, toxicity (oesophagitis, pneumonitis; bone 
marrow suppression)
Clinical question 2.7.3
In patients with stage III NSCLC undergoing radical three-dimensional conformal radiotherapy (3DCRT):
a) What are the most useful predictors of lung and oesophageal toxicity?
b) What are the most useful measures to reduce toxicity: clinical/technical?
Population: Patients with stage III NSCLC undergoing radical 3DCRT
Intervention: Radical therapy 3DCRT
Comparison: Radical radiotherapy and chemotherapy
Outcome: Reduce morbidity and side effects, toxicity (radiation pneumonitis, oesophagitis 
and pulmonary fibrosis)
Clinical question 2.7.4
In patients with NSCLC post surgery which groups should receive postoperative radiotherapy (PORT) or 
adjuvant RT?
a) pN2 R0
b) any pN, R1, R2 resection
Population: Patients with NSCLC post surgery
Intervention: RT post surgery
Comparison: No RT
Outcome: Survival and disease free progression
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Clinical question 2.7.5
In patients with small-cell lung cancer (SCLC), what is the evidence supporting the role of radiotherapy 
(including technical parameters)
a)  Limited-stage prophylactic cranial irradiation (PCI)
b)  Limited-stage thoracic radiotherapy
c)  Extensive-stage PCI
d)  Extensive-stage thoracic radiotherapy
Population: Patients with limited-stage and extensive-stage SCLC
Intervention: Prophylactic cranial irradiation, thoracic radiotherapy
Comparison: No prophylactic cranial irradiation, no thoracic radiotherapy
Outcome: Survival, progression-free survival, response rate
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Palliative Care
Clinical question 2.8.1
Does the involvement of specialist palliative care result in better quality of life for patient or family, symptom 
control, or improved cost effectiveness compared with standard care alone (no involvement from specialist 
palliative care)?
Population: Patients with cancer (or specifically, lung cancer)
Intervention: Specialist Palliative care services
Comparison: Usual care (without palliative care)
Outcome: Symptom control, quality of life, cost-effectiveness, prognosis
Clinical question 2.8.2
Who should comprise the palliative care multidisciplinary team?
Population: Patients with cancer (or specifically, lung cancer)
Intervention: Multidisciplinary team care
Comparison: Usual care
Outcome: Symptom control, quality of life, cost-effectiveness, prognosis
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Appendix 3: Summary of the tools to assist in the implementation of 
this National Clinical Guideline
NCCP. National Clinical Guidelines for Cancer – Methodology Manual. 
National Cancer Control Programme, 2014.
NCCP Website: Information for Health Professionals
NCCP Website: Patient Information
Health Information and Quality Authority (HIQA). National Standards for Safer Better Healthcare
Centre for Evidence Based Medicine
Improving Health: Changing Behaviour - NHS Health Trainer Handbook
UCL Centre for Behaviour Change
Michie, S; Atkins, L; West, R; (2014) The Behaviour Change Wheel: A Guide to Designing Interventions. 
(1st ed.). Silverback Publishing: London.
Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. (2008). Developing and evaluating 
complex interventions: the new Medical Research Council guidance. BMJ; 337.
Medical Research Council. (2008). Developing and evaluating complex 
interventions: new guidance. Available from: www.mrc.ac.uk/complexinterventionsguidance.
Guide for health professionals
30 Second Stop Smoking Advice, NCCP
Patient information booklets/leaflets
Rapid Access Lung Clinic - A Guide for Patients, NCCP
Quit smoking to reduce your cancer risk - NCCP cancer prevention factsheet, NCCP
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Appendix 4: Literature review protocol
  
SYSTEMATIC LITERATURE REVIEW PROTOCOL 
Literature searches to answer clinical questions identified by the relevant tumour group will be conducted using the following 
procedure. Questions should only be submitted if they have not been adequately answered in the guidelines adopted by the 
tumour group, or where guidelines need to be updated. Guidelines should be identified in consultation with library services.
Tumour 
Group
1 PICO(T) Analyse the clinical question using PICO(T) and complete a Clinical Query Request 
form. 
See below Annex 1: Clinical Query Request.
Tumour 
Group or 
Library 
Services
2 Question 
Category
Assign a question category, if appropriate:
Therapy/Intervention r Aetiology/Risk Factors r
Diagnosis r Prognosis/Prediction r Frequency/Rate r Phenomena r Other r
Library 
Services
3 Literature Search Conduct searches of the following bibliographic databases in the order specified 
below using keywords implicit in the PICO(T) strategy and any identified subject 
headings:
Cochrane 3.1 Cochrane Library
Comprising: the Cochrane Database of Systematic Reviews; the Cochrane Central 
Register of Controlled Trials (Central); the Database of Abstracts of Reviews of 
Effects; the Health Technology Assessment Database; the NHS Economic Evaluation 
Database. 
Use MeSH and keyword searches to identify systematic reviews and other relevant 
studies.
Point-of-Care 3.2 Point-of-Care Reference Tools
One or more of the following point-of-care reference tools: BMJ Best Practice; 
DynaMed; UpToDate.
Medline 3.3 Medline
Use MeSH and keyword searches. Limit results using the ‘Human’ search filter. 
Unless otherwise specified by the tumour group or warranted by the specific clinical 
question, limit results to studies from the previous five years. 
Where appropriate, limit intervention questions according to the following priority: 
Medline clinical queries; Cochrane systematic reviews; other systematic reviews or 
meta-analyses; RCTs; systematic reviews of cohort or cross-sectional studies; cohort 
or cross-sectional studies; general Medline or other sources.
Where appropriate, limit diagnosis, prognosis or aetiology questions according 
to the following priority: Medline clinical queries; systematic reviews of cohort or 
cross-sectional studies; cohort or cross-sectional studies; general Medline or other 
sources.
Embase 3.4 Embase
Repeat the Medline search strategy above using Embase, if available.
Other Databases 3.5 Other Bibliographic Databases
Repeat the Medline search strategy above using the Cumulative Index to Nursing 
and Allied Health Literature and/or PsycINFO, as appropriate.
Other Sources 3.6 Other Sources
Use any other sources for background or additional information, as appropriate. 
Other sources may include: PubMed, particularly for in-process or ahead-of-print 
citations; quality-assured, subject-specific Internet resources; clinical reference 
books; patient information materials; etc.
HSE Library Services
NCCP Guideline Development
www.hselibrary.ie
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Trial Registers 3.7 Trial Registers
When a relevant trial is identified through searching the bibliographic databases, a 
search of trial registers should be carried out to identify any related trials which have 
been completed but whose findings have not been published or made available. The 
tumour group should be alerted to the presence of these unpublished trials. The 
following sources may be included:
3.7.1 ClinicalTrials.gov: http://clinicaltrials.gov/
3.7.2 Cochrane Central Register of Controlled Trials (Central): http://www.
thecochranelibrary.com/
3.7.3 EU Clinical Trials Register: https://www.clinicaltrialsregister.eu/
3.7.4 International Prospective Register of Systematic Reviews (Prospero): http://www.
crd.york.ac.uk/prospero/search.asp
3.7.5 WHO International Clinical Trials Registry: http://apps.who.int/trialsearch/
3.8 For questions relating to economic evaluations, use the SIGN economic studies filter 
for Medline as a basis for the search strategy: http://www.sign.ac.uk/methodology/
filters.html#econ. The following source may also be consulted, if available: 
HEED: Health Economic Evaluations Database: http://onlinelibrary.wiley.com/
book/10.1002/9780470510933.
Library 
Services
4 Reference 
Management
Retain an electronic record of the search strategy and all search results using the 
Zotero reference management utility.
Library 
Services
5 Search Results Respond to the tumour group using the Clinical Query Response form to include:
§	 a copy of the search strategy
§	 bibliographic details of all search results identified
§	 optionally, a note of studies that seem to the librarian to be of 
particular relevance to the clinical question
See below Annex 2: Clinical Question Response.
Library 
Services
6 Retracted 
Publications
6.1 Set up an alert to review results lists returned to the tumour group to rapidly capture 
any articles that are subsequently retracted or withdrawn, and notify the tumour 
group accordingly.
Tumour 
Group/
Library 
Services
Retracted 
Publications
6.2 Review all articles included in recommendations of the completed guideline to 
confirm that they have not been subsequently retracted or withdrawn.
Library 
Services
7 Summary of 
Search Strategy
A summary of the search strategy is included as an addendum to the completed 
guideline. Complete the Clinical Question: Summary of Search Strategy form and 
return to the tumour group. 
See below Annex 3: Clinical Question: Summary of Search Strategy.
Library 
Services
8 [Pre-External 
Review] Update 
of Literature 
Search
Once internal review of the guideline has been completed, literature searches for 
all clinical questions should be updated to capture articles published in the interim 
between the original literature search and the final draft of the guideline. Updated 
literature searches should be conducted prior to submission of the guideline for 
external review.
Respond to the tumour group as previously using the Clinical Query Response form 
to include:
§	 a copy of the search strategy
§	 bibliographic details of all search results identified
§	 optionally, a note of studies that seem to the librarian to be of 
particular relevance to the clinical question
See below Annex 2: Clinical Question Response.
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ANNEX 1
CLINICAL QUESTION REQUEST TO LIBRARY
Your Contact Details
Name
Job Title
Work Address
Telephone
Email
Employee Number
Please state your clinical question
… and list any relevant keywords
… or (optional) enter keywords under the following headings (PICO)
PICO
Population/Problem
Intervention/Indicator
Comparator/Control
Outcome
Is your question specific to any of the categories below?
GENDER AGE GROUP DATE OF PUBLICATION
Male r
Female r
Infant (0 – 23 months) r
Child (2 – 12 years) r
Adolescent (13 – 18 years) r
Adult (19 – 65 years) r
Aged (> 65 years) r
Current year only r
0 – 5 years r
> 5 years r
Question Type
Therapy/Intervention r
Aetiology/Risk Factors r
Diagnosis r
Prognosis/Prediction r
Frequency/Rate r
Phenomena r
Other r
Additional Information
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ANNEX 2
CLINICAL QUESTION RESPONSE FROM LIBRARY
Dear _______________,
Thank you for your email. Please see attached in response to your clinical query and, below, details of the search strategy 
applied to your question. If you wish to source any of the references contained in these results, or to search further, please do 
not hesitate to contact us.
Best wishes,
_______________.
[ATTACH CLINICAL QUESTION REQUEST HERE]
Search Strategy
Primary Database(s) Searched
Search Strategy
Other/Secondary Resources 
Searched
Comments
Contact
Your Library Staff Contact
Date
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ANNEX 3
CLINICAL QUESTION: SUMMARY OF SEARCH STRATEGY
Clinical Question
PICO
Population/Problem
Intervention/Indicator
Comparator/Control
Outcome
Is your question specific to any of the categories below?
GENDER AGE GROUP DATE OF PUBLICATION
Male r
Female r
Infant (0 – 23 months) r
Child (2 – 12 years) r
Adolescent (13 – 18 years) r
Adult (19 – 65 years) r
Aged (> 65 years) r
Current year only r
0 – 5 years r
> 5 years r
Question Type
Therapy/Intervention r
Aetiology/Risk Factors r
Diagnosis r
Prognosis/Prediction r
Frequency/Rate r
Phenomena r
Other r
Search Strategy
Primary Database(s) 
Searched
Search Strategy [Copy of base Medline and/or PubMed search strategy HERE. Include subject headings 
and search hits].
Other/Secondary Resources 
Searched
Search Strategy: Other 
Resources
[Copy of other search strategies HERE. Include subject headings and search hits].
Comments [Short paragraph describing search].
Date
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ANNEX 4
SYSTEMATIC LITERATURE REVIEW WORKFLOW*
* Based in part on “Figure 10: Systematic Literature Review” of SIGN 50: A Guideline Developer’s Handbook. - Scottish Intercollegiate 
Guidelines Network (2011). SIGN 50: A Guideline Developer’s Handbook. Revised ed. Edinburgh: Scottish Intercollegiate Guidelines Network.
Protocol designed by the HSE/hospital librarians in conjunction with the NCCP.
STEP 1
IDENTIFY GAPS IN EXISTING CLINICAL GUIDELINES
STEP 2
FORMULATE CLEARLY DEFINED CLINICAL QUESTIONS
STEP 4
CRITICALLY APPRAISE SEARCH RESULTS
“NO”
“YES”
Is evidence sufficient to 
answer clinical question?
STEP 5
RECOMMENDATIONS
________________________________________________
Recommendations should incorporate:
• expert opinion
• patient values
•  cost implications
STEP 3
SEARCH LITERATURE USING KEYWORDS IMPLICIT IN 
PICO(T) AND ANY IDENTIFIED SUBJECT HEADINGS
PICO(T)
__________________________
• Population or Problem
• Intervention or Indicator
•  Comparator or Control
• Outcome
•  Time
SEARCH STRATEGY
__________________________
Retain copy of search strategy 
and include as appendix 
(“Summary of Search Strategy”) 
in completed guideline.
SEARCH STRATEGY
__________________________
Re-formulate clinical question 
and search again AND/OR seek 
expert consensus.
LITERATURE SEARCH
__________________________
• Cochrane
• Point-of-Care Reference 
Tools
•  Medline/PubMed
• Embase
•  Other Bibliographic 
Databases
•  Other Sources
• Trial Registers
•  Retracted Studies
Clinical Question
Request Form
Clinical Question
Request Form
Clinical Question
Request Form
SYSTEMATIC
LITERATURE REVIEW
WORKFLOW
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Appendix 5: Details of consultation process
This table summarises those invited to consult on the guideline. 
Clinical leaders and 
healthcare managers
National Clinical Leads group 
HSE Clinical Programme in Surgery 
HSE Clinical Programme in Radiology 
HSE Clinical Programme in Palliative Care 
HSE Clinical Programme in Medicines management & pharmacological interventions 
HSE Clinical Programme in Obstetrics and Gynaecology
HSE Clinical Programmes in Renal Failure
HSE Clinical Programme in Primary Care
CEOs of the Hospital Groups
CEOs of the designated Cancer Centres 
CEO/managers of the Cancer Network Hospitals
National groups, 
organisations, faculties & 
committees
Faculty of Surgery, RCSI
Faculty of Radiology, RCSI
Faculty of Pathology, RCSI
Chairs of Obstetrics and Gynaecology in GUH, CUH, TCD and UL 
Irish Society for Medical Oncologists (ISMO)
Irish Association for Nurses in Oncology (IANO) 
Irish College of General Practitioners (ICGP)
Irish Association of Emergency Medicine 
Irish Association of Directors of Nursing and Midwifery
Hospital Pharmacists Association of Ireland
Oncology Pharmacists Special Interest Group
Patient support and 
advocacy groups 
HSE Patient Forum
Irish Cancer Society 
Cancer Care West
Marie Keating Foundation
Gary Kelly Cancer Support Centre
Bray Cancer Support Centre
All Ireland Institute of Hospice and Palliative Care
The Irish Hospice Foundation
The Irish Association for Palliative Care
ASH Ireland
Irish Lung Foundation
The Irish Lung Cancer Nurses Group 
The Irish Thoracic Society
International Expert 
Review:
Ian Woolhouse Consultant Respiratory Medicine, Queen Elizabeth  
 Hospital, Birmingham 
Ms Ailsa Stein Programme Manager, Scottish Intercolllegiate 
 Guideline Network 
Professor Giorgio  Professor of Respiratory Medicine at the University of 
Scagliotti Torino, School of Medicine S. Luigi Gonzaga.
Professor Massimo Associate Professor of Medical Oncology University of 
Di Maio Turin, Department of Oncology, (Italy)
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Appendix 6: Budget Impact Assessment 
Part A: Economic Impact Report
Key message
This review of the literature on the economic evaluation of the diagnosis, staging and treatment of 
lung cancer and the budget impact analysis highlights potential economic consequences of the clinical 
guideline recommendations.
Economic literature review results 
The Guideline Development Group (GDG) undertook a literature search for evidence of clinical- and cost-
effectiveness, cost and resource impact, including primary (research studies) and secondary (reviews) 
sources. The literature sources searched are specified in the literature search strategy and include 
relevant resources, such as trial/guideline registries and relevant citation databases. The economic 
literature review was undertaken using the same search terms as derived from the clinical literature 
review (available as a separate document) but with an economic filter applied. The results of this 
search were then refined by focusing on studies carried out in countries where the population, costs 
and treatment were considered similar to the Irish setting. All papers included (Figure 9) were subject to 
appraisal using the SIGN ‘Economic Evaluations: Methodology Checklist 6’ by a health economist and are 
deemed of acceptable quality unless otherwise stated.
Budget impact of this National Clinical Guideline 
For recommendations which affect resource requirements, the budget impact was calculated. Additional 
resources, where required, will be sought through the HSE service planning process. 
The burden of cancer is growing, and the disease is becoming a major economic expenditure for all 
developed countries. In 2008, the worldwide cost of cancer due to premature death and disability (not 
including direct medical costs) was estimated to be US$895 billion. This is not simply due to an increase 
in absolute numbers, but also the rate of increase of expenditure on cancer. Several drivers of cost, such 
as over-use, rapid expansion, and shortening life cycles of cancer technologies (such as medicines and 
imaging modalities), and the lack of suitable clinical research and integrated health economic studies, 
have converged with more defensive medical practice, a less informed regulatory system and a lack of 
evidence-based sociopolitical debate. (Sullivan et al., 2011) 
“The cancer profession and industry should take responsibility and not accept a substandard evidence-
base and an ethos of very small benefit at whatever cost.” (Sullivan et al., 2011) Sullivan et al. (2011) 
believe that value and affordable cancer care can be introduced into the cancer policy lexicon without 
detracting from quality, and that the management tools, evidence, and methods are available to affect 
this transformation across all developed countries. 
A population-based cost analysis (Luengo-Fernandez et al., 2013) illustrated the economic burden of 
cancer on the European Union (EU). In 2009, cancer was estimated to have cost the EU €126 billion, 
with healthcare costs accounting for €51 billion (40%). In Ireland, inpatient care costs were estimated 
to account for €417 million of cancer-related healthcare costs out of a total of €619 million. Drug 
expenditure accounted for a further €127 million, while primary, outpatient and emergency care were 
estimated at €32 million, €30 million and €13 million, respectively. Across the EU, lung cancer had the 
highest economic cost (€18.8 billion) when compared to breast (€15 billion), colorectal (€13.1 billion) and 
prostate (€8.43 billion) cancer. The cost of lung cancer related productivity losses and informal care were 
estimated at €9.92 billion and €3.82 billion, respectively (Luengo-Fernandez et al., 2013). Irish healthcare 
costs for the treatment of lung cancer were estimated to cost €13 per person (Luengo-Fernandez et 
al., 2013). In comparison the European average cost per person for the treatment of lung cancer was 
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estimated to be €8. With cancer incidence expected to increase by 99% by 2040 (NCRI, 2014), there 
could be a significant increase seen in healthcare costs per person in Ireland. 
Methods 
The search strategy for economic literature is based on the search used in the clinical literature review, 
with the addition of a SIGN economic studies filter for Medline (Table 11. Economic literature review 
protocol) including the former Database of Abstracts of Reviews of Effects, NHS Economic Evaluation 
Database (EED), Health Technology Assessment Database, the Cochrane Library, and Google Scholar. 
The estimated costs per quality adjusted life year (QALY) or life years gained (LYG) given in the following 
summaries are those reported within each study for the given year and national currency. These cost-
effectiveness ratios have been complemented in brackets by euro estimates to correct for the exchange 
rate, purchasing power parity (PPP) between countries and health inflation to 2014 costs as per the 
Health Information and Quality Authority’s Economic Evaluation Guidelines (HIQA, 2014). 
The following summaries report the conclusions regarding cost-effectiveness made by the authors of 
the reviewed literature. It is important to recognise that those conclusions are particular to the health 
systems in the countries in which the studies are conducted in and reflect medical practice and healthcare 
costs at the time the studies were undertaken. These practices and costs can differ significantly between 
countries, even between nations of comparable per capita income. Clearly current medical practice in 
Ireland may differ from the context of the original studies and care must be taken not to over-interpret 
the relevance of such evidence for Ireland. More specifically, it is important to note that cost-effectiveness 
analysis (CEA) results can be highly contingent on what particular practices are compared and in what 
way. The conclusion that a given intervention is cost-effective in one setting may not hold true for 
another if the baseline standard of care against which that intervention is assessed differs between the 
two settings. 
Another reason for conclusions on cost-effectiveness to differ between countries relates to the prevailing 
cost-effectiveness threshold. While Ireland has no explicit cost-effectiveness threshold for non-drug 
interventions, cost-effectiveness ratios falling within the region of €45,000/QALY are conventionally 
considered cost-effective in Ireland. As this threshold differs from the thresholds typically used in other 
countries the statements of cost-effectiveness made in other contexts are not necessarily applicable 
to Ireland. In all cases possible the relevant Incremental Cost Effectiveness Ratios (ICERs) have been 
reported, thereby permitting comparison to the Irish threshold rather than relying on the original 
conclusion of each study relative to any national norms of cost-effectiveness in each case. It should be 
noted that there are constraints regarding cost-utility and heterogeneity of practice.
The reported costs and cost-effectiveness ratios have been inflated to 2014 euro values and adjusted 
for purchasing power parity (PPP). Nevertheless, it is also important to remember that there may still 
be a number of other factors which mean that cost-effectiveness ratios from other countries are not 
necessarily directly applicable to the Irish setting. For example, Ireland’s discount rate is higher than that 
applied in the UK, so many interventions assessed in the UK would have less favourable ratios if the Irish 
discount rate was applied. Similarly, some analyses are conducted from the societal perspective and may 
account for more costs and benefits than are considered in Irish cost-effectiveness analyses (CEAs), which 
only account for costs to the health sector and do not typically include non-health benefits. Accordingly, 
the euro-adjusted ratios reported here should only be considered broadly indicative of the level of cost-
effectiveness rather than precisely adjusted estimates for the Irish health system.
Finally, it should be noted that there is very little available literature on the cost-effectiveness of the 
interventions considered here. In most cases there is only one study per indication. This presents a 
considerable challenge in reaching conclusions regarding the likely cost-effectiveness of the interventions 
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in question. It would be preferable to have a range of studies to compare in order to better judge evidence 
quality and to provide insight into the effects of methodological and empirical factors from each study 
on the conclusions reached. However, the absence of a rich evidence base means that health economic 
evidence should be considered tentatively and the findings should only be considered broadly indicative 
of what might apply in Ireland currently. 
Medical Oncology cost effectiveness analysis 
The HSE has an approved robust reimbursement methodology in place to determine if medicines are 
reimbursed. This is underpinned by legislation. In light of that the budget impact and pharmacoeconomic 
assessment for this guideline defers to that process. 
The existing reimbursement process for new cancer drugs or new indications for existing cancer drugs is:
The Department of Health agreed a pricing and reimbursement framework agreement with the 
Pharmaceutical industry, the 2012 IPHA agreement. That has been further enhanced by the enactment 
and commencement of the Health (Pricing and Supply of Medical Goods) Act 2013, and the 2016 IPHA 
agreement.
In the agreement, the Department of Health agreed processes with the pharmaceutical industry with 
clearly documented procedures and timelines for the assessment of new medicines (IPHA agreement) in 
as timely a fashion as possible. The Health Act places statutory responsibilities on the HSE in relation to 
pricing and reimbursement of medicines.
The HSE, in any considerations around pricing and reimbursement is required to follow the procedures 
outlined in the agreement and the Act.
In accordance with those procedures, the National Centre for Pharmacoeconomics (NCPE) conducts 
Health Technology Assessments (HTA) which provide detailed information to the HSE on the potential 
budget impacts of the medicines and considers whether the medicines are cost effective at the current 
prices offered to the HSE.
The respective pharmaceutical companies submit dossiers to the NCPE which are examined in great detail 
in as short timeframes as possible. NCPE complete reports on the dossiers for the HSE and publishes its 
findings.
The NCPE reports are important inputs to assist decision making and are required to assist the HSE in 
ensuring that the most appropriate decisions are made.
The National Cancer Control Programme Technology Review Committee reviews proposals received from 
industry or expert groups in Ireland for funding of new cancer drugs, or expanded indications for existing 
cancer drugs or related predictive laboratory tests. Following appropriate deliberations, the Committee 
makes a recommendation on the introduction of the individual drug. When this is positive, the 
recommendation is then brought forward to the HSE Drugs Group for final decisions regarding funding.
The HSE assessment process is intended to arrive at decisions on the funding of each of the drugs that are 
clinically appropriate, fair, consistent and sustainable. The HSE engages with each of the pharmaceutical 
companies to discuss the issues raised in the NCPE reports.
The Department of Health approves the annual HSE Service Plan which contains financial provisions for 
new medicines which the HSE is required to manage to the best of its ability so as to provide access to 
as wide a range of new medicines as possible in a clinically appropriate, fair, consistent and sustainable 
manner.
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Potentially relevant citations 
identified through literature search 
(n=237)
Citations retrieved for a more 
detailed evaluation (n=25)
Excluded citations (n=212) 
Studies included for review and 
appraisal by health economist (n=8)
Figure 9. Economic literature review results breakdown
*Inclusion criteria
Costly utility model
Applicable to the Irish healthcare system
Applicable to patient population
English language
Clinically relevant outcomes
Relevant to guideline recommendations
*Exclusion criteria
Not a cost effectiveness study
Not in English language
Methodological or quality issues
Not applicable to Irish healthcare system
Applicable to patient population
Not relevant to guideline recommendations
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Table 11. Economic literature review protocol
ID Search
1 Economics/
2 “costs and cost analysis”/
3 Cost allocation
4 Cost-benefit analysis/
5 Cost control/
6 Cost savings/
7 Cost of illness/
8 Cost sharing/
9 “deductibles and coinsurance”/
10 Medical savings accounts/
11 Health care costs/
12 Direct service costs/
13 Drug costs/
14 Employer health costs/
15 Hospital costs/
16 Health expenditures/
17 Capital expenditures/
18 Value of life/
19 Exp economics, hospital/
20 Exp economics, medical/
21 Economics, nursing/
22 Economics, pharmaceutical/
23 Exp “fees and changes”/
24 Exp budgets/
25 (low adj cost).mp.
26 (high adj cost).mp.
27 (health?care adj cost$).mp.
28 (fiscal or funding or financial or finance).tw.
29 (cost adj estimate$).mp.
30 (cost adj variable).mp.
31 (unit adj cost$).mp.
32 (economic$ or pharmacoeconomic$ or price$ or pricing).tw.
33 Or/1-32
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Section I Economic literature appraisals
Radiology
Cost-effectiveness of positron emission tomography in staging of non-small cell lung cancer and 
management of solitary pulmonary nodules 
Cao et al. (2012) presents a systematic review of the use of positron emission tomography (PET) in the 
staging of non-small cell lung cancer (NSCLC) and the management of solitary pulmonary nodules. Their 
overall conclusion is that although the evidence appears mixed, it seems PET is either cost-saving or cost-
effective relative to other intervention strategies.
The analysis searched four databases (MEDLINE, EMBASE, NHS EED, and the Cochrane Health Technology 
Assessment Database) for literature on the cost-effectiveness of PET imaging. The authors assessed the 
identified studies against health economic analysis quality checklist and only included those studies with 
high scores in the primary analysis. In all, they identified 18 studies for review. Data including costs and 
effects were extracted from the studies and assessed. They also extracted the principal conclusion from 
each analysis. The review goes on to consider a number of other studies that are apparently considered 
relevant in the literature, but were either excluded due to low quality scores or not captured by the 
literature search.
The review notes that all of the analyses used decision analytic modelling to reach their findings. The 
review notes that results of the analyses are therefore contingent on the modelling assumptions made. It 
notes the heterogeneity of key assumptions regarding the test performance. The review draws particular 
attention to the number of studies interpreting the cost-effectiveness results incorrectly, primarily due to 
inappropriate comparisons between strategies. To correct for this they present revised interpretations of 
the cost-effectiveness ratios based on the reported costs and effects. It is important to note that there 
is great variety in the strategies compared, with different combinations of computed tomography and 
PET being considered. Despite this, the results show that strategies featuring PET are generally either 
cost-saving or have ICERs that are likely to be well within acceptable limits of cost-effectiveness. When 
the review considers the finding of other studies not captured by the search strategy, these other studies 
generally support the conclusion that PET imaging is either cost-saving or cost-effective. 
The review process is well described and the abstracting of data and correcting of erroneously 
interpreted cost-effectiveness ratios are all strengths of this review. However, despite implementing 
a clearly described search strategy, this analysis also goes on to review a large number of studies that 
were not captured by the search string, which seems counter to the purpose of the systematic review. 
A further note of caution is that while the review indicates that PET imaging can be cost-saving or cost-
effective, the results also show that PET imaging is not necessarily always cost-effective, as it depends on 
what particular combination of imaging is assessed. An additional caveat is that although the review by 
Cao et al. (2012) itself is relatively recent, the studies considered within the review date back to between 
1996 and 2007. So the relevance of the findings to current clinical practice and service provision costs 
may now be limited. In conclusion, the overall finding from this review should be interpreted as a heavily 
qualified endorsement of PET imaging as likely to be a rational strategy.
Cost-effectiveness of initial diagnostic strategy for pulmonary nodules presenting to thoracic surgeons
Deppen et al. (2014) present a cost-effectiveness model to examine the cost-effectiveness of computer 
assisted navigational bronchoscopy (NB) as an alternative to positron emission tomography (PET) as a 
diagnostic tool for patients with lung nodules. Their results suggest that NB is a cost-effective alternative 
to PET, although the differences in costs and effects appear relatively small.
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The analysis uses a model to compare four diagnostic strategies: the current strategy of PET imaging; NB; 
computed tomogaphy guided fine needle aspiration (CT-FNA); and video-assisted thoracoscopic surgical 
biopsy (VATS). VATS is used as follow-up diagnostic procedure in all strategies in which VATS is not the first 
test when the initial test fails to yield a diagnostic result. The principal analysis is conducted for nodules 
of between 1.5 and 2 cm in size and has a suspected lung cancer risk of 65% according to standard risk 
models in a 60 year old man with a history of smoking.
The results of the analysis find NB, CT-FNA and VATS all to be more costly and more effective than PET. 
NB and CT-FNA are found to be effectively equal in terms of costs and effects. VATS is dominated by NB 
and CT-FNA. The cost-effectiveness ratio of NB relative to PET is reported as $4,600/QALY (€3,945/QALY in 
2014 in inflation and PPP adjusted euro). Accordingly, NB would be interpreted as a highly cost-effective 
intervention as its ICER is well within commonly applied thresholds, such as the €45,000/QALY threshold 
applied in Ireland. The NB strategy only provides 0.05 more QALYs than the baseline PET strategy and the 
increase in costs of approximately $200 is less than 2% higher. 
The analysis is reasonably well described, but there is more detail in the model description and results 
that would have been beneficial. In particular, the analysis does not present many of the intermediary 
estimates such as the numbers of cases detected or numbers of false positives from the model, 
accordingly, it is not clear by what means the improved diagnostic performance leads to improved health 
outcomes. The analysis also did not apply discounting, which would have been appropriate in this case. 
While it seems unlikely that the application of discounting would result in the primary ICER estimate 
becoming greater than commonly applied cost-effectiveness thresholds, the failure to apply discounting 
is a concern as it signals methodological weakness. Similarly, the ICERs for dominated strategies are not 
reported correctly. Finally, the specific analysis to a given nodule size and estimated cancer risk means 
that it is unclear how the results presented here would apply to other cases more generally. Overall, while 
this study indicates NB is a cost-effective alternative to PET more evidence from other studies would be 
desirable.
Clinical effectiveness and cost-effectivenss of the diagnostic staging strategy of EBUS-TBNA combined 
with EUS-FNA compared with standard surgical staging techniques
Sharples et al. (2012) present a cost-effectiveness analysis of alternative diagnostic procedures for NSCLC 
as part of a broader clinical comparison of combined endoscopic ultrasound-guided fine needle aspiration 
(EUS-FNA) and endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) as an 
alternative to conventional surgical diagnostic technique of mediastinoscopy. They find combined EUS-
FNA EBUS-TBNA (endosonography) to have lower expected costs and higher expected effectiveness than 
mediastinoscopy, but do not find either of these results to be significantly different from zero. 
The analysis is based on a randomised control trial (RCT) of the two approaches at four sites which 
followed patients for six months. The results of the RCT are combined with quality of life data gathered 
within the study in a Bayesian cost-effectiveness analysis of the data that permits an examination of 
uncertainty in the findings. 
The analysis notes that the principal differences in costs arise due to both differences in the costs of the 
diagnostic procedure and differences in number of thoracotomies performed. The diagnostic costs were 
higher in the endosonography group, but this was partly offset by lower costs for thoracotomies. The 
resulting expected cost-effectiveness estimates find that endosonography dominates mediastinoscopy, 
but that the credible intervals for both incremental costs and effects estimates both cross zero.
This is a high quality study that is based on RCT evidence and directly elicited quality of life measures. The 
analysis is well documented and the results are clearly reported. The insignificant difference in costs and 
effects means it is difficult to strongly conclude in favour of endosonography. However, the conventional 
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approach within cost-effectiveness is to base recommendations on expected values, therefore on this 
basis endosonography is the preferred strategy. Nevertheless, the differences in expected costs and 
QALYs between the two strategies are relatively small.
Relevance to the guideline recommendation 
The above papers discuss the cost-effectiveness of non-invasive diagnostic techniques that are addressed in 
clinical questions 2.2.1, 2.2.2, 2.3.1 and 2.3.2. 
The evidence from a systematic review suggests that PET imaging is either cost-saving or cost-effective relative 
to other interventional strategies. However, the same study notes that PET is not always found to be cost-
effective. 
This is indirectly relevant to recommendation 2.2.1.3 which supports the use of PET-CT for nodal staging in 
patients with potentially resectable NSCLC prior to more invasive staging. 
The evidence also suggests navigational bronchoscopy, CT-FNA and VATS are all more cost-effective than PET, 
although there are several methodological issues highlighted with the internal validity of this analysis and 
further research is necessary. This is relevant to recommendations 2.2.1.4 and 2.2.2.1 which discuss the clinical 
effectiveness of PET-CT as part of the clinical pathway. 
EUS-FNA combined with EBUS-TBNA is reported to have higher sensitivity and negative predictive probability, 
and so is expected to be slightly more effective and less expensive than using surgical staging alone. This paper 
is particularly relevant to recommendations 2.2.2.1, 2.3.1.3 and 2.3.2.1. These recommendations are current 
practice and should not have any resource implications. 
The implementation plan (Appendix 7: Implementation Plan) outlines access to PET-CT as a possible barrier to 
successful implementation. If PET-CT is performed at hospitals that are not cancer centres then such hospitals 
will require the appropriate software to allow for results to be available for review at MDM in cancer centres. 
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Surgery 
Cost associated with lobectomy performed thoracoscopically or via thoracotomy
Burfeind Jr et al. (2010) conduct a cost-utility analysis comparing the two surgical methods for lobectomy. 
The conventional procedure is to use posterolateral thoracotomy (PLT), while the alternative is using 
thoracoscopy (TL). Their principal finding is that TL results in no less QALYs than PLT, but has statistically 
significantly reduced costs. Accordingly, the authors conclude that TL is a cost-saving procedure relative 
to standard PLT.
The analysis is primarily an observational analysis of 113 patients treated with either TL or PLT at a US 
medical centre between 2002 and 2004. The authors record the costs of surgery, including pre- and 
post-operative care for up to 30 days following the operation. The costs recorded are those incurred 
by the healthcare provider and relate to the direct use of resources. Patients completed quality of life 
questionnaires at four time points: preoperative, and 3, 6 and 12 month postoperatively to determine 
the differences in health related quality of life over a year following the operation. The procedures are 
considered equivalent in terms of overall survival from cancer, so there are no long term differences 
assumed for the costs of each intervention after the 30 days of observation. Discounting of costs and 
health effects was not applied because the differences in costs and effects of the procedures were only 
assessed over a short time span. Similarly, no adjustment is made for inflation. The analysis does not 
contain a sensitivity analysis as it is primarily an observational rather than a modelling study. It does 
clearly report error bounds on all the principal outcome measures reported.
The authors find no statistically significant difference in QALYs between the two procedures, hence they 
conclude them to be equally effective. They find the mean costs of PLT and TL to be $12,119 and $10,084 
respectively (€17,700 and €14,700 respectively in 2014 in inflation and PPP adjusted euro). They find 
the difference between these two costs to be statistically significant, and so conclude that TL is cost-
saving relative to PLT. The difference in costs between the interventions is largely attributed to lower pre-
operative costs and reduced length of stay for the less invasive TL procedure.
Overall this analysis appears well conducted and the conclusion that TL is cost-saving relative to PLT is 
credible. Nevertheless, there are some important limitations to this study that need to be recognised. 
The study does not feature randomisation between the two interventions. While this may raise concerns 
regarding the validity of the findings, it should also be noted that the study has demonstrated no 
difference in a range of patient characteristics between the intervention groups. More relevant to issues 
of external validity is the fact that the data for this study date from 2002 to 2004 and originate in the US, 
so the findings might not necessarily be representative of current care in Ireland. Notably, the quality 
of life measures employed failed to find a difference between the techniques, despite the finding of 
previous authors that TL is associated with reduced postoperative pain. This may be because the quality 
of life measure lacked sensitivity or was not employed at the relevant time point. However, this is not 
of great importance as it does not alter the conclusion that TL is a rational alternative to PLT given the 
evidence presented from this case.
Relevance to the guideline recommendations
The evidence suggests that thoracoscopy is significantly less expensive than posterolateral thoracotomy 
concluding that a saving of approximately €3,000 per patient from pre-operative evaluation to 30 days 
postoperatively. 
This is relevant to surgery questions 2.5.2 where the guideline development group recommend that 
in patients with clinical stage I (N0) non-small cell lung cancer (NSCLC), video-assisted thoracic surgery 
(thoracoscopy) should be considered as an alternative to thoracotomy for anatomic pulmonary resection. 
This is particularly relevant as the majority of patients in the Burfeind paper were pathological stage I lung 
cancer. The implementation plan (Appendix 7: Implementation Plan) states that the recommendation is 
current practice and there are no resource implications. 
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Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer
Chouaïd et al. (2014) present a systematic review of cost-effectiveness analyses of treatments for non-
small cell lung cancer (NSCLC). The overall conclusion reached by the authors is that the available 
evidence shows that most modern treatments recommended or recently developed tend to have cost-
effectiveness ratios that are in excess of what would currently be considered cost-effective.
This analysis systematically reviewed four databases (MEDLINE, NIHR Centre for Reviews and 
Dissemination, NHS HEED and PubMed). The search was run to assess the cost-effectiveness of first-
line and maintenance therapy for NSCLC. A large number of treatment and treatment combinations 
are examined in the review. These include, cisplatin-pemetrexed, cisplatin-gemcitabine, carboplatin-
paclitaxel, bevacizumab, cisplatin-vinorelbine, cisplatin-docetaxel, gemcitabine-vinorelbine, erlotinib, 
gefitinib, afatinib and crizotinib. While the review is systematically described, the data extraction and 
reporting are not. The results of the review are presented within the text rather than in tables. It broadly 
considers interventions with ICERs below $50,000/QALY (€46,200/QALY adjusted for inflation and PPP) to 
be cost-effective.
The report considers the reported costs and cost-effectiveness of the various treatment strategies, 
including alternative treatment combination used either in unselected patients or as targeted therapies. 
While the reporting is not consistent across the studies and a large number of ICERs are reported, most 
are in the hundreds of thousands of Euro or Dollars per QALY gained. Accordingly, these ICERs generally 
indicate that most of the therapies reviewed are not cost-effective.
Overall this review does not appear to be of high quality. The unstructured reporting of results for many 
treatment combinations and patient subgroups does not present the relevant evidence in an accessible 
format. The lack of focus on any one particular therapy or patient subgroup means there is no clear 
message to report to decision makers. Furthermore, the review does not appear to critically appraise 
the reviewed studies or assess the validity of the reported ICERs. Consequently, some inappropriately 
interpreted cost-effectiveness ratios have been reported in the review (for example the ICERs reported 
from Handorf et al.). Despite this, the overall conclusion of the review that most recent treatments 
considered for NSCLC do not appear to be acceptably cost-effective appears broadly correct given the 
literature cited.
Relevance to the guideline recommendations
The above article discusses the cost-effectiveness of techniques relevant to clinical question 2.6.5.
Please see above section detailing medical oncology cost effectiveness analysis.
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Radiation Oncology
Cost-effectiveness analysis comparing conventional versus stereotactic body radiotherapy for 
surgically ineligible stage I NSCLC
Mitera et al. (2014) use a simple retrospective observational analysis to compare the costs and effects 
of conventionally fractionated radiotherapy (CFRT) and stereotactic body radiotherapy (SBRT) for the 
treatment of stage I NSCLC. Their analysis indicates that SBRT is more costly and more effective than CFRT 
and has a cost-effectiveness ratio well within standard cost-effectiveness thresholds.
The analysis compares stage Ia and Ib NSCLC patients receiving CFRT or SBRT instead of surgical resection. 
The analysis is a retrospective analysis of costs and mortality of patients at a Canadian hospital. The 
analysis gives a detailed description of the costs captured in the analysis. 
The results show that the patients receiving SBRT have mean survival of 3.8 years, while those receiving 
CFRT have a mean survival of 2.8 years. The analysis estimates that the costs of CFRT and SBRT are 
CAN$6,886 and CAN$8,042, respectively (€5,700 and €6,600 respectively in 2014 in inflation and PPP 
adjusted euro). The authors use these differences in costs and effects to report an ICER of CAN$1,120/LYG 
(€920/LYG). Accordingly, the low ICER estimate relative to commonly applied thresholds would suggest 
SBRT is a highly cost-effective alternative to CFRT.
The results of this study cannot be considered reliable, as it is unclear if the relatively large survival benefit 
of SBRT can be attributed to superior treatment effect or to differences in the patient characteristics 
between those receiving CFRT and SBRT. The introduction to the review itself notes that no randomised 
studies have demonstrated any difference between CFRT and SBRT. Furthermore, there are potentially 
relevant differences between the patient groups receiving each therapy, with more men and higher 
stage patients receiving CFRT than SBRT. No statistical testing is shown to examine the differences in the 
patient characteristics. Accordingly, the cost-effectiveness evidence presented in this study should be 
disregarded. 
Comparison of surgical intervention and stereotactic body radiation therapy for stage I high-risk 
patients
Puri et al. (2012) presents a model based cost-effectiveness comparison of surgical resection and 
stereotactic body radiation therapy (SBRT) for high risk patients with stage I lung cancer. They conclude 
that while surgery is more costly than SBRT it is also more effective, supporting the cost-effectiveness of 
surgical resection rather than SBRT.
The analysis combines a retrospective analysis of high-risk patients receiving either surgery or SBRT with 
a simulation model. The observed recurrence rates from the observational study were adjusted using 
propensity score matching (PSM) with the aim of overcoming problems of selection bias between the 
two treatment groups. Using data from the PSM analysis they model the costs and effects of the two 
strategies. The effect estimates are not adjusted for quality of life, but rather are reported in life years 
gained (LYG). Costs and effects do not appear to be discounted. 
The reported results show surgery to be somewhat more effective, with an expected LYG of 0.45. Surgery 
is found to be more costly too, with incremental costs of $3,476 (€3,200/LYG in 2014 in inflation and PPP 
adjusted euro) and the resulting ICER is $7,753/LYG (€7,200/LYG). This ICER is well within conventionally 
applied thresholds, such as the €45,000/QALY threshold commonly used in Ireland. 
Overall this is a well described study. The attempt to correct for selection bias using PSM is appropriate and 
the discussion gives a clear description of the possible limitations of this method. The principal potential 
problem is that SBRT candidates are expected to have greater morbidity than those allocated to surgery 
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and PSM may not be fully able to correct for this. The lack of discounting is a notable methodological 
flaw and means the reported ICER is likely to be somewhat of an underestimate. However, given the 
relatively short amount of remaining life expectancy in most cases it is not likely that the discounted ICER 
would be so much higher as to rise above commonly applied thresholds. The study authors recognise 
the limits of the study design employed and suggest that prospective randomised studies are required 
to enhance confidence in the results reached. In conclusion, this report provides evidence of moderate 
quality supporting the cost-effectiveness of surgical resection rather than SBRT in high risk stage I lung 
cancer patients.
Cost-effectiveness analysis comparing conventionally fractionated radiotherapy versus stereotactic 
body radiotherapy for stage I NSCLC
Sher et al. (2011) presents a CEA of three alternative therapies for patients with early stage NSCLC not 
suitable for surgery. The analysis relates to peripheral tumours rather than those in the proximal bronchial 
tree. They compare radiofrequency ablation (RFA), three-dimensional conformal radiation therapy (3D-CRT) 
and stereotactic body radiotherapy (SBRT). They found 3D-CRT to be subject to extended dominance and 
SBRT to be the most costly and most effective, with a cost-effectiveness ratio relative to RFA that is within 
commonly applied thresholds.
The analysis employs a model to combine estimates from the literature on disease progression rates, costs, 
and health related quality of life related to the three strategies. Parameters that are particularly important 
to the model are local recurrence rates under each of the three therapies. The model gives particular 
consideration to adverse effects associated with the SBRT therapy. The analysis includes a detailed costing 
from the health payer perspective. The analysis also presents a range of sensitivity analyses. 
The results show that RFA is the least costly and least effective treatment. 3D-CRT is more costly and 
more effective, but subject to extended dominance, meaning it will never be a preferred strategy from 
the cost-effectiveness perspective. SBRT is the most costly and most effective strategy. SBRT is estimated 
to yield an incremental QALY gain of over half a QALY relative to RFA, which is a large gain proportional to 
remaining life-expectancy in this case. The ICER of SBRT relative to RFA is $14,100/QALY (€12,500/QALY 
in 2014 in inflation and PPP adjusted euro). Accordingly, SBRT would clearly be considered cost-effective 
relative to the thresholds of $50,000/QALY applied in the US and €45,000/QALY commonly applied in 
Ireland. Sensitivity analyses never find 3D-CRT to be the preferred strategy and almost always find SBRT 
to be the preferred strategy. 
This is a well presented study. The model is described adequately and the relevant costs and effects 
are accounted for. Discounting is applied appropriately. That 3D-CRT is dominated by other strategies is 
not reflected clearly in the paper and the reporting of an incorrect ICER for this strategy is one notable 
problem with the presentation of results but it does not affect the study’s conclusions. The base case 
results and sensitivity analysis all support the conclusion that SBRT is likely to be cost-effective. The 
analysis notes that 3D-CRT may be the preferred strategies for tumours in the centre of the chest, where 
SBRT is less well tolerated.
Relevance to the guideline recommendations
The above article discusses the cost-effectiveness of techniques relevant to clinical question 2.7.1.
The evidence suggests that SBRT is less costly than surgery in high-risk patients with early stage NSCLC. 
However, surgery met the standard for cost-effectiveness due to a longer expected overall survival. This 
is supported by recommendation 2.7.1.1.
The evidence also suggests that SBRT compared to 3D-CRT and RFA, was the most cost-effective treatment 
for medically inoperable early stage NSCLC. This is also supported by recommendation 2.7.1.1. 
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Table 12. Economic literature evidence table
Study Intervention Analysis Clinical & QALY  
Outcomes
Costs Results
Cao et al., 
2012
Positron Emission 
Tomography in 
staging of non-small 
cell lung cancer and 
management of 
solitary pulmonary 
nodules.
Country: United 
Kingdom 
Discount rate:
NA
Perspective:
NA
Time Horizon:
NA
Model type:
Systematic review
N/A N/A N/A
Deppen et al., 
2014
Role of NB, CT-FNA, 
FDG-PET and VATS in 
patients presenting 
with pulmonary 
nodules suggestive 
of lung cancer.
Country: USA
Discount rate:
Not applied
Perspective: 
Presenting to a 
thoracic surgeon 
(healthcare system) 
Time Horizon:
Not stated
Model type:
Decision analysis 
model
In two-way sensitivity 
analysis, FDG-PET 
remained the least 
costly diagnostic 
strategy across all 
combinations of 
sensitivity between 80% 
and 100% and specificity 
between 60% and 90%. 
Efficacy for FDG-PET 
ranged from 14.08 to 
14.22 QALYs across 
these combinations 
of sensitivity and 
specificity. Diagnosis 
by FDG-PET was the 
most effective and 
least costly strategy at 
the upper ranges of 
sensitivity and specificity 
when expected QALYs 
exceeded 14.17.
FDG-PET total cost 
($10,411) NB total 
cost ($10, 601) CT-
FNA total cost($10, 
603)VATS total cost 
$11,720 
The FDG-PET had the 
lowest expected cost 
for diagnosing patients 
($10,410) with an 
expected QALY of 14.12. 
Compared with FDG-PET, 
patients diagnosed using 
NB incurred an expected 
incremental cost of $191 
to obtain an additional 
0.05 QALYs and resulted 
in an incremental cost-
effectiveness ratio of 
$4,602 per additional 
QALY. Diagnosis by 
CT-FNA had a similar 
cost ($193) and efficacy 
with a QALY of 14.17 as 
compared with FDG-PET 
and marginally higher 
QALY (<0.01) when 
compared with NB. 
Diagnosis by VATS had 
both higher expected 
cost of $11,720 and 
a lower effectiveness 
(14.15 QALYs), and 
the other two biopsy 
strategies provided 
higher QALYs at a lower 
cost than VATS biopsy.
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Study Intervention Analysis Clinical & QALY  
Outcomes
Costs Results
Sharples et al., 
2012
Endobronchial 
and endosopic 
ultrasound relative 
to surgical staging 
in potentially 
resectable lung 
cancer.
Country: 
Multinational 
(UK, Belgium, 
Netherlands)
Discount rate:
Not applied
Perspective:
Healthcare system
Time Horizon:
6 months
Model type
Trial based economic 
analysis 
Sensitivity for detecting 
mediastinal nodal 
metastases was 79% 
[41/52; 95% confidence 
interval (CI) 66% to 
88%] for the surgical 
arm compared with 
94% (62/66; 95% CI 
85% to 98%) for the 
endosonography 
strategy (p=0.02). The 
corresponding NPVs 
were 86% (66/77; 95% 
CI 76% to 92%) and 93% 
(57/61; 95% CI 84% to 
97%) (p=0.18).
The expected QALY 
gain over 6 months was 
0.344 (95% CI 0.292 to 
0.383) for the endo-
sonography strategy 
and 0.329 (95% CI 0.274 
to 0.371) for surgical 
staging. The mean 
difference in QALYs 
was 0.015 (–0.023 to 
0.052) in favour of the 
endosonography arm 
(with surgical staging if 
negative).
Total mean cost of 
initial endosonograpy 
followed by surgical 
staging (£9,713) 
per patient over 6 
months. Surgical 
staging cost a mean of 
(£10,459).
In this randomised 
controlled trial (RCT), 
a strategy of using 
combined state-of-
the-art, non invasive 
endosonography 
(EUS–FNA and EBUS-
TBNA) followed by 
surgical staging (only 
if these tests were 
negative) had higher 
sensitivity and negative 
predicted probability, 
resulted in a lower 
rate of unnecessary 
thoracotomy and better 
quality of life during 
staging, and was slightly 
more effective and less 
expensive than the 
current practice of lung 
cancer staging using 
surgical staging alone.
Burfeind et al., 
2010
Lobectomy 
(thoracoscopically vs 
thoracotomy)
Country: USA
Discount rate:
Not carried out due 
to short time period
Perspective:
Medical centre
Time Horizon:
30 days
Model type:
Cost-minimisation 
analysis
The number of chest 
tube days as well 
as length of stay 
was statistically less 
for the TL group 
while the incidence 
of other common 
adverse outcomes was 
equivalent between the 
groups. In addition to 
the variables listed in 
the table, no patient in 
either group required 
re-operation for 
bleeding or received a 
transfusion, and there 
were no postoperative 
myocardial infarctions, 
strokes, empysemas or 
bronchopleural fistulae.
The mean QALY for 
the PLT group was 
0.74 ± 0.22 and for the 
TL group was 0.72 ± 
0.18. These were not 
statistically different, 
p=0.68.
Total costs for the PLT 
group were $11,998 
± $3549 and for the 
TL group $10,120 
± $2817. The PLT 
strategy remained 
statistically more 
expensive than the TL 
strategy with p=0.005.
Baseline characteristics 
were similar in the 
two groups. Total costs 
($US) were significantly 
greater for the strategy 
of PLT ($12,119) than for 
TL ($10,084; p=0.0012). 
Even when only stage I 
and II lung cancers were 
included (n = 32 PLT, n 
= 69 TL), total costs for 
PLT were still higher than 
that for TL ($11,998 vs 
$10,120; p=0.005). The 
mean QALY for the PLT 
group was 0.74 ± 0.22 
and for the TL group was 
0.72 ± 0.18 (p=0.68). 
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Study Intervention Analysis Clinical & QALY  
Outcomes
Costs Results
Puri et al., 
2012
Surgical intervention 
vs stereotactic body 
radiation therapy in 
stage I lung cancer in 
high risk patients. 
Country: USA 
Discount rate:
Not applied
Perspective:
Payer’s 
Time Horizon:
Lifetime 
Model type:
Decision analysis 
In the surgical group 
operative mortality was 
4 (7%) of 57. Median 
survival was 4.2 years, 
and 4-year survival 
was 51.4% (n = 21). 
Thirteen of 53 surgical 
survivors with incidental 
N1/N2 disease (11 
with N1 and 2 with N2 
disease) were eligible for 
chemotherapy. Of these, 
7 patients underwent 
chemotherapy. In the 
SBRT arm there was 
no treatment-related 
mortality, and the rate 
of major morbidity was 
1.8% (1/57). None of 
the patients undergoing 
SBRT received 
chemotherapy. Median 
survival was 2.9 years, 
and 4-year survival was 
30.1% (n = 12, p=.101).
QALYs – were not 
determined
The expected cost of 
treating patients with 
surgical intervention 
was $17,629, and 
there was an expected 
survival of 3.39 years 
during the 5-year 
period evaluated in 
modeling. Compared 
with SBRT, patients 
treated with 
surgical intervention 
incurred an expected 
incremental cost 
of $3476 but lived 
an additional 0.45 
years, resulting in an 
incremental cost-
effectiveness ratio of 
$7753 per additional 
year of survival.
Fifty-seven patients in 
each arm were selected 
by means of propensity 
score matching. Median 
survival with surgical 
intervention was 4.1 
years, and 4-year 
survival was 51.4%. 
With stereotactic body 
radiation therapy, 
median survival was 
2.9 years, and 4-year 
survival was 30.1%. 
Cause-specific survival 
was identical between 
the 2 groups, and the 
difference in overall 
survival was not 
statistically significant. 
For decision modeling, 
stereotactic body 
radiation therapy was 
estimated to have a 
mean expected survival 
of 2.94 years at a cost 
of $14,153 and mean 
expected survival with 
surgical intervention 
was 3.39 years at a 
cost of $17,629, for 
an incremental cost-
effectiveness ratio of 
$7753.
Sher et al., 
2011
Steroetactic body 
radiotherapy and 
radiofrequenncy 
ablation for 
medically 
inoperable, early 
stage non-small lung 
cancer.
Country: USA
Discount rate:
3%.
Perspective:
Payer’s (Medicare)
Time Horizon:
Lifetime 
Model type
Cost-effectiveness 
analysis 
In the base-case 
analysis, RFA, 3D-CRT, 
and SBRT were 
associated with a 
mean cost per quality-
adjusted life-expectancy 
of $44,648/1.45, 
$48,842/1.53, and 
$51,133/1.91, 
respectively. The ICER 
of 3D-CRT over RFA was 
$52,400/QALY. However, 
the ICER of SBRT over 
3D-CRT was $6,000/
QALY, and thus the 
ICER of SBRT over RFA 
was $14,100/QALY. In 
other words, if all three 
treatment options are 
available to the clinician, 
in the base case, SBRT 
is  clearly the most 
cost-effective treatment, 
whereas if SBRT delivery 
is not feasible, RFA is the 
next most cost-effective 
option.
Total cost associated 
with SBRT 
($14,741.13), 3D-CRT 
($11,014.77), RFA 
($5,897.62)
The incremental cost-
effectiveness ratio 
for SBRT over 3D-CRT 
was $6,000/quality-
adjusted life-year, 
and the incremental 
cost-effectiveness 
ratio for SBRT over RFA 
was $14,100/quality-
adjusted life-year. One-
way sensitivity analysis 
showed that the results 
were robust across a 
range of tumour sizes, 
patient utility values, 
and costs. This result 
was confirmed with 
probabilistic sensitivity 
analyses that varied 
local control rates and 
utilities.
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Study Intervention Analysis Clinical & QALY  
Outcomes
Costs Results
Chouaid et al., 
2014
Rejected N/A N/A N/A N/A
Mitera et al., 
2014
Rejected N/A N/A N/A N/A
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Part B: Budget Impact Analysis 
Radiology
All figures were calculated using incidence figures for 2013 from the NCRI , due to the extensive budget 
requirement for PET-CT availabliity of PET-CT scans should be considered for all cancer centres.
Radiology
Clinical question 2.2.1 In non-small cell lung cancer (NSCLC) patients with mediastinal and hilar adenopathy 
what is the efficacy of CT (contrast and non-contrast) and PET-CT in the diagnosis of lung cancer?
Recommendation number: Additional 
resource 
required:
Resource cost: No. required: Total cost:
2.2.1.1
Contrast enhanced CT scanning of the chest 
and upper abdomen to include the entire liver 
is recommended in all patients with suspected 
lung cancer, regardless of chest X-ray results. 
None N/A N/A €0
2.2.1.2
A tissue diagnosis of lung cancer should not be 
inferred from CT appearances alone. 
None N/A N/A €0
2.2.1.3
PET-CT is recommended for mediastinal and 
hilar lymph node staging in patients with 
potentially radically treatable non-small cell 
lung cancer (NSCLC) prior to invasive staging.
PET-CT €1,199 483 €579,117
2.2.1.4
In patients with PET activity in a mediastinal 
lymph node and normal appearing nodes by 
CT (and no distant metastases), sampling of 
the mediastinum is recommended over staging 
by imaging alone.
None N/A N/A €0
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Clinical Question 2.2.2 In patients with peripheral lung nodules, what is the efficacy of the following tests in 
the diagnosis of lung cancer? - Percutaneous fine needle aspiration and transthoracic needle biopsy - Guided 
bronchoscopy - Video assisted thoracoscopic surgery (VATS)
Recommendation number: Additional 
resource 
required:
Resource cost: No. required: Total cost:
2.2.2.1
Percutaneous FNA, TTNB, guided 
bronchoscopy and VATS are all appropriate 
first-line modalities for tissue diagnosis of 
peripheral lung nodules.
None N/A N/A €0
2.2.2.2
While percutaneous TTNA/biopsy has a higher 
diagnostic yield, bronchoscopy (including 
guided approaches where available) may 
provide a diagnosis for peripheral lesions. 
None N/A N/A €0
Clinical question 2.2.3 In NSCLC patients with early stage disease who are high risk surgery candidates, what is 
the effectiveness of ablative techniques?
Recommendation number: Additional 
resource 
required:
Resource cost: No. required: Total cost:
2.2.3.1
In patients with clinical stage Ia tumours who 
are high risk surgical candidates, ablative 
techniques may be considered to achieve local 
control. 
None N/A N/A €0
Clinical question 2.2.4 For patients with NSCLC who have undergone surgical resection or radiotherapy with 
curative intent, is there a role for imaging surveillance?
Recommendation number: Additional 
resource 
required:
Resource cost No. Required Total cost:
2.2.4.1
Consider close follow-up for patients who 
have undergone treatment with curative 
intent (including surgery and radiotherapy), to 
include periodic radiological evaluation with 
CT.
*CT will be required in these patients and 
costing can only be determined when a 
definitive imaging follow-up schedule is 
determined.
CT TAP €131 658* €86,198
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Clinical question 2.2.5 For patients with NSCLC which of the following tests is most accurate for detecting 
metastatic spread to indeterminate adrenal nodules/masses: chemical shift MRI, non-contrast CT, PET-CT?
Recommendation number: Resource 
required:
Resource cost: No. required: Total cost:
2.2.5.1
A negative PET-CT reliably excludes adrenal 
metastases in patients with NSCLC.
None N/A N/A €0
2.2.5.2
In NSCLC patients with PET-CT positive for 
adrenal metastasis, histological confirmation 
should be considered unless there is 
overwhelming clinical and imaging evidence of 
widespread metastatic disease.
None N/A N/A €0
2.2.5.3
In NSCLC patients with indeterminate adrenal 
lesions on PET-CT further assessment with 
adrenal specific CT or MRI criteria may 
be considered. If non-invasive imaging 
findings are indeterminate, adrenal sampling 
such as EUS-FNA, percutaneous biopsy or 
adrenalectomy may be considered.
None N/A N/A €0
Clinical question 2.2.6 For patients with NSCLC which of the following tests is most accurate for detecting brain 
metastases: MRI, CT, PET-CT?
Recommendation number: Additional 
resource 
required:
Resource cost: No. required: Total cost:
2.2.6.1
Offer patients with signs/symptoms suggestive 
of brain metastases, contrast-enhanced CT of 
the head followed by contrast-enhanced MRI if 
normal or MRI as an initial test. 
None N/A N/A €0
2.2.6.2 
Offer MRI or CT of the head in patients with 
stage III NSCLC selected for treatment with 
curative intent.
None N/A N/A €0
2.2.6.3
Do not routinely offer imaging of the brain in 
patients with stage I and II NSCLC.
None N/A N/A €0
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Clinical question 2.2.7 For patients with NSCLC which of the following tests is most accurate for detecting bone 
metastases: isotope bone scan, CT, MRI, PET-CT?
Recommendation number: Additional 
resource 
required:
Resource cost: No. required: Total cost:
2.2.7.1
For patients with NSCLC with suspected 
bone metastasis, evaluation with PET-CT is 
recommended over bone scintigraphy or CT.
None N/A N/A €0
2.2.7.2
Bone scintigraphy is not necessary when PET-
CT has not shown bone metastases.
None N/A N/A €0
Clinical question 2.2.8 In patients with limited-stage small-cell lung cancer (SCLC) on diagnostic CT, does PET-CT 
change management?
Recommendation no: Additional 
resource 
required
Resource cost No. Required Total Cost
2.2.8.1
In patients with clinically limited-stage small-
cell lung cancer (SCLC), PET-CT is suggested to 
exclude occult metastases.
None N/A N/A €0
Radiology Total Costs €665,315
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Respiratory Medicine
Clinical question 2.3.1 What is the efficacy of bronchoscopy in identifying lung cancer?
Recommendation number: Additional 
resource 
required:
Resource cost: No. required: Total cost:
2.3.1.1
Patients with central lesions (within proximal 
one-third of the hemithorax) alone (considered 
reachable by standard bronchoscopy) who 
are otherwise fit should undergo flexible 
bronchoscopy in order to establish a 
histological or cytological diagnosis.
None N/A N/A €0
2.3.1.2
Visible tumours should be sampled using 
more than one technique to optimise 
sensitivity.
None N/A N/A €0
2.3.1.3
Consider bronchoscopy to provide a diagnosis 
for peripheral lesions, although percutaneous 
FNA biopsy has a higher diagnostic yield.
None N/A N/A €0
Clinical question 2.3.2 In patients with mediastinal adenopathy: What is the efficacy of EBUS, EBUS/EUS and 
mediastinoscopy in the diagnosis of lung cancer?
Recommendation number: Additional 
resource 
required:
Resource cost: No. required: Total cost:
2.3.2.1
Endoscopic assessment of the mediastinal 
lymph nodes with EBUS-TBNA with or 
without EUS-FNA should be offered to 
patients with suspected lung cancer prior to 
mediastinoscopy.
None N/A N/A €0
Clinical question 2.3.3 In patients with pleural effusion and suspected lung cancer, what is the efficacy of pleural 
sampling in the diagnosis of lung cancer?
Recommendation number: Additional 
resource 
required:
Resource cost: No. required: Total cost:
2.3.3.1
In patients being considered for active 
therapy, pleural effusion should be 
investigated with pleural aspiration.
None N/A N/A €0
2.3.3.2
If pleural fluid cytology is negative, and 
treatment will change depending on the 
nature of the pleural fluid, pleural biopsy 
using image guided or thoracoscopic biopsy is 
recommended.
None N/A N/A €0
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Clinical question 2.3.4 What is the role of palliative interventions in the management of malignant airway 
obstruction?
Recommendation number: Additional 
resource 
required:
Resource cost: No. required: Total cost:
2.3.4.1
In lung cancer patients with symptomatic 
(including breathlessness, haemoptysis and 
cough) malignant airway obstruction, any of 
the following therapeutic interventions may 
be considered: bronchoscopic debulking, 
tumour ablation modalities, airway stent 
placement and radiotherapy (external beam 
or brachytherapy).
None N/A N/A €0
Respiratory Medicine Total Cost: €0
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Pathology
Clinical question 2.4.1
a) What is the benefit of histopathological analysis for small-cell lung cancer (SCLC) vs. non-small cell lung cancer 
(NSCLC)?  
b) When should immunohistochemical analysis be performed?  
c) What is the best panel(s) of immunohistochemical stains for NSCLC subtypes?
Recommendation number: Additional 
resource 
required:
Resource 
cost:
No. required: Total cost:
2.4.1.1
Distinguishing between small-cell carcinoma 
and non-small cell carcinoma of the lung 
is recommended. For challenging cases, a 
diagnostic panel of immunohistochemical assays 
is recommended to increase the diagnostic 
accuracy.
None N/A N/A €0
2.4.1.2
In individuals with pathologically diagnosed 
non-small cell cancer (NSCLC), additional 
discrimination between adenocarcinoma 
and squamous cell carcinoma, even on 
cytologic material or small tissue samples is 
recommended.
None N/A N/A €0
Clinical question 2.4.2 What is the efficacy of the following diagnostic tools in identifying and staging lung 
cancer?
- ROSE at EBUS 
- Frozen section
Recommendation number: Additional 
resource 
required:
Resource 
cost:
No. required: Total cost:
2.4.2.1
Endobronchial ultrasound rapid on-site 
evaluation (EBUS ROSE) should be made 
available whenever resources permit. 
*Based on expert opinion.
ROSE at 
EBUS
Unknown 745*
2.4.2.2
Consider intra-operative frozen section analysis 
in primary diagnosis when preoperative 
diagnosis is not available.
None N/A N/A €0
2.4.2.3
In selected cases intra-operative frozen section 
analysis for staging may be considered.
None N/A N/A €0
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Clinical question 2.4.3 In patients with NSCLC, how do cytological samples compare with tissue biopsy samples 
for tumour sub-typing, immunohistochemistry and predictive markers assessed by FISH or mutational analysis?
Recommendation number: Resource 
required:
Resource 
cost:
No. required: Total cost:
2.4.3.1
Cytology samples can be used to provide 
material suitable for both NSCLC sub-typing and 
some molecular analysis, provided the samples 
are appropriately handled and processed.
None N/A N/A €0
Clinical question 2.4.4 What are optimal formalin fixation times for future molecular diagnostics?
Recommendation number: Resource 
required:
Resource 
cost:
No. required: Total cost:
2.4.4.1
Fixation times of 6 to 12 hours for small biopsy 
samples and 8 to 18 hours for larger surgical 
specimens generally give best results, although 
expert consensus opinion is that fixation times 
of 6 to 48 hours should give acceptable results.
None N/A N/A €0
Pathology Total Cost €0
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Surgery
Clinical queation 2.5.1 In patients with stage I & II non-small cell lung cancer (NSCLC) how does the extent of 
lung resection effect outcomes? 
Recommendation number: Additional 
resource 
required:
Resource 
cost:
No. required: Total cost:
2.5.1.1
For patients with clinical stage I and II non-small 
cell lung cancer (NSCLC) who are medically fit 
for surgical resection, a lobectomy rather than 
sublobar resection is recommended.
None N/A N/A €0
Clinical question 2.5.2 In patients with clinical stage I NSCLC undergoing lobectomy, how does video-assisted 
thoracic surgery (VATS) compare to thoracotomy?
Recommendation number: Additional 
resource 
required:
Resource 
cost:
No. required: Total cost:
2.5.2.1
For patients with clinical stage I NSCLC, video-
assisted thoracic surgery (thoracoscopy) should 
be considered as an alternative to thoracotomy 
for anatomic pulmonary resection.
Longer 
operating 
time & higher 
capital costs. 
 
Identified 
higher 
operative 
times (median 
173 min vs. 
143 min,  
P < 0.0001) 
for subjects 
having VATS 
resection (Paul 
et al., 2010).
30 mins 
theatre time = 
€917
471 €431,907
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Clinical question 2.5.3 Which pulmonary function tests should be used to determine fitness for resection?
Recommendation number: Additional 
resource 
required:
Resource 
cost:
No. required: Total cost:
2.5.3.1
Pulmonary function testing (spirometry, 
diffusion capacity, lung volume) should be 
performed in all patients being considered for 
surgical resection.
None N/A N/A €0
2.5.3.2
Postoperative predictive values should be 
calculated using broncho-pulmonary segment 
counting. If a mismatch is suspected ventilation 
perfusion scan should be performed.
None N/A N/A €0
2.5.3.3
Offer patients surgery if they have an FEV1 & DLCO 
within normal limits (postoperative predicted 
values >60%). 
None N/A N/A €0
2.5.3.4
Patients with ppo-FEV1 and/or DLCO <30% should 
have formal cardiopulmonary exercise testing 
with measurement of VO2 max. 
None N/A N/A €0
2.5.3.5
Patients with ppo-FEV1 and/or DLCO >30% and 
<60% – supplementary functional exercise 
assessments should be considered.
None N/A N/A €0
2.5.3.6
In patients with lung cancer being considered 
for surgery and a VO2 max <15mL/kg/min 
predicted, it is recommended that they are 
counselled about minimally invasive surgery, 
sublobar resections or non-operative treatment 
options for their lung cancer.
None N/A N/A €0
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Clinical question 2.5.4 In patients with lung cancer, how should non-pulmonary co-morbidity influence surgical 
selection?
Recommendation number: Additional 
resource 
required:
Resource 
cost:
No. required: Total cost:
2.5.4.1
Lung cancer surgery remains the best 
opportunity for potential cure in patients with 
significant co-morbidity. Efforts to contain 
and manage that risk should start with 
preoperative scoring (thoracoscore) and should 
ideally include attendance at a preoperative 
assessment clinic, where practical. 
None N/A N/A €0
2.5.4.2
Seek a cardiology review in patients with an 
active cardiac condition or ≥3 risk factors or 
poor cardiac functional capacity. 
None N/A N/A €0
2.5.4.3
Offer surgery without further investigations to 
patients with ≤2 risk factors and good cardiac 
functional capacity.
None N/A N/A €0
Clinical question 2.5.5 Should lung cancer surgery be offered to octogenarians?
Recommendation number: Additional 
resource 
required:
Resource 
cost:
No. required: Total cost:
2.5.5.1
Age >80 years should not automatically 
preclude surgery. Decisions should be based 
on oncological stage, co-morbidity and 
physiological testing.
None N/A N/A €0
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Clinical question 2.5.6 In patients with NSCLC what is the optimum surgical approach for? 
a) Multifocal tumours  
b) Synchronous tumours
Recommendation number: Additional 
resource 
required:
Resource 
cost:
No. required: Total cost:
2.5.6.1 Multifocal 
In patients with suspected or proven 
multifocal lung cancer (without mediastinal 
or extrapulmonary disease), curative-intent 
treatment may be considered, following 
discussion at a multidisciplinary team meeting.
None N/A N/A €0
2.5.6.2 Synchronous 
In patients with suspected or proven 
synchronous primary lung cancers (without 
mediastinal or extrapulmonary disease), 
curative-intent treatment may be considered, 
following discussion at a multidisciplinary team 
meeting.
None N/A N/A €0
Clinical question 2.5.7 In patients with NSCLC, what is the optimal lymph node strategy at surgical resection? 
Recommendation number: Additional 
resource 
required:
Resource 
cost:
No. required: Total cost:
2.5.7.1
Systematic mediastinal lymph node dissection 
should be performed in all patients having a 
lung cancer resection. 
None N/A N/A €0
Clinical question 2.5.8 In patients with malignant pleural effusion associated with lung cancer, what is the best 
treatment strategy?
Recommendation number: Additional 
resource 
required:
Resource 
cost:
No. required: Total cost:
2.5.8.1
In patients with malignant pleural effusion 
whose symptoms improved following drainage, 
a number of options are available depending on 
performance status and documentation of lung 
re-expansion:
-  In patients with good performance status 
with lung re-expansion, thoracoscopy with 
talc pleurodesis is recommended. 
-  In patients with non-expandable lung, 
tunnelled catheters may be considered. 
-  In patients with poor performance 
status with lung re-expansion, options 
include: tunnelled pleural catheter, serial 
thoracentesis, or bedside talc pleurodesis.
None N/A N/A €0
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Clinical question 2.5.9 Should surgical resection be considered in patients with NSCLC, who have treatable 
isolated brain or adrenal metastases at the time of presentation? 
Recommendation number: Additional 
resource 
required:
Resource 
cost:
No. required: Total cost:
2.5.9.1
In patients with an isolated brain metastasis 
and a synchronous resectable primary NSCLC, 
sequential resection of the primary tumour and 
definitive treatment of the brain metastasis 
may be considered, following discussion at a 
multidisciplinary team meeting.
None N/A N/A €0
2.5.9.2
In patients with an isolated adrenal metastasis 
and a synchronous resectable primary NSCLC, 
sequential resection of the primary tumour and 
definitive treatment of the adrenal metastasis 
may be considered, following discussion at a 
multidisciplinary team meeting.
None N/A N/A €0
Clinical question 2.5.10 Should surgical resection be considered as part of the multimodality treatment of 
patients with stage IIIa (N2) NSCLC?
Recommendation number: Additional 
resource 
required:
Resource 
cost:
No. required: Total cost:
2.5.10.1
Consider surgery as part of multimodality 
management in patients with T1-3 N2 (non-
fixed, non-bulky, single zone) M0 disease.
None N/A N/A €0
Clinical question 2.5.11 In patients with small-cell lung cancer (SCLC) what is the role of surgery? 
Recommendation number: Additional 
resource 
required:
Resource 
cost:
No. required: Total cost:
2.5.11.1
Patients with clinical stage I small-cell lung 
cancer (SCLC) and excellent performance status 
may be considered for resection following 
extensive staging investigation as part of a 
multimodality treatment regimen. 
None N/A N/A €0
Surgery Total Cost €431,907
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Medical Oncology
Clinical question 2.6.1 In patients with non-small cell lung cancer (NSCLC) (excluding pancoast tumours) having 
curative surgery, how effective is pre-operative neoadjuvant chemotherapy or chemoradiotherapy? 
Recommendation number: Additional 
resource 
required:
Resource 
cost:
No. required: Total cost:
2.6.1.1
Preoperative chemoradiotherapy
For patients with non-small cell lung cancer 
(NSCLC) who are suitable for surgery, do not 
offer neoadjuvant chemoradiotherapy outside a 
clinical trial. 
N/A N/A N/A €0
2.6.1.2
Preoperative chemotherapy
Following discussion at a multidisciplinary team 
meeting, appropriate patients with NSCLC who 
are suitable for surgery can be considered for 
neoadjuvant chemotherapy.
Restaging 
Scan (CT 
TAP)
€131 483 €63,273
Clinical question 2.6.2 In patients with locally advanced NSCLC having radical radiotherapy, is concurrent 
chemoradiotherapy more effective than sequential chemoradiotherapy?
Recommendation number: Additional 
resource 
required:
Resource 
cost:
No. required: Total cost:
2.6.2.1
Concurrent chemoradiotherapy should be 
administered to patients with locally advanced 
NSCLC (suitable for radical radiotherapy) who 
have a good performance status (0-1).
None N/A N/A €0
Clinical question 2.6.3 In patients with locally advanced NSCLC having concurrent radical chemoradiotherapy, 
what is the effectiveness of: 
a) Induction (first-line) chemotherapy 
b) Consolidation chemotherapy
Recommendation number: Additional 
resource 
required:
Resource 
cost:
No. required: Total cost:
2.6.3.1
Induction or consolidation chemotherapy 
are not routinely recommended for patients 
receiving concurrent radical chemoradiotherapy.
N/A N/A N/A €0
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Clinical Question 2.6.4 In patients with advanced/stage IV NSCLC what is the effectiveness of first-line 
chemotherapy and is there any evidence that particular regimens or drugs are more effective or less toxic than 
others?
Recommendation number: Additional 
resource 
required:
Resource 
cost:
No. required: Total cost:
2.6.4.1
Effectiveness of first-line cytotoxic 
chemotherapy 
In patients with a good performance status (PS) 
(i.e. Eastern Cooperative Oncology Group [ECOG] 
level 0 or 1) and stage IV NSCLC a platinum-based 
chemotherapy regimen is recommended based 
on the survival advantage and improvement in 
quality of life (QOL) over best supportive care 
(BSC).
N/A N/A N/A €0
2.6.4.2
Effectiveness of first-line cytotoxic 
chemotherapy 
In patients with stage IV NSCLC and a good 
performance status, two-drug combination 
chemotherapy is recommended. The addition of 
a third cytotoxic chemo-therapeutic agent is not 
recommended because it provides no survival 
benefit and may be harmful. 
N/A N/A N/A €0
2.6.4.3
Effectiveness of first-line cytotoxic chemotherapy 
In patients receiving palliative chemotherapy for 
stage IV NSCLC, it is recommended that the choice 
of chemotherapy is guided by histological type of 
NSCLC.
N/A N/A N/A €0
2.6.4.4
Effectiveness of first-line cytotoxic chemotherapy 
Bevacizumab plus platinum-based chemotherapy 
may be considered an option in carefully selected 
patients with advanced NSCLC. Risks and benefits 
should be discussed with patients before decision 
making.
N/A N/A N/A €0
2.6.4.5
Effectiveness of first-line targeted therapy  
First-line single agent EGFR tyrosine kinase 
inhibitors (TKI) should be offered to patients with 
sensitising  EGFR mutation positive NSCLC. Adding 
combination chemotherapy to TKI confers no 
benefit and should not be used.
N/A N/A N/A €0
2.6.4.6
Effectiveness of first-line targeted therapy  
Crizotinib should be considered as first-line 
therapy in patients with ALK positive NSCLC 
tumours.
N/A N/A N/A €0
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Clinical Question 2.6.5 In patients with advanced/stage IV NSCLC is there any evidence for maintenance systemic 
therapy?
Recommendation number: Additional 
resource 
required:
Resource 
cost:
No. required: Total cost:
2.6.5.1
In patients with stage IV non-squamous NSCLC 
who do not experience disease progression and 
have a preserved performance status after 4-6 
cycles of platinum-based therapy, treatment 
with maintenance pemetrexed is suggested.
N/A N/A N/A €0
2.6.5.2
In patients with stage IV NSCLC, switch 
maintenance therapy with chemotherapy agents 
other than pemetrexed has not demonstrated 
an improvement in overall survival and is not 
recommended.
N/A N/A N/A €0
2.6.5.3
In patients with stage IV NSCLC who do not 
experience disease progression after 4-6 cycles 
of platinum-based double agent chemotherapy, 
there is insufficient evidence to recommend 
maintenance therapy with erlotinib. 
N/A N/A N/A €0
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Clinical question 2.6.6 In patients with advanced/stage IV NSCLC aged over 70, and/or with poor performance 
status, what is the effectiveness of first-line therapy?
Recommendation number: Additional 
resource 
required:
Resource 
cost:
No. required: Total cost:
2.6.6.1
In elderly patients (age 70-79 years) with 
stage IV NSCLC who have good performance 
status and limited co-morbidities, treatment 
with a platinum doublet chemotherapy is 
recommended. 
Increased liklihood 
of hospital 
admissions of 
elderly patients. 
Increased 
frequency and 
duration of 
hospital stay 
and an increase 
in need for 
community 
supports (e.g. 
home care team, 
hospice) therefore 
the additional 
resources are 
not applicable 
specifically to the 
implementation of 
this guideline.
N/A N/A €0
2.6.6.2
In patients with stage IV NSCLC with a 
performance status of 2, single agent 
chemotherapy may be considered. Platinum 
doublet chemotherapy is suggested 
over single agent chemotherapy if the 
performance status of 2 is cancer related 
rather than co-morbidity associated. 
N/A N/A N/A €0
2.6.6.3
Unfit patients of any age (performance 
status (3-4)) do not benefit from cytotoxic 
chemotherapy. However if patients harbor 
an EGFR or ALK mutation positive tumour, 
they may be considered for treatment with 
targeted therapies.
N/A N/A N/A €0
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Clinical question 2.6.7 In patients with advanced/stage IV NSCLC how effective is second and third-line therapy 
in patients with NSCLC who progress and relapse?
Recommendation number: Additional 
resource 
required:
Resource 
cost:
No. required: Total cost:
2.6.7.1
Second-line systemic anticancer therapy (SACT) 
with single agent drugs should be considered. 
The choice of agent to be used should be made 
on a case by case basis taking into account 
previous treatment, mutation status and co-
morbidities.
N/A N/A N/A €0
Clinical question 2.6.8 Is there any evidence that particular regimens or drugs are more effective or less toxic 
than others for the first-line treatment of limited-stage and extensive-stage small-cell lung cancer (SCLC)?
Recommendation number: Additional 
resource 
required:
Resource 
cost:
No. required: Total cost:
2.6.8.1
In patients with either limited-stage or 
extensive-stage small-cell lung cancer (SCLC), 
platinum-based chemotherapy with either 
cisplatin or carboplatin plus etoposide is 
recommended. 
N/A N/A N/A €0
2.6.8.2
Non-platinum combinations can be considered 
in patients with limited-stage and extensive-
stage SCLC.
N/A N/A N/A €0 
Clinical question 2.6.9 In patients with limited-stage and extensive-stage SCLC is there any role for maintenance 
chemotherapy?
Recommendation number: Additional 
resource 
required:
Resource 
cost:
No. required: Total cost:
2.6.9.1
There is no data to support maintenance 
therapy in limited-stage or extensive-stage SCLC.
N/A N/A N/A €0
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Clinical question 2.6.10 How effective is second-line systemic therapy in patients with SCLC who progress and 
relapse?
Recommendation number: Additional 
resource 
required:
Resource 
cost:
No. required: Total cost:
2.6.10.1
In patients with relapsed refractory SCLC, 
second-line therapy should be considered. 
N/A N/A N/A €0
2.6.10.2
Re-initiation of the previously administered first-
line chemotherapy regimen is recommended 
in patients with SCLC who relapse greater 
than six months from completion of initial 
chemotherapy. 
N/A N/A N/A €0
2.6.10.3
Single agent chemotherapy should be 
considered in patients with primary refractory 
SCLC to maintain or improve quality of life.
N/A N/A N/A €0
Medical Oncology Total Cost €63,316
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Radiation Oncology
Clinical question 2.7.1 In patients with non-small cell lung cancer (NSCLC) early stage disease (T1-T2 N0 M0) who 
are unfit for surgery, what is the effectiveness of stereotactic radiotherapy, standard radical radiotherapy and 
radiofrequency ablation?
Recommendation number: Additional 
resource 
required:
Resource 
cost:
No. required: Total cost:
2.7.1.1
Every patient with early stage disease (T1-T2 N0 
M0) should be evaluated for fitness for surgery. If 
unfit for surgery, or surgery is declined, patients 
should be considered for radical treatment, 
preferably SBRT/SABR or radical radiotherapy
Unknown Unknown Unknown Unknown
2.7.1.2
Radiofrequency ablation (RFA) can be considered 
for patients with clinical stage Ia tumours who 
are not suitable for surgery following discussion 
at a multidisciplinary team meeting. (Refer to 
Clinical question 2.2.3). 
None N/A N/A €0 
Clinical question 2.7.2 In patients with stage I-III NSCLC undergoing radical external beam radiation therapy what 
is the role and effectiveness of the following: 
a) New technology (IMRT/4DCT- breathing adapted radiotherapy) 
b) Altered radiation fractionation schedules (Hyper and/or accelerated fractionation) 
c) Dose
Recommendation number: Additional 
resource 
required:
Resource 
cost:
No. required: Total cost:
2.7.2.1
In patients receiving combined 
chemoradiotherapy standard fractionation 
should be used to deliver a radical dose 
equivalent to 60 – 66 Gy.
a) Yes, with 
investment 
in upgrading 
equipment - 
Cost Unknown 
b) Yes with 
resource 
implications 
if altered 
fractionation 
was to be 
implemented 
but it is not 
current practice 
due to the low 
clinical benefit
Unknown Unknown  €0
2.7.2.2
When a radical dose is considered, 3D-CRT is the 
minimum technique to be used. 
4DCT Unknown Unknown Unknown
2.7.2.3
When available, CHART can be considered 
in patients with non-operable stage I-III non-
small cell lung cancer (NSCLC) not receiving 
chemotherapy.
Unknown Unknown Unknown Unknown
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Clinical question 2.7.3 In patients with stage III NSCLC undergoing radical three-dimensional conformal 
radiotherapy (3DCRT): 
a) What are the most useful predictors of lung and oesophageal toxicity? 
b) What are the most useful measures to reduce toxicity: clinical/technical?
Recommendation number: Additional 
resource 
required:
Resource 
cost:
No. required: Total cost:
2.7.3.1
Perform three-dimensional treatment planning 
in patients undergoing radical thoracic 
radiotherapy. 4DCT should be performed where 
available.
4DCT Unknown Unknown Unknown
2.7.3.2
The dose volume parameters for the organs at 
risk (e.g. oesophagus, lung) need to be taken 
into account. It is prudent to limit V20 to ≤30–
35% and mean lung dose to ≤20–23 Gy (with 
conventional fractionation) if one wants to limit 
the risk of radiation pneumonitis to ≤20% in 
definitively treated patients with NSCLC.
None N/A N/A N/A
Clinical question 2.7.4 In patients with NSCLC post surgery, which groups should receive postoperative 
radiotherapy (PORT) or adjuvant RT? 
a) pN2 R0 
b) any pN, R1, R2 resection
Recommendation number: Additional 
resource 
required:
Resource 
cost:
No. required: Total cost:
2.7.4.1
In patients with R1 resection, regardless of 
N status, postoperative radiotherapy (PORT) 
should be proposed sequentially delivering a 
radical dose of 60 Gy in 30 fractions.
4D IMRT Unknown Unknown Unknown
2.7.4.2
In patients with a pN2 stage and a complete 
resection there is no consensus to the benefit of 
PORT. If considered, PORT should be delivered at 
a dose of 50 Gy standard fractionation.
None N/A N/A €0
2.7.4.3
PORT is not indicated in patients with a 
complete resection R0 and N0 disease. 
None N/A N/A €0
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Clinical question 2.7.5 In patients with small-cell lung cancer (SCLC), what is the evidence supporting the role of 
radiotherapy (including technical parameters) 
a) Limited-stage prophylactic cranial irradiation (PCI) 
b) Limited-stage thoracic radiotherapy   
c) Extensive-stage PCI 
d) Extensive-stage thoracic radiotherapy  
Recommendation number: Additional 
resource 
required:
Resource 
cost:
No. required: Total cost:
2.7.5.1
Consolidation prophylactic cranial irradiation 
(PCI) is recommended in patients with limited-
stage small-cell lung cancer (SCLC) having a 
response to chemoradiotherapy.
Thoracic RT Unknown Unknown Unknown
2.7.5.2
In combined modality care, thoracic 
radiotherapy is recommended in patients with 
limited-stage SCLC and should be initiated as 
early as possible.
Thoracic RT Unknown Unknown Unknown
2.7.5.3
Consolidation PCI is recommended in patients 
with extensive-stage SCLC having a response to 
chemotherapy.
Consolidation 
PCI
Unknown Unknown Unknown
2.7.5.4
Consolidation thoracic radiotherapy may be 
considered in patients with extensive-stage 
SCLC having a response to chemotherapy.
Thoracic RT Unknown Unknown Unknown
Radiation Oncology Total Cost: €0
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Palliative Care
Clinical question 2.8.1 Does the involvement of specialist palliative care result in better quality of life for patient 
or family, symptom control, or improved cost-effectiveness compared with standard care alone (no involvement 
from specialist palliative care)?
Recommendation number: Additional 
resource 
required:
Resource 
cost:
No. required: Total cost:
2.8.1.1
Patients with stage IV non-small cell lung cancer 
(NSCLC) should be offered concurrent specialist 
palliative care and standard oncological care at 
initial diagnosis.
None N/A N/A €0
Clinical question 2.8.2 Who should comprise the palliative care multidisciplinary team?
Recommendation number: Additional 
resource 
Required:
Resource 
cost:
No. Required: Total cost:
No recommendation only Good Practice Point  None N/A N/A €0
Palliative Care Total Costs €0
Total cost of guideline implementation:
Subgroup Cost of implementation 
Radiology €665,315
Respiratory Medicine 0
Pathology 0
Surgery €431,907
Medical Oncology €63,273
Radiation Oncology 0
Palliative Care 0
Cost of audit on implementation (€27,000 x 2 p/a x 3 years) €162,000
Total cost of implementation: €1,322,495
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A
 
sh
ou
ld
 b
e 
off
er
ed
 to
 p
ati
en
ts
 w
it
h 
su
sp
ec
te
d 
lu
ng
 
ca
nc
er
 p
ri
or
 to
 m
ed
ia
sti
no
sc
op
y.
 
Cu
rr
en
t 
pr
ac
tic
e.
Cu
rr
en
t 
pr
ac
tic
e.
N
/A
N
/A
Q
2.
3.
3 
In
 p
ati
en
ts
 w
it
h 
pl
eu
ra
l 
eff
us
io
n 
an
d 
su
sp
ec
te
d 
lu
ng
 
ca
nc
er
, w
ha
t 
is
 t
he
 e
ffi
ca
cy
 
of
 p
le
ur
al
 s
am
pl
in
g 
in
 t
he
 
di
ag
no
si
s 
of
 lu
ng
 c
an
ce
r?
 
In
 p
ati
en
ts
 b
ei
ng
 c
on
si
de
re
d 
fo
r 
ac
tiv
e 
th
er
ap
y,
 
pl
eu
ra
l e
ff
us
io
n 
sh
ou
ld
 b
e 
in
ve
sti
ga
te
d 
w
it
h 
pl
eu
ra
l 
as
pi
ra
tio
n.
 
If 
pl
eu
ra
l fl
ui
d 
cy
to
lo
gy
 is
 n
eg
ati
ve
, a
nd
 t
re
at
m
en
t 
w
ill
 c
ha
ng
e 
de
pe
nd
in
g 
on
 t
he
 n
at
ur
e 
of
 t
he
 
pl
eu
ra
l fl
ui
d,
 p
le
ur
al
 b
io
ps
y 
us
in
g 
im
ag
e 
gu
id
ed
 o
r 
th
or
ac
os
co
pi
c 
bi
op
sy
 is
 re
co
m
m
en
de
d.
Ca
nc
er
 c
en
tr
es
 s
ho
ul
d 
ha
ve
 
ac
ce
ss
 to
 th
or
ac
os
co
py
.
-
-
-
Q
2.
3.
4 
W
ha
t 
is
 t
he
 r
ol
e 
of
 
pa
lli
ati
ve
 in
te
rv
en
tio
ns
 in
 t
he
 
m
an
ag
em
en
t 
of
 m
al
ig
na
nt
 
ai
rw
ay
 o
bs
tr
uc
tio
n?
 
In
 lu
ng
 c
an
ce
r 
pa
tie
nt
s 
w
it
h 
sy
m
pt
om
ati
c 
(in
cl
ud
in
g 
br
ea
th
le
ss
ne
ss
, h
ae
m
op
ty
si
s 
an
d 
co
ug
h)
 m
al
ig
na
nt
 
ai
rw
ay
 o
bs
tr
uc
tio
n,
 a
ny
 o
f t
he
 fo
llo
w
in
g 
th
er
ap
eu
tic
 
in
te
rv
en
tio
ns
 m
ay
 b
e 
co
ns
id
er
ed
: b
ro
nc
ho
sc
op
ic
 
de
bu
lk
in
g,
 t
um
ou
r 
ab
la
tio
n 
m
od
al
iti
es
, a
ir
w
ay
 s
te
nt
 
pl
ac
em
en
t 
an
d 
ra
di
ot
he
ra
py
 (e
xt
er
na
l b
ea
m
 o
r 
br
ac
hy
th
er
ap
y)
.
Ca
nc
er
 c
en
tr
es
 s
ho
ul
d 
ha
ve
 a
cc
es
s 
to
 a
pp
ro
pr
ia
te
 
in
te
rv
en
tio
ns
.
-
-
-
Q
2.
4.
1 
a)
 W
ha
t 
is
 t
he
 b
en
efi
t 
of
 h
is
to
pa
th
ol
og
ic
al
 a
na
ly
si
s 
fo
r 
sm
al
l-c
el
l l
un
g 
ca
nc
er
 (S
CL
C)
 
vs
. n
on
-s
m
al
l c
el
l l
un
g 
ca
nc
er
 
(N
SC
LC
)?
 
b)
 W
he
n 
sh
ou
ld
 
im
m
un
oh
is
to
ch
em
ic
al
 a
na
ly
si
s 
be
 p
er
fo
rm
ed
? 
c)
 W
ha
t 
is
 t
he
 b
es
t 
pa
ne
l(s
) o
f 
im
m
un
oh
is
to
ch
em
ic
al
 (I
H
C)
 
st
ai
ns
 fo
r 
N
SC
LC
 s
ub
ty
pe
s?
 
D
is
tin
gu
is
hi
ng
 b
et
w
ee
n 
sm
al
l-c
el
l c
ar
ci
no
m
a 
an
d 
no
n-
sm
al
l c
el
l c
ar
ci
no
m
a 
of
 t
he
 lu
ng
 is
 
re
co
m
m
en
de
d.
 F
or
 c
ha
lle
ng
in
g 
ca
se
s,
 a
 d
ia
gn
os
tic
 
pa
ne
l o
f i
m
m
un
oh
is
to
ch
em
ic
al
 a
ss
ay
s 
is
 
re
co
m
m
en
de
d 
to
 in
cr
ea
se
 t
he
 d
ia
gn
os
tic
 a
cc
ur
ac
y.
 
In
 in
di
vi
du
al
s 
w
it
h 
pa
th
ol
og
ic
al
ly
 d
ia
gn
os
ed
 
no
n-
sm
al
l c
el
l c
ar
ci
no
m
a 
(N
SC
LC
), 
ad
di
tio
na
l 
di
sc
ri
m
in
ati
on
 b
et
w
ee
n 
ad
en
oc
ar
ci
no
m
a 
an
d 
sq
ua
m
ou
s 
ce
ll 
ca
rc
in
om
a,
 e
ve
n 
on
 c
yt
ol
og
ic
 m
at
er
ia
l 
or
 s
m
al
l ti
ss
ue
 s
am
pl
es
 is
 r
ec
om
m
en
de
d.
 
Re
so
ur
ce
 &
 ti
m
e 
sa
vi
ng
s;
 if
 
tis
su
e 
us
ed
 ju
di
ci
ou
sl
y.
N
/A
N
/A
N
/A
Q
2.
4.
2 
W
ha
t 
is
 t
he
 e
ffi
ca
cy
 o
f 
th
e 
fo
llo
w
in
g 
di
ag
no
sti
c 
to
ol
s 
in
 id
en
tif
yi
ng
 a
nd
 s
ta
gi
ng
 lu
ng
 
ca
nc
er
?
– 
RO
SE
 a
t 
EB
U
S 
– 
Fr
oz
en
 s
ec
tio
n 
En
do
br
on
ch
ia
l u
lt
ra
so
un
d 
ra
pi
d 
on
-s
ite
 e
va
lu
ati
on
 
(E
BU
S 
RO
SE
) s
ho
ul
d 
be
 m
ad
e 
av
ai
la
bl
e 
w
he
ne
ve
r 
re
so
ur
ce
s 
pe
rm
it.
 
Co
ns
id
er
 in
tr
a-
op
er
ati
ve
 fr
oz
en
 s
ec
tio
n 
an
al
ys
is
 in
 
pr
im
ar
y 
di
ag
no
si
s 
w
he
n 
pr
eo
pe
ra
tiv
e 
di
ag
no
si
s 
is
 n
ot
 
av
ai
la
bl
e.
In
 s
el
ec
te
d 
ca
se
s 
in
tr
a-
op
er
ati
ve
 fr
oz
en
 s
ec
tio
n 
an
al
ys
is
 fo
r 
st
ag
in
g 
m
ay
 b
e 
co
ns
id
er
ed
.
Re
so
ur
ce
s 
re
qu
ir
ed
 
– 
co
ns
ul
ta
nt
/m
ed
ic
al
 
sc
ie
nti
st
 a
nd
 e
qu
ip
m
en
t 
– 
au
to
m
at
ed
 s
tr
ai
ne
rs
, 
m
ic
ro
sc
op
e.
-
O
pp
or
tu
ni
ty
 (p
hy
si
ca
l).
En
ab
le
m
en
t,
 
En
vi
ro
nm
en
ta
l r
es
tr
uc
tu
ri
ng
.
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Cl
in
ic
al
 Q
ue
sti
on
s
Re
co
m
m
en
da
ti
on
 
Fa
ci
lit
at
or
s/
ba
rr
ie
rs
 to
 
im
pl
em
en
ta
ti
on
Ta
rg
et
 b
eh
av
io
ur
 (B
)
CO
M
*
Po
ss
ib
le
 in
te
rv
en
ti
on
 
fu
nc
ti
on
s
Q
2.
4.
3 
In
 p
ati
en
ts
 w
it
h 
N
SC
LC
, 
ho
w
 d
o 
cy
to
lo
gi
ca
l s
am
pl
es
 
co
m
pa
re
 w
it
h 
tis
su
e 
bi
op
sy
 
sa
m
pl
es
 fo
r 
tu
m
ou
r 
su
b-
ty
pi
ng
, 
im
m
un
oh
is
to
ch
em
is
tr
y 
an
d 
pr
ed
ic
tiv
e 
m
ar
ke
rs
 a
ss
es
se
d 
by
 
FI
SH
 o
r 
m
ut
ati
on
al
 a
na
ly
si
s?
 
Cy
to
lo
gy
 s
am
pl
es
 c
an
 b
e 
us
ed
 to
 p
ro
vi
de
 m
at
er
ia
l 
su
ita
bl
e 
fo
r 
bo
th
 N
SC
LC
 s
ub
-t
yp
in
g 
an
d 
so
m
e 
m
ol
ec
ul
ar
 a
na
ly
si
s,
 p
ro
vi
de
d 
th
e 
sa
m
pl
es
 a
re
 
ap
pr
op
ria
te
ly
 h
an
dl
ed
 a
nd
 p
ro
ce
ss
ed
. 
Co
st
 s
av
in
gs
.
G
ui
de
s 
tr
ea
tm
en
t.
 
Fe
w
er
 p
ro
ce
du
re
s.
N
/A
N
/A
Q
2.
4.
4 
W
ha
t 
ar
e 
op
tim
al
 
fo
rm
al
in
 fi
xa
tio
n 
tim
es
 fo
r 
fu
tu
re
 m
ol
ec
ul
ar
 d
ia
gn
os
tic
s?
 
Fi
xa
tio
n 
tim
es
 o
f 6
 to
 1
2 
ho
ur
s 
fo
r 
sm
al
l b
io
ps
y 
sa
m
pl
es
 a
nd
 8
 to
 1
8 
ho
ur
s 
fo
r 
la
rg
er
 s
ur
gi
ca
l 
sp
ec
im
en
s 
ge
ne
ra
lly
 g
iv
e 
be
st
 re
su
lts
, a
lth
ou
gh
 
ex
pe
rt
 c
on
se
ns
us
 o
pi
ni
on
 is
 t
ha
t 
fix
ati
on
 ti
m
es
 o
f 6
 
to
 4
8 
ho
ur
s 
sh
ou
ld
 g
iv
e 
ac
ce
pt
ab
le
 r
es
ul
ts
.
En
su
re
s 
th
at
 ti
ss
ue
 is
 
su
ita
bl
e 
fo
r 
m
ol
ec
ul
ar
 
an
al
ys
is
. 
Be
st
 u
se
 o
f m
at
er
ia
l. 
O
pti
m
is
in
g 
D
N
A
 q
ua
lit
y.
 
N
/A
N
/A
N
/A
Q
2.
5.
1 
In
 p
ati
en
ts
 w
it
h 
st
ag
e 
I 
&
 II
 n
on
-s
m
al
l c
el
l l
un
g 
ca
nc
er
 
(N
SC
LC
) h
ow
 d
oe
s 
th
e 
ex
te
nt
 o
f 
lu
ng
 r
es
ec
tio
n 
eff
ec
t 
ou
tc
om
es
? 
Fo
r 
pa
tie
nt
s 
w
it
h 
cl
in
ic
al
 s
ta
ge
 I 
an
d 
II 
no
n-
sm
al
l 
ce
ll 
lu
ng
 c
an
ce
r 
 (N
SC
LC
) w
ho
 a
re
 m
ed
ic
al
ly
 fi
t 
fo
r 
su
rg
ic
al
 r
es
ec
tio
n,
 a
 lo
be
ct
om
y 
ra
th
er
 t
ha
n 
su
bl
ob
ar
 
re
se
cti
on
 is
 r
ec
om
m
en
de
d.
 
Cu
rr
en
t 
pr
ac
tic
e.
 
Cu
rr
en
t 
pr
ac
tic
e.
N
/A
N
/A
Q
2.
5.
2 
In
 p
ati
en
ts
 w
it
h 
cl
in
ic
al
 
st
ag
e 
I N
SC
LC
 u
nd
er
go
in
g 
lo
be
ct
om
y,
 h
ow
 d
oe
s 
vi
de
o-
as
si
st
ed
 t
ho
ra
ci
c 
su
rg
er
y 
(V
AT
S)
 
co
m
pa
re
 to
 t
ho
ra
co
to
m
y?
 
Fo
r 
pa
tie
nt
s 
w
it
h 
cl
in
ic
al
 s
ta
ge
 I 
N
SC
LC
, v
id
eo
-
as
si
st
ed
 th
or
ac
ic
 s
ur
ge
ry
 (t
ho
ra
co
sc
op
y)
 s
ho
ul
d 
be
 
co
ns
id
er
ed
 a
s 
an
 a
lte
rn
ati
ve
 to
 t
ho
ra
co
to
m
y 
fo
r 
an
at
om
ic
 p
ul
m
on
ar
y 
re
se
cti
on
. 
Lo
ng
er
 o
pe
ra
tin
g 
tim
e 
&
 
hi
gh
er
 c
ap
ita
l c
os
ts
. 
Re
du
ce
d 
LO
S.
 
Id
en
tifi
ed
 h
ig
he
r o
pe
ra
tiv
e 
tim
es
 (m
ed
ia
n 
17
3 
m
in
 
vs
 1
43
 m
in
, P
 <
 .0
00
1)
 
fo
r s
ub
je
ct
s 
ha
vi
ng
 V
AT
S 
re
se
cti
on
 (P
au
l e
t a
l.,
 2
01
0)
.
Re
so
ur
ce
s 
re
qu
ir
ed
.
O
pp
or
tu
ni
ty
– 
ph
ys
ic
al
.
En
vi
ro
nm
en
ta
l r
es
tr
uc
tu
ri
ng
,
En
ab
le
m
en
t.
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Cl
in
ic
al
 Q
ue
sti
on
s
Re
co
m
m
en
da
ti
on
 
Fa
ci
lit
at
or
s/
ba
rr
ie
rs
 to
 
im
pl
em
en
ta
ti
on
Ta
rg
et
 b
eh
av
io
ur
 (B
)
CO
M
*
Po
ss
ib
le
 in
te
rv
en
ti
on
 
fu
nc
ti
on
s
Q
2.
5.
3 
W
hi
ch
 p
ul
m
on
ar
y 
fu
nc
tio
n 
te
st
s 
sh
ou
ld
 b
e 
us
ed
 to
 
de
te
rm
in
e 
fit
ne
ss
 fo
r 
re
se
cti
on
?
Pu
lm
on
ar
y 
fu
nc
tio
n 
te
sti
ng
 (s
pi
ro
m
et
ry
, d
iff
us
io
n 
ca
pa
ci
ty
, l
un
g 
vo
lu
m
e)
 s
ho
ul
d 
be
 p
er
fo
rm
ed
 in
 a
ll 
pa
tie
nt
s 
be
in
g 
co
ns
id
er
ed
 fo
r s
ur
gi
ca
l r
es
ec
tio
n.
 Po
st
op
er
ati
ve
 p
re
di
cti
ve
 v
al
ue
s 
sh
ou
ld
 b
e 
ca
lc
ul
at
ed
 
us
in
g 
br
on
ch
o-
pu
lm
on
ar
y 
se
gm
en
t c
ou
nti
ng
. I
f a
 
m
is
m
at
ch
 is
 s
us
pe
ct
ed
 v
en
til
ati
on
 p
er
fu
si
on
 s
ca
n 
sh
ou
ld
 b
e 
pe
rf
or
m
ed
. 
O
ffe
r p
ati
en
ts
 s
ur
ge
ry
 if
 th
ey
 h
av
e 
an
 F
EV
1 &
 D
LC
O
 w
ith
in
 
no
rm
al
 li
m
its
 (p
os
to
pe
ra
tiv
e 
pr
ed
ic
te
d 
va
lu
es
 >
60
%
). 
Pa
tie
nt
s 
w
ith
 p
po
-F
EV
1 a
nd
/o
r D
LC
O
 <
30
%
 s
ho
ul
d 
ha
ve
 fo
rm
al
 c
ar
di
op
ul
m
on
ar
y 
ex
er
ci
se
 te
sti
ng
 w
ith
 
m
ea
su
re
m
en
t o
f V
O
2 
m
ax
.
Pa
tie
nt
s 
w
ith
 p
po
-F
EV
1 a
nd
/o
r D
LC
O
 >
30
%
 a
nd
 <
60
%
 –
 
su
pp
le
m
en
ta
ry
 fu
nc
tio
na
l e
xe
rc
is
e 
as
se
ss
m
en
ts
 s
ho
ul
d 
be
 c
on
sid
er
ed
. 
In
 p
ati
en
ts
 w
ith
 lu
ng
 c
an
ce
r b
ei
ng
 c
on
si
de
re
d 
fo
r 
su
rg
er
y 
an
d 
a 
VO
2 
m
ax
 <
15
m
L/
kg
/m
in
 p
re
di
ct
ed
, 
it 
is 
re
co
m
m
en
de
d 
th
at
 th
ey
 a
re
 c
ou
ns
el
le
d 
ab
ou
t 
m
in
im
al
ly
 in
va
si
ve
 s
ur
ge
ry
, s
ub
lo
ba
r r
es
ec
tio
ns
 o
r  
no
n-
op
er
ati
ve
 tr
ea
tm
en
t o
pti
on
s 
fo
r t
he
ir 
lu
ng
 c
an
ce
r.
FE
V/
D
LC
O
 –
 
cu
rr
en
t 
pr
ac
tic
e.
 
N
ot
e:
 p
os
si
bl
e 
re
so
ur
ce
 
im
pl
ic
ati
on
s 
if 
it
 n
ot
 c
ur
re
nt
 
pr
ac
tic
e 
in
 a
 p
ar
tic
ul
ar
 
ho
sp
ita
l (
i.e
. e
xe
rc
is
e 
as
se
ss
m
en
t,
 lo
w
 te
ch
 –
 fr
ee
 
bu
t 
re
so
ur
ce
 im
pl
ic
ati
on
s 
– 
eq
ui
pm
en
t 
&
 s
ta
ffi
ng
, 
CP
ET
 –
 e
xp
en
si
ve
 te
st
).
Cu
rr
en
t 
pr
ac
tic
e.
O
pp
or
tu
ni
ty
 –
 p
hy
si
ca
l 
Ca
pa
bi
lit
y 
– 
ph
ys
ic
al
.
En
ab
le
m
en
t 
Tr
ai
ni
ng
.
Q
2.
5.
4 
In
 p
ati
en
ts
 w
it
h 
lu
ng
 
ca
nc
er
, h
ow
 s
ho
ul
d 
no
n-
pu
lm
on
ar
y 
co
-m
or
bi
di
ty
 
in
flu
en
ce
 s
ur
gi
ca
l s
el
ec
tio
n?
 
Lu
ng
 c
an
ce
r s
ur
ge
ry
 re
m
ai
ns
 th
e 
be
st
 o
pp
or
tu
ni
ty
 
fo
r 
po
te
nti
al
 c
ur
e 
in
 p
ati
en
ts
 w
it
h 
si
gn
ifi
ca
nt
 c
o-
m
or
bi
di
ty
. E
ff
or
ts
 to
 c
on
ta
in
 a
nd
 m
an
ag
e 
th
at
 r
is
k 
sh
ou
ld
 s
ta
rt
 w
it
h 
pr
eo
pe
ra
tiv
e 
sc
or
in
g 
(t
ho
ra
co
sc
or
e)
 
an
d 
sh
ou
ld
 id
ea
lly
 in
cl
ud
e 
att
en
da
nc
e 
at
 a
 
pr
eo
pe
ra
tiv
e 
as
se
ss
m
en
t 
cl
in
ic
, w
he
re
 p
ra
cti
ca
l. 
Se
ek
 a
 c
ar
di
ol
og
y 
re
vi
ew
 in
 p
ati
en
ts
 w
it
h 
an
 a
cti
ve
 
ca
rd
ia
c 
co
nd
iti
on
 o
r 
≥3
 r
is
k 
fa
ct
or
s 
or
 p
oo
r 
ca
rd
ia
c 
fu
nc
tio
na
l c
ap
ac
it
y.
 
O
ffe
r 
su
rg
er
y 
w
it
ho
ut
 fu
rt
he
r 
in
ve
sti
ga
tio
ns
 to
 
pa
tie
nt
s 
w
it
h 
≤2
 r
is
k 
fa
ct
or
s 
an
d 
go
od
 c
ar
di
ac
 
fu
nc
tio
na
l c
ap
ac
it
y.
 
Cu
rr
en
t 
pr
ac
tic
e.
N
ot
e:
 p
os
si
bl
e 
la
bo
ra
to
ry
 
re
so
ur
ce
s 
if 
ex
tr
a 
no
de
s 
ar
e 
di
ss
ec
te
d.
Cu
rr
en
t 
pr
ac
tic
e.
N
/A
N
/A
Q
2.
5.
5 
Sh
ou
ld
 lu
ng
 c
an
ce
r 
su
rg
er
y 
be
 o
ffe
re
d 
to
 
oc
to
ge
na
ri
an
s?
 
A
ge
 >
80
 y
ea
rs
 s
ho
ul
d 
no
t 
au
to
m
ati
ca
lly
 p
re
cl
ud
e 
su
rg
er
y.
 D
ec
is
io
ns
 s
ho
ul
d 
be
 b
as
ed
 o
n 
on
co
lo
gi
ca
l 
st
ag
e,
 c
o-
m
or
bi
di
ty
 a
nd
 p
hy
si
ol
og
ic
al
 te
sti
ng
. 
In
cr
ea
se
 in
 r
ef
er
ra
ls
 fo
r 
su
rg
er
y 
w
ith
 a
 d
ro
p 
in
 
re
fe
rr
al
s 
to
 o
th
er
 t
re
at
m
en
t 
m
od
al
ity
 g
ro
up
s.
In
cr
ea
se
 in
 IC
U
 b
ed
-ti
m
e.
 
In
cr
ea
se
 in
 r
es
ou
rc
e 
in
pu
t 
(p
re
- a
nd
 p
os
t-
op
er
ati
ve
).
O
pp
or
tu
ni
ty
 –
 p
hy
si
ca
l  
M
oti
va
tio
n 
– 
au
to
m
ati
c.
En
vi
ro
nm
en
ta
l r
es
tr
uc
tu
ri
ng
, 
En
ab
le
m
en
t,
 
Pe
rs
ua
si
on
,
Co
er
ci
on
,
M
od
el
lin
g.
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CO
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2.
5.
6 
In
 p
ati
en
ts
 w
it
h 
N
SC
LC
, 
w
ha
t 
is
 t
he
 o
pti
m
um
 s
ur
gi
ca
l 
ap
pr
oa
ch
 fo
r?
a)
 M
ul
tif
oc
al
 t
um
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 p
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 c
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, c
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 b
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 m
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 c
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, c
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 b
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 m
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ad
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m
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re
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l r
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 p
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ra
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 r
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l l
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 c
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 p
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 p
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 c
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 p
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 p
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 d
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 p
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 p
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 p
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 b
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 p
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 r
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l c
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r b
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 p
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 b
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 b
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l m
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 p
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 b
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 m
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 p
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 p
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 b
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 m
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at
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 m
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 p
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 p
ri
m
ar
y 
tu
m
ou
r 
an
d 
de
fin
iti
ve
 t
re
at
m
en
t 
of
 t
he
 a
dr
en
al
 m
et
as
ta
si
s 
m
ay
 b
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 m
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m
al
l n
um
be
r 
of
 p
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 b
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 p
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f m
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 p
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 p
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m
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 p
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 c
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 b
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 p
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 r
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m
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 p
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 c
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 c
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) c
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 c
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l c
el
l l
un
g 
ca
nc
er
 
(N
SC
LC
) w
ho
 a
re
 s
ui
ta
bl
e 
fo
r 
su
rg
er
y,
 d
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 c
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 p
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 c
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 c
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 p
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ra
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ra
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ad
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 b
e 
ad
m
in
is
te
re
d 
to
 p
ati
en
ts
 w
it
h 
lo
ca
lly
 a
dv
an
ce
d 
N
SC
LC
 (s
ui
ta
bl
e 
fo
r 
ra
di
ca
l r
ad
io
th
er
ap
y)
 w
ho
 h
av
e 
a 
go
od
 p
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 p
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 c
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 c
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 c
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l c
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l c
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 c
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 o
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 b
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 p
al
lia
tiv
e 
ch
em
ot
he
ra
py
 fo
r 
st
ag
e 
IV
 N
SC
LC
, i
t 
is
 r
ec
om
m
en
de
d 
th
at
 t
he
 c
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 c
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 c
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 b
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 c
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 b
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 d
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ra
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 t
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 p
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 p
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 c
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 b
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 p
os
iti
ve
 N
SC
LC
 t
um
ou
rs
.
Ch
em
ot
he
ra
py
 a
nd
 E
G
FR
 
TK
I –
 C
ur
re
nt
 p
ra
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 p
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 b
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f p
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 p
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 c
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ra
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ra
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 d
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 d
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 r
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 w
it
h 
ad
va
nc
ed
/s
ta
ge
 
IV
 N
SC
LC
 a
ge
d 
ov
er
 7
0,
 a
nd
/o
r 
w
it
h 
po
or
 p
er
fo
rm
an
ce
 s
ta
tu
s,
 
w
ha
t 
is
 t
he
 e
ffe
cti
ve
ne
ss
 o
f 
fir
st
-li
ne
 t
he
ra
py
? 
In
 e
ld
er
ly
 p
ati
en
ts
 (a
ge
 7
0-
79
 y
ea
rs
) w
it
h 
st
ag
e 
IV
 
N
SC
LC
 w
ho
 h
av
e 
go
od
 p
er
fo
rm
an
ce
 s
ta
tu
s 
an
d 
lim
ite
d 
co
-m
or
bi
di
tie
s,
 t
re
at
m
en
t 
w
it
h 
a 
pl
ati
nu
m
 
do
ub
le
t 
ch
em
o-
th
er
ap
y 
is
 r
ec
om
m
en
de
d.
 
In
 p
ati
en
ts
 w
it
h 
st
ag
e 
IV
 N
SC
LC
 w
it
h 
a 
pe
rf
or
m
an
ce
 
st
at
us
 o
f 2
, s
in
gl
e 
ag
en
t 
ch
em
ot
he
ra
py
 m
ay
 b
e 
co
ns
id
er
ed
. P
la
tin
um
 d
ou
bl
et
 c
he
m
ot
he
ra
py
 is
 
su
gg
es
te
d 
ov
er
 s
in
gl
e 
ag
en
t 
ch
em
ot
he
ra
py
 if
 t
he
 
pe
rf
or
m
an
ce
 s
ta
tu
s 
of
 2
 is
 c
an
ce
r 
re
la
te
d 
ra
th
er
 t
ha
n 
co
-m
or
bi
di
ty
 a
ss
oc
ia
te
d.
 
U
nfi
t 
pa
tie
nt
s 
of
 a
ny
 a
ge
 (p
er
fo
rm
an
ce
 s
ta
tu
s 
(3
-
4)
) d
o 
no
t 
be
ne
fit
 fr
om
 c
yt
ot
ox
ic
 c
he
m
ot
he
ra
py
. 
H
ow
ev
er
 if
 p
ati
en
ts
 h
ar
bo
r 
an
 E
G
FR
 o
r 
A
LK
 m
ut
ati
on
 
po
si
tiv
e 
tu
m
ou
r, 
th
ey
 m
ay
 b
e 
co
ns
id
er
ed
 fo
r 
tr
ea
tm
en
t w
ith
 ta
rg
et
ed
 th
er
ap
ie
s.
Cu
rr
en
t 
Pr
ac
tic
e.
-
-
-
Q
2.
6.
7
In
 p
ati
en
ts
 w
it
h 
ad
va
nc
ed
/
st
ag
e 
IV
 N
SC
LC
 h
ow
 e
ffe
cti
ve
 is
 
se
co
nd
 a
nd
 t
hi
rd
-li
ne
 t
he
ra
py
 
in
 p
ati
en
ts
 w
it
h 
N
SC
LC
 w
ho
 
pr
og
re
ss
 a
nd
 r
el
ap
se
? 
Se
co
nd
-li
ne
 s
ys
te
m
ic
 a
nti
ca
nc
er
 t
he
ra
py
 (S
A
CT
) w
it
h 
si
ng
le
 a
ge
nt
 d
ru
gs
 s
ho
ul
d 
be
 c
on
si
de
re
d.
 T
he
 c
ho
ic
e 
of
 a
ge
nt
 to
 b
e 
us
ed
 s
ho
ul
d 
be
 m
ad
e 
on
 a
 c
as
e 
by
 
ca
se
 b
as
is
 ta
ki
ng
 in
to
 a
cc
ou
nt
 p
re
vi
ou
s 
tr
ea
tm
en
t,
 
m
ut
ati
on
 s
ta
tu
s 
an
d 
co
-m
or
bi
di
tie
s.
Cu
rr
en
t 
pr
ac
tic
e.
-
-
-
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Cl
in
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s
Re
co
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ci
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Ta
rg
et
 b
eh
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ur
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)
CO
M
*
Po
ss
ib
le
 in
te
rv
en
ti
on
 
fu
nc
ti
on
s
Q
2.
6.
8
Is
 t
he
re
 a
ny
 e
vi
de
nc
e 
th
at
 
pa
rti
cu
la
r 
re
gi
m
en
s 
or
 d
ru
gs
 
ar
e 
m
or
e 
eff
ec
tiv
e 
or
 le
ss
 to
xi
c 
th
an
 o
th
er
s 
fo
r 
th
e 
fir
st
-li
ne
 
tr
ea
tm
en
t 
of
 li
m
ite
d-
st
ag
e 
an
d 
ex
te
ns
iv
e-
st
ag
e 
sm
al
l-c
el
l l
un
g 
ca
nc
er
?
In
 p
ati
en
ts
 w
it
h 
ei
th
er
 li
m
ite
d-
st
ag
e 
or
 e
xt
en
si
ve
-
st
ag
e 
sm
al
l-c
el
l l
un
g 
ca
nc
er
 (S
CL
C)
, p
la
tin
um
-b
as
ed
 
ch
em
ot
he
ra
py
 w
it
h 
ei
th
er
 c
is
pl
ati
n 
or
 c
ar
bo
pl
ati
n 
pl
us
 e
to
po
si
de
 is
 re
co
m
m
en
de
d.
 
N
on
-p
la
tin
um
 c
om
bi
na
tio
ns
 c
an
 b
e 
co
ns
id
er
ed
 in
 
pa
tie
nt
s 
w
it
h 
lim
ite
d-
st
ag
e 
an
d 
ex
te
ns
iv
e-
st
ag
e 
SC
LC
Cu
rr
en
t 
pr
ac
tic
e.
-
-
-
Q
2.
6.
9
In
 p
ati
en
ts
 w
it
h 
lim
ite
d-
st
ag
e 
an
d 
ex
te
ns
iv
e-
st
ag
e 
SC
LC
 is
 
th
er
e 
an
y 
ro
le
 fo
r 
m
ai
nt
en
an
ce
 
ch
em
ot
he
ra
py
?
Th
er
e 
is
 n
o 
da
ta
 to
 s
up
po
rt
 m
ai
nt
en
an
ce
 th
er
ap
y 
in
 
lim
ite
d-
st
ag
e 
or
 e
xt
en
si
ve
-s
ta
ge
 S
CL
C.
 
Cu
rr
en
t 
pr
ac
tic
e.
-
-
-
Q
2.
6.
10
H
ow
 e
ffe
cti
ve
 is
 s
ec
on
d-
lin
e 
sy
st
em
ic
 t
he
ra
py
 in
 p
ati
en
ts
 
w
it
h 
SC
LC
 w
ho
 p
ro
gr
es
s 
an
d 
re
la
ps
e?
In
 p
ati
en
ts
 w
it
h 
re
la
ps
ed
 r
ef
ra
ct
or
y 
SC
LC
, s
ec
on
d-
lin
e 
th
er
ap
y 
sh
ou
ld
 b
e 
co
ns
id
er
ed
. 
Re
-in
iti
ati
on
 o
f t
he
 p
re
vi
ou
sl
y 
ad
m
in
is
te
re
d 
fir
st
-li
ne
 
ch
em
ot
he
ra
py
 r
eg
im
en
 is
 r
ec
om
m
en
de
d 
in
 p
ati
en
ts
 
w
it
h 
SC
LC
 w
ho
 r
el
ap
se
 g
re
at
er
 t
ha
n 
si
x 
m
on
th
s 
fr
om
 
co
m
pl
eti
on
 o
f i
ni
tia
l c
he
m
ot
he
ra
py
. 
Si
ng
le
 a
ge
nt
 c
he
m
ot
he
ra
py
 s
ho
ul
d 
be
 c
on
si
de
re
d 
in
 
pa
tie
nt
s 
w
it
h 
pr
im
ar
y 
re
fr
ac
to
ry
 S
CL
C 
to
 m
ai
nt
ai
n 
or
 
im
pr
ov
e 
qu
al
it
y 
of
 li
fe
.
-
-
-
-
Q
2.
7.
1 
In
 p
ati
en
ts
 w
it
h 
no
n-
sm
al
l c
el
l l
un
g 
ca
nc
er
 (N
SC
LC
) 
ea
rl
y 
st
ag
e 
di
se
as
e 
(T
1-
T2
 N
0 
M
0)
 w
ho
 a
re
 u
nfi
t 
fo
r 
su
rg
er
y,
 
w
ha
t 
is
 t
he
 e
ffe
cti
ve
ne
ss
 o
f 
st
er
eo
ta
cti
c 
ra
di
ot
he
ra
py
 , 
st
an
da
rd
 ra
di
ca
l r
ad
io
th
er
ap
y 
an
d 
ra
di
of
re
qu
en
cy
 a
bl
ati
on
? 
Ev
er
y 
pa
tie
nt
 w
it
h 
ea
rl
y 
st
ag
e 
di
se
as
e 
(T
1-
T2
 N
0 
M
0)
 
sh
ou
ld
 b
e 
ev
al
ua
te
d 
fo
r 
fit
ne
ss
 fo
r 
su
rg
er
y.
 If
 u
nfi
t 
fo
r 
su
rg
er
y,
 o
r 
su
rg
er
y 
is
 d
ec
lin
ed
, p
ati
en
ts
 s
ho
ul
d 
be
 
co
ns
id
er
ed
 fo
r 
ra
di
ca
l t
re
at
m
en
t,
 p
re
fe
ra
bl
y 
SB
RT
/
SA
BR
 o
r 
ra
di
ca
l r
ad
io
th
er
ap
y.
 
Ra
di
of
re
qu
en
cy
 a
bl
ati
on
 (R
FA
) c
an
 b
e 
co
ns
id
er
ed
 
fo
r 
pa
tie
nt
s 
w
it
h 
cl
in
ic
al
 s
ta
ge
 Ia
 t
um
ou
rs
 w
ho
 a
re
 
no
t 
su
ita
bl
e 
fo
r 
su
rg
er
y 
fo
llo
w
in
g 
di
sc
us
si
on
 a
t 
a 
m
ul
tid
is
ci
pl
in
ar
y 
te
am
 m
ee
tin
g.
 (R
ef
er
 to
 c
lin
ic
al
 
qu
es
tio
n 
2.
2.
3)
Po
te
nti
al
 n
ew
 p
ati
en
t 
po
pu
la
tio
n 
in
 t
he
 fu
tu
re
 
(~
10
0-
12
0 
pe
r 
ye
ar
)
In
cr
ea
se
 in
 R
FA
 r
es
ou
rc
e 
m
ay
 b
e 
re
qu
ir
ed
.
O
pp
or
tu
ni
ty
 (p
hy
si
ca
l).
En
ab
le
m
en
t,
En
vi
ro
nm
en
ta
l r
es
tr
uc
tu
ri
ng
.
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on
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Re
co
m
m
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da
ti
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Fa
ci
lit
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s/
ba
rr
ie
rs
 to
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ta
ti
on
Ta
rg
et
 b
eh
av
io
ur
 (B
)
CO
M
*
Po
ss
ib
le
 in
te
rv
en
ti
on
 
fu
nc
ti
on
s
Q
2.
7.
2 
In
 p
ati
en
ts
 w
it
h 
st
ag
e 
I-
III
 N
SC
LC
 u
nd
er
go
in
g 
ra
di
ca
l 
ex
te
rn
al
 b
ea
m
 r
ad
ia
tio
n 
th
er
ap
y 
w
ha
t i
s 
th
e 
ro
le
 a
nd
 
eff
ec
tiv
en
es
s 
of
 t
he
 fo
llo
w
in
g:
 
a)
 N
ew
 te
ch
no
lo
gy
 
(IM
RT
/4
D
CT
- b
re
at
hi
ng
 a
da
pt
ed
 
ra
di
ot
he
ra
py
) 
b)
 A
lte
re
d 
ra
di
ati
on
 
fr
ac
tio
na
tio
n 
sc
he
du
le
s 
(H
yp
er
 a
nd
/o
r a
cc
el
er
at
ed
 
fr
ac
tio
na
tio
n)
 
c)
 D
os
e 
In
 p
ati
en
ts
 r
ec
ei
vi
ng
 c
om
bi
ne
d 
ch
em
or
ad
io
th
er
ap
y 
st
an
da
rd
 fr
ac
tio
na
tio
n 
sh
ou
ld
 b
e 
us
ed
 to
 d
el
iv
er
 a
 
ra
di
ca
l d
os
e 
eq
ui
va
le
nt
 to
 6
0 
– 
66
 G
y.
W
he
n 
a 
ra
di
ca
l d
os
e 
is
 c
on
si
de
re
d 
3D
-C
RT
 is
 t
he
 
m
in
im
um
 te
ch
ni
qu
e 
to
 b
e 
us
ed
. 
W
he
n 
av
ai
la
bl
e,
 C
H
A
RT
 c
an
 b
e 
co
ns
id
er
ed
 in
 p
ati
en
ts
 
w
it
h 
no
n-
op
er
ab
le
 s
ta
ge
 I-
III
 n
on
-s
m
al
l c
el
l l
un
g 
ca
nc
er
 (N
SC
LC
) n
ot
 r
ec
ei
vi
ng
 c
he
m
ot
he
ra
py
. 
N
ew
 te
ch
no
lo
gy
 –
 c
os
t 
of
 
ca
pi
ta
l i
nv
es
tm
en
t 
in
 4
D
CT
 
+ 
tr
ai
ni
ng
,
in
cr
ea
se
d 
co
m
pl
ex
it
y 
in
 
tr
ea
tm
en
t p
la
nn
in
g 
an
d 
w
or
kl
oa
d 
pe
r 
pa
tie
nt
, 4
D
 
Tr
ea
tm
en
t d
el
iv
er
y 
an
d 
ve
ri
fic
ati
on
.
Re
so
ur
ce
s 
re
qu
ir
ed
.
O
pp
or
tu
ni
ty
 (p
hy
si
ca
l).
Ca
pa
bi
lit
y 
(p
hy
si
ca
l).
En
ab
le
m
en
t,
En
vi
ro
nm
en
ta
l r
es
tr
uc
tu
ri
ng
.
En
ab
le
m
en
t
Tr
ai
ni
ng
.
Q
2.
7.
3 
In
 p
ati
en
ts
 w
it
h 
st
ag
e 
III
 N
SC
LC
 u
nd
er
go
in
g 
ra
di
ca
l 
th
re
e-
di
m
en
si
on
al
 c
on
fo
rm
al
 
ra
di
ot
he
ra
py
 (3
D
-C
RT
):
 
a)
 W
ha
t 
ar
e 
th
e 
m
os
t 
us
ef
ul
 
pr
ed
ic
to
rs
 o
f l
un
g 
an
d 
oe
so
ph
ag
ea
l t
ox
ic
it
y?
 
b)
 W
ha
t 
ar
e 
th
e 
m
os
t 
us
ef
ul
 
m
ea
su
re
s 
to
 r
ed
uc
e 
to
xi
ci
ty
: 
cl
in
ic
al
/t
ec
hn
ic
al
? 
Pe
rf
or
m
 t
hr
ee
-d
im
en
si
on
al
 t
re
at
m
en
t 
pl
an
ni
ng
 in
 
pa
tie
nt
s 
un
de
rg
oi
ng
 r
ad
ic
al
 t
ho
ra
ci
c 
ra
di
ot
he
ra
py
. 
4D
CT
 s
ho
ul
d 
be
 p
er
fo
rm
ed
 w
he
re
 a
va
ila
bl
e.
 
Th
e 
do
se
 v
ol
um
e 
pa
ra
m
et
er
s 
fo
r 
th
e 
or
ga
ns
 a
t 
ris
k 
(e
.g
. o
es
op
ha
gu
s,
 lu
ng
) n
ee
d 
to
 b
e 
ta
ke
n 
in
to
 
ac
co
un
t.
 It
 is
 p
ru
de
nt
 to
 li
m
it
 V
20
 to
 ≤
30
–3
5%
 a
nd
 
m
ea
n 
lu
ng
 d
os
e 
to
 ≤
20
–2
3 
G
y 
(w
it
h 
co
nv
en
tio
na
l 
fr
ac
tio
na
tio
n)
 if
 o
ne
 w
an
ts
 to
 li
m
it
 t
he
 r
is
k 
of
 
ra
di
ati
on
 p
ne
um
on
iti
s 
to
 ≤
20
%
 in
 d
efi
ni
tiv
el
y 
tr
ea
te
d 
pa
tie
nt
s 
w
it
h 
N
SC
LC
. 
4D
 C
RT
 d
es
ira
bl
e 
as
 a
 
pl
an
ni
ng
 o
pti
on
 d
ue
 to
 
ev
id
en
ce
 s
ug
ge
sti
ng
 
re
du
ce
d 
to
xi
ci
ty
.
A
cc
es
s 
to
 4
D
 C
RT
Re
so
ur
ce
s 
re
qu
ir
ed
. 
O
pp
or
tu
ni
ty
 (p
hy
si
ca
l).
En
ab
le
m
en
t,
En
vi
ro
nm
en
ta
l r
es
tr
uc
tu
ri
ng
.
Q
2.
7.
4 
In
 p
ati
en
ts
 w
it
h 
N
SC
LC
 
po
st
 s
ur
ge
ry
, w
hi
ch
 g
ro
up
s 
sh
ou
ld
 r
ec
ei
ve
 p
os
to
pe
ra
tiv
e 
ra
di
ot
he
ra
py
 R
T 
(P
O
RT
) o
r 
ad
ju
va
nt
 R
T?
 
a)
 p
N
2 
R0
 
b)
 a
ny
 p
N
, R
1,
 R
2 
re
se
cti
on
 
In
 p
ati
en
ts
 w
it
h 
R1
 r
es
ec
tio
n,
 r
eg
ar
dl
es
s 
of
 N
 s
ta
tu
s,
 
po
st
op
er
ati
ve
 r
ad
io
th
er
ap
y 
(P
O
RT
) s
ho
ul
d 
be
 
pr
op
os
ed
 s
eq
ue
nti
al
ly
 d
el
iv
er
in
g 
a 
ra
di
ca
l d
os
e 
of
 6
0 
G
y 
in
 3
0 
fr
ac
tio
ns
. 
In
 p
ati
en
ts
 w
it
h 
a 
pN
2 
st
ag
e 
an
d 
a 
co
m
pl
et
e 
re
se
cti
on
 t
he
re
 is
 n
o 
co
ns
en
su
s 
to
 t
he
 b
en
efi
t 
of
 
PO
RT
. I
f c
on
si
de
re
d,
 P
O
RT
 s
ho
ul
d 
be
 d
el
iv
er
ed
 a
t 
a 
do
se
 o
f 5
0 
G
y 
st
an
da
rd
 fr
ac
tio
na
tio
n.
 
PO
RT
 is
 n
ot
 in
di
ca
te
d 
in
 p
ati
en
ts
 w
it
h 
a 
co
m
pl
et
e 
re
se
cti
on
 R
0 
an
d 
N
0 
di
se
as
e.
 
4D
 IM
RT
 s
ho
ul
d 
be
 
pe
rf
or
m
ed
 in
 t
he
se
 p
ati
en
ts
 
w
he
re
 a
va
ila
bl
e.
A
cc
es
s 
to
 4
D
 C
RT
Re
so
ur
ce
s 
re
qu
ir
ed
. 
O
pp
or
tu
ni
ty
 (p
hy
si
ca
l).
En
ab
le
m
en
t,
En
vi
ro
nm
en
ta
l r
es
tr
uc
tu
ri
ng
.
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Cl
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Re
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ba
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rg
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eh
av
io
ur
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CO
M
*
Po
ss
ib
le
 in
te
rv
en
ti
on
 
fu
nc
ti
on
s
Q
2.
7.
5 
In
 p
ati
en
ts
 w
it
h 
sm
al
l-
ce
ll 
lu
ng
 c
an
ce
r 
(S
CL
C)
, w
ha
t 
is
 t
he
 e
vi
de
nc
e 
su
pp
or
tin
g 
th
e 
ro
le
 o
f r
ad
io
th
er
ap
y 
(in
cl
ud
in
g 
te
ch
ni
ca
l p
ar
am
et
er
s)
 
a)
 L
im
ite
d-
st
ag
e 
pr
op
hy
la
cti
c 
cr
an
ia
l i
rr
ad
ia
tio
n 
(P
CI
) 
b)
 L
im
ite
d-
st
ag
e 
th
or
ac
ic
 
ra
di
ot
he
ra
py
 
c)
 E
xt
en
si
ve
-s
ta
ge
 P
CI
 
d)
 E
xt
en
si
ve
-s
ta
ge
 t
ho
ra
ci
c 
ra
di
ot
he
ra
py
 
Co
ns
ol
id
ati
on
 p
ro
ph
yl
ac
tic
 c
ra
ni
al
 ir
ra
di
ati
on
 (P
CI
) 
is
 re
co
m
m
en
de
d 
in
 p
ati
en
ts
 w
ith
 li
m
ite
d-
st
ag
e 
sm
al
l-c
el
l l
un
g 
ca
nc
er
 (S
CL
C)
 h
av
in
g 
a 
re
sp
on
se
 to
 
ch
em
or
ad
io
th
er
ap
y.
 
In
 c
om
bi
ne
d 
m
od
al
ity
 c
ar
e,
 th
or
ac
ic
 ra
di
ot
he
ra
py
 is
 
re
co
m
m
en
de
d 
in
 p
ati
en
ts
 w
ith
 li
m
ite
d-
st
ag
e 
SC
LC
 a
nd
 
sh
ou
ld
 b
e 
in
iti
at
ed
 a
s 
ea
rly
 a
s 
po
ss
ib
le
. 
Co
ns
ol
id
ati
on
 P
CI
 is
 re
co
m
m
en
de
d 
in
 p
ati
en
ts
 
w
ith
 e
xt
en
si
ve
-s
ta
ge
 S
CL
C 
ha
vi
ng
 a
 re
sp
on
se
 to
 
ch
em
ot
he
ra
py
. 
Co
ns
ol
id
ati
on
 th
or
ac
ic
 ra
di
ot
he
ra
py
 m
ay
 b
e 
co
ns
id
er
ed
 in
 p
ati
en
ts
 w
ith
 e
xt
en
si
ve
-s
ta
ge
 S
CL
C 
ha
vi
ng
 a
 re
sp
on
se
 to
 c
he
m
ot
he
ra
py
. 
Cu
rr
en
t 
pr
ac
tic
e,
 
Co
ns
ol
id
ati
on
 t
ho
ra
ci
c 
RT
 
- F
ut
ur
e 
st
an
da
rd
 o
f c
ar
e 
(p
en
di
ng
 p
ee
r r
ev
ie
w
ed
 
pu
bl
ic
ati
on
).
A
cc
es
s 
to
 c
on
so
lid
ati
on
 
th
or
ac
ic
 R
T.
Q
2.
8.
1 
D
oe
s 
th
e 
in
vo
lv
em
en
t 
of
 
sp
ec
ia
lis
t 
pa
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Appendix 8: Audit criteria and monitoring
It is important that both the implementation of the guideline and patient outcomes are audited to ensure 
that this guideline positively impacts on patient care. 
The following audit criteria will be monitored as KPIs:
Diagnosis
For patients diagnosed with a primary lung cancer, clinical TNM stage is recorded at MDM in 95% of cases.
Time to treatment – Surgery
Patients diagnosed with a primary lung cancer where surgery is the first treatment shall be offered an 
appointment for surgery within 30 working days of the date of the decision to operate by the multidisciplinary 
team.
Time to treatment - Chemotherapy
For patients receiving their first cycle of systemic therapy for lung cancer in the day ward setting, the timeline 
between the date of receipt of the finalised treatment plan in the day ward and the administration of the first 
cycle of intravenous systemic therapy will not exceed 15 working days.
Time to treatment  - Radiotherapy 
Radiation therapy shall be carried out in a timely manner.
Time to treatment - Small-cell lung cancer
Patients diagnosed with a small cell lung cancer have treatment initiated within 10 working days of the 
histological diagnosis.
Surgery
For those patients with primary lung cancer who have a resection, pathological TNM stage is recorded.
Surgery
Volume and type of surgical resections for primary lung cancer will be recorded.
Surgery
For those patients with primary lung cancer who have a resection, intraoperative mediastinal lymph node staging 
is undertaken and recorded.
Pathology
Resection pathology reports include a standard set of prognostic indicators that will be reported by a designated 
pathologist according to the Royal College of Pathology minimum datasets.
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The following national audits are recommended:
Radiology:
Recommendation 2.2.1.3 
PET-CT is recommended for mediastinal and hilar lymph node staging in patients with potentially 
radically treatable non-small cell lung cancer (NSCLC) prior to invasive staging. (C)
Recommendation 2.2.6.3 
Do not routinely offer imaging of the brain in patients with stage I and II NSCLC. (C)
Recommendation 2.2.7.2 
Bone scintigraphy is not necessary when PET-CT has not shown bone metastases. (B)
Respiratory Medicine
Recommendation 2.3.1.2
Visible tumours should be sampled using more than one technique to optimise sensitivity. (B)
Pathology
Recommendation 2.4.2.1
Endobronchial ultrasound rapid on-site evaluation (EBUS ROSE) should be made available whenever 
resources permit. (B)
Medical Oncology
Recommendation 2.6.4.5
Effectiveness of first-line targeted therapy 
First-line single agent EGFR tyrosine kinase inhibitors (TKI) should be offered to patients with sensitising 
EGFR mutation positive NSCLC. Adding combination chemotherapy to TKI confers no benefit and should 
not be used. (A)
Radiation Oncology
Recommendation 2.7.4.1 
In patients with R1 resection, regardless of N status, postoperative radiotherapy (PORT) should be 
proposed sequentially delivering a radical dose of 60 Gy in 30 fractions. (B)
Palliative Care
Recommendation 2.8.1.1
Patients with stage IV non-small cell lung cancer (NSCLC) should be offered concurrent specialist 
palliative care and standard oncological care at initial diagnosis. (B)
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Appendix 9: Glossary and abbreviations 
Glossary 
Definitions within the context of this document
Case Control Study The observational epidemiologic study of persons with the disease (or other 
outcome variable) of interest and a suitable control (comparison, reference) 
group of persons without the disease. The relationship of an attribute to the 
disease is examined by comparing the diseased and nondiseased with regard 
to how frequently the attribute is present or, if quantitative, the levels of the 
attribute, in each of the groups. (CEBM website)
Case Series A group or series of case reports involving patients who were given similar 
treatment. Reports of case series usually contain detailed information about 
the individual patients. This includes demographic information (for example, 
age, gender, ethnic origin) and information on diagnosis, treatment, response 
to treatment, and follow-up after treatment. (CEBM website)
Cohort study The analytic method of epidemiologic study in which subsets of a defined 
population can be identified who are, have been, or in the future may be 
exposed or not exposed, or exposed in different degrees, to a factor or factors 
hypothesized to influence the probability of occurrence of a given disease 
or other outcome. The main feature of cohort study is observation of large 
numbers over a long period (commonly years) with comparison of incidence 
rates in groups that differ in exposure levels. (CEBM website)
Validity The extent to which a variable or intervention measures what it is supposed 
to measure or accomplishes what it is supposed to accomplish. The internal 
validity of a study refers to the integrity of the experimental design. The 
external validity of a study refers to the appropriateness by which its results 
can be applied to non-study patients or populations. (CEBM website)
Meta-analysis A systematic review may or may not include a meta-analysis, which is a 
quantitative summary of the results. (CEBM website)
Randomised trial An epidemiological experiment in which subjects in a population are 
randomly allocated into groups, usually called study and control groups, to 
receive or not receive an experimental preventive or therapeutic procedure, 
maneuver, or intervention. The results are assessed by rigorous comparison 
of rates of disease, death, recovery, or other appropriate outcome in the 
study and control groups. (CEBM website)
Systematic review The application of strategies that limit bias in the assembly, critical appraisal, 
and synthesis of all relevant studies on a specific topic. Systematic reviews 
focus on peer-reviewed publications about a specific health problem and 
use rigorous, standardised methods for selecting and assessing articles. 
A systematic review may or may not include a meta-analysis, which is a 
quantitative summary of the results. (CEBM website)
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Abbreviations
The following abbreviations are used in this document:
3DCRT Three-Dimensional Conformal Radiotherapy
4DCT Four-Dimensional Computed Tomography
AE Adverse Event
AAH Adenomatous Alveolar Hyperplasia
AGREE II Appraisal of Guidelines for Research and Evaluation II
ALK Anaplastic Lymphoma Kinase
ANC Absolute Neutrophil Count
ASCO American Society of Clinical Oncology
AUC Area Under the Curve
BAC Bronchioloalveolar Carcinoma
BED Biologically Effective Dose
BH Beaumont Hospital
BSC Best Supportive Care
BTS British Thoracic Society
CAV Cyclophosphamide, Doxorubicin and Vincristine 
CB Core Needle Biopsy
CDR Clinical Decision Rule
CEA Cost-Effectiveness Analysis
CEBM Centre for Evidence-Based Medicine
CEO Chief Executive Officer
CFRT Conventionally Fractionated Radiotherapy
CHART Continuous Hyperfractionated Accelerated Radiation Therapy
CI Confidence Interval
CISH Chromogenic In Situ Hybridisation
CK5 Cytokeratin 5
CK6 Cytokeratin 6
CNS Central Nervous System
COM-B Capability; Opportunity; Motivation; Behaviour
COPD Chronic Obstructive Pulmonary Disease
CQ Clinical Question
CrI Credible Interval
CRT Chemoradiotherapy
CSO Central Statistics Office
CT Computed Tomography
CUH Cork University Hospital
CXR Chest X-ray
D
LCO
Diffusing Capacity of the Lung for Carbon Monoxide
DM Distant Metastasis
DoH Department of Health
DOR Duration of Response
DP Docetaxel, Cisplatin
DVH Dose Volume Histogram
EBP Evidence Based Practice
EBUS Endobronchial Ultrasound
EBUS FNA Endobronchial Ultrasound Fine Needle Aspiration 
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EBUS ROSE Endobronchial Ultrasound Rapid On Site Evaluation
EBUS TBNA Endobronchial Ultrasound Transbronchial Needle Aspiration
ECOG Eastern Cooperative Oncology Group
ED Extensive Disease
EGFR Epidermal Growth Factor Receptor
EGFRM Epidermal Growth Factor Receptor Mutation
ENB Electromagnetic Navigation Bronchoscopy
ESMO European Society for Medical Oncology
EU European Union
EUS Endoscopic Ultrasound
EUS-FNA Endoscopic Ultrasound – Fine Needle Aspiration
FACT-L Functional Assessment of Cancer Therapy-Lung
FEV
1
Forced Expiratory Volume in 1 Second
FDG-PET Fludeoxyglucose Positron Emission Tomography
FISH Fluorescence In Situ Hybridisation
FN False Negative
FNA Fine Needle Aspiration
FP False Positive
GBP Great British Pound
GDG Guideline Development Group
GGO Ground Glass Opacity
GI Gastrointestinal
GP General Practioner
GUH Galway University Hospital
HART Hyperfractionated Accelerated Radiotherapy
HIQA Health Information and Quality Authority
HR Hazard Ratio
HSE Health Service Executive
HTA Health Technology Assessment 
IANO Irish Association for Nurses in Oncology
IASLC International Association for the Study of Lung Cancer
ICERs Incremental Cost Effectiveness Ratios
ICGP Irish College of General Practitioners
ICU Intensive Care Unit
IHC Immunohistochemistry
IMRT Intensity-Modulated Radiation Therapy
IPHA Irish Pharmaceutical Healthcare Association
IQR Intra-Quartile Range
IRC Independent Review Committee
ISMO Irish Society for Medical Oncologists
IV Intravenous
KPI Key Performance Indicator
LD Limited Disease
LKB Lyman–Kutcher–Burman
IRC Independent Review Committee
LRP Locoregional Progression
LRR Locoregional Recurrence
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LYG Life Years Gained
MDM Multidisciplinary Meeting
MDT Multidisciplinary Team
MFLC Multifocal Lung Cancer
MLD Mean Lung Dose
MLND Mediastinal Lymph Node Dissection
MMUH Mater Misericordiae University Hospital
MPH Mater Private Hospital
MRC Medical Research Council
MRI Magnetic Resonance Imaging
MTC Mixed Treatment Comparison
NALA National Adult Literacy Agency
NB Navigational Broncoscopy
NCCN National Comprehensive Cancer Network
NCCP National Cancer Control Programme
NCHD Non-Consultant Hospital Doctor
NCPE National Centre for Pharmacoeconomics
NCRI National Cancer Registry Ireland
NE Non-Estimable
NHS National Health Service
NICE National Institute for Health and Care Excellence
NOS Not Otherwise Specified
NPV Negative Predictive Value
NSCLC Non-Small Cell Lung Cancer
NTCP Normal Tissue Complication Probability
OR Odds Ratio
ORR Objective Response Rate
OS Overall Survival
PCI Prophylactic Cranial Irradiation
PET Positron Emission Tomography
PET-CT Positron Emission Tomography-Computed Tomography
PFS Progression-Free Survival
PICO Population/Patient; Intervention; Comparison/Control; Outcome
PLT Posterolateral Thoracotomy
PORT Postoperative Radiotherapy
ppo Postoperative Predictive
PPP Purchasing Power Parity
PPV Positive Predictive Value
PS Performance Status
PSM Propensity Score Matching
PTV Planning Target Volume
QALY Quality-Adjusted Life Year
QOL Quality of Life
QUANTEC Quantitative Analyses of Normal Tissue Effects in the Clinic
QUB Queens University Belfast
RCPath The Royal College of Pathologists
RCSI Royal College of Surgeons in Ireland
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RCT Randomised Controlled Trial
R-EBUS Radial Endobronchial Ultrasound
RECIST Response Evaluation Criteria In Solid Tumours
RFA Radiofrequency Ablation
ROC Receiver Operating Characteristic
ROSE Rapid On Site Evaluation
RR Response Rate
RT Radiation Therapy
SABR Stereotactic Ablative Radiotherapy
SACT Systemic Anticancer Therapy
SBRT Stereotactic Ablative Radiation Therapy
SCLC Small-Cell Lung Cancer
SFH St. Francis Hospice
SIGN Scottish Intercollegiate Guideline Network
SJH St. James’ Hospital
SPECT Single-Photon Emission Computed Tomography
SUV Standardised Uptake Volume
SVUH St. Vincent’s University Hospital
TBNA Transbronchial Needle Aspiration 
TCD Trinity College Dublin
TCP Tumour Control Probability
TKI Tyrosine Kinase Inhibitor
TL Thoracoscopy
TLCO Transfer Factor of Carbon Monoxide
TRT Thoracic Radiotherapy
TTF-1 Thyroid Transcription Factor-1
TTNA Transthoracic Needle Aspiration
TTNB Transthoracic Needle Biopsy
UICC Union for International Cancer Control
UHL University Hospital Limerick
VATS Video-Assisted Thoracoscopic Surgery
VB Virtual Bronchoscopy
VO
2
 max Maximal Oxygen Consumption
WHO World Health Organisation
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Appendix 10: Levels of Evidence & Grading Systems 
Table 13 Levels of Evidence for diagnostic studies (Oxford CEBM, 2009)
1a Systematic review (with homogeneity*) of Level 1 diagnostic studies; clinical decision rule (CDR”) with 
1b studies from different clinical centres.
1b Validating** cohort study with good reference standards” “ ”; or CDR tested within one clinical centre. 
1c Absolute SpPins (specificity) and SnNouts (sensitivity)” “.
2a Systematic review (with homogeneity*) of Level >2 diagnostic studies.
2b Exploratory** cohort study with good reference standards; CDR after deviation, or validated only on 
split-samples§§§ or databases.
3a Systematic review (with homogeneity*) of 3b and better studies.
3b Non-consecutive study; or without consistently applied reference standards.
4 Case-control study, poor or non-independent reference standard.
5 Expert opinion without explicit critical appraisal, or based on physiology, bench research or first 
principles.
* By homogeneity we mean a systematic review that is free of worrisome variations (heterogeneity) in the directions and degrees of results between 
individual studies. Not all systematic reviews with statistically significant heterogeneity need be worrisome, and not all worrisome heterogeneity need be 
statistically significant. As noted above, studies displaying worrisome heterogeneity should be tagged with a “-” at the end of their designated level.
” Clinical Decision Rule (these are algorithms or scoring systems that lead to a prognostic estimation or a diagnostic category).
** Validating studies test the quality of a specific diagnostic test, based on prior evidence. An exploratory study collects information and trawls the data (e.g. 
using a regression analysis) to find which factors are ‘significant’.
” “ ” Good reference standards are independent of the test, and applied blindly or objectively to applied to all patients. Poor reference standards are 
haphazardly applied, but still independent of the test. Use of a non-independent reference standard (where the ‘test’ is included in the ‘reference’, or where 
the ‘testing’ affects the ‘reference’) implies a level 4 study.
” “ An “Absolute SpPin” is a diagnostic finding whose Specificity is so high that a positive result rules-in the diagnosis. An “Absolute SnNout” is a diagnostic 
finding whose Sensitivity is so high that a negative result rules-out the diagnosis.
§§§ Split-sample validation is achieved by collecting all the information in a single tranche, then artificially dividing this into “derivation” and “validation” 
samples.
Table 14 Grades of recommendations for diagnostic studies (Oxford CEBM, 2009)
A Consistent level 1 studies.
B Consistent level 2 or 3 studies; or 
Extrapolations from level 1 studies.
C Level 4 studies; or
Extrapolations from level 2 or 3 studies.
D Level 5 evidence; or
Troublingly inconsistent or inconclusive studies of any level. 
Extrapolations are where data is used in a situation that has potentially clinically important differences than the original study situation.
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Table 15 Levels of Evidence for interventional studies (SIGN grading system 1999-2012)
1++ High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias.
1+ Well conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias.
1- Meta-analyses, systematic reviews, or RCTs with a high risk of bias.
2++ High quality systematic reviews of case control or cohort studies.
High quality case control or cohort studies with a very low risk of confounding or bias and a high 
probability that the relationship is causal.
2+ Well conducted case control or cohort studies with a low risk of confounding or bias and a moderate 
probability that the relationship is causal.
2- Case control or cohort studies with a high risk of confounding or bias and a significant risk that the 
relationship is not causal.
3 Non-analytic studies (e.g. case reports, case series).
4 Expert opinion.
Table 16 Grades of recommendations for interventional studies (SIGN grading system 1999-2012)
A At least one meta-analysis, systematic review, or RCT rated as 1++, and directly applicable to the target 
population; or
A body of evidence consisting principally of studies rated as 1+, directly applicable to the target 
population, and demonstrating overall consistency of results.
B A body of evidence including studies rated as 2++, directly applicable to the target population, and 
demonstrating overall consistency of results; or
Extrapolated evidence from studies rated as 1++ or 1+.
C A body of evidence including studies rated as 2+, directly applicable to the target population and 
demonstrating overall consistency of results; or
Extrapolated evidence from studies rated as 2++
D Evidence level 3 or 4; or
Extrapolated evidence from studies rated as 2+
Note: the grade of recommendation does not necessarily reflect the clinical importance of the recommendation.
Good practice point 
Recommended best practice based on the clinical experience of the GDG.
191| A National Clinical Guideline | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
References
Section 1: Background
Department Of Health (DoH). 2017. National Cancer Strategy 2017-2026. Available: 
http://health.gov.ie/wp-content/uploads/2017/07/National-Cancer-Strategy-2017-2026.pdf
Department of Health and Children (DoHC). 2006. A Strategy for Cancer Control in Ireland. Available: www.dohc.ie/
publications/cancer_control_2006.html 
National Cancer Registry Ireland (NCRI) 2016. Cancer in Ireland 1994-2014: Annual Report of the National Cancer Registry. 
NCR, Cork, Ireland.
National Cancer Registry Ireland (NCRI). 2014. Cancer Projections for Ireland (2015 – 2040), NCR, Cork, Ireland
Section 2: National Clinical Guideline Recommendations
Section 2.2: Radiology
Akeson, P., Larsson, E. M., Kristoffersen, D. T., Jonsson, E. & Holtås, S. 1995. Brain metastases--comparison of gadodiamide 
injection-enhanced MR imaging at standard and high dose, contrast-enhanced CT and non-contrast-enhanced MR imaging. 
Acta Radiol, 36,300-6.
 
American College of Chest Physicians 2007. Diagnosis and management of lung cancer: ACCP guidelines. Chest. 132 (3 Suppl): 
1s-19s. 
Benamore, R., Shepherd, F. A., Leighl, N., Pintilie, M., Patel, M., Feld, R. & Herman, S. 2007. Does intensive follow-up alter 
outcome in patients with advanced lung cancer? J Thorac Oncol, 2, 273-81. 
Birim, O., Kappetein, A. P., Stijnen, T. & Bogers, A. J. 2005. Meta-analysis of positron emission tomographic and computed 
tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg, 79, 375-
82. 
Blum, R., MacManus, M.P., Rischin, D., Michael, M., Ball, D. and Hicks, R.J., 2004. Impact of positron emission tomography on 
the management of patients with small-cell lung cancer: preliminary experience. Am J Clin Oncol, 27(2), pp.164-171. 
Boland, G. W., Dwamena, B. A., Jagtiani Sangwaiya, M., Goehler, A. G., Blake, M. A., Hahn, P. F., Scott, J. A. & Kalra, M. K. 2011. 
Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance.
Radiology, 259, 117-26. 
Bodtger, U., Vilmann, P., Clementsen, P., Galvis, E., Bach, K. & Skov, B. G. 2009. Clinical impact of endoscopic ultrasound-fine 
needle aspiration of left adrenal masses in established or suspected lung cancer. J Thorac Oncol, 4, 1485-9. 
Bradley, J. D., Dehdashti, F., Mintun, M. A., Govindan, R., Trinkaus, K. & Siegel, B. A. 2004. Positron emission tomography in 
limited-stage small-cell lung cancer: a prospective study. J Clin Oncol, 22, 3248-54. 
Brady, M. J., Thomas, J., Wong, T. Z., Franklin, K. M., Ho, L. M. & Paulson, E. K. 2009. Adrenal nodules at FDG PET/CT in patients 
known to have or suspected of having lung cancer: a proposal for an efficient diagnostic algorithm. Radiology, 250, 523-30. 
Brierly, J. D., Gospodarowicz, M. K. & Wittekind, C. 2016. TNM Classification of Malignant Tumours, 8th Edition, Wiley-Blackwell.
Brink, I., Schumacher, T., Mix, M., Ruhland, S., Stoelben, E., Digel, W., Henke, M., Ghanem, N., Moser, E. & Nitzsche, E. U. 2004. 
Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging, 31, 1614-20. 
Calman, L., Beaver, K., Hind, D., Lorigan, P., Roberts, C. & Lloyd-Jones, M. 2011. Survival benefits from follow-up of patients 
with lung cancer: a systematic review and meta-analysis. J Thorac Oncol, 6, 1993-2004. 
192 | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
| A National Clinical Guideline
Cheran, S. K., Herndon, J. E. & Patz, E. F. 2004. Comparison of whole-body FDG-PET to bone scan for detection of bone 
metastases in patients with a new diagnosis of lung cancer. Lung Cancer, 44, 317-25. 
Cho, A. R., Lim, I., Na, I., Choe, D., Park, J., Kim, B., Cheon, G., Choi, C. & Lim, S. 2011. Evaluation of Adrenal Masses in Lung 
Cancer Patients Using F-18 FDG PET/CT. Nucl Med Mol Imaging, 45, 52-58. 
Davis, P. C., Hudgins, P. A., Peterman, S. B. & Hoffman, J. C. 1991. Diagnosis of cerebral metastases: double-dose delayed CT vs 
contrast-enhanced MR imaging. AJNR Am J Neuroradiol, 12, 293-300. 
de Langen, A. J., Raijmakers, P., Riphagen, I., Paul, M. A. & Hoekstra, O. S. 2006. The size of mediastinal lymph nodes and its 
relation with metastatic involvement: a meta-analysis. Eur J Cardiothorac Surg, 29, 26-9. 
De Leyn, P., Lardinois, D., Van Schil, P. E., Rami-Porta, R., Passlick, B., Zielinski, M., Waller, D. A., Lerut, T. & Weder, W. 2007. ESTS 
guidelines for preoperative lymph node staging for non-small cell lung cancer. Eur J Cardiothorac Surg, 32, 1-8. 
Detterbeck, F. C. & Jones, D. R. 2001. Table 5-5. Reliability of computed tomography staging of N1 (hilar) node involvement 
[table]. In: DETTERBECK, F. C., SOCINSKI, M. A. & ROSENMAN, J. G. (eds.) Diagnosis and treatment of lung cancer: an evidence-
based guide for the practicing clinician. Philadelphia: W.B. Saunders.
Detterbeck, F. C., Jones, D. R. & Alden Parker, L. J. 2001a. Table 5-6. Reliability of computed tomography assessment of 
mediastinal nodes [table]. In: DETTERBECK, F. C. R. M., SOCINSKI, M. A. & ROSENMAN, J. G. (eds.) Diagnosis and treatment of 
lung cancer: an evidence-based guide for the practicing clinician. Philadelphia: W.B. Saunders.
Detterbeck, F. C., Jones, D. R. & Molina, P. L. 2001b. Table 6-9. Confirmability tests for suspected adrenal metastases in cancer 
patients [table]. In: DETTERBECK, F. C., RIVERA, M. P., SOKINSKI, M. A. & ROSENMAN, J. G. (eds.) Diagnosis and treatment of 
lung cancer: an evidence-based guide for the practicing clinician. Philadelphia: W.B. Saunders.
Detterbeck, F. C., Jones, D. R. & Molina, P. L. 2001c. Table 6-10. Confirmatory tests for benign adrenal adenoma [table]. In: 
DETTERBECK, F. C., RIVERA, M. P., SOKINSKI, M. A. & ROSENMAN, J. G. (eds.) Diagnosis and treatment of lung cancer: an 
evidence-based guide for the practicing clinician. Philadelphia: W.B. Saunders.
Detterbeck, F. C. & Rivera, M. P. 2001a. Table 4-8. Sensitivity of bronchoscopy in diagnosing lung cancer [table]. In: DETTERBECK, 
F. C., SOCINSKI, M. A. & ROSENMAN, J. G. (eds.) Diagnosis and treatment of lung cancer: an evidence-based guide for the 
practicing clinician. Philadelphia: W.B. Saunders.
Detterbeck, F. C. & Rivera, M. P. 2001b. Table 4-9. Reliability of needle biopsy of pulmonary nodules to assess the presence of 
cancer [table]. In: DETTERBECK, F. C., SOCINSKI, M. A. & ROSENMAN, J. G. (eds.) Diagnosis and treatment of lung cancer: an 
evidence-based guide for the practicing clinician. Philadelphia: W.B. Saunders.
DeWitt, J., Alsatie, M., LeBlanc, J., McHenry, L. & Sherman, S. 2007. Endoscopic ultrasound-guided fine-needle aspiration of 
left adrenal gland masses. Endoscopy, 39, 65-71. 
Ferguson, J. and Walker, W., 2006. Developing a VATS lobectomy programme—can VATS lobectomy be taught?. Eur J 
Cardiothorac Surg, 29(5), pp.806-809. 
Ferrigno, D. & Buccheri, G. 1994. Cranial computed tomography as a part of the initial staging procedures for patients with 
non-small-cell lung cancer. Chest, 106, 1025-9. 
Glazer, G. M., Gross, B. H., Aisen, A. M., Quint, L. E., Francis, I. R. & Orringer, M. B. 1985. Imaging of the pulmonary hilum: a 
prospective comparative study in patients with lung cancer. AJR Am J Roentgenol, 145, 245-8. 
Gould, M. K., Maclean, C. C., Kuschner, W. G., Rydzak, C. E. & Owens, D. K. 2001. Accuracy of positron emission tomography 
for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA, 285, 914-24. 
Hatter, J., Kohman, L. J., Mosca, R. S., Graziano, S. L., Veit, L. J. & Coleman, M. 1994. Preoperative evaluation of stage I and stage 
II non-small cell lung cancer. Ann Thorac Surg, 58, 1738-41. 
Hetzel, M., Arslandemir, C., König, H. H., Buck, A. K., Nüssle, K., Glatting, G., Gabelmann, A., Hetzel, J., Hombach, V. & 
Schirrmeister, H. 2003. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact 
on patient management. J Bone Miner Res, 18, 2206-14. 
193| A National Clinical Guideline | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
Hiraki, T., Gobara, H., Mimura, H., Matsui, Y., Toyooka, S. & Kanazawa, S. 2011. Percutaneous radiofrequency ablation of clinical stage I 
non-small cell lung cancer. J Thorac Cardiovasc Surg, 142, 24-30. 
Hsia, T. C., Shen, Y. Y., Yen, R. F., Kao, C. H. & Changlai, S. P. 2002. Comparing whole body 18F-2-deoxyglucose positron emission 
tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small 
cell lung cancer. Neoplasma, 49, 267-71. 
Ichinose, Y., Hara, N., Ohta, M., Motohiro, A., Maeda, T., Nobe, T. & Yagawa, K. 1989. Preoperative examination to detect 
distant metastasis is not advocated for asymptomatic patients with stages 1 and 2 non-small cell lung cancer. Preoperative 
examination for lung cancer. Chest, 96, 1104-9. 
Kalemkerian, G. P. & Gadgeel, S. M. 2013. Modern staging of small cell lung cancer. J Natl Compr Canc Netw, 11, 99-104. 
Kamel, E.M., Zwahlen, D., Wyss, M.T., Stumpe, K.D., von Schulthess, G.K. and Steinert, H.C., 2003. Whole-body 18F-FDG PET 
improves the management of patients with small cell lung cancer. J Nucl Med, 44(12), pp.1911- 1917. 
Kormas, P., Bradshaw, J. R. & Jeyasingham, K. 1992. Preoperative computed tomography of the brain in non-small cell 
bronchogenic carcinoma. Thorax, 47, 106-8. 
Kumar, R., Xiu, Y., Yu, J. Q., Takalkar, A., El-Haddad, G., Potenta, S., Kung, J., Zhuang, H. & Alavi, A. 2004. 18F-FDG PET in 
evaluation of adrenal lesions in patients with lung cancer. J Nucl Med, 45, 2058-62. 
Kut, V., Spies, W., Spies, S., Gooding, W. and Argiris, A., 2007. Staging and monitoring of small cell lung cancer using [18F] 
fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET). Am J Clin Oncol, 30(1), pp.45-50.
Lanuti, M., Sharma, A., Willers, H., Digumarthy, S. R., Mathisen, D. J. & Shepard, J. A. 2012. Radiofrequency ablation for stage I 
non-small cell lung cancer: management of locoregional recurrence. Ann Thorac Surg, 93, 921-7; discussion 927-88. 
Lim, E., Baldwin, D., Beckles, M., Duffy, J., Entwisle, J., Faivre-Finn, C., Kerr, K., Macfie, A., McGuigan, J., Padley, S., Popat, S., 
Screaton, N., Snee, M., Waller, D., Warburton, C., Win, T., British Thoracic Society & Society for Cardiothoracic Surgery in Great 
Britain and Ireland. 2010. Guidelines on the radical management of patients with lung cancer. Thorax, 65 Suppl 3, iii1-27. 
Lu, Y., Xie, D., Huang, W., Gong, H. & Yu, J. 2010. 18F-FDG PET/CT in the evaluation of adrenal masses in lung cancer patients. 
Neoplasma, 57, 129-34. 
Mack, M. J., Hazelrigg, S. R., Landreneau, R. J. & Acuff, T. E. 1993. Thoracoscopy for the diagnosis of the indeterminate solitary 
pulmonary nodule. Ann Thorac Surg, 56, 825-30. 
Mitruka, S., Landreneau, R. J., Mack, M. J., Fetterman, L. S., Gammie, J., Bartley, S., Sutherland, S. R., Bowers, C. M., Keenan, 
R. J., Ferson, P. F. & et al. 1995. Diagnosing the indeterminate pulmonary nodule: percutaneous biopsy versus thoracoscopy. 
Surgery, 118, 676-84. 
Moore, S., Corner, J., Haviland, J., Wells, M., Salmon, E., Normand, C., Brada, M., O’Brien, M. & Smith, I. 2002. Nurse led follow 
up and conventional medical follow up in management of patients with lung cancer: randomised trial. BMJ, 325, 1145. 
National Institute for Health and Care Excellence (NICE). 2011. CG 121: Lung cancer: The diagnosis and treatment of lung 
cancer. London: National Institute for Health and Care Excellence (NICE). 
Roberts, J. R., Blum, M. G., Arildsen, R., Drinkwater, D. C., Jr., Christian, K. R., Powers, T. A. & Merrill, W. H. 1999. Prospective 
comparison of radiologic, thoracoscopic, and pathologic staging in patients with early non-small cell lung cancer. Ann Thorac 
Surg, 68, 1154-8. 
Schmidt-Hansen, M., Baldwin, D. R., Hasler, E., Zamora, J., Abraira, V. & Roqué I Figuls, M. 2014. PET-CT for assessing mediastinal 
lymph node involvement in patients with suspected resectable non-small cell lung cancer. Cochrane Database Syst Rev, 11, 
CD009519. 
Schreiber, G. & McCrory, D. C. 2003. Performance characteristics of different modalities for diagnosis of suspected lung cancer: 
summary of published evidence. Chest, 123, 115S-128S. 
194 | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
| A National Clinical Guideline
Scottish Intercollegiate Guidelines Network (SIGN). 2014. Management of lung cancer – a national clinical guideline. Edinburgh: 
SIGN. (SIGN publication no. 137).[Cited 09 Jun 2015]. Available: www.sign.ac.uk 
Silvestri, G. A., Gonzalez, A. V., Jantz, M. A., Margolis, M. L., Gould, M. K., Tanoue, L. T., Harris, L. J. & Detterbeck, F. C. 2013. 
Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: american college of chest 
physicians evidence-based clinical practice guidelines. Chest, 143, e211S-e250S.
Silvestri, G. A., Gould, M. K., Margolis, M. L., Tanoue, L. T., McCrory, D., Toloza, E., Detterbeck, F. & Physicians, A. C. o. C. 2007. 
Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest, 
132,178S-201S. 
Song, J. W., Oh, Y. M., Shim, T. S., Kim, W. S., Ryu, J. S. & Choi, C. M. 2009. Efficacy comparison between (18)F-FDG PET/CT and 
bone scintigraphy in detecting bony metastases of non-small-cell lung cancer. Lung Cancer, 65, 333-8. 
Sugiyama, T., Hirose, T., Hosaka, T., Kusumoto, S., Nakashima, M., Yamaoka, T., Okuda, K., Ohmori, T. & Adachi, M. 2008. 
Effectiveness of intensive follow-up after response in patients with small cell lung cancer. Lung Cancer, 59, 255- 61 
Sze, G., Shin, J., Krol, G., Johnson, C., Liu, D. & Deck, M. D. 1988. Intraparenchymal brain metastases: MR imaging versus 
contrast-enhanced CT. Radiology, 168, 187-94. 
Takenaka, D., Ohno, Y., Matsumoto, K., Aoyama, N., Onishi, Y., Koyama, H., Nogami, M., Yoshikawa, T., Matsumoto, S. & 
Sugimura, K. 2009. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-
weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy. J 
Magn Reson Imaging, 30,298-308. 
Taphoorn, M. J., Heimans, J. J., Kaiser, M. C., de Slegte, R. G., Crezee, F. C. & Valk, J. 1989. Imaging of brain metastases. 
Comparison of computerized tomography (CT) and magnetic resonance imaging (MRI). Neuroradiology, 31, 391-5. 
Thomas, K. & Gould, M. 2016. Selection of modality for diagnosis and staging of patients with suspected non-small cell lung 
cancer. [Online]. UpToDate, Waltham, MA: Post TW (Ed). [Accessed December 23, 2016].
van Loon, J., Offermann, C., Bosmans, G., Wanders, R., Dekker, A., Borger, J., Oellers, M., Dingemans, A.M., van Baardwijk, A., 
Teule, J. and Snoep, G., 2008. 18 FDG-PET based radiation planning of mediastinal lymph nodes in limited disease small cell 
lung cancer changes radiotherapy fields: a planning study. Radiotherapy and Oncology, 87(1), pp.49-54. 
van Loon, J., De Ruysscher, D., Wanders, R., Boersma, L., Simons, J., Oellers, M., Dingemans, A.M.C., Hochstenbag, M., Bootsma, 
G., Geraedts, W. and Pitz, C., 2010. Selective nodal irradiation on basis of 18 FDG-PET scans in limited-disease small-cell lung 
cancer: a prospective study. Int J Radiat Oncol Biol Phys, 77(2), pp.329-336. 
Virgo, K. S., Mckirgan, L. W., Caputo, M. C., Mahurin, D. M., Chao, L. C., Caputo, N. A., Naunheim, K. S., Flye, M. W., Gillespie, K. 
N. & Johnson, F. E. 1995. Post-treatment management options for patients with lung cancer. Ann Surg, 222, 700-10. 
Wain, J. C. 1993. Video-assisted thoracoscopy and the staging of lung cancer. Ann Thorac Surg, 56, 776-8. 
Wang Memoli, J.S.W., Nietert, P.J. and Silvestri, G.A., 2012. Meta-analysis of guided bronchoscopy for the evaluation of the 
pulmonary nodule. Chest, 142(2), pp.385-393. 
Welch, T. J., Sheedy, P. F., Stephens, D. H., Johnson, C. M. & Swensen, S. J. 1994. Percutaneous adrenal biopsy: review of a 10-
year experience. Radiology, 193, 341-4.
Yao, X., Gomes, M. M., Tsao, M. S., Allen, C. J., Geddie, W. & Sekhon, H. 2012. Fine-needle aspiration biopsy versus core-needle 
biopsy in diagnosing lung cancer: a systematic review. Curr Oncol, 19, e16-27. 
Yokoi, K., Kamiya, N., Matsuguma, H., Machida, S., Hirose, T., Mori, K. & Tominaga, K. 1999. Detection of brain metastasis in 
potentially operable non-small cell lung cancer: a comparison of CT and MRI. Chest, 115, 714-9. 
Younes, R. N., Gross, J. L. & Deheinzelin, D. 1999. Follow-up in lung cancer: how often and for what purpose? Chest, 115, 1494-
9. 
195| A National Clinical Guideline | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
Zieren, H. U., Müller, J. M., Petermann, D. & Pichlmaier, H. 1994. [The effectiveness of standardized follow-up studies after 
resection of non-small cell bronchial carcinoma]. Langenbecks Arch Chir, 379, 299-306.
Section 2.3: Respiratory Medicine
Best, L. A., Munichor, M., Ben-Shakhar, M., Lemer, J., Lichtig, C. & Peleg, H. 1987. The contribution of anterior mediastinotomy 
in the diagnosis and evaluation of diseases of the mediastinum and lung. Ann Thorac Surg, 43, 78- 81. 
Bielsa, S., Panadés, M. J., Egido, R., Rue, M., Salud, A., Matías-Guiu, X., Rodríguez-Panadero, F. & Porcel, J. M. 2008. [Accuracy 
of pleural fluid cytology in malignant effusions]. [Abstract Only] An Med Interna, 25, 173-7. 
Bolliger, C. T., Mathur, P. N., Beamis, J. F., Becker, H. D., Cavaliere, S., Colt, H., Diaz-Jimenez, J. P., Dumon, J. F., Edell, E., Kovitz, 
K. L., Macha, H. N., Mehta, A. C., Marel, M., Noppen, M., Strausz, J. & Sutedja, T. G. 2002. ERS/ATS statement on interventional 
pulmonology. European Respiratory Society/American Thoracic Society. Eur Respir J, 19, 356-73. 
Brierly, J. D., Gospodarowicz, M. K. & Wittekind, C. 2016. TNM Classification of Malignant Tumours, 8th Edition, Wiley-Blackwell.
Dales, R. E., Stark, R. M. & Raman, S. 1990. Computed tomography to stage lung cancer. Approaching a controversy using 
meta-analysis. Am Rev Respir Dis, 141, 1096-101. 
Detterbeck, F. C., Mazzone, P. J., Naidich, D. P. & Bach, P. B. 2013. Screening for lung cancer: Diagnosis and management of 
lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 143, e78S-92S.
Detterbeck, F. C. & Rivera, M. P. 2001a. Table 4-8. Sensitivity of bronchoscopy in diagnosing lung cancer [table]. In: Detterbeck, 
F. C., Socinski, M. A. & Rosenman, J. G. (eds.) Diagnosis and treatment of lung cancer: an evidence-based guide for the 
practicing clinician. Philadelphia: W.B. Saunders. 
De Leyn, P., Dooms, C., Kuzdzal, J., Lardinois, D., Passlick, B., Rami-Porta, R., Turna, A., Van Schil, P., Venuta, F., Waller, D., 
Weder, W. & Zielinski, M. 2014. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell 
lung cancer. Eur J Cardiothorac Surg, 45, 787-98.
Ernst, A., Feller-Kopman, D., Becker, H. D. & Mehta, A. C. 2004. Central airway obstruction. Am J Respir Crit Care Med, 169, 
1278-97. 
Ernst, A., Silvestri, G. A. & Johnstone, D. 2003. Interventional pulmonary procedures: Guidelines from the American College of 
Chest Physicians. Chest, 123, 1693-717. 
Herth, F.J., Mathur, P.N., Finlay G. 2016. Clinical presentation, diagnostic evaluation, and management of central airway 
obstruction in adults. In: UpToDate, Post TW (Ed), UpToDate, WAltham, MA (Accessed on July 16, 2014).
Lim, E., Baldwin, D., Beckles, M., Duffy, J., Entwisle, J., Faivre-Finn, C., Kerr, K., Macfie, A., McGuigan, J., Padley, S., Popat, S., 
Screaton, N., Snee, M., Waller, D., Warburton, C., Win, T., British Thoracic Society & Society for Cardiothoracic Surgery in Great 
Britain and Ireland. 2010. Guidelines on the radical management of patients with lung cancer. Thorax, 65 Suppl 3, iii1-27. 
Metintas, M., Ak, G., Dundar, E., Yildirim, H., Ozkan, R., Kurt, E., Erginel, S., Alatas, F. & Metintas, S. 2010. Medical thoracoscopy 
vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial. 
Chest, 137, 1362-8. 
National Institute for Health and Care Excellence (NICE). 2011. CG 121: Lung cancer: The diagnosis and treatment of lung 
cancer. London: National Institute for Health and Care Excellence (NICE). 
Sanchez de Cos, J., Hernandez, J. H., Lopez, M. F., Sanchez, S. P., Gratacos, A. R. & Porta, R. R. 2011. SEPAR guidelines for lung 
cancer staging. Arch Bronconeumol, 47, 454-65.
Schreiber, G. & McCrory, D. C. 2003. Performance characteristics of different modalities for diagnosis of suspected lung cancer: 
summary of published evidence. Chest, 123, 115S-128S. 
196 | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
| A National Clinical Guideline
Scottish Intercollegiate Guidelines Network (SIGN). 2014. Management of lung cancer – a national clinical guideline. Edinburgh: 
SIGN. (SIGN publication no. 137).[Cited 09 Jun 2015]. Available: www.sign.ac.uk 
Seijo, L. M. & Sterman, D. H. 2001. Interventional pulmonology. N Engl J Med, 344, 740-9. 
Sharples, L. D., Jackson, C., Wheaton, E., Griffith, G., Annema, J. T., Dooms, C., Tournoy, K. G., Deschepper, E., Hughes, V., 
Magee, L., Buxton, M. & Rintoul, R. C. 2012. Clinical effectiveness and cost-effectiveness of endobronchial and endoscopic 
ultrasound relative to surgical staging in potentially resectable lung cancer: results from the ASTER randomised controlled 
trial. Health Technol Assess, 16, 1-75, iii-iv. 
Silvestri, G. A., Gonzalez, A. V., Jantz, M. A., Margolis, M. L., Gould, M. K., Tanoue, L. T., Harris, L. J. & Detterbeck, F. C. 2013. 
Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: american college of chest 
physicians evidence-based clinical practice guidelines. Chest, 143, e211S-e250S.
Stephens, K. E., Jr. & Wood, D. E. 2000. Bronchoscopic management of central airway obstruction. J Thorac Cardiovasc Surg, 
119, 289-96. 
Thomas, K. & Gould, M. 2016. Selection of modality for diagnosis and staging of patients with suspected non-small cell lung 
cancer. [Online]. UpToDate, Waltham, MA: Post TW (Ed). [Accessed December 23, 2016]. 
Yasufuku, K., Pierre, A., Darling, G., de Perrot, M., Waddell, T., Johnston, M., da Cunha Santos, G., Geddie, W., Boerner, S., Le, 
L. W. & Keshavjee, S. 2011. A prospective controlled trial of endobronchial ultrasound-guided transbronchial needle aspiration 
compared with mediastinoscopy for mediastinal lymph node staging of lung cancer. J Thorac Cardiovasc Surg, 142, 1393-400.
Section 2.4: Pathology 
Asano, H., Toyooka, S., Tokumo, M., Ichimura, K., Aoe, K., Ito, S., Tsukuda, K., Ouchida, M., Aoe, M., Katayama, H., Hiraki, A., 
Sugi, K., Kiura, K., Date, H. & Shimizu, N. 2006. Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase 
chain reaction assay. Clin Cancer Res, 12, 43-8. 
Besse, B., Ropert, S. & Soria, J. C. 2007. Targeted therapies in lung cancer. Annals of Oncology, 18, ix135-ix142. 
Bishop, J. A., Sharma, R. & Illei, P. B. 2010. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, 
breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol, 41, 20-5. 
Borczuk, A. C., Shah, L., Pearson, G. D., Walter, K. L., Wang, L., Austin, J. H., Friedman, R. A. & Powell, C. A. 2004. Molecular 
signatures in biopsy specimens of lung cancer. Am J Respir Crit Care Med, 170, 167-74.
Brierly, J. D., Gospodarowicz, M. K. & Wittekind, C. 2016. TNM Classification of Malignant Tumours, 8th Edition, Wiley-Blackwell. 
Camilo, R., Capelozzi, V. L., Siqueira, S. A. & Del Carlo Bernardi, F. 2006. Expression of p63, keratin 5/6, keratin 7, and surfactant-A 
in non-small cell lung carcinomas. Hum Pathol, 37, 542-6. 
Chu, P. G. & Weiss, L. M. 2002. Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 
cases. Mod Pathol, 15, 6-10. 
Cohen, M. H., Gootenberg, J., Keegan, P. & Pazdur, R. 2007. FDA drug approval summary: bevacizumab (Avastin®) plus 
carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. 
The Oncologist, 12,713-718. 
College of American Pathologists. 2012. CAP Laboratory accreditation checklists [Online]. Available: http://www. cap.org/
apps/cap.portal [Accessed April 11 2012].
Gordon, G. J., Richards, W. G., Sugarbaker, D. J., Jaklitsch, M. T. & Bueno, R. 2003. A prognostic test for adenocarcinoma of the 
lung from gene expression profiling data. Cancer Epidemiol Biomarkers Prev, 12, 905-10. 
Herbst, R. S. 2006. Toxicities of antiangiogenic therapy in non–small-cell lung cancer. Clinical lung cancer, 8, S23-S30.
Herbst, R. S. & Sandler, A. 2008. Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC. 
The Oncologist, 13, 1166-1176. 
197| A National Clinical Guideline | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
Higashiyama, M., Kodama, K., Takami, K., Higaki, N., Nakayama, T. & Yokouchi, H. 2003. Intraoperative lavage cytologic analysis 
of surgical margins in patients undergoing limited surgery for lung cancer. J Thorac Cardiovasc Surg, 125, 101-7. 
Johnson, D.H., Fehrenbacher, L., Novotny, W.F., Herbst, R.S., Nemunaitis, J.J., Jablons, D.M., Langer, C.J., DeVore, R.F., 
Gaudreault, J., Damico, L.A. and Holmgren, E., 2004. Randomized phase II trial comparing bevacizumab plus carboplatin and 
paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung 
cancer. J Clin Oncol, 22(11), pp.2184-2191. 
Kargi, A., Gurel, D. & Tuna, B. 2007. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung 
carcinomas. Appl Immunohistochem Mol Morphol, 15, 415-20. 
Kaufmann, O. & Dietel, M. 2000. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary 
adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology, 36, 8-16. 
Khayyata, S., Yun, S., Pasha, T., Jian, B., McGrath, C., Yu, G., Gupta, P. & Baloch, Z. 2009. Value of P63 and CK5/6 in distinguishing 
squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol, 37, 178-83. 
Kimura, H., Fujiwara, Y., Sone, T., Kunitoh, H., Tamura, T., Kasahara, K. & Nishio, K. 2006. EGFR mutation status in tumour-
derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. Br J Cancer, 95, 1390-5. 
Lam, W. K. & Watkins, D. N. 2007. Lung cancer: future directions. Respirology, 12, 471-477. 
Lau, S. K., Luthringer, D. J. & Eisen, R. N. 2002. Thyroid transcription factor-1: a review. Appl Immunohistochem Mol Morphol, 
10, 97-102. 
Li, A. R., Chitale, D., Riely, G. J., Pao, W., Miller, V. A., Zakowski, M. F., Rusch, V., Kris, M. G. & Ladanyi, M. 2008. EGFR mutations 
in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical 
expression. J Mol Diagn, 10, 242-8.
Lim, E. H., Zhang, S. L., Li, J. L., Yap, W. S., Howe, T. C., Tan, B. P., Lee, Y. S., Wong, D., Khoo, K. L., Seto, K. Y., Tan, L., Agasthian, 
T., Koong, H. N., Tam, J., Tan, C., Caleb, M., Chang, A., Ng, A. & Tan, P. 2009. Using whole genome amplification (WGA) of low-
volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung 
cancer (NSCLC). J Thorac Oncol, 4, 12-21. 
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J. 
S., Squire, J., Thunnissen, E. & Ladanyi, M. 2013. Molecular testing guideline for selection of lung cancer patients for EGFR and 
ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of 
Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol, 8, 823-59. 
Loo, P. S., Thomas, S. C., Nicolson, M. C., Fyfe, M. N. & Kerr, K. M. 2010. Subtyping of undifferentiated non-small cell carcinomas 
in bronchial biopsy specimens. J Thorac Oncol, 5, 442-7. 
Marchevsky, A. M., Changsri, C., Gupta, I., Fuller, C., Houck, W. & McKenna, R. J. 2004. Frozen section diagnoses of small 
pulmonary nodules: accuracy and clinical implications. Ann Thorac Surg, 78, 1755-9. 
Miller, V. A., Riely, G. J., Zakowski, M. F., Li, A. R., Patel, J. D., Heelan, R. T., Kris, M. G., Sandler, A. B., Carbone, D. P., Tsao, A., 
Herbst, R. S., Heller, G., Ladanyi, M., Pao, W. & Johnson, D. H. 2008. Molecular characteristics of bronchioloalveolar carcinoma 
and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol, 26, 1472-8. 
Motoi, N., Szoke, J., Riely, G. J., Seshan, V. E., Kris, M. G., Rusch, V. W., Gerald, W. L. & Travis, W. D. 2008. Lung adenocarcinoma: 
modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary 
and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol, 32, 810-27.
Nicholson, A. G., Gonzalez, D., Shah, P., Pynegar, M. J., Deshmukh, M., Rice, A. & Popat, S. 2010. Refining the diagnosis and EGFR 
status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 
5/6, and P63, and EGFR mutation analysis. J Thorac Oncol, 5, 436-41. 
Oki, M., Saka, H., Kitagawa, C., Kogure, Y., Murata, N., Adachi, T. & Ando, M. 2013. Rapid on-site cytologic evaluation during 
endobronchial ultrasound-guided transbronchial needle aspiration for diagnosing lung cancer: a randomized study. Respiration, 
85(6), pp.486-492. 
198 | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
| A National Clinical Guideline
Ordóñez, N. G. 2000. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in 
distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol, 24, 
598-606. 
Otani, H., Toyooka, S., Soh, J., Yamamoto, H., Suehisa, H., Kobayashi, N., Gobara, H., Mimura, H., Kiura, K., Sano, Y., Kanazawa, 
S. & Date, H. 2008. Detection of EGFR gene mutations using the wash fluid of CT-guided biopsy needle in NSCLC patients. J 
Thorac Oncol, 3, 472-6. 
Rekhtman, N., Brandt, S. M., Sigel, C. S., Friedlander, M. A., Riely, G. J., Travis, W. D., Zakowski, M. F. & Moreira, A. L. 2011. 
Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor 
subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol, 6, 451-8. 
Rivera, M. P., Mehta, A. C. & American College of Chest Physicians 2007. Initial diagnosis of lung cancer: ACCP evidence-based 
clinical practice guidelines (2nd edition). Chest, 132, 131S-148S.
 
Rossi, G., Pelosi, G., Graziano, P., Barbareschi, M. & Papotti, M. 2009a. A reevaluation of the clinical significance of histological 
subtyping of non--small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments. Int J Surg Pathol, 
17,206-18. 
Rossi, G., Papotti, M., Barbareschi, M., Graziano, P. & Pelosi, G. 2009b. Morphology and a limited number of immunohistochemical 
markers may efficiently subtype non-small-cell lung cancer. J Clin Oncol, 27, e141-2; author reply e143-4.
Savic, S., Tapia, C., Grilli, B., Rufle, A., Bihl, M. P., de Vito Barascud, A., Herzog, M., Terracciano, L., Baty, F. & Bubendorf, L. 2008. 
Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. Br 
J Cancer, 98, 154-60. 
Scottish Intercollegiate Guidelines Network (SIGN). 2014. Management of lung cancer – a national clinical guideline. Edinburgh: 
SIGN. (SIGN publication no. 137).[Cited 09 Jun 2015]. Available: www.sign.ac.uk 
Sigel, C. S., Moreira, A. L., Travis, W. D., Zakowski, M. F., Thornton, R. H., Riely, G. J. & Rekhtman, N. 2011. Subtyping of non-
small cell lung carcinoma: a comparison of small biopsy and cytology specimens. J Thorac Oncol, 6, 1849-56. 
Solomon, S. B., Zakowski, M. F., Pao, W., Thornton, R. H., Ladanyi, M., Kris, M. G., Rusch, V. W. & Rizvi, N. A. 2010. Core needle 
lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis. AJR Am J Roentgenol, 194, 266-9. 
Srinivasan, M., Sedmak, D. & Jewell, S. 2002. Effect of fixatives and tissue processing on the content and integrity of nucleic 
acids. Am J Pathol, 161, 1961-71. 
Suh, J., Rekhtman, N., Ladanyi, M. 2011. Testing of new IASLC/ATS/ERS criteria for diagnosis of lung adenocarcinoma (AD) in 
small biopsies: minimize immunohistochemistry (IHC) to maximize tissue for molecular studies. Mod Pathol. 24 (Supplement 
1). 
The Royal College of Pathologists (2016). Dataset for lung cancer histopathology reports. September 2016
Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K., Yatabe, Y., Powell, C. A., Beer, D., Riely, G., Garg, K., 
Austin, J. H., Rusch, V. W., Hirsch, F. R., Jett, J., Yang, P. C., Gould, M. & Society, A. T. 2011. International Association for the 
Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification 
of lung adenocarcinoma: executive summary. Proc Am Thorac Soc, 8, 381-5.
Travis, W. D. 2002. Pathology of lung cancer. Clin Chest Med, 23, 65-81, viii. 
Trisolini, R., Cancellieri, A., Tinelli, C., Paioli, D., Scudeller, L., Casadei, G. P., Parri, S. F., Livi, V., Bondi, A., Boaron, M. & Patelli, M. 
2011. Rapid on-site evaluation of transbronchial aspirates in the diagnosis of hilar and mediastinal adenopathy: a randomized 
trial. Chest, 139, 395-401. 
Utsumi, T., Sawabata, N., Inoue, M. & Okumura, M. 2010. Optimal sampling methods for margin cytology examination following 
lung excision. Interact Cardiovasc Thorac Surg, 10, 434-6.
Watanabe, T., Okada, A., Imakiire, T., Koike, T. & Hirono, T. 2005. Intentional limited resection for small peripheral lung cancer 
based on intraoperative pathologic exploration. Jpn J Thorac Cardiovasc Surg, 53, 29-35. 
199| A National Clinical Guideline | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
Wolff, A. C., Hammond, M. E., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. 
M., Langer, A., McShane, L. M., Paik, S., Pegram, M. D., Perez, E. A., Press, M. F., Rhodes, A., Sturgeon, C., Taube, S. E., Tubbs, 
R., Vance, G. H., van de Vijver, M., Wheeler, T. M., Hayes, D. F. & Pathologists, A. S. o. C. O. C. o. A. 2007. American Society of 
Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 
2 testing in breast cancer. Arch Pathol Lab Med, 131, 18-43.
World Health Organisation 2015. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. Fourth edition.
Wu, S. G., Gow, C. H., Yu, C. J., Chang, Y. L., Yang, C. H., Hsu, Y. C., Shih, J. Y., Lee, Y. C. & Yang, P. C. 2008. Frequent epidermal 
growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. Eur Respir J, 32, 924-30. 
Wu, M., Wang, B., Gil, J., Sabo, E., Miller, L., Gan, L. & Burstein, D. E. 2003. p63 and TTF-1 immunostaining. A useful marker 
panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung. Am J Clin 
Pathol, 119, 696-702. 
Yamada, S. & Kohno, T. 2004. Video-assisted thoracic surgery for pure ground-glass opacities 2 cm or less in diameter. Ann 
Thorac Surg,77, 1911-5. 
Yamato, Y., Tsuchida, M., Watanabe, T., Aoki, T., Koizumi, N., Umezu, H. & Hayashi, J. 2001. Early results of a prospective study 
of limited resection for bronchioloalveolar adenocarcinoma of the lung. Ann Thorac Surg, 71, 971-4. 
Yatabe, Y., Mitsudomi, T. & Takahashi, T. 2002. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol, 26, 767-73. 
Yoshida, J., Nagai, K., Yokose, T., Nishimura, M., Kakinuma, R., Ohmatsu, H. & Nishiwaki, Y. 2005. Limited resection trial for 
pulmonary ground-glass opacity nodules: fifty-case experience. J Thorac Cardiovasc Surg, 129, 991-6. 
Zhang, X., Zhao, Y., Wang, M., Yap, W. S. & Chang, A. Y. 2008. Detection and comparison of epidermal growth factor receptor 
mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer. Lung Cancer, 60, 175-82. 
Zudaire, I., Lozano, M. D., Vazquez, M. F., Pajares, M. J., Agorreta, J., Pio, R., Zulueta, J. J., Yankelevitz, D. F., Henschke, C. I. 
& Montuenga, L. M. 2008. Molecular characterization of small peripheral lung tumors based on the analysis of fine needle 
aspirates. Histol Histopathol, 23, 33-40.
Section 2.5: Surgery
Abrahams, J. M., Torchia, M., Putt, M., Kaiser, L. R. & Judy, K. D. 2001. Risk factors affecting survival after brain metastases from 
non-small cell lung carcinoma: a follow-up study of 70 patients. J Neurosurg, 95, 595-600. 
Allen, M. S., Darling, G. E., Pechet, T. T., Mitchell, J. D., Herndon, J. E., Landreneau, R. J., Inculet, R. I., Jones, D. R., Meyers, B. 
F., Harpole, D. H., Putnam, J. B., Rusch, V. W. & ACOSOG Z Study Group. 2006. Morbidity and mortality of major pulmonary 
resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann 
Thorac Surg, 81, 1013-9; discussion 1019-20. 
Antakli, T., Schaefer, R. F., Rutherford, J. E. & Read, R. C. 1995. Second primary lung cancer. Ann Thorac Surg, 59, 863- 6; 
discussion 867. 
Benzo, R., Kelley, G.A., Recchi, L., Hofman, A. and Sciurba, F., 2007. Complications of lung resection and exercise capacity: a 
meta-analysis. Respir Med, 101(8), pp.1790-1797. 
Billing, P. S., Miller, D. L., Allen, M. S., Deschamps, C., Trastek, V. F. & Pairolero, P. C. 2001. Surgical treatment of primary lung 
cancer with synchronous brain metastases. J Thorac Cardiovasc Surg, 122, 548-53. 
Bonnette, P., Puyo, P., Gabriel, C., Giudicelli, R., Regnard, J. F., Riquet, M., Brichon, P. Y. & Thorax, G. 2001. Surgical management 
of non-small cell lung cancer with synchronous brain metastases. Chest, 119, 1469-75. 
Brierly, J. D., Gospodarowicz, M. K. & Wittekind, C. 2016. TNM Classification of Malignant Tumours, 8th Edition, Wiley-Blackwell. 
British Thoracic Society (BTS). 2001. BTS guidelines: guidelines on the selection of patients with lung cancer for surgery. 
Thorax, 56, 89-108. 
200 | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
| A National Clinical Guideline
Brunelli, A., Al Refai, M., Monteverde, M., Borri, A., Salati, M. & Fianchini, A. 2002. Stair climbing test predicts cardio-pulmonary 
complications after lung resection. Chest, 121, 1106-10. 
Cattaneo, S. M., Park, B. J., Wilton, A. S., Seshan, V. E., Bains, M. S., Downey, R. J., Flores, R. M., Rizk, N. & Rusch, V. W. 2008. 
Use of video-assisted thoracic surgery for lobectomy in the elderly results in fewer complications. Ann Thorac Surg, 85, 231-5; 
discussion 235-6. 
Darling, G.E., Allen, M.S., Decker, P.A., Ballman, K., Malthaner, R.A., Inculet, R.I., Jones, D.R., McKenna, R.J., Landreneau, R.J., 
Rusch, V.W. and Putnam, J.B., 2011. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy 
during pulmonary resection in the patient with N0 or N1 (less than hilar) non–small cell carcinoma: Results of the American 
College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg, 141(3), pp.662-670.
Davis, S., Crino, L., Tonato, M., Darwish, S., Pelicci, P. G. & Grignani, F. 1993. A prospective analysis of chemotherapy following 
surgical resection of clinical stage I-II small-cell lung cancer. Am J Clin Oncol, 16, 93-5. 
Deschamps, C., Pairolero, P. C., Trastek, V. F. & Payne, W. S. 1990. Multiple primary lung cancers. Results of surgical treatment. 
J Thorac Cardiovasc Surg, 99, 769-77; discussion 777-8. 
Detterbeck, F. C. 2001. Diagnosis and treatment of lung cancer: an evidence-based guide for the practicing clinician, 
Philadelphia; London, W.B. Saunders. 
Detterbeck, F. C. & Gibson, C. J. 2008. Turning gray: the natural history of lung cancer over time. J Thorac Oncol, 3, 781-92. 
Eagle, K. A., Rihal, C. S., Mickel, M. C., Holmes, D. R., Foster, E. D. & Gersh, B. J. 1997. Cardiac risk of noncardiac surgery: 
influence of coronary disease and type of surgery in 3368 operations. CASS Investigators and University of Michigan Heart 
Care Program. Coronary Artery Surgery Study. Circulation, 96, 1882-7. 
Falcoz, P. E., Conti, M., Brouchet, L., Chocron, S., Puyraveau, M., Mercier, M., Etievent, J. P. & Dahan, M. 2007. The Thoracic 
Surgery Scoring System (Thoracoscore): risk model for in-hospital death in 15,183 patients requiring thoracic surgery. J Thorac 
Cardiovasc Surg, 133,325-32. 
Ferguson, M. K., DeMeester, T. R., DesLauriers, J., Little, A. G., Piraux, M. & Golomb, H. 1985. Diagnosis and management of 
synchronous lung cancers. J Thorac Cardiovasc Surg, 89, 378-85. 
Flores, R. M., Park, B. J., Dycoco, J., Aronova, A., Hirth, Y., Rizk, N. P., Bains, M., Downey, R. J. & Rusch, V. W. 2009. Lobectomy 
by video-assisted thoracic surgery (VATS) versus thoracotomy for lung cancer. J Thorac Cardiovasc Surg, 138, 11-8. 
Fujimori, K., Yokoyama, A., Kurita, Y. & Terashima, M. 1997. A pilot phase 2 study of surgical treatment after induction 
chemotherapy for resectable stage I to IIIA small cell lung cancer. Chest, 111, 1089-93. 
Furák, J., Troján, I., Szöke, T., Agócs, L., Csekeö, A., Kas, J., Svastics, E., Eller, J. & Tiszlavicz, L. 2005. Lung cancer and its operable 
brain metastasis: survival rate and staging problems. Ann Thorac Surg, 79, 241-7. 
Getman, V., Devyatko, E., Dunkler, D., Eckersberger, F., End, A., Klepetko, W., Marta, G. & Mueller, M. R. 2004. Prognosis 
of patients with non-small cell lung cancer with isolated brain metastases undergoing combined surgical treatment. Eur J 
Cardiothorac Surg, 25, 1107-13. 
Ginsberg, R. J. & Rubinstein, L. V. 1995. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung 
cancer. Lung Cancer Study Group. Ann Thorac Surg, 60, 615-22; discussion 622-3. 
Ginsberg, R. J. & Rubinstein, L. 1994. The comparison of limited resection to lobectomy for T1N0 non-small cell lung cancer: 
LCSG 821. Chest, 106, 318S-319S.
Girard, N., Cottin, V., Tronc, F., Etienne-Mastroianni, B., Thivolet-Bejui, F., Honnorat, J., Guyotat, J., Souquet, P. J. & Cordier, J. F. 
2006. Chemotherapy is the cornerstone of the combined surgical treatment of lung cancer with synchronous brain metastases. 
Lung Cancer,53, 51-8. 
Girish, M., Trayner, E., Dammann, O., Pinto-Plata, V. and Celli, B., 2001. Symptom-limited stair climbing as a predictor of 
postoperative cardiopulmonary complications after high-risk surgery. Chest, 120(4), pp.1147-1151. 
201| A National Clinical Guideline | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
Goldstraw, P. 2009. The 7th Edition of TNM in Lung Cancer: what now? J Thorac Oncol, 4, 671-3. 
Howington, J. A., Blum, M. G., Chang, A. C., Balekian, A. A. & Murthy, S. C. 2013. Treatment of stage I and II non-small cell 
lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical 
practice guidelines. Chest, 143, e278S-313S. 
Holden, D.A., Rice, T.W., Stelmach, K. and Meeker, D.P., 1992. Exercise testing, 6-min walk, and stair climb in the evaluation of 
patients at high risk for pulmonary resection. Chest, 102(6), pp.1774-1779. 
Iwasaki, A., Shirakusa, T., Yoshinaga, Y., Enatsu, S. & Yamamoto, M. 2004. Evaluation of the treatment of non-small cell lung 
cancer with brain metastasis and the role of risk score as a survival predictor. Eur J Cardiothorac Surg, 26, 488- 93. 
Izbicki, J. R., Passlick, B., Karg, O., Bloechle, C., Pantel, K., Knoefel, W. T. & Thetter, O. 1995. Impact of radical systematic 
mediastinal lymphadenectomy on tumor staging in lung cancer. Ann Thorac Surg, 59, 209-14. 
Janes, S. M., Rahman, N. M., Davies, R. J. & Lee, Y. C. 2007. Catheter-tract metastases associated with chronic indwelling 
pleural catheters. Chest, 131, 1232-4.
Kakinuma, R., Ohmatsu, H., Kaneko, M., Kusumoto, M., Yoshida, J., Nagai, K., Nishiwaki, Y., Kobayashi, T., Tsuchiya, R., Nishiyama, 
H., Matsui, E., Eguchi, K. & Moriyama, N. 2004. Progression of focal pure ground-glass opacity detected by low-dose helical 
computed tomography screening for lung cancer. J Comput Assist Tomogr, 28, 17-23. 
Kozower, B. D., Larner, J. M., Detterbeck, F. C. & Jones, D. R. 2013. Special treatment issues in non-small cell lung cancer: 
Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice 
guidelines. Chest, 143, e369S-99S. Available: http://publications.chestnet.org/data/Journals/CHEST/926876/chest_143_5_
suppl_e369S.pdf?resultClick=1 
Kim, T. J., Goo, J. M., Lee, K. W., Park, C. M. & Lee, H. J. 2009. Clinical, pathological and thin-section CT features of persistent 
multiple ground-glass opacity nodules: comparison with solitary ground-glass opacity nodule. Lung Cancer, 64, 171-8. 
Lad, T., Piantadosi, S., Thomas, P., Payne, D., Ruckdeschel, J. & Giaccone, G. 1994. A prospective randomized trial to determine 
the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. 
Chest, 106, 320S-323S. 
Lee, J. G., Lee, C. Y., Kim, D. J., Chung, K. Y. & Park, I. K. 2008. Non-small cell lung cancer with ipsilateral pulmonary metastases: 
prognosis analysis and staging assessment. Eur J Cardiothorac Surg, 33, 480-4.
 
Lee, T. H., Marcantonio, E. R., Mangione, C. M., Thomas, E. J., Polanczyk, C. A., Cook, E. F., Sugarbaker, D. J., Donaldson, M. 
C., Poss, R., Ho, K. K., Ludwig, L. E., Pedan, A. & Goldman, L. 1999. Derivation and prospective validation of a simple index for 
prediction of cardiac risk of major noncardiac surgery. Circulation, 100, 1043-9. 
Light, R. W., Doelken, P. 2015. Diagnosis and management of pleural causes of unexpandable lung. In: UpToDate, Post TW (Ed), 
UpToDate, Waltham, MA. (Accessed on May 07, 2015) 
Lim, E., Ali, A., Cartwright, N., Sousa, I., Chetwynd, A., Polkey, M., Geddes, D., Pepper, J., Diggle, P. & Goldstraw, P. 2006. Effect 
and duration of lung volume reduction surgery: mid-term results of the Brompton trial. Thorac Cardiovasc Surg, 54, 188-92.
Lim, E., Baldwin, D., Beckles, M., Duffy, J., Entwisle, J., Faivre-Finn, C., Kerr, K., Macfie, A., McGuigan, J., Padley, S., Popat, S., 
Screaton, N., Snee, M., Waller, D., Warburton, C., Win, T., British Thoracic Society & Society for Cardiothoracic Surgery in Great 
Britain and Ireland. 2010. Guidelines on the radical management of patients with lung cancer. Thorax, 65 Suppl 3, iii1-27. 
Lim, E., Belcher, E., Yap, Y. K., Nicholson, A. G. & Goldstraw, P. 2008. The role of surgery in the treatment of limited disease 
small cell lung cancer: time to reevaluate. J Thorac Oncol, 3, 1267-71.
Loewen, G.M., Watson, D., Kohman, L., Herndon, J.E., Shennib, H., Kernstine, K., Olak, J., Mador, M.J., Harpole, D., Sugarbaker, 
D. and Green, M., 2007. Preoperative exercise VO 2 measurement for lung resection candidates: results of Cancer and 
Leukemia Group B Protocol 9238. J Thorac Oncol, 2(7), pp.619-625. 
Martini, N. & Melamed, M. R. 1975. Multiple primary lung cancers. J Thorac Cardiovasc Surg, 70, 606-12. 
202 | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
| A National Clinical Guideline
Modi, A., Vohra, H. A. & Weeden, D. F. 2009. Does surgery for primary non-small cell lung cancer and cerebral metastasis 
have any impact on survival? Interact Cardiovasc Thorac Surg, 8, 467-73. 
Morgan A.D.1989.Simple exercise testing. Respir Med, 83:383e7. 
Moazami, N., Rice, T. W., Rybicki, L. A., Adelstein, D. J., Murthy, S. C., Decamp, M. M., Barnett, G. H., Chidel, M. A., Suh, J. H. 
& Blackstone, E. H. 2002. Stage III non-small cell lung cancer and metachronous brain metastases. J Thorac Cardiovasc Surg, 
124, 113-22.
Mussi, A., Pistolesi, M., Lucchi, M., Janni, A., Chella, A., Parenti, G., Rossi, G. & Angeletti, C. A. 1996. Resection of single brain 
metastasis in non-small-cell lung cancer: prognostic factors. J Thorac Cardiovasc Surg, 112, 146-53. 
Nakata, M., Sawada, S., Yamashita, M., Saeki, H., Kurita, A., Takashima, S. & Tanemoto, K. 2004. Surgical treatments for multiple 
primary adenocarcinoma of the lung. Ann Thorac Surg, 78, 1194-9. 
Ng, C. S., Wan, S., Hui, C. W., Wan, I. Y., Lee, T. W., Underwood, M. J. & Yim, A. P. 2007. Video-assisted thoracic surgery 
lobectomy for lung cancer is associated with less immunochemokine disturbances than thoracotomy. Eur J Cardiothorac Surg, 
31, 83-7. 
Olsen, G. N., Bolton, J. W., Weiman, D. S. & Hornung, C. A. 1991. Stair climbing as an exercise test to predict the postoperative 
complications of lung resection. Two years’ experience. Chest, 99, 587-90.
Pagni, S., Federico, J. A. & Ponn, R. B. 1997. Pulmonary resection for lung cancer in octogenarians. Ann Thorac Surg, 63, 785-9. 
Park, J. H., Lee, K. S., Kim, J. H., Shim, Y. M., Kim, J., Choi, Y. S. & Yi, C. A. 2009. Malignant pure pulmonary ground-glass opacity 
nodules: prognostic implications. Korean J Radiol, 10, 12-20. 
Pastorino, U., Bellomi, M., Landoni, C., De Fiori, E., Arnaldi, P., Picchio, M., Pelosi, G., Boyle, P. & Fazio, F. 2003. Early lung-
cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet, 362, 593-7. 
Paul, S., Altorki, N. K., Sheng, S., Lee, P. C., Harpole, D. H., Onaitis, M. W., Stiles, B. M., Port, J. L. & D’amico, T. A. 2010. 
Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the 
STS database. J Thorac Cardiovasc Surg, 139, 366-78.
Penel, N., Brichet, A., Prevost, B., Duhamel, A., Assaker, R., Dubois, F. & Lafitte, J. J. 2001. Pronostic factors of synchronous 
brain metastases from lung cancer. Lung Cancer, 33, 143-54. 
Raz, D. J., Lanuti, M., Gaissert, H. C., Wright, C. D., Mathisen, D. J. & Wain, J. C. 2011. Outcomes of patients with isolated 
adrenal metastasis from non-small cell lung carcinoma. Ann Thorac Surg, 92, 1788-92; discussion 1793. 
Ribet, M. & Dambron, P. 1995. Multiple primary lung cancers. Eur J Cardiothorac Surg, 9, 231-6. 
Rosengart, T. K., Martini, N., Ghosn, P. & Burt, M. 1991. Multiple primary lung carcinomas: prognosis and treatment. Ann 
Thorac Surg, 52,773-8; discussion 778-9. 
Rusch, V. W., Asamura, H., Watanabe, H., Giroux, D. J., Rami-Porta, R., Goldstraw, P. & Committee, M. o. I. S. 2009. The IASLC 
lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM 
classification for lung cancer. J Thorac Oncol, 4, 568-77. 
Rusch, V. W., Crowley, J., Giroux, D. J., Goldstraw, P., Im, J. G., Tsuboi, M., Tsuchiya, R. & Vansteenkiste, J. 2007. The IASLC 
Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM 
classification for lung cancer. J Thorac Oncol, 2(7), 603-12.
Sabur, N. F., Chee, A., Stather, D. R., Maceachern, P., Amjadi, K., Hergott, C. A., Dumoulin, E., Gonzalez, A. V. & Tremblay, A. 
2013. The impact of tunneled pleural catheters on the quality of life of patients with malignant pleural effusions. Respiration, 
85, 36-42. 
Schreiber, D., Rineer, J., Weedon, J., Vongtama, D., Wortham, A., Kim, A., Han, P., Choi, K. & Rotman, M. 2010. Survival outcomes 
with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated? Cancer, 116, 1350-7. 
203| A National Clinical Guideline | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
Scottish Intercollegiate Guidelines Network (SIGN). 2014. Management of lung cancer – a national clinical guideline. Edinburgh: 
SIGN. (SIGN publication no. 137). [Cited 09 Jun 2015]. Available: www.sign.ac.uk 
Sharkey, A. A., P. Anikin, V. Belcher, E. Kendall, S. Lim, E. Naidu, B. Parry, Wyn. Loubani, M. 2015. Thoracoscore and European 
Society Objective Score Fail to Predict Mortality in the UK. World J Oncol, 6, 270-275..
 
Shaw, P. & Agarwal, R. 2004. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev, CD002916. 
Shepherd, F. A., Ginsberg, R. J., Patterson, G. A., Evans, W. K. & Feld, R. 1989. A prospective study of adjuvant surgical resection 
after chemotherapy for limited small cell lung cancer. A University of Toronto Lung Oncology Group study. J Thorac Cardiovasc 
Surg, 97,177-86. 
Shirakusa, T., Tsutsui, M., Iriki, N., Matsuba, K., Saito, T., Minoda, S., Iwasaki, T., Hirota, N. & Kuono, J. 1989. Results of resection 
for bronchogenic carcinoma in patients over the age of 80. Thorax, 44, 189-91. 
Singh, S.J., Morgan, M.D., Hardman, A.E., Rowe, C. and Bardsley, P.A., 1994. Comparison of oxygen uptake during a conventional 
treadmill test and the shuttle walking test in chronic airflow limitation. Eur Respir J, 7(11), pp.2016-2020. 
Sudharshan, S., Ferraris, V. A., Mullett, T. & Ramaiah, C. 2011. Effectiveness of tunneled pleural catheter placement in patients 
with malignant pleural effusions. Int J Angiol, 20, 39-42. 
Suzuki, K., Servais, E. L., Rizk, N. P., Solomon, S. B., Sima, C. S., Park, B. J., Kachala, S. S., Zlobinsky, M., Rusch, V. W. & Adusumilli, 
P. S. 2011. Palliation and pleurodesis in malignant pleural effusion: the role for tunneled pleural catheters. J Thorac Oncol, 6, 
762-7. 
Tanita, T., Tabata, T., Shibuya, J., Noda, M., Hoshikawa, Y., Ueda, S., Hasumi, T., Sakuma, T., Ashino, Y. & Ono, S. 1995. [Surgical 
treatment of lung cancer over 80 years of age: investigation from post operative complications]. Kyobu Geka, 48, 354-9. 
Thornton, R. H., Miller, Z., Covey, A. M., Brody, L., Sofocleous, C. T., Solomon, S. B. & Getrajdman, G. I. 2010. Tunneled pleural 
catheters for treatment of recurrent malignant pleural effusion following failed pleurodesis. J Vasc Interv Radiol, 21, 696-700. 
Travis, W. D., Garg, K., Franklin, W. A., Wistuba, I. I., Sabloff, B., Noguchi, M., Kakinuma, R., Zakowski, M., Ginsberg, M., Padera, 
R., Jacobson, F., Johnson, B. E., Hirsch, F., Brambilla, E., Flieder, D. B., Geisinger, K. R., Thunnisen, F., Kerr, K., Yankelevitz, D., 
Franks, T. J., Galvin, J. R., Henderson, D. W., Nicholson, A. G., Hasleton, P. S., Roggli, V., Tsao, M. S., Cappuzzo, F. & Vazquez, M. 
2005. Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar 
carcinoma. J Clin Oncol, 23, 3279-87.
Tremblay, A. & Michaud, G. 2006. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural 
effusion. Chest, 129, 362-8. 
Vallieres, E., Shepherd, F. A., Crowley, J., Van Houtte, P., Postmus, P. E., Carney, D., Chansky, K., Shaikh, Z. & Goldstraw, P. 2009. 
The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung 
cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol, 4, 1049-59. 
van Bodegom, P. C., Wagenaar, S. S., Corrin, B., Baak, J. P., Berkel, J. & Vanderschueren, R. G. 1989. Second primary lung cancer: 
importance of long term follow up. Thorax, 44, 788-93. 
Van Nostrand, D., Kjelsberg, M.O. and Humphrey, E.W., 1968. Preresectional evaluation of risk from pneumonectomy. Surg 
Gynecol Ostet, 127(2), pp.306-312. 
Watanabe, A., Koyanagi, T., Ohsawa, H., Mawatari, T., Nakashima, S., Takahashi, N., Sato, H. & Abe, T. 2005. Systematic node 
dissection by VATS is not inferior to that through an open thoracotomy: a comparative clinicopathologic retrospective study. 
Surgery, 138, 510-7. 
Weinmann, M., Jeremic, B., Toomes, H., Friedel, G. & Bamberg, M. 2003. Treatment of lung cancer in the elderly. Part I: non-
small cell lung cancer. Lung Cancer, 39, 233-53. 
Weksler, B., Nason, K. S., Shende, M., Landreneau, R. J. & Pennathur, A. 2012. Surgical resection should be considered for stage 
I and II small cell carcinoma of the lung. Ann Thorac Surg, 94, 889-93. 
204 | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
| A National Clinical Guideline
Whitson, B. A., Groth, S. S., Duval, S. J., Swanson, S. J. & Maddaus, M. A. 2008. Surgery for early-stage non-small cell lung 
cancer: a systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy. Ann 
Thorac Surg, 86(6), 2008-16.
Win, T., Jackson, A., Groves, A.M., Wells, F.C., Ritchie, A.J., Munday, H. and Laroche, C.M., 2004. Relationship of shuttle walk 
test and lung cancer surgical outcome. Eur J Cardiothorac Surg, 26(6), pp.1216-1219. 
Win, T., Jackson, A., Groves, A.M., Sharples, L.D., Charman, S.C. and Laroche, C.M., 2006. Comparison of shuttle walk with 
measured peak oxygen consumption in patients with operable lung cancer. Thorax, 61(1), pp.57-60. 
Wroński, M., Arbit, E., Burt, M. & Galicich, J. H. 1995. Survival after surgical treatment of brain metastases from lung cancer: a 
follow-up study of 231 patients treated between 1976 and 1991. J Neurosurg, 83, 605-16. 
Wu, Y., Huang, Z. F., Wang, S. Y., Yang, X. N. & Ou, W. 2002. A randomized trial of systematic nodal dissection in resectable non-
small cell lung cancer. Lung Cancer, 36, 1-6. 
Yang, X., Wang, S. & Qu, J. 2009. Video-assisted thoracic surgery (VATS) compares favorably with thoracotomy for the treatment 
of lung cancer: a five-year outcome comparison. World J Surg, 33, 1857-61.
Section 2.6: Medical Oncology 
Ahn, J. S., Ahn, Y. C., Kim, J. H., Lee, C. G., Cho, E. K., Lee, K. C., Chen, M., Kim, D. W., Kim, H. K., Min, Y. J., Kang, J. H., Choi, J. 
H., Kim, S. W., Zhu, G., Wu, Y. L., Kim, S. R., Lee, K. H., Song, H. S., Choi, Y. L., Sun, J. M., Jung, S. H., Ahn, M. J. & Park, K. 2015. 
Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After 
Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. J Clin Oncol, 33, 2660-6. 
Amarasena, I. U., Chatterjee, S., Walters, J. A., Wood-Baker, R. & Fong, K. M. 2015. Platinum versus non-platinum chemotherapy 
regimens for small cell lung cancer. Cochrane Database Syst Rev, Cd006849. 
Aupérin, A., Le Péchoux, C., Rolland, E., Curran, W. J., Furuse, K., Fournel, P., Belderbos, J., Clamon, G., Ulutin, H. C., Paulus, 
R., Yamanaka, T., Bozonnat, M. C., Uitterhoeve, A., Wang, X., Stewart, L., Arriagada, R., Burdett, S. & Pignon, J. P. 2010. Meta-
analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol, 28, 
2181-90. 
Barlesi, F., Scherpereel, A., Rittmeyer, A., Pazzola, A., Ferrer Tur, N., Kim, J. H., Ahn, M. J., Aerts, J. G., Gorbunova, V., Vikstrom, 
A., Wong, E. K., Perez-Moreno, P., Mitchell, L. & Groen, H. J. 2013. Randomized phase III trial of maintenance bevacizumab 
with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous 
non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol, 31, 3004-11.
Bezjak, A., Temin, S., Franklin, G., Giaccone, G., Govindan, R., Johnson, M. L., Rimner, A., Schneider, B. J., Strawn, J. & Azzoli, C. 
G. 2015. Definitive and Adjuvant Radiotherapy in Locally Advanced Non–Small-Cell Lung Cancer: American Society of Clinical 
Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical 
Practice Guideline. J Clin Oncol, 33, 2100-5.
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., Barlesi, 
F., Kohlhaufl, M., Arrieta, O., Burgio, M. A., Fayette, J., Lena, H., Poddubskaya, E., Gerber, D. E., Gettinger, S. N., Rudin, C. M., 
Rizvi, N., Crino, L., Blumenschein, G. R., Jr., Antonia, S. J., Dorange, C., Harbison, C. T., Graf Finckenstein, F. & Brahmer, J. R. 
2015. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med, 373, 1627-39. 
Botrel, T. E., Clark, O., Clark, L., Paladini, L., Faleiros, E. & Pegoretti, B. 2011. Efficacy of bevacizumab (Bev) plus chemotherapy 
(CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): 
systematic review and meta-analysis. Lung Cancer, 74, 89-97. 
Brahmer, J., Reckamp, K. L., Baas, P., Crino, L., Eberhardt, W. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, 
E., Waterhouse, D., Ready, N., Gainor, J., Aren Frontera, O., Havel, L., Steins, M., Garassino, M. C., Aerts, J. G., Domine, M., 
Paz-Ares, L., Reck, M., Baudelet, C., Harbison, C. T., Lestini, B. & Spigel, D. R. 2015. Nivolumab versus Docetaxel in Advanced 
Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med, 373, 123-35. 
Brierly, J. D., Gospodarowicz, M. K. & Wittekind, C. 2016. TNM Classification of Malignant Tumours, 8th Edition, Wiley-Blackwell. 
205| A National Clinical Guideline | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
Cao, C., Wang, J., Bunjhoo, H., Xu, Y. & Fang, H. 2012. Risk profile of bevacizumab in patients with non-small cell lung cancer: 
a meta-analysis of randomized controlled trials. Acta Oncol, 51, 151-6. 
Cappuzzo, F., Ciuleanu, T., Stelmakh, L., Cicenas, S., Szczésna, A., Juhász, E., Esteban, E., Molinier, O., Brugger, W., Melezínek, 
I., Klingelschmitt, G., Klughammer, B., Giaccone, G. & Investigators, S. 2010. Erlotinib as maintenance treatment in advanced 
non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol, 11, 521-9. 
Chen, Y. M., Tsai, C. M., Fan, W. C., Shih, J. F., Liu, S. H., Wu, C. H., Chou, T. Y., Lee, Y. C., Perng, R. P. & Whang-Peng, J. 2012. Phase 
II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or 
older. J Thorac Oncol, 7, 412-8. 
Ciuleanu, T., Brodowicz, T., Zielinski, C., Kim, J. H., Krzakowski, M., Laack, E., Wu, Y. L., Bover, I., Begbie, S., Tzekova, V., Cucevic, 
B., Pereira, J. R., Yang, S. H., Madhavan, J., Sugarman, K. P., Peterson, P., John, W. J., Krejcy, K. & Belani, C. P. 2009. Maintenance 
pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, 
double-blind, phase 3 study. Lancet, 374, 1432-40. 
Ciuleanu, T., Stelmakh, L., Cicenas, S., Miliauskas, S., Grigorescu, A. C., Hillenbach, C., Johannsdottir, H. K., Klughammer, B. & 
Gonzalez, E. E. 2012. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, 
non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol, 
13, 300-8. 
Delbaldo, C., Michiels, S., Rolland, E., Syz, N., Soria, J. C., Le Chevalier, T. & Pignon, J. P. 2007. Second or third additional 
chemotherapy drug for non-small cell lung cancer in patients with advanced disease. Cochrane Database Syst Rev, Cd004569. 
Di Maio, M., Chiodini, P., Georgoulias, V., Hatzidaki, D., Takeda, K., Wachters, F. M., Gebbia, V., Smit, E. F., Morabito, A., Gallo, 
C., Perrone, F. & Gridelli, C. 2009. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as 
second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol, 27, 1836-43. 
Garassino, M. C., Martelli, O., Broggini, M., Farina, G., Veronese, S., Rulli, E., Bianchi, F., Bettini, A., Longo, F., Moscetti, L., 
Tomirotti, M., Marabese, M., Ganzinelli, M., Lauricella, C., Labianca, R., Floriani, I., Giaccone, G., Torri, V., Scanni, A. & MarsonI, 
S. 2013. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-
type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol, 14, 981-8. 
Greenhalgh, J., Dwan, K., Boland, A., Bates, V., Vecchio, F., Dundar, Y., Jain, P. & Green, J. A. 2016. First-line treatment of 
advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane 
Database Syst Rev, Cd010383. 
Gronberg, B. H., Bremnes, R. M., Flotten, O., Amundsen, T., Brunsvig, P. F., Hjelde, H. H., Kaasa, S., Von Plessen, C., Stornes, 
F., Tollali, T., Wammer, F., Aasebo, U. & Sundstrom, S. 2009. Phase III study by the Norwegian lung cancer study group: 
pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-
cell lung cancer. J Clin Oncol, 27, 3217-24. 
Hanna, N., Bunn, P. A., Jr., Langer, C., Einhorn, L., Guthrie, T., Jr., Beck, T., Ansari, R., Ellis, P., Byrne, M., Morrison, M., Hariharan, 
S., Wang, B. & Sandler, A. 2006. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/ cisplatin in patients 
with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol, 24, 2038-43.
Hanna, N., Neubauer, M., Yiannoutsos, C., Mcgarry, R., Arseneau, J., Ansari, R., Reynolds, C., Govindan, R., Melnyk, A., Fisher, 
W., Richards, D., Bruetman, D., Anderson, T., Chowhan, N., Nattam, S., Mantravadi, P., Johnson, C., Breen, T., White, A., Einhorn, 
L., Group, H. O. & Oncology, U. 2008. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without 
consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. 
Oncology. J Clin Oncol, 26, 5755-60. 
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., Von Pawel, J., Gatzemeier, U., Tsao, T. C., Pless, M., 
Muller, T., Lim, H. L., Desch, C., Szondy, K., Gervais, R., Shaharyar, Manegold, C., Paul, S., Paoletti, P., EINHORN, L. & BUNN, P. 
A., JR. 2004. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously 
treated with chemotherapy. J Clin Oncol, 22, 1589-97. 
206 | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
| A National Clinical Guideline
Herbst, R. S., Baas, P., Kim, D. W., Felip, E., Perez-Gracia, J. L., Han, J. Y., Molina, J., Kim, J. H., Arvis, C. D., Ahn, M. J., Majem, 
M., Fidler, M. J., De Castro, G., Jr., Garrido, M., Lubiniecki, G. M., Shentu, Y., Im, E., Dolled-Filhart, M. & Garon, E. B. 2016. 
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): 
a randomised controlled trial. Lancet, 387, 1540-50. 
Herbst, R. S., O’Neill, V. J., Fehrenbacher, L., Belani, C. P., Bonomi, P. D., Hart, L., Melnyk, O., Ramies, D., Lin, M. & Sandler, A. 
2007. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with 
chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol, 25, 4743-50. 
Hermes, A., Bergman, B., Bremnes, R., Ek, L., Fluge, S., Sederholm, C., Sundstrom, S., Thaning, L., Vilsvik, J., Aasebo, U. & 
Sorenson, S. 2008. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a 
randomized phase III trial. J Clin Oncol, 26, 4261-7. 
Janne, P. A., Yang, J. C., Kim, D. W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M. J., Kim, S. W., Su, W. C., Horn, L., 
Haggstrom, D., Felip, E., Kim, J. H., Frewer, P., Cantarini, M., Brown, K. H., Dickinson, P. A., Ghiorghiu, S. & Ranson, M. 2015. 
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med, 372, 1689-99. 
Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., Devore, R. F., 
Gaudreault, J., Damico, L. A., Holmgren, E. & Kabbinavar, F. 2004. Randomized phase II trial comparing bevacizumab plus 
carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-
small-cell lung cancer. J Clin Oncol, 22, 2184-91. 
Kawaguchi, T., Ando, M., Asami, K., Okano, Y., Fukuda, M., Nakagawa, H., Ibata, H., Kozuki, T., Endo, T., Tamura, A., Kamimura, 
M., Sakamoto, K., Yoshimi, M., Soejima, Y., Tomizawa, Y., Isa, S., Takada, M., Saka, H. & Kubo, A. 2014. Randomized phase 
III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: 
Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol, 32, 1902-8. 
Kelly, K., Chansky, K., Gaspar, L. E., Albain, K. S., Jett, J., Ung, Y. C., Lau, D. H., Crowley, J. J. & Gandara, D. R. 2008. Phase III trial 
of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III 
non-small-cell lung cancer: SWOG S0023. J Clin Oncol, 26, 2450-6. 
Kim, D. W., Mehra, R., Tan, D. S., Felip, E., Chow, L. Q., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., Riely, G. J., 
Solomon, B. J., Wolf, J., Thomas, M., Schuler, M., Liu, G., Santoro, A., Sutradhar, S., Li, S., Szczudlo, T., Yovine, A. & Shaw, A. T. 
2016. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results 
from the multicentre, open-label, phase 1 trial. Lancet Oncol, 17, 452-63. 
Kulkarni, S., Vella, E., Coakley, N., Cheng, S., Gregg, R., Ung, Y. & Ellis, P. 2015. The use of systemic treatment in the maintenance 
of patients with non small cell lung cancer. Toronto (ON): Cancer Care Ontario, Program in Evidence-based Care Evidence-
based Series. 
Lara, P. N., Jr., Natale, R., Crowley, J., Lenz, H. J., Redman, M. W., Carleton, J. E., Jett, J., Langer, C. J., Kuebler, J. P., Dakhil, S. R., 
Chansky, K. & Gandara, D. R. 2009. Phase III trial of irinotecan/cisplatin compared with etoposide/ cisplatin in extensive-stage 
small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol, 27, 2530-5. 
Lima, A. B., Macedo, L. T. & Sasse, A. D. 2011. Addition of bevacizumab to chemotherapy in advanced non-small cell lung 
cancer: a systematic review and meta-analysis. PLoS One, 6, e22681. 
Mok, T. S., Wu, Y. L., Ahn, M. J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, 
W. S., Lee, C. K., Sebastian, M., Templeton, A., Mann, H., Marotti, M., Ghiorghiu, S., Papadimitrakopoulou, V. A. & Investigators, 
A. 2017. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med, 376, 629-640.
Miller, V. A., Hirsh, V., Cadranel, J., Chen, Y. M., Park, K., Kim, S. W., Zhou, C., Su, W. C., Wang, M., Sun, Y., Heo, D. S., Crino, L., Tan, 
E. H., Chao, T. Y., Shahidi, M., Cong, X. J., Lorence, R. M. & Yang, J. C. 2012. Afatinib versus placebo for patients with advanced, 
metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-
Lung 1): a phase 2b/3 randomised trial. Lancet Oncol, 13, 528-38. 
National Comprehensive Cancer Network (NCCN). V8 2017. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) 
– Non-Small Cell Lung Cancer. Accessed [September  20, 2017]. 
207| A National Clinical Guideline | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
National Institute for Health and Care Excellence (NICE). 2011. CG 121: Lung cancer: The diagnosis and treatment of lung 
cancer. London: National Institute for Health and Care Excellence (NICE).
Niho, S., Kunitoh, H., Nokihara, H., Horai, T., Ichinose, Y., Hida, T., Yamamoto, N., Kawahara, M., Shinkai, T., Nakagawa, K., 
Matsui, K., Negoro, S., Yokoyama, A., Kudoh, S., Kiura, K., Mori, K., Okamoto, H., Sakai, H., Takeda, K., Yokota, S., Saijo, N. & 
Fukuoka, M. 2012. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese 
patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer, 76, 362-7. 
Noda, K., Nishiwaki, Y., Kawahara, M., Negoro, S., Sugiura, T., Yokoyama, A., Fukuoka, M., Mori, K., Watanabe, K., Tamura, T., 
Yamamoto, S. & Saijo, N. 2002. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung 
cancer. N Engl J Med, 346, 85-91. 
NSCLC Collaborative Group 2010. Chemotherapy and supportive care versus supportive care alone for advanced non-small cell 
lung cancer. Cochrane Database Syst Rev, Cd007309. 
NSCLC Meta-Analysis Collaborative Group 2014. Preoperative chemotherapy for non-small-cell lung cancer: a systematic 
review and meta-analysis of individual participant data. Lancet, 383, 1561-71. 
O’Brien, M. E., Ciuleanu, T. E., Tsekov, H., Shparyk, Y., Cucevia, B., Juhasz, G., Thatcher, N., Ross, G. A., Dane, G. C. & Crofts, T. 
2006. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-
cell lung cancer. J Clin Oncol, 24, 5441-7. 
O’Rourke, N., Roqué I Figuls, M., Farré Bernadó, N. & Macbeth, F. 2010. Concurrent chemoradiotherapy in non-small cell lung 
cancer. Cochrane Database Syst Rev, CD002140.
Ou, S. H., Ahn, J. S., De Petris, L., Govindan, R., Yang, J. C., Hughes, B., Lena, H., Moro-Sibilot, D., Bearz, A., Ramirez, S. V., 
Mekhail, T., Spira, A., Bordogna, W., Balas, B., Morcos, P. N., Monnet, A., Zeaiter, A. & Kim, D. W. 2016. Alectinib in Crizotinib-
Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. J Clin Oncol, 34, 661-8. 
Paz-Ares, L., De Marinis, F., Dediu, M., Thomas, M., Pujol, J. L., Bidoli, P., Molinier, O., Sahoo, T. P., Laack, E., Reck, M., Corral, 
J., Melemed, S., John, W., Chouaki, N., Zimmermann, A. H., Visseren-Grul, C. & Gridelli, C. 2012. Maintenance therapy with 
pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed 
plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised 
controlled trial. Lancet Oncol, 13, 247-55. 
Paz-Ares, L. G., De Marinis, F., Dediu, M., Thomas, M., Pujol, J. L., Bidoli, P., Molinier, O., Sahoo, T. P., Laack, E., Reck, M., Corral, 
J., Melemed, S., John, W., Chouaki, N., Zimmermann, A. H., Visseren-Grul, C. & Gridelli, C. 2013. PARAMOUNT: Final overall 
survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with 
pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol, 31, 2895-902.
 
Pilkington, G., Boland, A., Brown, T., Oyee, J., Bagust, A. & Dickson, R. 2015. A systematic review of the clinical effectiveness of 
first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer. Thorax, 70, 359-67. 
Reck, M., Von Pawel, J., Fischer, J. R., Kortsik, C., Bohnet, S., Von Eiff, M., Koester, W., Thomas, M., Schnabel, P. & Deppermann, 
K. M. Erlotinib versus carboplatin/vinorelbine in elderly patients (age 70 or older) with advanced non-small cell lung carcinoma 
(NSCLC): A randomized phase II study of the German Thoracic Oncology Working Group. J Clin Oncol, 28(15_suppl), pp.7565-
7565.
Reck, M., Von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N. & 
Manegold, C. 2009. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for 
nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol, 27, 1227-34. 
Rittmeyer, A., Gorbunova, V., Vikstrom, A., Scherpereel, A., Kim, J. H., Ahn, M. J., Chella, A., Chouaid, C., Campbell, A. K. & 
Barlesi, F. 2013. Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving 
bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089). J Thorac Oncol, 8, 1409-16. 
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R. & Johnson, D. H. 2006. Paclitaxel-
carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med, 355, 2542-50. 
208 | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
| A National Clinical Guideline
Santos, F. N., De Castria, T. B., Cruz, M. R. & Riera, R. 2015. Chemotherapy for advanced non-small cell lung cancer in the 
elderly population. Cochrane Database Syst Rev, Cd010463.
Scagliotti, G. V., Parikh, P., Von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, 
R., Zukin, M., Lee, J. S., Mellemgaard, A., Park, K., Patil, S., Rolski, J., Goksel, T., De Marinis, F., Simms, L., Sugarman, K. P. & 
Gandara, D. 2008. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive 
patients with advanced-stage non-small-cell lung cancer. J Clin Oncol, 26, 3543-51. 
Scagliotti, G. V., Park, K., Patil, S., Rolski, J., Goksel, T., Martins, R., Gans, S. J., Visseren-Grul, C. & Peterson, P. 2009. Survival 
without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-
small cell lung cancer: a risk-benefit analysis of a large phase III study. Eur J Cancer, 45, 2298-303. 
Scottish Intercollegiate Guidelines Network (SIGN). 2014. Management of lung cancer – a national clinical guideline. Edinburgh: 
SIGN. (SIGN publication no. 137).[Cited 09 Jun 2015]. Available: www.sign.ac.uk
Shaw, A. T., Gandhi, L., Gadgeel, S., Riely, G. J., Cetnar, J., West, H., Camidge, D. R., Socinski, M. A., Chiappori, A., Mekhail, T., 
Chao, B. H., Borghaei, H., Gold, K. A., Zeaiter, A., Bordogna, W., Balas, B., Puig, O., Henschel, V. & Ou, S. H. 2016. Alectinib in 
ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol, 17, 234-
42. 
Shaw, A. T., Kim, D. W., Mehra, R., Tan, D. S., Felip, E., Chow, L. Q., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., Riely, 
G. J., Solomon, B. J., Wolf, J., Thomas, M., Schuler, M., Liu, G., Santoro, A., Lau, Y. Y., Goldwasser, M., Boral, A. L. & Engelman, 
J. A. 2014. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med, 370, 1189-97. 
Shaw, A. T., Kim, D. W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M. J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., Wu, Y. L., 
Thomas, M., O’byrne, K. J., Moro-Sibilot, D., Camidge, D. R., Mok, T., Hirsh, V., Riely, G. J., Iyer, S., Tassell, V., Polli, A., Wilner, 
K. D. & Jänne, P. A. 2013. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med, 368, 2385-94. 
Shepherd, F. A., Dancey, J., Ramlau, R., Mattson, K., Gralla, R., O’Rourke, M., Levitan, N., Gressot, L., Vincent, M., Burkes, R., 
Coughlin, S., Kim, Y. & Berille, J. 2000. Prospective randomized trial of docetaxel versus best supportive care in patients with 
non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 18, 2095-103. 
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., 
Smylie, M., Martins, R., Van Kooten, M., Dediu, M., Findlay, B., Tu, D., Johnston, D., Bezjak, A., Clark, G., Santabarbara, P. & 
Seymour, L. 2005. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 353, 123-32. 
Solomon, B. J., Mok, T., Kim, D. W., Wu, Y. L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., Iyer, S., 
Reisman, A., Wilner, K. D., Tursi, J. & Blackhall, F. 2014. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N 
Engl J Med, 371, 2167-77. 
Soria, J. C., Felip, E., Cobo, M., Lu, S., Syrigos, K., Lee, K. H., Goker, E., Georgoulias, V., Li, W., Isla, D., Guclu, S. Z., Morabito, 
A., Min, Y. J., Ardizzoni, A., Gadgeel, S. M., Wang, B., Chand, V. K. & Goss, G. D. 2015. Afatinib versus erlotinib as second-line 
treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled 
phase 3 trial. Lancet Oncol, 16, 897-907. 
Soria, J. C., Mauguen, A., Reck, M., Sandler, A. B., Saijo, N., Johnson, D. H., Burcoveanu, D., Fukuoka, M., Besse, B., Pignon, J. P. 
& Group, M.-A. O. B. I. A. N. C. 2013. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab 
to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol, 24, 
20-30. 
Vokes, E. E., Herndon, J. E., Kelley, M. J., Cicchetti, M. G., Ramnath, N., Neill, H., Atkins, J. N., Watson, D. M., Akerley, W., Green, 
M. R. & B, C. A. L. G. 2007. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy 
alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol, 
25, 1698-704. 
von Pawel, J., Jotte, R., Spigel, D. R., O’brien, M. E., Socinski, M. A., Mezger, J., Steins, M., Bosquée, L., Bubis, J., Nackaerts, 
K., Trigo, J. M., Clingan, P., Schütte, W., Lorigan, P., Reck, M., Domine, M., Shepherd, F. A., Li, S. & Renschler, M. F. 2014. 
Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J 
Clin Oncol, 32, 4012-9. 
209| A National Clinical Guideline | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
Zhou, H., Zeng, C., Wei, Y., Zhou, J. & Yao, W. 2013. Duration of chemotherapy for small cell lung cancer: a meta-analysis. PLoS 
One, 8, e73805.
Zukin, M., Barrios, C. H., Pereira, J. R., Ribeiro, R. E. A., Beato, C. A., Do Nascimento, Y. N., Murad, A., Franke, F. A., Precivale, 
M., Araujo, L. H., Baldotto, C. S., Vieira, F. M., Small, I. A., Ferreira, C. G. & Lilenbaum, R. C. 2013. Randomized phase III trial of 
single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern 
Cooperative Oncology Group performance status of 2. J Clin Oncol, 31, 2849-53.
Section 2.7 Radiation Oncology
Ambrogi, M. C., Fanucchi, O., Dini, P., Melfi, F., Davini, F., Lucchi, M., Massimetti, G. & Mussi, A. 2015. Wedge resection and 
radiofrequency ablation for stage I nonsmall cell lung cancer. Eur Respir J, 45, 1089-97. 
Arriagada, R., Bergman, B., Dunant, A., Le Chevalier, T., Pignon, J. P. & Vansteenkiste, J. 2004. Cisplatin-based adjuvant 
chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med, 350, 351-60. 
Aupérin, A., Le Péchoux, C., Rolland, E., Curran, W. J., Furuse, K., Fournel, P., Belderbos, J., Clamon, G., Ulutin, H. C., Paulus, 
R., Yamanaka, T., Bozonnat, M. C., Uitterhoeve, A., Wang, X., Stewart, L., Arriagada, R., Burdett, S. & Pignon, J. P. 2010. Meta-
analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol, 28, 
2181-90. 
Belani, C. P., Wang, W., Johnson, D. H., Wagner, H., Schiller, J., Veeder, M., Mehta, M. & Group, E. C. O. 2005. Phase III study 
of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic 
radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell 
lung cancer. J Clin Oncol, 23, 3760-7. 
Belderbos, J., Heemsbergen, W., Hoogeman, M., Pengel, K., Rossi, M. & Lebesque, J. 2005. Acute esophageal toxicity in non-
small cell lung cancer patients after high dose conformal radiotherapy. Radiother Oncol, 75, 157-64. 
Bogart, J. A. & Aronowitz, J. N. 2005. Localized non-small cell lung cancer: adjuvant radiotherapy in the era of effective systemic 
therapy. Clin Cancer Res, 11, 5004s-5010s. 
Brierly, J. D., Gospodarowicz, M. K. & Wittekind, C. 2016. TNM Classification of Malignant Tumours, 8th Edition, Wiley-Blackwell. 
Cole, A. J., O’Hare, J. M., McMahon, S. J., McGarry, C. K., Butterworth, K. T., McAleese, J., Jain, S., Hounsell, A. R., Prise, K. M., 
Hanna, G. G. & O’Sullivan, J. M. 2014. Investigating the potential impact of four-dimensional computed tomography (4DCT) on 
toxicity, outcomes and dose escalation for radical lung cancer radiotherapy. Clin Oncol (R Coll Radiol), 26, 142-50. 
Crabtree, T. D., Denlinger, C. E., Meyers, B. F., El Naqa, I., Zoole, J., Krupnick, A. S., Kreisel, D., Patterson, G. A. & Bradley, J. D. 
2010. Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. J Thorac Cardiovasc 
Surg, 140, 377-86. 
De Ruysscher, D., van Baardwijk, A., Steevens, J., Botterweck, A., Bosmans, G., Reymen, B., Wanders, R., Borger, J., Dingemans, 
A. M., Bootsma, G., Pitz, C., Lunde, R., Geraedts, W., Oellers, M., Dekker, A. & Lambin, P. 2012. Individualised isotoxic 
accelerated radiotherapy and chemotherapy are associated with improved long-term survival of patients with stage III NSCLC: 
a prospective population-based study. Radiother Oncol, 102, 228-33. 
Douillard, J. Y., Rosell, R., De Lena, M., Carpagnano, F., Ramlau, R., Gonzales-Larriba, J. L., Grodzki, T., Pereira, J. R., Le Groumellec, 
A., Lorusso, V., Clary, C., Torres, A. J., Dahabreh, J., Souquet, P. J., Astudillo, J., Fournel, P., Artal-Cortes, A., Jassem, J., Koubkova, 
L., His, P., Riggi, M. & Hurteloup, P. 2006. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely 
resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised 
controlled trial. Lancet Oncol, 7, 719-27. 
Fay, M., Tan, A., Fisher, R., Mac Manus, M., Wirth, A. & Ball, D. 2005. Dose-volume histogram analysis as predictor of radiation 
pneumonitis in primary lung cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys, 61, 1355-63. 
Fried, D. B., Morris, D. E., Poole, C., Rosenman, J. G., Halle, J. S., Detterbeck, F. C., Hensing, T. A. & Socinski, M. A. 2004. 
Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-
cell lung cancer. J Clin Oncol, 22, 4837-45. 
210 | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
| A National Clinical Guideline
Gandara, D. R., Chansky, K., Albain, K. S., Leigh, B. R., Gaspar, L. E., Lara, P. N., Jr., Burris, H., Gumerlock, P., Kuebler, J. P., 
Bearden, J. D., 3rd, Crowley, J. & Livingston, R. 2003. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB 
non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol, 21, 2004-10. 
Gebitekin, C., Gupta, N. K., Satur, C. M., Olgac, G., Martin, P. G., Saunders, N. R. & Walker, D. R. 1994. Fate of patients with 
residual tumour at the bronchial resection margin. Eur J Cardiothorac Surg, 8, 339-42; discussion 342-4. 
Ghiribelli, C., Voltolini, L., Paladini, P., Luzzi, L., Di Bisceglie, M. & Gotti, G. 1999. Treatment and survival after lung resection 
for non-small cell lung cancer in patients with microscopic residual disease at the bronchial stump. Eur J Cardiothorac Surg, 
16, 555-9. 
Graham, M. V., Purdy, J. A., Emami, B., Harms, W., Bosch, W., Lockett, M. A. & Perez, C. A. 1999. Clinical dose-volume histogram 
analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys, 45, 323-9.
Grills, I. S., Mangona, V. S., Welsh, R., Chmielewski, G., McInerney, E., Martin, S., Wloch, J., Ye, H. & Kestin, L. L. 2010. Outcomes 
after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol, 28, 928-35. 
Haasbeek, C. J., Palma, D., Visser, O., Lagerwaard, F. J., Slotman, B. & Senan, S. 2012. Early-stage lung cancer in elderly patients: 
a population-based study of changes in treatment patterns and survival in the Netherlands. Ann Oncol, 23, 2743-7.
Heikkila, L., Harjula, A., Suomalainen, R. J., Mattila, P. & Mattila, S. 1986. Residual carcinoma in bronchial resection line. Ann 
Chir Gynaecol, 75, 151-4.
Huncharek, M. & McGarry, R. 2004. A meta-analysis of the timing of chest irradiation in the combined modality treatment of 
limited-stage small cell lung cancer. Oncologist, 9, 665-72. 
Jassem, J. 2007. The role of radiotherapy in lung cancer: where is the evidence? Radiother Oncol, 83, 203-13. 
Jeremic, B., Shibamoto, Y., Nikolic, N., Milicic, B., Milisavljevic, S., Dagovic, A., Aleksandrovic, J. & Radosavljevic-Asic, G. 1999. 
Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A 
randomized study. J Clin Oncol, 17, 2092-9.
Kimura, H. & Yamaguchi, Y. 1994. Survival of noncuratively resected lung cancer. Lung Cancer, 11, 229-42. 
Kong, F. M., Ten Haken, R., Eisbruch, A. & Lawrence, T. S. 2005. Non-small cell lung cancer therapy-related pulmonary toxicity: 
an update on radiation pneumonitis and fibrosis. Semin Oncol, 32, S42-54. 
Kwa, S. L., Lebesque, J. V., Theuws, J. C., Marks, L. B., Munley, M. T., Bentel, G., Oetzel, D., Spahn, U., Graham, M. V., Drzymala, 
R. E., Purdy, J. A., Lichter, A. S., Martel, M. K. & Ten Haken, R. K. 1998. Radiation pneumonitis as a function of mean lung dose: 
an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys, 42, 1-9. 
Le Pechoux, C., Dunant, A., Senan, S., Wolfson, A., Quoix, E., Faivre-Finn, C., Ciuleanu, T., Arriagada, R., Jones, R., Wanders, 
R., Lerouge, D. & Laplanche, A. 2009. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with 
limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 
22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol, 10, 467-74. 
Liao, Z. X., Komaki, R. R., Thames, H. D., Jr., Liu, H. H., Tucker, S. L., Mohan, R., Martel, M. K., Wei, X., Yang, K., Kim, E. S., 
Blumenschein, G., Hong, W. K. & Cox, J. D. 2010. Influence of technologic advances on outcomes in patients with unresectable, 
locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys, 76, 775-
81. 
Liewald, F., Hatz, R. A., Dienemann, H. & Sunder-Plassmann, L. 1992. Importance of microscopic residual disease at the 
bronchial margin after resection for non-small-cell carcinoma of the lung. J Thorac Cardiovasc Surg, 104, 408-412. 
Lim, E., Baldwin, D., Beckles, M., Duffy, J., Entwisle, J., Faivre-Finn, C., Kerr, K., Macfie, A., McGuigan, J., Padley, S., Popat, S., 
Screaton, N., Snee, M., Waller, D., Warburton, C., Win, T., British Thoracic Society & Society for Cardiothoracic Surgery in Great 
Britain and Ireland. 2010. Guidelines on the radical management of patients with lung cancer. Thorax, 65 Suppl 3, iii1-27. 
211| A National Clinical Guideline | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
Lu, H., Fang, L., Wang, X., Cai, J. & Mao, W. 2014. A meta-analysis of randomized controlled trials comparing early and late 
concurrent thoracic radiotherapy with etoposide and cisplatin/carboplatin chemotherapy for limited-disease small-cell lung 
cancer. Mol Clin Oncol, 2, 805-810. 
Lung Cancer Disease Site Group (LCDSG). 2000. Altered fractionation of radical radiation therapy in the management of 
unresectable non-smallcell lung cancer. Ontario: Cancer Care Ontario Practice Guidelines Initiative 
Machtay, M., Bae, K., Movsas, B., Paulus, R., Gore, E. M., Komaki, R., Albain, K., Sause, W. T. & Curran, W. J. 2012. Higher 
biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung 
carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys, 
82,425-34. 
Marks, L. B., Bentzen, S. M., Deasy, J. O., Kong, F. M., Bradley, J. D., Vogelius, I. S., El Naqa, I., Hubbs, J. L., Lebesque, J. V., 
Timmerman, R. D., Martel, M. K. & Jackson, A. 2010. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys, 
76,S70-6.
 
Massard, G., Doddoli, C., Gasser, B., Ducrocq, X., Kessler, R., Schumacher, C., Jung, G. M. & Wihlm, J. M. 2000. Prognostic 
implications of a positive bronchial resection margin. Eur J Cardiothorac Surg, 17, 557-65. 
Mauguen, A., Le Pechoux, C., Saunders, M. I., Schild, S. E., Turrisi, A. T., Baumann, M., Sause, W. T., Ball, D., Belani, C. P., 
Bonner, J. A., Zajusz, A., Dahlberg, S. E., Nankivell, M., Mandrekar, S. J., Paulus, R., Behrendt, K., Koch, R., Bishop, J. F., Dische, 
S., Arriagada, R., De Ruysscher, D. & Pignon, J. P. 2012. Hyperfractionated or accelerated radiotherapy in lung cancer: an 
individual patient data meta-analysis. J Clin Oncol, 30, 2788-97. 
Milano, M. T., Constine, L. S. & Okunieff, P. 2007. Normal tissue tolerance dose metrics for radiation therapy of major organs. 
Semin Radiat Oncol, 17, 131-40.
National Institute for Health and Care Excellence (NICE). 2011. CG 121: Lung cancer: The diagnosis and treatment of lung 
cancer. London: National Institute for Health and Care Excellence (NICE). 
Palma, D. A., Warner, A., Louie, A. V., Senan, S., Slotman, B. & Rodrigues, G. B. 2016. Thoracic Radiotherapy for Extensive Stage 
Small-Cell Lung Cancer: A Meta-Analysis. Clin Lung Cancer, 17, 239-44.
Palma, D., Lagerwaard, F., Rodrigues, G., Haasbeek, C. & Senan, S. 2012. Curative treatment of Stage I non-small-cell lung 
cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review. Int J Radiat Oncol Biol Phys, 
82, 1149-56. 
Patel, S., Macdonald, O. K. & Suntharalingam, M. 2009. Evaluation of the use of prophylactic cranial irradiation in small cell 
lung cancer. Cancer, 115, 842-50. 
Pignon, J. P., Arriagada, R., Ihde, D. C., Johnson, D. H., Perry, M. C., Souhami, R. L., Brodin, O., Joss, R. A., Kies, M. S. & Lebeau, 
B. 1992. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med, 327, 1618-24. 
Pijls-Johannesma, M. C., De Ruysscher, D., Lambin, P., Rutten, I. & Vansteenkiste, J. F. 2005. Early versus late chest radiotherapy 
for limited stage small cell lung cancer. Cochrane Database Syst Rev, CD004700. 
PORT Meta-analysis Trialists Group. 1998. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and 
meta-analysis of individual patient data from nine randomised controlled trials. Lancet, 352, 257-63. 
Qiao, X., Tullgren, O., Lax, I., Sirzen, F. & Lewensohn, R. 2003. The role of radiotherapy in treatment of stage I non-small cell 
lung cancer. Lung Cancer, 41, 1-11. 
Roach, M., 3rd, Gandara, D. R., Yuo, H. S., Swift, P. S., Kroll, S., Shrieve, D. C., Wara, W. M., Margolis, L. & Phillips, T. L. 1995. 
Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol, 13, 
2606-12. 
Rowell, N. P. & Williams, C. J. 2004. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit 
for or declining surgery (medically inoperable). Cochrane Database Syst Rev, Cd002935. 
212 | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
| A National Clinical Guideline
Saunders, M., Dische, S., Barrett, A., Harvey, A., Gibson, D. & Parmar, M. 1997. Continuous hyperfractionated accelerated 
radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART 
Steering Committee. Lancet, 350,161-5.
Saunders, M., Dische, S., Barrett, A., Harvey, A., Griffiths, G. & Palmar, M. 1999. Continuous, hyperfractionated, accelerated 
radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised 
multicentre trial. CHART Steering committee. Radiother Oncol, 52, 137-48. 
Sause, W., Kolesar, P., Taylor S, I. V., Johnson, D., Livingston, R., Komaki, R., Emami, B., Curran, W., Byhardt, R., Dar, A. R. 
& Turrisi, A. 2000. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation 
Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest, 117, 358-64. 
Scagliotti, G. V., Fossati, R., Torri, V., Crino, L., Giaccone, G., Silvano, G., Martelli, M., Clerici, M., Cognetti, F. & Tonato, M. 2003. 
Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl 
Cancer Inst, 95, 1453-61. 
Schultheiss, T. E., Kun, L. E., Ang, K. K. & Stephens, L. C. 1995. Radiation response of the central nervous system. Int J Radiat 
Oncol Biol Phys, 31, 1093-112. 
Scottish Intercollegiate Guidelines Network (SIGN). 2014. Management of lung cancer – a national clinical guideline. Edinburgh: 
SIGN. (SIGN publication no. 137).[Cited 09 Jun 2015]. Available: www.sign.ac.uk 
Senan, S., De Ruysscher, D., Giraud, P., Mirimanoff, R. & Budach, V. 2004. Literature-based recommendations for treatment 
planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol, 71, 139-46. 
Senthi, S., Haasbeek, C. J., Slotman, B. J. & Senan, S. 2013. Outcomes of stereotactic ablative radiotherapy for central lung 
tumours: a systematic review. Radiother Oncol, 106, 276-82. 
Senthi, S., Lagerwaard, F. J., Haasbeek, C. J., Slotman, B. J. & Senan, S. 2012. Patterns of disease recurrence after stereotactic 
ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol, 13, 802-9. 
Slotman, B., Faivre-Finn, C., Kramer, G., Rankin, E., Snee, M., Hatton, M., Postmus, P., Collette, L., Musat, E. & Senan, S. 2007. 
Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med, 357, 664-72. 
Slotman, B. J., Mauer, M. E., Bottomley, A., Faivre-Finn, C., Kramer, G. W., Rankin, E. M., Snee, M., Hatton, M., Postmus, P. E., 
Collette, L. & Senan, S. 2009. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-
related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the 
EORTC Radiation Oncology and Lung Cancer Groups. J Clin Oncol, 27, 78-84.
Slotman, B. J., van Tinteren, H., Praag, J. O., Knegjens, J. L., El Sharouni, S. Y., Hatton, M., Keijser, A., Faivre-Finn, C. & Senan, S. 
2015. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet, 
385, 36-42. 
Snijder, R. J., Brutel de la Riviere, A., Elbers, H. J. & van den Bosch, J. M. 1998. Survival in resected stage I lung cancer with 
residual tumor at the bronchial resection margin. Ann Thorac Surg, 65, 212-6. 
Spiro, S. G., James, L. E., Rudd, R. M., Trask, C. W., Tobias, J. S., Snee, M., Gilligan, D., Murray, P. A., Ruiz de Elvira, M. C., 
O’Donnell, K. M., Gower, N. H., Harper, P. G., Hackshaw, A. K. & Group, L. L. C. 2006. Early compared with late radiotherapy in 
combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized 
clinical trial and meta-analysis. J Clin Oncol, 24, 3823-30. 
Trodella, L., Granone, P., Valente, S., Valentini, V., Balducci, M., Mantini, G., Turriziani, A., Margaritora, S., Cesario, A., Ramella, 
S., Corbo, G. M., D’Angelillo, R. M., Fontana, A., Galetta, D. & Cellini, N. 2002. Adjuvant radiotherapy in non-small cell lung 
cancer with pathological stage I: definitive results of a phase III randomized trial. Radiother Oncol, 62, 11-9. 
van Baardwijk, A., Bosmans, G., Bentzen, S. M., Boersma, L., Dekker, A., Wanders, R., Wouters, B. G., Lambin, P. & De Ruysscher, 
D. 2008a. Radiation dose prescription for non-small-cell lung cancer according to normal tissue dose constraints: an in silico 
clinical trial. Int J Radiat Oncol Biol Phys, 71, 1103-10. 
213| A National Clinical Guideline | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
van Baardwijk, A., Bosmans, G., Boersma, L., Wanders, S., Dekker, A., Dingemans, A. M., Bootsma, G., Geraedts, W., Pitz, C., 
Simons, J., Lambin, P. & De Ruysscher, D. 2008b. Individualized radical radiotherapy of non-small-cell lung cancer based on 
normal tissue dose constraints: a feasibility study. Int J Radiat Oncol Biol Phys, 71, 1394-401. 
Vansteenkiste, J., De Ruysscher, D., Eberhardt, W. E., Lim, E., Senan, S., Felip, E., Peters, S. & Group, E. G. W. 2013. Early and 
locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 
Ann Oncol, 24 Suppl 6, vi89-98. 
Wang, J. Y., Chen, K. Y., Wang, J. T., Chen, J. H., Lin, J. W., Wang, H. C., Lee, L. N. & Yang, P. C. 2002. Outcome and prognostic 
factors for patients with non-small-cell lung cancer and severe radiation pneumonitis. Int J Radiat Oncol Biol Phys, 54, 735-41. 
Wind, J., Smit, E. J., Senan, S. & Eerenberg, J. P. 2007. Residual disease at the bronchial stump after curative resection for lung 
cancer. Eur J Cardiothorac Surg, 32, 29-34.
Section 2.8: Palliative Care 
Brierly, J. D., Gospodarowicz, M. K. & Wittekind, C. 2016. TNM Classification of Malignant Tumours, 8th Edition, Wiley-Blackwell. 
Department of Health (DoH). 2001. Report of the National Advisory Committee on Palliative Care. Available:http://health.gov.
ie/blog/publications/report-of-the-national-advisory-committee-on-palliative-care/ 
Smith, T. J., Temin, S., Alesi, E. R., Abernethy, A. P., Balboni, T. A., Basch, E. M., Ferrell, B. R., Loscalzo, M., Meier, D. E., Paice, 
J. A., Peppercorn, J. M., Somerfield, M., Stovall, E. & Von Roenn, J. H. 2012. American Society of Clinical Oncology provisional 
clinical opinion: the integration of palliative care into standard oncology care. J Clin Oncol, 30, 880-7. 
Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., Dahlin, C. M., Blinderman, C. D., Jacobsen, 
J., Pirl, W. F., Billings, J. A. & Lynch, T. J. 2010. Early palliative care for patients with metastatic non-small-cell lung cancer. N 
Engl J Med,363, 733-42.
Section 3: Development of the National Clinical Guideline
Brouwers, M.C., Kho, M.E., Browman, G.P., Burgers, J.S., Cluzeau, F., Feder, G., Fervers, B., for the AGREE Next Steps Consortium. 
2010. AGREE Next Steps Consortium. AGREE II: Advancing guideline development, reporting and evaluation in health care. 
Can Med Assoc J. 2010;13:E839–E842. 
Department of Health and Children (DoHC). 2006. A Strategy for Cancer Control in Ireland. Available: www.dohc. ie/
publications/cancer_control_2006.html 
Hickey, P. & Evans, D. 2014. Smoking in Ireland 2014:Synopsis of Key Patterns. HSE National Tobacco Control Office,: Health 
Service Executive. 
Luengo-Fernandez, R., Leal, J., Gray, A. & Sullivan, R. 2013. Economic burden of cancer across the European Union: a population-
based cost analysis. Lancet Oncol, 14, 1165-74. 
Michie, S., Van Stralen, M., & West, R. 2011. The behaviour change wheel: A new method for characterising and designing 
behaviour change interventions. Implement Sci, 6(1), 42. 
National Cancer Registry Ireland (NCRI). 2014. Cancer Projections for Ireland (2015 – 2040). National Cancer Registry. NCR, 
Cork, Ireland. 
National Cancer Registry Ireland (NCRI). 2015. Cancer in Ireland 1994-2013: Annual Report of the National Cancer Registry. 
NCR, Cork, Ireland.
National Cancer Registry Ireland (NCRI) 2016. Cancer in Ireland 1994-2014: Annual Report of the National Cancer Registry. 
NCR, Cork, Ireland. 
Oxford Centre For Evidence-Based Medicine (Oxford Cebm). 2009. Oxford Centre for Evidence-based Medicine – Levels of 
Evidence (March 2009). Available: www.cebm.net/oxford-centre-evidence-based-medicinelevels-evidence-march-2009/ 
214 | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
| A National Clinical Guideline
Sackett, D.L., Straus, S.E., Richardson, W.S., Rosenberg, W., & Haynes, R.B. 2000. Evidence based medicine. How to practice 
and teach EBM, 2nd edn. Churchill Livingstone, Edinburgh. 
Scottish Intercollegiate Guidelines Network (SIGN). 2011. A guideline developers’ handbook. Edinburgh: SIGN; 2011. (SIGN 
publication no. 50). [cited 01 Nov 2014]. Available: www.sign.ac.uk
Section 4: Appendices
Burfeind, W. R., Jr., Jaik, N. P., Villamizar, N., Toloza, E. M., Harpole, D. H., Jr. & D’amico, T. A. 2010. A cost-minimisation analysis 
of lobectomy: thoracoscopic versus posterolateral thoracotomy. Eur J Cardiothorac Surg, 37, 827-32. 
Cao, J. Q., Rodrigues, G. B., Louie, A. V. & Zaric, G. S. 2012. Systematic review of the cost-effectiveness of positron-emission 
tomography in staging of non--small-cell lung cancer and management of solitary pulmonary nodules. Clin Lung Cancer, 13, 
161-70. 
Chouaid, C., Crequit, P., Borget, I. & Vergnenegre, A. 2015. Economic evaluation of first-line and maintenance treatments for 
advanced non-small cell lung cancer: a systematic review. Clinicoecon Outcomes Res, 7, 9-15. 
Deppen, S. A., Davis, W. T., Green, E. A., Rickman, O., Aldrich, M. C., Fletcher, S., Putnam, J. B., Jr. & Grogan, E. L. 2014. Cost-
effectiveness of initial diagnostic strategies for pulmonary nodules presenting to thoracic surgeons. Ann Thorac Surg, 98, 
1214-22. 
Health Information And Quality Authority 2014. Guidelines for the Economic Evaluation of Health Technologies in Ireland. 
Dublin: HIQA. 
Luengo-Fernandez, R., Leal, J., Gray, A. & Sullivan, R. 2013. Economic burden of cancer across the European Union: a population-
based cost analysis. Lancet Oncol, 14, 1165-74. 
Michie, S. & Johnston, M. 2004. Changing clinical behaviour by making guidelines specific. BMJ, 328, 343 - 345. 
Michie, S., Van Stralen, M. M. & West, R. 2011. The behaviour change wheel: a new method for characterising and designing 
behaviour change interventions. Implement Sci, 6, 42. 
Mitera, G., Swaminath, A., Rudoler, D., Seereeram, C., Giuliani, M., Leighl, N., Gutierrez, E., Dobrow, M. J., Coyte, P. C., Yung, 
T., Bezjak, A. & Hope, A. J. 2014. Cost-effectiveness analysis comparing conventional versus stereotactic body radiotherapy for 
surgically ineligible stage I non-small-cell lung cancer. J Oncol Pract, 10, e130-6. 
NCRI 2014. Cancer Projections for Ireland 2015-2040. 
Paul, S., Altorki, N. K., Sheng, S., Lee, P. C., Harpole, D. H., Onaitis, M. W., Stiles, B. M., Port, J. L. & D’amico, T. A. 2010. 
Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the 
STS database. J Thorac Cardiovasc Surg, 139, 366-78.
Puri, V., Crabtree, T. D., Kymes, S., Gregory, M., Bell, J., Bradley, J. D., Robinson, C., Patterson, G. A., Kreisel, D., Krupnick, A. S. 
& Meyers, B. F. 2012. A comparison of surgical intervention and stereotactic body radiation therapy for stage I lung cancer in 
high-risk patients: a decision analysis. J Thorac Cardiovasc Surg, 143, 428-36. 
Sharples, L. D., Jackson, C., Wheaton, E., Griffith, G., Annema, J. T., Dooms, C., Tournoy, K. G., Deschepper, E., Hughes, V., 
Magee, L., Buxton, M. & Rintoul, R. C. 2012. Clinical effectiveness and cost-effectiveness of endobronchial and endoscopic 
ultrasound relative to surgical staging in potentially resectable lung cancer: results from the ASTER randomised controlled 
trial. Health Technol Assess, 16, 1-75, iii-iv. 
Sher, D. J., Wee, J. O. & Punglia, R. S. 2011. Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency 
ablation for medically inoperable, early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys, 81, e767-74. 
Scottish Intercollegiate Guidelines Network (SIGN). 2011. A guideline developers’ handbook. Edinburgh: SIGN; 2011. (SIGN 
publication no. 50). [cited 01 Nov 2014]. Available: www.sign.ac.uk
215| A National Clinical Guideline | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N. J., Amir, E., Khayat, D., Boyle, P., Autier, P., Tannock, I. F., Fojo, T., 
Siderov, J., Williamson, S., Camporesi, S., Mcvie, J. G., Purushotham, A. D., Naredi, P., Eggermont, A., Brennan, M. F., Steinberg, 
M. L., De Ridder, M., Mccloskey, S. A., Verellen, D., Roberts, T., Storme, G., Hicks, R. J., Ell, P. J., Hirsch, B. R., Carbone, D. P., 
Schulman, K. A., Catchpole, P., Taylor, D., Geissler, J., Brinker, N. G., Meltzer, D., Kerr, D. & Aapro, M. 2011. Delivering affordable 
cancer care in high-income countries. Lancet Oncol, 12, 933-80.
216 | Diagnosis, staging and treatment of  
	 patients	with	lung	cancer
| A National Clinical Guideline

Department of Health, Hawkins House, Hawkins Street, Dublin, D02 VW90, Ireland
Tel: +353 1 6354000  •  Fax: +353 1 6354001  •  www.health.gov.ie
